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Abstract 
This thesis examines three main themes; depression, suicidality, and non-fatal 
overdose involving pharmaceutical and over-the-counter (OTC) medications.1 At 
any given time depression affects approximately one in every twenty adults in 
Australia. People with depression are at elevated risk of attempted and completed 
suicide compared to those without. Medication overdose is a frequently chosen 
method of suicidal behaviour, and accounts for one in ten suicide deaths and close to 
nine out of ten non-fatal episodes of suicidal behaviour for which hospital treatment 
is sought. 
The study reported here had six primary aims; (i) to quantify medication overdose 
presentations over a 12-month period to the Emergency Department (ED) of a major 
metropolitan public hospital in Melbourne, Australia, (ii) to describe the medication 
overdose patient group, including comparison with two other relevant types of 
presentation, illicit drug overdose, and actual or potential self-harm by means other 
than overdose, (iii) to explore the relationship between depression, suicidal ideation 
and medication overdose, (iv) to identify the medications typically used in overdose 
and their means of acquisition, (v) to explore patient experiences of emergency care 
following a medication overdose, and (vi) to comment on the feasibility of 
introducing a brief intervention within the ED with the intention of addressing the 
issue of medication overdose. Three data sources were employed: computerised ED 
records, interviews with a sub-sample of patients attending the ED following a 
appropriateness of their prescribing practices, to encourage them to more closely 
                                                          
medication overdose, and observation of ED processes in relation to these cases. 
One of the most important findings of the study was the large contribution made by 
benzodiazepine medications to the overall medication overdose statistics. When 
considered in conjunction with the patient interview data, it appeared that many 
patients included in the study were prescribed benzodiazepines in a manner that 
contradicts current national prescribing guidelines. The problem of medication 
overdose could be partially addressed by working with doctors to ensure the 
1 OTC medications are those which are available for purchase from pharmacies, supermarkets, and other outlets 
without prescription. 
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monitor the treatment progress of at-risk patients, and to increase awareness of other 
evidence-based forms of treatment for depression and anxiety. 
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1 Literature Review 
There are three themes covered by this literature review; depression, suicidality, and 
non-fatal overdose involving pharmaceutical and OTC medications. In relation to 
depression, a definition is provided, co-morbidity with other mental health 
conditions discussed, and current knowledge regarding risk factors, prevalence, 
treatment options, and outcomes summarised. The review then addresses various 
types of suicidal behaviour, theories of such behaviour, means of actual and 
attempted suicide, risk factors, prevalence, and interventions. Thirdly, 
pharmaceutical medication overdose is considered. Included is a summary of the 
medications typically involved, their physiological effects in an overdose, interaction 
with other substances including illicit drugs and alcohol, and prevalence of overdose. 
A review of studies conducted in emergency medical care settings about medication 
overdose is presented in the final section, with a particular focus on studies that also 
addressed the role of depression and/or suicidality in the overdose. 
1.1 Depression 
1.1.1 Definition 
The cluster of psychological and behavioural characteristics now popularly termed 
“depression” has been noted throughout recorded human history and across cultures 
(Beck, 1967; J. Jenkins, Kleinman, & Good, 1991; Joyce, 2004a). There are two 
widely recognised clinical diagnostic systems for the identification of depression in 
current use (Joyce, 2004a). The American Psychiatric Association produce the 
Diagnostic and Statistical Manual of Mental Disorders which provides empirically 
founded diagnostic criteria for a range of psychiatric conditions, and which is 
intended for use in clinical, research and educational settings. The current version of 
this manual is DSM-IV-TR (American Psychiatric Association, 2000). Alternatively, 
the World Health Organisation publish the International Statistical Classification of 
Diseases and Related Health Problems, of which the current edition is ICD-10 
(World Health Organisation, 2004). In recent years there has been a deliberate effort 
to improve the compatibility of these two diagnostic systems (Gilbert, 1992). As the 
study reported in this thesis utilised a measure of depressive symptomatology 
 12
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
consistent with DSM-IV-TR criteria (Beck, Steer, & Brown, 2000), only that 
diagnostic system is detailed here.  
Conditions involving a disturbance in mood, such as depression, are grouped 
together in DSM-IV-TR as “Mood Disorders”. Mood disorders include Depressive 
Disorders, Bipolar Disorders, and Other Mood Disorders (American Psychiatric 
Association, 2000). It has been suggested that there is considerable overlap between 
the different categories of mood disorder (G. Brown, 1991). 
The main focus of this thesis is Depressive Disorders, of which there are three 
subtypes; Major Depressive Disorder, Dysthymic Disorder, and Depressive Disorder 
Not Otherwise Specified. Major Depressive Disorder may be diagnosed when a 
person has experienced one or more Major Depressive Episodes (see below), and the 
episode(s) cannot be better accounted for by another disorder. The full diagnostic 
criteria for the disorder are included in Appendix A, page 329. A Major Depressive 
Episode may be diagnosed when a person has had at least five out of nine specified 
depressive symptoms in the last two weeks.2 Symptoms include depressed mood, 
diminished interest or pleasure in activities, significant weight loss or gain, insomnia 
or hypersomnia, psychomotor agitation or retardation, fatigue/loss of energy, feelings 
of worthlessness or guilt, difficulty concentrating, and thoughts of death or suicidal 
ideation. Further, to constitute a Major Depressive Episode, the symptoms should 
have caused distress to the person, impaired functioning, and should not have 
resulted from substance use or a medical condition (American Psychiatric 
Association, 2000). The full criteria for a Major Depressive Episode are included in 
Appendix B, page 330. 
Dysthymic Disorder is a form of depression where the symptoms, although 
protracted, are not severe enough to warrant diagnosis of Major Depressive Disorder. 
Dysthymic Disorder may be diagnosed when a person has experienced depressed 
mood for two years (for most of the day, more days than not), two or more other 
depressive symptoms have also been present, the person has not been symptom-free 
for any longer than two months in the past two years, and the condition cannot better 
accounted for by another disorder (American Psychiatric Association, 2000). 
Diagnostic criteria are listed in Appendix C, page 331. Depressive Disorder Not 
                                                          
2 At least one of the symptoms must be depressed mood or loss of interest. 
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Otherwise Specified may be diagnosed when depressive symptoms have been 
present, but do not meet the criteria for Major Depressive Disorder, Dysthymic 
Disorder, or a range of other disorders (American Psychiatric Association, 2000). 
There is considerable overlap between depression and other disorders described in 
DSM-IV-TR, particularly Substance-Related Disorders and Anxiety Disorders.3 The 
overlap will be discussed further in ‘Co-morbidity’, page 16. However, as substance 
use is of particular relevance to this thesis, DSM-IV-TR categorisation of problems 
related to substance use is explained here. Substance-related problems are classified 
in two ways: as Substance Use Disorders (i.e. Substance Abuse or Dependence), or 
as Substance-Induced Disorders (of which there are several, including Substance-
Induced Mood Disorder) (American Psychiatric Association, 2000). It can be 
difficult to ascertain whether the mood symptoms experienced by a person who has 
used alcohol or other drugs were induced by intoxication or withdrawal, or whether 
they indicate a true primary mood disorder. The main distinguishing feature of 
Substance-Induced Mood Disorder is that the substance use is likely to be 
aetiologically related to the mood symptoms noted. An individual does not have to 
meet the criteria for substance abuse or dependence for this disorder to be diagnosed. 
The full criteria are included in Appendix D, page 332. 
A small number of the people who participated in this study had Bipolar Disorder 
(characterised by symptoms such as elevated, irritable or expansive mood, inflated 
self-esteem or grandiosity, flight of ideas, and excessive involvement in pleasurable 
activities that are likely to have painful consequences), but as this disorder was not 
the central focus of the study it will not be described in detail here. Women who 
have recently given birth may experience postnatal mood disturbance, but as with 
Bipolar Disorders, such depression was not the focus of this study and therefore the 
condition is not covered in this review. 
Although the criteria for Major Depressive Disorder in DSM-IV-TR are specific, the 
literature and research evidence to date has used a range of definitions and terms to 
describe the concept of depression. Given the variability of language applied to 
                                                          
3 Anxiety disorders include (but are not limited to) Panic Disorder, Agoraphobia, Specific Phobia, Social Phobia, 
Obsessive-Compulsive Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder and Generalised Anxiety 
Disorder (American Psychiatric Association, 2000). 
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depression in scientific, clinical, and everyday use, this more encompassing term (i.e. 
“depression”) has been used when reviewing the literature and throughout the thesis. 
Two other commonly interchanged terms, “mood disorder” and “affective disorder” 
have also been used in this thesis, even though they have a broader range of 
meaning. 
1.1.2 Prevalence 
According to the World Health Organisation depression was the fourth largest 
contributor to the global burden of disease (as measured by disability adjusted life 
years, or DALYs) in 2000 (World Health Organisation, 2006a). It was further 
estimated that by 2020 depression will be second only to ischaemic heart disease in 
terms of worldwide disease burden. The apparent increase in the prevalence of 
depression may be partly attributable to improved recognition and recording of 
cases, however, Becker and Kleinman (1991) suggested that the evidence points to a 
real increase in the prevalence of these disorders, particularly in the developing 
world. 
In a review of studies conducted in Australia, New Zealand, Britain, and the United 
States, Joyce and Mitchell (2004) suggested that the current (last month) prevalence 
of major depression was 3-5% of the population. Data presented in DSM-IV-TR 
indicated that at any one point in time the prevalence among females was 5-9%, and 
2-3% among males (American Psychiatric Association, 2000). 
Internationally reported lifetime prevalence figures have been found to vary widely 
from 4% to over 30%, with the variability most likely due to methodological 
differences and recall bias (Joyce & Mitchell, 2004). The reported lifetime risk of 
developing a Major Depressive Disorder according to DSM-IV-TR was 10-25% for 
females and 5-12% for males (American Psychiatric Association, 2000). It was 
further reported that those who had a single Major Depressive Episode were at 
elevated risk of having a second (60%), and among those who did, the chance of a 
third episode was 70%, and thereafter the chance of a repeated episode was 90% 
(American Psychiatric Association, 2000). 
The estimates above are supported by Australian data. It has been estimated that at 
any one time 3-5% of the population will evidence depressive symptomatology, and 
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further, that 15% of the general Australian population will suffer from depression at 
some point during their lifetime (Mitchell, 1999). Population-based surveys have 
demonstrated that over 5% of the Australian population suffer from depression each 
year (Australian Bureau of Statistics, 1998).4 Virtually identical rates of major 
depression have been found whether the ICD-10 or DSM-IV criteria were used 
(3.3% and 3.2% respectively within the last month, and 6.7% and 6.3% respectively 
within the last 12 months) (Andrews, Henderson, & Hall, 2001). Depression has 
been reported as the fourth most commonly seen condition by General Practitioners 
(GPs) in Australia, contributing to 3.6 million visits to GPs each year (Britt, Miller, 
Knox, Charles, Valenti, Henderson et al., 2001). 
Depression can begin in childhood, and it has been estimated that in any one year, 1-
2% of children up to the age of 12 have clinical depression, although the signs of 
depression may be somewhat different in childhood (Martin, 2004). Up to 15% of 
children experience at least one depressive episode by adolescence, and those who 
have been depressed in childhood are more likely to have depression in adolescence 
and adulthood. In reviewing the Australian evidence relating to depression during 
adolescence, Hazell (2004) reported that most people who ever suffer from major 
depression experienced their first depressive episode during their teenage years, with 
a peak age of onset from 15-19. In that review of the data, approximately 5% of 
those aged 13-17 met the criteria for depression. Thereafter the rates of depression 
increase more rapidly for girls than boys. A community-based survey conducted in 
Queensland of over three thousand 15-24 year olds yielded results consistent with 
those above. Depressive symptomatology was reported by approximately one in 
eight males and one in four females (Donald, Dower, Lucke, & Raphael, 2001). The 
rate among females was significantly higher than among males. 
1.1.3 Co-morbidity 
Co-morbidity refers to the presence of more than one disease, disorder, or syndrome 
at the same time. Co-morbidity represents a serious problem because the onset of 
illness is generally earlier, the course is often more severe, treatment outcomes are 
                                                          
4 The survey reported here used the Composite International Diagnostic Interview (CIDI) to assess mental health. 
The CIDI uses the ICD-10 diagnostic criteria for depression. 
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generally poorer, and the individual may have lower social stability (Blanchard, 
2000; Teesson, 2000). 
It has been recognised that there is a high degree of co-morbidity among psychiatric 
disorders. In particular, depression has been shown to overlap with anxiety and 
substance use. The 1997 Australian National Survey of Mental Health and Wellbeing 
involved over 10,000 participants from the general adult population. The study found 
that approximately one in six people met the criteria for an affective (mood) disorder, 
an anxiety disorder, or a substance use disorder within the previous 12 months, and 
one in eleven had met the criteria within the previous month (Andrews et al., 2001).5 
Of those, approximately 25% also met the criteria for at least one of the other two 
groups of disorder, while 1% met the criteria for all three (Teesson, 2000). The 
pattern of co-morbidity differed somewhat between males and females. Males more 
often had a substance use disorder co-occurring with either depression or anxiety, 
while females tended to have comorbid anxiety and depression (Teesson, 2000). 
Similarly, Todd and Sellman (2004) reported that about 25-40% of those with a 
mood disorder also had a history of substance abuse or dependence. Conversely, 
approximately half those with substance use problems also had a lifetime history of 
co-occurring mental health disorders, predominantly anxiety and depression (Todd & 
Sellman, 2004). 
A higher co-morbidity estimate between depression and other psychiatric conditions 
was reported in a U.S. review (40-65%), although it has been noted that estimates 
obtained via clinical research are likely to be larger than those derived from 
population-based research (Blanchard, 2000; Kushner, Abrams, & Borchardt, 2000). 
This phenomenon, called Berkson’s Bias, most probably arises because those with 
multiple disorders are more likely to seek treatment than those with only one 
disorder (Swendsen & Merikangas, 2000). Depression has also been found to co-
occur with other psychiatric conditions such as psychosis and personality disorders, 
                                                          
5 In this study Affective Disorders included Major Depression and Dysthymia. Anxiety Disorders included Panic 
Disorder, Agoraphobia, Social Phobia, Generalised Anxiety Disorder, Obsessive-Compulsive Disorder and Post-
Traumatic Stress Disorder. Substance Use Disorders included Alcohol Dependence, Alcohol Misuse/Harmful 
Use, Drug Dependence and Drug Misuse/Harmful Use.  
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though the prevalence of these disorders among the entire population of people with 
depression is comparatively low (Skinstad & Swain, 2001; Teesson, 2000).6 
While DSM-IV-TR (American Psychiatric Association, 2000) identifies depression 
and anxiety as distinct disorders, it has long been noted that they share many of the 
same features. Indeed, instruments designed to measure one of these disorders have 
often shown poor discriminant validity from those intended to measure the other 
(Clark & Watson, 1991). Symptoms recognised as belonging to both disorders 
include agitation, difficulty concentrating, insomnia, and loss of energy, whereas 
symptoms that distinguish anxiety from depression are panic attacks and agoraphobic 
avoidance (Clark & Watson, 1991). Depression can be distinguished from anxiety in 
terms of loss of pleasure, waking early in the morning and being unable to return to 
sleep (Clark & Watson, 1991).  
Mullaney (1989) proposed eight possible mechanisms for the inter-relationship 
between anxiety and depression; (1) they are interwoven and inseparable disorders, 
(2) they are distinct disorders, (3) they are distinct disorders although difficult to 
separate, (4) anxiety is part of depression, (5) the two disorders are symptomatically 
different but not mutually exclusive, (6) the two disorders are hierarchical with 
depressive symptomatology being more severe than anxious symptomatology, (7) the 
two disorders often occur together however depression can exist alone, and (8) the 
two disorders are indistinguishable and in therapeutic terms there is little to be 
gained from separating them. Gilbert (1992) noted that there is some evidence in 
support of each of these mechanisms. However, for this research it was recognised 
that although the two disorders are closely associated, the exact nature of the 
association was not central to the research question (i.e. anxiety was not measured as 
it was expected that the score on a standardised measure would correlate highly with 
depression scores in any case). 
The mechanism for co-morbidity between depression and substance use disorders is 
also not clear. Todd and Sellman (2004) noted both mood and substance use 
disorders are “aetiologically complex conditions”; therefore their co-occurrence is 
                                                          
6 While relatively few people with depression have co-occurring psychosis, one study found that almost half of 
those attending a public health service with schizophrenia as a primary diagnosis also had current or past 
problems with substance use (Swofford, Scheller-Gilkey, Miller, Woolwine, & Mance, 2000). 
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also likely to be complex. In some cases the depression may be a symptom of 
substance use which improves once the dependence has been addressed (i.e. 
substance use precedes depression) (Verheul, Kranzler, Poling, Tennen, Ball, & 
Rounsaville, 2000). In other cases the self-medication hypothesis may apply, 
whereby depression occurs first and substances are used to alleviate negative feelings 
(or in the case of anxiety, to overcome feelings of fear), though it has been argued 
that this alone is an insufficient explanation for comorbidity (Todd & Sellman, 
2004). It has also been suggested that substance use, mood, and anxiety disorders 
have a common underlying aetiology (e.g. genetics, neurobiological, environmental 
risk factors, etc) (Blanchard, 2000; Hall, Lynskey, & Teeson, 2000; Kushner et al., 
2000; Lynskey, 1998; Teesson, 2000; Todd & Sellman, 2004). 
"Substance use and mood disorders are increasingly seen as arising through a 
complex interaction of factors acting across all levels of brain-mind 
organisation, including genes, neurochemicals, temperament and character, 
psychological, social, cultural and spiritual factors. In any one individual, 
various aetiological factors interact to lend vulnerability to, precipitate and 
maintain co-occurring substance use and mood disorders." (Todd & Sellman, 
2004, p. 307) 
In a review of the epidemiological, clinical, family, and genetic studies concerning 
the co-morbidity of depression and various substance use disorders, Swendsen and 
Merikangas (2000) concluded that while all of the above-mentioned factors were 
probably relevant and had multiple pathways of association, in the case of 
alcoholism and depression, the primary pathway was probably causal. That is, 
alcohol was shown to cause impairment in important areas of functioning (social, 
occupational, health) which led to stress and ultimately depression.7 Furthermore, 
alcohol could also exert a direct effect on depressive symptomatology. However, the 
authors were unable to clearly define the pathway of association between depression 
and other types of substance dependence (Swendsen & Merikangas, 2000). 
                                                          
7 Although most of the studies reviewed by Swendsen and Merinkangas (2000) involved male or mixed gender 
populations, a series of studies reviewed by those authors found depression predicted alcoholism among female 
twins, suggesting the pathway of causality may be gender-related. 
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1.1.4 Theories of depression 
Numerous theories have been proposed regarding the aetiology of depression. These 
can loosely be categorised as psychoanalytic, interpersonal, cognitive, and 
physiological. Each theory emphasizes a different aspect of depression, though 
possibly none provide a full account of depressive thought, behaviour and 
symptomatology. Nor are the theories entirely distinct; for example, some of the later 
cognitive theories incorporate elements of the earlier psychodynamic theories. The 
quality of empirical evidence to support various theories of depression has been 
variable. Given the enormous breadth of writing in the area, and the focus of the 
current research, the different theoretical perspectives on depression will not be 
reviewed here. Theories of depression can be found in the work of Abraham (1911, 
1916 & 1924), Freud (1917), Rado (1928), Klein (1934), Bibring (1953), Bowlby 
(1975), Beck (1979), Ellis and Dryden (1987), Beck, Rush, Shaw and Emery (1979), 
and Meichenbaum (1977), summaries of which may be found in the following 
publications (Beck, 1967; Becker & Kleinman, 1991; Becker & Schmaling, 1991; 
Fremouw, Perczel, & Ellis, 1990; Gilbert, 1984, , 1992). 
1.1.5 Risk factors 
Regardless of the overall theoretical orientation adopted towards depression, a 
number of factors which contribute to the onset, maintenance, and recurrence of 
depression have been identified by empirical research. However, as yet there is no 
coherent model for how these various factors interrelate. As summarised by Gilbert 
(1992), 
“…although we can make reliable diagnoses it remains uncertain how much 
more we can say about depression. Clearly severity stands out as the single 
most important aspect for treatment considerations, but how genes, 
psychological style, life events, and culture all interact to produce an 
individual’s symptom profile at any point in time (and these profiles are often 
highly unstable) remains mysterious.” (Gilbert, 1992, p. 58). 
While Donald and Dower (2002) argued that naming discrete risk factors for 
depression is a reductionist approach that overlooks the complexity of interrelated 
characteristics at the individual, family, community and cultural level, they 
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acknowledged that such discrete categories have a use in developing targeted 
prevention and intervention efforts. As the current research aims to characterise 
medication overdose patients on a range of variables including severity of depressive 
symptomatology (see Research Questions, page 103) an attempt has been made here 
to list the variables that previous research has found to be associated with depression. 
However, it should be noted that association does not imply causation, and that a 
discussion of directionality is beyond the scope of this review. Further, the variables 
presented here are loosely grouped according to subheadings, though many could be 
categorised in more than one way. Given the importance of substance use in 
depression, this risk factor was discussed in detail in the earlier section on Co-
morbidity (page 16) and will not be covered again here. 
Biology 
Research into the biological factors contributing to depression has investigated the 
role of various elements including genes, neurotransmitters, and neuroendocrine 
function. Depression has been demonstrated to cluster in families, partly as a 
consequence of genetic factors which may confer either vulnerability to, or 
protection from, the condition (Schweitzer & Tuckwell, 2004; Sullivan, 2004). A 
recent meta-analysis found that immediate relatives of people with depression were 
almost three times more likely that those without to also suffer from major 
depression (although this figure was based on clinical samples, and may therefore be 
an overestimate due to the greater likelihood of treatment seeking in some families) 
(Sullivan, 2004). A genetic link has also been found in twin and adoption studies, 
with an estimated 37% of liability to depression being accounted for by heredity 
(Sullivan, 2004). Such studies have also found environment to be important, 
however, the effect was due to individual-specific experiences, rather than shared 
environmental factors that applied equally to both twins. Schweitzer (2004) further 
argued that biochemical changes associated with experiencing environmental stress 
triggers depression in genetically vulnerable persons. The specific genes involved in 
depression have not been identified, but it appears likely that there are multiple genes 
that contribute to the condition (Schweitzer & Tuckwell, 2004). 
Much of the work concerning the role of neurotransmitters in depression was 
prompted by the coincidental observation that medications affecting the operation of 
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these were associated with an elevation in mood (Schweitzer & Tuckwell, 2004). It 
has since been clearly established that depression is associated with noradrenalin and 
serotonin dysregulation (Alchin & Tranby, 1995; Schweitzer & Tuckwell, 2004). 
Other neurotransmitters likely to be involved in depression include dopamine,8 
acetylcholine, opiates, and γ-aminobutyric acid, though these have been less 
extensively studied than serotonin and noradrenaline. The different classes of 
antidepressant medication available exert their effect by modulating the levels of 
neurotransmitters available in the multiple brain regions implicated in depression. 
The specific mechanism of action of the relevant neurotransmitters in depression has 
not yet been definitively established, and given its complexity, is beyond the scope 
of this review. 
There is evidence to suggest hormonal factors may be associated with depression. 
Firstly, neurotransmitters, as described above, are known to influence the secretion 
of hormones from glands such as the pituitary and hypothalamus. Therefore, 
dysregulation of neurotransmitter function has a flow on effect to neuroendocrine 
function. Secondly, individuals suffering from an endocrine function disorder such as 
hyperthyroidism have been demonstrated to experience disturbance in mood, 
suggesting that the hormonal imbalance associated with their primary disorder can 
also lead to mood-related symptoms (Schweitzer & Tuckwell, 2004). While less than 
1% of depressed patients have hyperthyroidism, subclinical abnormalities in the level 
of relevant hormones are common among depressed samples. 
Hormone levels may be measured in body fluids such as blood, saliva, and urine. 
Given the known link between neurotransmitter and endocrine function, 
measurement of hormone levels may provide valuable information about 
neurotransmitter function, which is less easily measured directly.9 The involvement 
of hormones has also been inferred from enlargement of the adrenal and pituitary 
glands. Most studies focusing on neuroendocrine function have examined the limbic-
hypothalmic-pituitary-adrenal axis which is implicated in the body’s stress response. 
As for neurotransmitters above, the exact role of hormones in depression is still 
unknown and the available evidence too complex to be covered completely here. 
                                                          
8 Dopamine may be particularly relevant in bipolar disorder, as well as depression. 
9 Hormones studied include cortisol, adrenocorticotrophic hormone, corticotrophin-releasing factor, growth 
hormone and thyroid-stimulating hormone. 
 22
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
However, in reviewing the previous research evidence, Schweitzer and Tuckwell 
(2004) concluded that at least 50% of those with depression have a chronically 
overactive hypothalmic-pituitary-adrenal (HPA) axis. This system has been shown to 
respond to antidepressant treatment, and failure to do so has been associated with 
higher risk of relapse to depression. The role of the hormone oestrogen in depression 
has also been studied and a summary of the available evidence relating to this is 
presented in the section concerning gender below. 
Finally, other recent developments in the area of neurobiology and depression have 
shown promise in furthering knowledge about the biological underpinnings of 
depression. These include neuroimaging to observe brain structure and function 
(Mali, Lagopoulos, Soares, & Vieta, 2004), molecular biology, and immune function 
(Schweitzer & Tuckwell, 2004). Regarding the latter, preliminary evidence 
demonstrated that both neurotransmitter and neuroendocrine function interact with 
the immune system, and further, that compromised immune-endocrine function may 
be a factor in the onset of depression. However, additional research is required 
before any conclusions about the roles of immunology, brain structure and function, 
and molecular biology in mood disorders can be drawn (Schweitzer & Tuckwell, 
2004). 
Gender 
Studies of depression have consistently shown a higher rate of depression among 
females than males in clinical and general population settings (Andrews et al., 2001; 
Donald & Dower, 2002; Wilhelm, 2004). Recent community-based studies reported 
that females were approximately 1.6 times more likely to experience depression than 
males (the ratio remained constant for 1 month, 12 month, and lifetime prevalence), 
though the sex difference tended to reduce among older populations (i.e. increased 
rates of depression among older men). Sex differences were particularly evident in 
cases of mild to moderately severe depression and dysthymia, and during 
childbearing years. Females were also reported to have longer episodes and higher 
rates of recurrence than males (Wilhelm, 2004). 
It is likely that gender differences in the rates of depression are related to both 
biological and social factors. Biological factors studied have included genetics and 
hormones (see Biology, page 21). There has been no evidence found to link 
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depression to the X chromosome itself. However, depression has been found to be 
related to “neuroticism” which has a genetic component (Wilhelm, 2004). Given that 
depression in women has been associated with times of hormonal change such as 
puberty, premenstruation, pre and postnatal, and at perimenopause, the role of female 
hormones in the disorder has been investigated. The evidence relating to oestrogen 
was equivocal with some authors suggesting that oestrogen treatment improved 
depression among perimenopausal women (Schweitzer & Tuckwell, 2004), and 
others finding no link with between oestrogen and depression (Wilhelm, 2004). In 
reviewing the available evidence, the latter author suggested that rather than 
oestrogen, oxytocin (a hormone related to child birth and lactation) may be involved. 
There are a number of psychosocial factors that may contribute to the higher rates of 
depression seen in women, including differences in emotional recall and expression, 
help-seeking behaviour, learned behaviour, coping styles, and access to resources 
(Andrews et al., 2001; Donald & Dower, 2002; Wilhelm, 2004). For example, it has 
been suggested that generally speaking women may be more inclined to adopt 
internalised, emotion-focused coping strategies, while men tend to use externalised, 
action-coping techniques. It has further been argued that men are more likely than 
women to use alcohol to cope with negative affective states, and therefore problems 
may manifest themselves as substance-related, rather than affect-related (Wilhelm, 
2004). 
The gender difference in prevalence rates for depression may also be an artefact of 
current diagnostic systems. It has been argued that the DSM-IV criteria for 
depression are female oriented, and that if substance abuse and sociopathy were 
recognised as possibly symptomatic of depression, more males would be diagnosed 
as such (Blair-West & Mellsop, 2001). 
Family factors 
The role of the family of origin in the development of depression is subject to some 
debate, as evidence pertaining to this issue has generally relied on subjective, 
retrospective self-reports by individuals experiencing emotional difficulties (i.e. 
responses may have been influenced by recall bias or post-justification). Despite 
these concerns research reviews have consistently reported family of origin to be 
associated with depression (Donald & Dower, 2002; J. Jenkins et al., 1991), a view 
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supported by clinician reports of the relevance of family experience (J. Jenkins et al., 
1991). For example; 
“The clinical and research experience of numerous cross-cultural 
investigators has led them to assign dysfunctional family dynamics an 
instrumental role in the development of the disorder.” (J. Jenkins et al., 1991, 
p. 841) 
Depression has been found to be more common among children with at least one 
parent with a depressive disorder than those without (J. Jenkins et al., 1991). This 
may be partly due to a genetic predisposition towards depression, but may also be 
due to learned behaviour from within the family structure. Other family factors 
identified have included experiencing a negative childhood, aloof, controlling and 
over-protective parents, parental psychiatric problems, parental discord, family 
conflict, and poor quality relationships within the family (Donald & Dower, 2002; J. 
Jenkins et al., 1991). While family connectedness has been identified as a protective 
factor against depression, a study of young adults found that in the presence of 
certain other types of risk (e.g. sexual identity conflict) high levels of family 
connectedness were associated with greater depressive symptomatology, suggesting 
that overly involved family structures may also be problematic (Donald & Dower, 
2002).  
In adults, conflict within a primary relationship has been associated with depression 
(J. Jenkins et al., 1991). Separation, divorce, and being widowed have also been 
noted as risk factors for affective disorders (Andrews et al., 2001). 
Personality 
Certain personality styles have been found to be more common among those with 
depression, although the direction of causality has not been established. As with 
depression itself, it is not clear at what point “normal” dimensions of personality 
actually constitute a disorder. However, even in the absence of a personality 
disorder, certain traits have been frequently noted in people with depression.  Gilbert 
asserted that “…personality styles that reflect lability in affect control systems…” 
are common among depressed people (Gilbert, 1992, p. 112). This author further 
argued that characteristics such as emotional dependency, interpersonal sensitivity, 
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having a high need for approval, and either inhibited or excessive need for 
achievement with the goal of receiving approbation are often features of those 
vulnerable to depression (though not exclusively so). In contrast, an autonomous 
personality style may offer resilience to depression. In reviewing the literature 
Donald and Dower (2002) also concluded that intra-personal variables such as 
neuroticism, locus of control, self-esteem, self-efficacy, and problem solving abilities 
were related to depression (Donald & Dower, 2002). This finding was supported by a 
study of adolescents seeking psychiatric care which found that poor psychosocial 
functioning and pessimism about the future were associated with psychiatric 
problems (Laukkanen, Korhonen, Peiponen, Nuutinen, & Viinamaki, 2001). 
The role of personality is crucial when the question of treatment arises, as it has been 
noted that a person with an underlying personality disorder may have a more gradual 
response to treatment than a person who is depressed but without this complication, 
and further, may require a therapist particularly skilled to help the person develop a 
more adaptive personality structure (Gilbert, 1992). 
Socio-economic status (SES) 
Lower socio-economic groups, as defined by features such as occupation, income, 
unemployment, homelessness, and education, have been found to have higher rates 
of depressive symptomatology (Andrews et al., 2001; Donald & Dower, 2002; J. 
Jenkins et al., 1991). An Australian study using data from the 1997 Mental Health 
and Wellbeing Survey found a significant linear relationship between the risk of 
having an affective disorder and socio-economic condition as measured by level of 
education and employment status, with the risk increasing as condition decreased (R. 
Taylor, Page, Morrell, Carter, & Harrison, 2004). This association may have 
reflected social causation (i.e. low status caused poor mental health), or social 
selection (i.e. poor mental health limited ability to gain status). The study authors 
leaned towards social causation as an explanatory model, and therefore concluded 
that mental illness should not only be responded to by individual treatment, but also 
by broader social and economic reform. 
It has been argued that the association between depression and low SES is not only 
associated with financial and social standing, but the number of adverse life events 
experienced, with those of lower SES likely to endure more such experiences simply 
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because they are in a less advantaged position with fewer social supports. This 
closely associated risk factor is discussed below under psychosocial stress. 
Psychosocial stress 
There is a large literature on the link between stressful or adverse life experiences 
and depression (Alchin & Tranby, 1995; Becker & Kleinman, 1991; Paykel, 2004). 
In a review of relevant studies, Paykel (2004) identified three elements of 
psychosocial stress: life events, chronic stress, and social support. A life event was 
defined as a specific change in the external world.10 Depressed individuals have been 
shown to experience a greater average number of life events prior to the onset of the 
condition than non-depressed people. Studies that have calculated the attributable 
risk (i.e. the proportion of depression that can be attributed to life events), have 
yielded estimates of approximately 40% (Paykel, 2004). Life events involving an 
element of loss were particularly significant, with interpersonal separation, 
bereavement, loss of self-esteem, and experiences of humiliation and entrapment all 
found to be associated with the onset of depression and other psychiatric disorders. 
Chronic stress, defined as a persistent situation of ongoing difficulty, was found to be 
related to the onset of depression, both in the presence and absence of specific life 
events. High levels of social support (i.e. the extent to which a person had access to 
the emotional concern, aid, and attention of others) were found to be protective, and 
their absence a chronic stressor. 
Although relevant in the onset, maintenance, and recurrence of depression, Paykel 
(2004) indicated that psychosocial stress is a difficult concept to measure. For 
example, in relation to life events, individual recall may be inaccurate, the number or 
significance of life events may be overestimated in order to explain the depression, 
depression may itself produce an increase in the number of life events experienced, 
and finally, individual differences in the perceived stressfulness of various life events 
may exist (Paykel, 2004). Further, it has been suggested that there is a somewhat 
circular relationship between life events, chronic stress, and level of social support 
(for example, those prone to depression may self-select into higher risk 
environments, be less skilled at developing social networks, and so on (Cohen, 1988; 
Paykel, 2004). 
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Many different types of adverse life experience, chronic stressors, and social 
circumstances could potentially contribute to the development of depression. 
Psychosocial stressors most frequently identified in the literature as related to 
depression include sexual abuse, being an immigrant or refugee (especially when 
associated with trauma, torture, or displacement)11, failure at school or university, 
lower levels of education, social change such as rapid urbanization and 
industrialization, and the break up of a primary relationship (Andrews et al., 2001; 
Donald & Dower, 2002; J. Jenkins et al., 1991). 
Sexual orientation 
A US population-based study compared the rates of mood, anxiety, and substance 
use disorders among gay, lesbian, and bisexual mid-life adults with the rates among 
heterosexual adults of the same age (Cochran, Greer Sullivan, & Mays, 2003). 
Results showed higher rates of depression among gay and bisexual men than 
heterosexual men. Comorbid mental disorders were also higher among the gay, 
lesbian, and bisexual participants than the rest of the sample. 
Another US study sought to examine whether the mental health differences noted 
between sexual minority groups and the heterosexual majority were due to sexual 
orientation per se, or other variables relating to the social environment (Safren & 
Heimberg, 1999). Gay, lesbian, and bisexual adolescents were compared with 
heterosexual adolescents regarding depression, hopelessness, and suicidality. Higher 
levels of distress were found in the gay, lesbian, and bisexual group, however, this 
difference was no longer apparent once stress, social support, and coping 
mechanisms were controlled for. These findings suggest that the higher rates of 
depression and suicidality observed among sexual minority groups may be 
modifiable by prevention and intervention efforts aimed to improve aspects of the 
social environment. Bullying during adolescence due to sexual orientation has been 
associated with poorer mental health in adulthood (Rivers, 2004). Sexual identity 
conflict has also been noted as a risk factor for depression in an Australian 
community-based study of adolescents (Donald & Dower, 2002). 
                                                                                                                                                                    
10 This included events such as illness, although this is an internal change. 
11 Rates of depression have been shown to improve with time after settlement, particularly if there is ongoing 
contact with others from the same cultural background (J. Jenkins et al., 1991) 
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Protective factors 
In addition to identifying risk factors for depression, research has also been 
conducted to determine what characteristics, in the presence of such risk, appear to 
protect against the development of depression. Factors concerning the social 
environment, such as intrapersonal skills, social connectedness, and social support 
have all been found to act as a buffer (Donald & Dower, 2002; Paykel, 2004). 
1.1.6 Depression treatment and outcomes 
This section outlines treatments currently available for depression and their efficacy, 
as well as other treatment-related issues. The information on depression treatment is 
relevant to this review because the current research aimed to canvass the mental 
health treatment histories of medication overdose patients (see Research Questions, 
page 103). 
Treatment uptake 
Depression, particularly in its milder forms, is regarded as a treatable condition 
(Mitchell, 1999). However, a crucial factor in relation to the efficacy of treatment is 
identification; many depressed people may not consult a doctor, some of those who 
do so may not necessarily be identified as depressed, and even among those correctly 
diagnosed, only a proportion will receive appropriate and adequate treatment. It has 
been estimated that only about half of people seen in primary care settings with a 
current major depressive episode are identified as such (Joyce, 2004a). Undiagnosed 
mental illness such as depression has been identified as a risk factor for suicide, as 
has non-compliance with pharmacological treatments (Callor, Petersen, Gray, Grey, 
Lamoreaux, & Bennett, 2005). 
Despite the prevalence rates mentioned earlier, and the number of GP consultations 
in Australia concerning depression, results from the Australian National Survey of 
Mental Health and Wellbeing indicated that service utilisation in relation to mental 
health problems was poor, with only 35% of those who reported having a problem 
within the last year actually having a consultation for it (Andrews et al., 2001). 
Similarly, in a U.S. study of depressed inpatients, the majority were under-treated 
pharmacologically, irrespective of whether or not they had previously attempted 
suicide (Oquendo, Malone, Ellis, Sackeim, & Mann, 1999). 
 29
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
Types of treatment 
The treatments for depression can be split into two major categories; 
pharmacological treatments and psychological treatments. A number of other 
treatments have received less extensive clinical research. In terms of treatment 
selection, it has been suggested that psychological interventions alone (such as 
counselling) may be suitable for mild depression, but that in cases of severe 
depression a better response may be achieved when antidepressant medication is also 
used (Mitchell, 1999). 
In discussing good clinical management for depression, Joyce (2004b) suggested the 
following elements were crucial: assessment of symptoms, evaluating the safety of 
the individual and significant others, providing education about the disorder, 
establishing a therapeutic alliance with the individual, providing support and care, 
providing advice and recommendations regarding the treatment options available, 
monitoring treatment response, enhancing treatment compliance, evaluating and 
managing any impairments associated with the condition, and preventing relapse. 
Pharmacological treatments 
Broadly, the class of drugs usually prescribed to treat depression are called 
antidepressants. Since their first use in the 1950s, antidepressants have become the 
treatment of choice for depression, with 78% of people presenting to GPs for 
depression in Australia being prescribed these medications (Britt et al., 2001). 
Antidepressant medications available include tricyclic antidepressants (TCAs), 
monoamine oxidase inhibitors (MAOIs), reversible monoamine oxidase inhibitors 
(RIMAs), tetracyclic antidepressants (TECAs), selective serotonin reuptake 
inhibitors (SSRIs), serotonin and noradrenalin reuptake inhibitors (SNRIs), and 
noradrenergic and specific serotonergic antidepressants (NaSSAs). Within most of 
the groups there are chemical/generic subgroupings, and within each of those, 
several brands available. Each of the antidepressant medication groups has its own 
specific route of action, therapeutic effect on target symptoms, and side effects 
(Alchin & Tranby, 1995; Austin & Mitchell, 1998; BeyondBlue: The National 
Depression Initiative, 2002; N. Buckley, Whyte, Dawson, McManus, & Ferguson, 
1995a; P. Ellis & Smith, 2002; MIMS Australia, 2002; Mitchell, 1999). Further 
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discussion of specific antidepressant medications can be found later in this literature 
review (see Antidepressants, page 78). 
In reviewing the evidence as to the effectiveness of antidepressants, Norman et al. 
(2004) found that controlled clinical trials of antidepressant medications showed 
effectiveness rates (i.e. significant clinical improvement) of 70-80%, irrespective of 
the aetiology of the depression. Broadly speaking, the various classes of 
antidepressant were equally effective as one another, though on an individual level 
there may have been marked differences in the level of improvement, depending on 
the medication used. These findings contrast with a review of studies submitted to 
the U.S. Food and Drug Administration for antidepressant approval which concluded 
that while there was a significant difference between various antidepressant 
medications and inert placebo, this difference was very small and unlikely to be of 
clinical significance (Kirsch, Moore, Scoboria, & Nicholls, 2002). However, the 
authors also indicated that this finding assumed that the medication and placebo 
effects were additive. If the true medication effects were in fact greater than the 
difference between the apparent medication effect and the placebo response, then the 
clinical significance of the difference would also be greater. Kirsch et al. (2002) 
suggested that drug trials incorporating balanced placebo designs could be used to 
answer this question. 
In the absence of a personal or first degree relative history of antidepressant use, it 
may be difficult to predict which type of antidepressant will be the most effective for 
an individual and therefore Norman et al. (2004) suggested that this choice be made 
on the basis of the potential side effects and risk profile (for example, avoid highly 
toxic antidepressants in those at-risk of overdose). Similarly, while there are 
recommended dose ranges, the specific amount to be taken needs to be titrated 
according to the individual response (Norman et al., 2004). Emerging work in the 
area of pharmacogenetics may assist in better matching individuals to medications by 
identifying inherited susceptibility to negative side effects and in selecting the 
medication most likely to have a therapeutic effect for a particular individual 
(Kennedy, Rogers, & Joyce, 2004). 
Where an effective antidepressant has been selected, it has been suggested that the 
sleep and appetite disturbances associated with depression should begin to improve 
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within about two weeks of commencing antidepressant treatment (Norman et al., 
2004). Symptoms relating to agitation, anxiety, depressed mood and hopelessness 
should lift next, while energy levels, concentration, libido and helplessness improve 
last. Some antidepressants may not achieve their full effect for up to eight weeks 
(Norman et al., 2004). If an antidepressant is found to work, it has been 
recommended that treatment be continued for at least 12 months, or the length of any 
previous episode, if that is longer (Norman et al., 2004). If an antidepressant does not 
work, it may be that the dose is too low or being taken incorrectly. Otherwise it may 
be appropriate to change the antidepressant prescribed, although care needs to be 
taken to observe any recommended washout period (Norman et al., 2004). 
Psychological treatments 
Despite the widespread prescription of antidepressant medication by GPs, a growing 
trend towards the provision of psychological counselling by the GP, or referral of 
patients to specialist counselling services has also been noted (Britt et al., 2001). An 
Austrlaian study found that counselling occurred in 41% of GP visits relating to 
depression, and this is increasing over time (Britt et al., 2001). 
Numerous therapeutic approaches may be applied in dealing with depression, 
including psychodynamic therapy, interpersonal therapy (IPT) and cognitive 
behavioural therapy (CBT) (McKenzie, Carter, & Luty, 2004). Psychodynamic 
therapy is based on psychoanalytic theories (e.g. Freud, Klein, Bibring), which 
emphasise the importance of early experiences of loss and attachment in the 
development of depression. According to McKenzie (2004), therapy of this type 
involves an assessment phase, during which the practitioner listens, endeavours to 
establish a therapeutic alliance, and, along with the client, identifies the problem. 
The process of clarifying the problem with the client is intended to assist the 
individual in gaining further insight about his or her circumstances. Finally, this form 
of therapy utilises the relationship between the client and the therapist to recreate 
significant issues stemming from earlier in life with a view to resolving them in the 
present (i.e. transference). 
Interpersonal therapy focuses on the immediate social environment of the individual, 
and the role of this in precipitating and maintaining depression (McKenzie et al., 
2004). That is, chronic social stress is associated with the onset of depression, while 
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socially supportive relationships are protective against it (e.g. Meyer, Bowlby). 
Rather less emphasis is placed on determining early life origins of present difficulties 
in interpersonal therapy than in psychoanalytically oriented therapies. As with 
psychodynamic therapy, IPT begins with an assessment phase, although this mainly 
focuses on current functioning and relationships. Therapy then concentrates on 
improving interpersonal functioning in relation to specific problem areas, with the 
idea that depression will lift as functioning improves. 
Cognitively oriented therapies such as CBT are based on the view that behaviour is 
partly determined by cognitions (e.g. Beck) (McKenzie et al., 2004). Therapeutic 
approaches based on a cognitive theoretical orientation assume that cognitive 
processes are “accessible and modifiable” (Fremouw et al., 1990, p. 112). The task 
of therapy is to encourage awareness of the link between cognition and emotion and 
modify those cognitions that do not contribute to the emotional wellbeing of the 
person via self-statements, behavioural homework, and a range of other tasks. For 
example, according to cognitive theory, having a negative schema is characteristic of 
depression, and the task of therapy is to reactivate a set of positive schemata. This 
reactivation is achieved through identifying the automatic thoughts and rules that 
reinforce the negative schema and working to alter these thoughts and rules (Gilbert, 
1992). This approach has been used in relation to a range of disorders, including 
depression, anxiety, anger, stress, chronic pain, eating disorders, and suicidal 
behaviour. 
Research results concerning the efficacy of different psychological treatments have 
been equivocal. Study limitations have included differences in the severity of 
depression of study participants, difficulty in distinguishing treatment types (i.e. 
overlap between modalities), and problems with ensuring the rigorous application of 
the treatment under investigation. Despite these limitations, reviews of research in 
the area have tended to support the efficacy of psychologically based treatments. 
Several studies have demonstrated psychological therapies such as CBT and IPT to 
be effective in the treatment of depression (Gilbert, 1992; Mitchell, 1999). A recent 
Cochrane review investigating the efficacy of structured psychosocial interventions 
delivered by GPs found there was promising evidence for problem solving training in 
reducing depression (Huibers, Beurskens, Bleijenberg, & van Schayck, 2003). In 
reporting on various meta-analytic studies of psychologically based treatments, 
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McKenzie (2004) concluded that there is not a great deal of difference in efficacy 
between psychotherapy, IPT and CBT; they are all about as effective as each other, 
and at least as effective as antidepressant medication. 
The efficacy of psychological treatments may partly depend upon the severity of the 
illness. Mild to moderate depression has been shown to respond equally well to 
either medication or strategies such as CBT, but severe depression may not improve 
with counselling alone. Combining pharmacological and psychological treatment has 
been found to be more effective in cases of severe depression (McKenzie et al., 
2004). 
Regardless of therapeutic orientation, it has been found that the therapeutic alliance 
is of crucial importance and the competence of the practitioner a key factor in 
treatment outcome (McKenzie et al., 2004). As for pharmacological treatments, it 
may be that some individuals are better suited to some therapeutic strategies than 
others, though there is no clear evidence about this yet. 
Length of treatment 
It has been suggested that continuing treatment (whether pharmacological or 
psychological) for at least 4-6 months post remission of depressive symptomatology 
may help in reducing relapse to depression (McKenzie et al., 2004). With regard to 
pharmacological treatments, a review of over 40 years of research evidence 
concluded that continued treatment post remission was consistently superior to 
placebo (Mulder, 2004). 
Other treatments 
There are several other treatments that have been used for depression, though less 
commonly, and often with a less comprehensive evidence base. Jorm et al. (2002) 
conducted a systematic review of the literature concerning the effectiveness of 
complementary and self-help treatments for depression.  Treatments reviewed were 
divided into four categories; medicines (e.g. ginko biloba, glutamine, homoeopathy, 
St John's wort, vitamins), physical treatments (e.g. acupuncture, light therapy, 
massage), lifestyle (e.g. bibliotherapy, exercise, meditation, relaxation, yoga), and 
dietary change (e.g. alcohol avoidance, fish oil, sugar avoidance). A full description 
of each of these treatment types is beyond the scope of this literature review, but in 
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summary, when compared with standard treatments such as antidepressant 
medication and CBT, there was evidence for the efficacy of some alternative 
treatments for mild to moderate depression. The authors concluded that interventions 
with the best evidence were St John's wort, exercise, bibliotherapy, and light therapy, 
and that interventions with some evidence included acupuncture,12 massage, folate, 
and yoga. However, these treatments were not demonstrated to be as effective as 
conventional treatments, though the authors cautioned that the lack of evidence may 
have been due to insufficient large scale studies into alternative treatments, rather 
than the treatments not working. 
Below is further information regarding two other treatments for depression, 
electroconvulsive therapy, and St John’s wort. These are included here because they 
are well known treatments, both of which have been the subject of considerable 
research. 
 Electroconvulsive therapy (ECT) 
This treatment modality involves inducing a fit or convulsion in the patient by 
administering an electrical charge to the patient. It has been theorised that the 
anticonvulsant response triggered in the brain by inducing the convulsion assists in 
modifying the affective state of the individual (Tiller, 2004). 
Electroconvulsive therapy is generally only considered in very severe cases of 
depression that do not appear to respond to other forms of treatment, or where there 
is a significant threat of suicide. Treatment delivery may vary on a number of 
dimensions, including placement of the electrodes (unilateral, bilateral, or frontal), 
different waveform patterns, and frequency and duration of treatment. Recent 
improvements have also been made in terms of the anaesthesia and muscles relaxants 
provided, and pre-oxygenation of patients to prevent hypoxia. The therapy is 
generally delivered as a series of treatments (2-3 per week for several weeks); though 
in some instances longer-term maintenance treatments may be deemed necessary 
over 6-12 months. Side effects are mainly cognitive in nature and include confusion, 
impairment of autobiographical memory, and difficulties with speech (particularly 
                                                          
12 A recent Cochrane review (Smith & Hay, 2004) concluded that there was insufficient evidence to determine 
whether acupuncture was an effective or ineffective treatment modality for depression. 
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word finding and expression). However, it has been argued that these side effects are 
generally mild and transient (Tiller, 2004). 
In reporting on the previous research literature, including a systematic and meta-
analytic review, Tiller (2004) concluded that ECT was consistently found to be more 
effective than pharmacotherapeutic treatments for depression, and in most studies 
there was a lower rate of mortality among those treated with ECT than those not. 
However, it was also suggested that many patients who could potentially benefit 
from ECT were reluctant to receive it. 
Electroconvulsive therapy is a relatively rare from of treatment. In the state of 
Victoria in 1998-99 there were only 44 people treated per 100,000 resident 
population (age adjusted rate), three quarters of these with a diagnosis of depression 
(Wood & Burgess, 2003). The treatment was more commonly used among women 
and older people. 
 St John’s wort 
St John’s wort (botanical name Hypericum perforatum L) is a flowering herb used to 
alleviate depression, anxiety, and sleeping difficulties. A recent Cochrane review of 
37 studies investigating the effectiveness of St John’s wort in treating depression 
concluded that there is some evidence for the usefulness of this plant (Linde, 
Mulrow, Berner, & Egger, 2005). The herb appeared to be more effective than 
placebo, and about as effective as antidepressants in treating mild to moderate 
depression. However, it was not found to be a useful treatment for severe depression. 
The authors cautioned that the content of St John’s wort preparations may vary 
considerably from product to product, and therefore that the results only applied to 
those specifically tested. St John’s wort was also found to interact with conventional 
antidepressants and therefore should not be taken concurrently with such 
medications. 
Factors limiting treatment efficacy 
Various factors have been found to make treatment, especially psychologically-based 
treatment, less effective. These factors included severity of the illness, delusions, 
lack of insight, lack of motivation to change, and inability to relate to others (Gilbert, 
1992; McKenzie et al., 2004). In addition, life factors outside treatment, such as 
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stressful events and a low level of social resources have been related to relapse 
(Moos, 1991). It has also been argued that due to the lack of detail in diagnostic 
systems, treatments may not necessarily be that well targeted to specific subtypes of 
depression, and that some forms of treatment may be more appropriate than others 
for particular types of depression (Parker, 2004). For example, it has been said that 
mild depression may respond well to psychotherapeutic interventions alone, 
moderate to severe depression is better treated by medication in combination with 
psychotherapy, and that electro-convulsive therapy may be suitable for very severe 
depression (Norman et al., 2004) 
Relapse 
Depression may be regarded as a recurring condition. It has been found that among 
those in their first episode, more than half have a recurrent episode, for those in their 
second episode, the likelihood of a subsequent episode is over 80%, and from the 
third episode onwards, the odds of further episodes exceeds 90% (Joyce, 2004b). A 
review of long-term outcome studies involving mainly inpatient samples found that 
between 10-20% of participants continued to experience chronic depression without 
remission, although symptom severity fluctuated (Mulder, 2004). Of the remainder, 
70-80% experienced at least one, and sometimes several, recurrences within 5 years. 
Over a 10-year period only about a fifth of those who had an episode of depression 
demonstrated sustained recovery (Mulder, 2004).13 While this may seem a bleak 
outlook, it has been suggested that maintaining treatment and encouraging people to 
identify warning signs and to seek help early may assist in reducing the chance of 
recurrence, or at least, minimising the severity of subsequent episodes (Joyce, 
2004b). 
A Danish study that investigated relapse among people who had a psychiatric 
inpatient admission for depression found that the likelihood of relapse and re-
hospitalization increased with the severity of the index episode of depression, such 
that those diagnosed with severe depression were at 1.7 times the risk of relapse than 
those with mild depression at the first episode (Kessing, 2004). Likewise, those with 
                                                          
13 These figures were based on inpatient samples likely to have severe depression. The evidence relating to first-
episode, outpatient samples suggested marginally better outcomes. 
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severe depression were also more likely to subsequently commit suicide (2%) than 
those with mild depression (0.5%).14 
Treatment resistant depression 
There are a very small number of people who show no symptom improvement in 
response to standard pharmacological or psychological treatments for depression, 
and a greater number who have only a partial or short-lived improvement. It has been 
reported that approximately 10% of patients treated for depression show no 
improvement within a year, and an additional 10-20% show only some improvement 
(Joyce, 2004b). In such instances it has been argued that good clinical management 
dictates a review of the initial diagnosis (including exclusion of other conditions that 
may explain the symptoms such as hyperthyroidism or diabetes), a review of the 
adequacy of the treatment (for example, antidepressant type or dose, or effectiveness 
of psychotherapy), a review of comorbid disorders such as anxiety, anorexia nervosa, 
and personality disorders with a view to addressing these, and finally, reassessment 
of the social environment of the individual, which may also hinder treatment 
progress (Joyce, 2004b). In cases where improvement does not occur even after 
review, it has been suggested that the focus of treatment be shifted from the idea of 
attaining symptom improvement in the short to medium-term, to teaching the 
individual strategies to cope with ongoing chronic depression. This could include 
strategies such as daily activity planning and mild exercise, though continued 
attempts with conventional treatments have also been recommended (Joyce, 2004b). 
Some cases of chronic, apparently treatment-resistant depression spontaneously 
remit after many years (Parker, Anderson, & Haddad, 2003). 
Prevention 
A recent Cochrane review examined the evidence base for psychological (skills 
based) and educational (information only) interventions intended to prevent 
depression among children and adolescents (Merry, McDowell, Hetrick, Bir, & 
Muller, 2004). The review considered universal and targeted interventions that aimed 
to reduce immediate depressive symptomatology or to prevent the onset of 
depression. The review found that studies done to date were problematic (e.g. 
                                                          
14 The findings of this study were based on survival analysis rather than an equal follow-up period for each case. 
Therefore cases included in the study had observation periods ranging from 1 day to 6 years. 
 38
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
inadequate blinding to treatment condition, insufficient investigation of the effects of 
booster sessions), and that further research was required. However, the authors 
tentatively concluded that there was some evidence for the short-term efficacy of 
psychological interventions in reducing depression within a one year time frame, and 
that the potential of educational interventions warranted further investigation. 
1.1.7 Summary 
Depression is a mood disorder characterised by feelings of sadness and loss of 
pleasure or interest in normal activities. Other physical, cognitive, and emotional 
symptoms may be apparent such as changes in appetite and sleep patterns, reduced 
levels of energy, feelings of guilt, and difficulty concentrating. The condition makes 
a significant contribution to the global burden of disease: Australian data suggests 
that 15% of the population will suffer from depression at some point in their lives, 
and up to 5% at any one time. Depression commonly co-exists with other conditions, 
particularly anxiety and substance use. A number of risk factors for depression have 
been identified, including neurobiology, gender, familial characteristics, personality, 
SES, stress, substance use, and sexual orientation. Currently used treatments for 
depression include pharmacotherapies and psychological counselling. There is 
evidence to suggest such treatments are moderately effective, though depression may 
remit without treatment. Recurrence of depression is common. 
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1.2 Suicidality 
1.2.1 Definition 
As with depression, suicide and suicidal behaviour have been noted throughout 
recorded human history (Fremouw et al., 1990). Suicide and related behaviours have 
been variously defined in the literature and there does not appear to be any 
commonly agreed upon terminology in research or clinical practice (De Leo, Burgis, 
Bertolote, Kerkhof, & Bille-Brahe, 2006; Graham, Reser, Scuderi, Smith, Turley, & 
Zubrick, 1999; Maris, Berman, & Silverman, 2000; Nock & Kessler, 2006; 
O'Carroll, Berman, Maris, Moscicki, Tanney, & Silverman, 1997). At the broadest 
level it appears useful to distinguish between completed suicides, non-fatal suicidal 
behaviour, and suicidal ideation or thought. There is some difficulty in encapsulating 
the varying aspects of suicidal behaviour; for example, whether or not physical harm 
actually occurred, and how strong the intention was to die. The study of such 
behaviours is called suicidology, and as Maris and colleagues state; 
“Suicidology includes not only completed suicide and non-fatal attempted 
suicide but also partial self-destruction, suicidal gestures and ideation, 
parasuicide…, deliberate self-harm, self-mutilation and a panorama of related 
self-destructive behaviours and attitudes.” (Maris et al., 2000, p 4). 
In this thesis, the term “suicidality” will be used as a global term to encompass 
actively suicidal behaviour, suicidal behaviour with ambiguous intent, and suicidal 
thought of varying degrees of intensity. 
Completed suicide 
It has been proposed that there are three essential elements of completed suicide; (i) 
death from injury, poisoning or suffocation, (ii) self-infliction, and (iii) some degree 
of intent to kill oneself, although this intention may be somewhat ambivalent and 
changeable over time (O'Carroll, Berman, Maris, Moscicki, Tanney, & Silverman, 
1996). It has been argued that it may be difficult to determine whether a death was 
actually a suicide; the first two elements are usually clear, but intention may be very 
hard to determine after the fact (Maris et al., 2000). A fourth element has also been 
added such that suicide can be indirect or passive (Maris et al., 2000). 
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Non-fatal suicidal behaviour 
There are several terms for an apparent suicide attempt that does not result in death. 
The term attempted suicide is popularly applied to these circumstances. However, it 
is important to maintain a distinction between suicide-related behaviours where the 
actual intention is to die, and circumstances in which there is a notion or idea of self-
killing, but no intention to actually do so (O'Carroll et al., 1997). The term 
parasuicide is also fairly widely used and has the advantage of not making any 
reference to the intent of the person and can therefore be employed in situations 
where a person denies intent or is unclear about their intentions. This term has also 
been favoured by some writers because it is regarded as non-pejorative (Fremouw et 
al., 1990; Graham et al., 1999). Another commonly used phrase is deliberate self-
harm. Again, this does not assume that the person has a clear and unambiguous 
intent to kill themselves, however its limitation is that it does not distinguish 
instances of self-mutilation that do not involve any intent to die (Graham et al., 
1999). A further suggestion is the term non-fatal suicidal behaviour (De Leo et al., 
2006; O'Carroll et al., 1997). The latter two terms are used throughout this thesis. 
Self-destructive behaviour may also be included under the general umbrella of 
suicidality, although there may be no intention to hurt one’s self. Smoking, drug 
and/or alcohol use, risky sports, hazardous occupations, eating disorders, medical 
non-compliance, and an almost infinite range of other human activities may be 
regarded as potentially self-destructive. Most people would see such behaviours as a 
normal part of human experience and not necessarily related to suicide at all (Maris 
et al., 2000). 
Suicidal ideation 
Suicidal ideation is when a person entertains the thought of self-killing, but does not 
necessarily act upon those thoughts and may have little or no intention to die 
(O'Carroll et al., 1997). Many people in the general community experience a degree 
of suicidal ideation at some point in their lives (Lewinsohn, Rohde, & Seeley, 1996). 
However, ideation may vary in intensity and duration, and a positive relationship has 
been found between the frequency and intensity of ideation and suicide attempts 
(Lewinsohn et al., 1996; Mann, Waternaux, Haas, & Malone, 1999). 
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Relationship between suicidal ideation, non-fatal suicidal behaviour and completed 
suicide 
Theorists differ as to whether the various behaviours described above lie on a 
continuum of suicidality, with completed suicide as the most extreme. There are 
some who argue for the continuum model (Lewinsohn et al., 1996), while others 
regard different suicidal behaviours as overlapping, but distinct (Hawton & Catalan, 
1987; Maris et al., 2000). 
It has been suggested that there are differences in the characteristics of those who 
think about suicide, those who attempt suicide, and those who actually kill 
themselves by suicide; 
“There are many important differences between completed suicides and 
non-fatal suicide attempts. Some of these differences include the method 
used, the number of suicide attempts, sex, age, the site of the self-injury, 
interpersonal dynamics, leaving a suicide note, physical health and social 
isolation – just to mention a few. The psychodynamics, motivation and 
intent, for example, of fatal and non-fatal suicide attempts are often quite 
different”. (Maris et al., 2000, p 5). 
To determine the overlap in the different behaviours it is useful to consider the 
relationship between suicide attempts and completed suicide. 
Many of the same factors are characteristic of both attempted suicide and completed 
suicide (see Other Risk Factors, page 54), but it is also of interest to know how well 
a history of suicidal behaviour predicts subsequent death by suicide. Despite the 
difficulty in ascertaining the rate of either behaviour it has been estimated that 10-
15% of people who make a suicide attempt subsequently kill themselves (Maris et 
al., 2000). Therefore most people who make one or several suicide attempts 
eventually die from other causes, and about two-thirds of those who make a non-fatal 
suicide attempt never make another (Fremouw et al., 1990). Similarly, completed 
suicide is not necessarily characterised by a history of suicidal behaviour. In a review 
of the literature Lewinsohn (1996) indicated that between a third and a half of all 
people who completed suicide had previously made an attempt, that is, 
approximately 70% of cases of suicide died at the first attempt (Lewinsohn et al., 
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1996; Maris et al., 2000). Intensity of ideation has been found to be predictive of 
attempts after one year (Lewinsohn et al., 1996). 
Completed suicides are more likely to involve the person taking precautions against 
being discovered and therefore saved during the suicidal act, whereas non-fatal 
suicidal behaviour more often occurs in circumstances where discovery and 
intervention are likely (Fremouw et al., 1990). However, evidence has been found to 
suggest that people who had previously self-harmed are not only at increased risk of 
subsequent death by suicide compared to the general community, they are also at 
increased risk of premature mortality from other accidental and natural causes (i.e. 
non-suicide factors) (Carter, Reith, Whyte, & McPherson, 2005a; Reith, Whyte, 
Carter, McPherson, & Carter, 2004). 
1.2.2 Prevalence/incidence 
Issues in estimating prevalence/incidence 
The prevalence of suicide and suicide-related behaviours may be estimated from a 
range of sources such as coronial reports, hospital admissions data, and population 
surveys. However, several factors have been implicated in the under-reporting of 
these behaviours including stigma associated with suicide, difficulty of determining 
the intent of a deceased person, and variable coding practices (Australian Institute for 
Suicide Research and Prevention, 2003; Hassan, 1995; Moscicki, 1995; Steenkamp 
& Harrison, 2000). 
The Australian Bureau of Statistics (ABS) collates death data to provide overall 
death statistics for the nation and currently uses the International Classification of 
Diseases (ICD-10) as the basis for coding. It is likely that statistics produced by the 
ABS have somewhat underestimated the true number of deaths by suicide, as some 
cases were still before the Coroner at the time the relevant annual data were 
compiled, and may have therefore been classified as having accidental, ill-defined, or 
unspecified causes of death, though the subsequent coronial finding may have been 
one of suicide (Australian Bureau of Statistics, 2006b). Further, ABS statistics have 
related to the number of suicides registered in any given year, rather than those 
actually occurring in that year. Approximately 7% of cases each year are carried into 
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the following year (Australian Bureau of Statistics, 2006b; Steenkamp & Harrison, 
2000). 
Non-fatal suicidal behaviour is possibly even more difficult than completed suicide 
to accurately measure. Hospital admissions data have been plagued by the same 
coding issues as death data, especially if the degree of intent was not clear. 
Furthermore, not all people who engaged in non-fatal suicidal behaviour necessarily 
present for medical treatment (Baume & McTaggart, 1998; Graham et al., 1999; 
Hillman, Silburn, Green, & Zubrick, 2000). Population surveys which include 
questions on suicide-related thoughts and behaviour may offer more complete 
capture, but rely upon retrospective self-report which may be subject to change over 
time (Cantor & Neulinger, 2000). 
Completed suicide 
The World Health Organisation (WHO) estimated that 814,000 people died by self-
inflicted injuries worldwide in 2000 and further, that suicide was one of the three 
leading causes of death in people aged 15-34 years (World Health Organisation, 
2001).15 Suicide has been found to account for 2.2% of all deaths worldwide 
(Australian Institute for Suicide Research and Prevention, 2003). At a global level, 
the age standardised rate of suicide was estimated to be 15.1 deaths per 100,000 
(24.0 for males and 6.8 for females) (World Health Organisation, 2001). Australia 
was placed 31st out of 99 countries for which suicide statistics were available (World 
Health Organisation, 2006b). It has been cautioned that variable reporting practices 
worldwide limit the reliability of international comparison, and also that figures for 
all countries were most likely to be underestimates, though to differing degrees 
(Australian Institute for Suicide Research and Prevention, 2003). 
The rate of suicide increased in Australia between the mid sixties and the mid 
nineties, and declined from the late nineties onwards (Australian Institute for Suicide 
Research and Prevention, 2003). The ABS reported that 1.6% of all deaths registered 
in Australia during 2004 were suicide,16 accounting for 2,089 individuals (Australian 
                                                          
15 Along with transport accidents and all cancers. 
16 Suicide was defined as a death “recognised as due to other than natural causes and established by a coronial 
inquiry that death results from a deliberate act of the deceased with the intention of taking his or her own life.” 
(Australian Bureau of Statistics, 2006b, p. 15) 
 44
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
Bureau of Statistics, 2006b). Suicide was the most common cause of death by injury 
in Australia in 2002, accounting for 30% of all such deaths (Kreisfeld, Newson, & 
Harrison, 2004). Seventy-nine percent of suicide deaths were male. The age-
standardised rate of suicide in 2004 was 16.8 per 100,000 for males and 4.3 per 
100,000 for females (10.4 per 100,000 overall). These figures were consistent with 
those from 2002 (Kreisfeld et al., 2004). The proportion of all deaths attributed to 
suicide varied with age, with suicide accounting for more than 20% of deaths among 
people aged 20-34 (though the age bracket with the highest number of deaths for 
females was 45-49 at a rate of 7.1 deaths per 100,000) (Australian Bureau of 
Statistics, 2006b). Differences according to age and gender are discussed in further 
detail in the section regarding ‘Other risk factors’, page 54. 
Non-fatal suicidal behaviour 
Non-fatal suicidal behaviour may occur at a rate of up to twenty times that of fatal 
suicidal behaviour (Australian Institute for Suicide Research and Prevention, 2003). 
In the 2001-2002 financial year there were over 330,000 cases of hospitalisation for 
injury and poisoning in Australia, and 7% (22,530 cases) of these were intentionally 
self-inflicted (Berry & Harrison, 2006). More females than males were hospitalised 
in this period (13,618 cases compared to 8,911, or 140.3/100,000 compared to 
92.3/100,000). An estimated 1% of all such hospitalisations in 1997/98 resulted in 
death, and these cases accounted for about 10% of all suicide deaths (Steenkamp & 
Harrison, 2000). 
Data on hospitalisations necessarily underestimate the true rate of self-harm in the 
community because they only take into account those patients who are admitted. 
Many more people may be treated by ambulance officers, in an ED, or by a GP 
without being hospitalised, and a further unknown number may not seek any form of 
treatment. It is likely that the majority of suicide attempts receive no medical 
attention (De Leo et al., 2006). It has also been suggested that hospital separation 
data for self-poisonings may substantially underestimate true prevalence rates of 
suicidal behaviour, with more accurate estimates being obtained via clinical review 
of patient records (Rhodes, Links, Streiner, Dawe, Cass, & Janes, 2002), which may 
be a prohibitively time consuming exercise. 
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Another way of expressing data concerning the extent of non-fatal suicidal behaviour 
is the proportion of the population who report engaging in it. Data from the 
Australian National Survey of Mental Health and Wellbeing were analysed to 
estimate the cumulative incidence of suicide attempts within a 12-month time frame 
and over the lifetime (Pirkis, Burgess, & Dunt, 2000). Of the 10, 641 participants, 
0.4% reported having made a suicide attempt in the last 12 months, and 3.6% within 
their lifetime. Females outnumbered males over both time periods (Pirkis et al., 
2000). Retrospective reporting may have led to an underestimate of non-suicidal 
behaviour. 
In a community-based survey of over three thousand 15-24 year olds in the state of 
Queensland, 7% reported ever having made a suicide attempt (9% of females and 4% 
of males). Approximately 1% of young people reported having made a plan to kill 
themselves within a four-week period (Donald et al., 2001). A survey conducted of 
Year 10 and 11 students on the Gold Coast found 6.2% had deliberately self-harmed 
in the previous year, again with females outnumbering males, and the preferred 
methods being cutting and medication overdose (De Leo & Heller, 2004). Only 10% 
of those who deliberately self-harmed reported seeking hospital treatment. Slightly 
lower rates of ever inflicting deliberate self-harm were obtained in a Victorian 
survey of Year 10 students (5.1% overall, 6.4% of females and 4% of males) with the 
main methods used being laceration, poisoning, and deliberate recklessness (Patton, 
Harris, Carlin, Hibbert, Coffey, Schwartz et al., 1997). However, the authors 
estimated that only 0.2% had ever made a “true” suicide attempt, as in most cases the 
student had not planned the behaviour and did not see the death as a likely 
consequence. In a US non-clinical sample of 1,986 military recruits, 4% reported a 
history of deliberate self-harm with no suicidal intent (Klonsky, Oltmanns, & 
Turkheimer 2003). 
Suicidal ideation 
In reviewing the evidence regarding the extent of suicidal ideation in non-clinical 
populations, Fremouw (1990) reported that between 24% and 80% of such 
populations have given suicide at least some consideration, although these estimates 
do not give any indication of the seriousness or intensity of those thoughts. A survey 
of the Australian population found a somewhat lower incidence, with 3.4% reporting 
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experiencing suicidal ideation in the last 12 months, and 16% over the course of their 
lifetime (Pirkis et al., 2000). Over both time frames more females than males 
reported suicidal ideation. Twelve percent of all respondents who reported suicidal 
ideation in the last 12 months acted on these thoughts by making an attempt (Pirkis 
et al., 2000). A third of the sample in a Queensland community-based survey of 
young people reported having had serious suicidal thoughts in their lifetime (Donald 
et al., 2001), while a South Australian study of 2,489 Year 8 students found 27% of 
females and 19% of males had ever experienced suicidal ideation (Allison, Roeger, 
Martin, & Keeves, 2001). It is not clear whether the higher rates of suicidal ideation 
found in the two studies involving young people (Allison et al., 2001; Donald et al., 
2001) compared with the general Australian population sample (Pirkis et al., 2000) 
reflected true differences, or a recall bias, whereby the general population group 
were less inclined to report earlier experiences of suicidal ideation with the passage 
of time. 
1.2.3 Theories of suicidality 
This section presents a brief summary of some of the major explanatory models for 
suicidal behaviour. 
Emile Durkheim was a French sociologist and one of the first people to study suicide 
scientifically. He compared rates of suicide in different social groups and developed 
a theory of suicide based on social typology (Durkheim, 1951 (1897)). His argument 
was that tendency to suicide was not only individually but socially determined. 
Durkheim proposed that there were four broad types of suicide; egoistic, altruistic, 
anomic and fatalistic, falling on two dimensions. Egoistic and altruistic suicides were 
regarded as opposite ends of the same pole and were characterised by social 
participation. Egoistic suicides were seen to occur in those social groups where there 
was an emphasis on individuality and a lack of social integration. In contrast, 
altruistic suicides were those which occurred in circumstances where there was a 
high sense of collectivism. Examples of altruistic suicide could include religious 
martyrs or Japanese kamikaze pilots. According to Durkheim, the second social 
dimension of suicide was that defined by the degree of social deregulation versus 
hyper-regulation, with anomic and fatalistic suicides falling on opposite ends of a 
spectrum. Those suicides occurring in the wake of a significant disruption to 
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normality, such as following a divorce or other stressful life event, were anomic. A 
suicide that occurred in circumstances of excessive regulation, such as imprisonment, 
was termed fatalistic (Durkheim, 1951 (1897); Hassan, 1995; Hassan; Maris et al., 
2000). 
In his interpretation of suicidal behaviour, Freud concluded that humans were subject 
to both life (eros) and death (thantos) wishes (Maris et al., 2000; J. Williams & 
Pollock, 2000). Freud argued that the act of suicide involved hostility or a death wish 
towards another person that the individual was unable to tolerate. Hostility was 
therefore seen to be redirected towards the self, that is, internalised and expressed as 
suicidal behaviour (Maris et al., 2000; J. Williams & Pollock, 2000). 
Further developing this theme, Menninger (1938, in Maris et al., 2000) described 
suicide as “murder in the 180th degree”. He proposed three aspects of suicide: hate, 
depression, and guilt. Suicide was therefore seen to have three functions; revenge (a 
wish to kill), depression/hopelessness (a wish to die), and guilt (a wish to be killed) 
(Maris et al., 2000; J. Williams & Pollock, 2000). 
Beck’s conceptualisation of suicidal behaviour shared the strong focus on cognition 
evident in his work on depression (G. Brown, Jeglic, Henriques, & Beck, 2006). 
According to Beck, cognitions about and interpretations of events had a large role in 
determining an individual’s emotional and behavioural responses to those events 
(including suicidal responses). Beck’s theory of hopelessness suggested that 
cognitive distortions led some people to view their current circumstances as 
untenable, to be pessimistic about the future, and to assume any effort they might 
make to change things for the better to be doomed to failure. Such thinking was seen 
to contribute to suicidality (G. Brown et al., 2006). 
Schneidman argued that most suicides were caused by psychological pain, which he 
termed “psychache” (Jobes & Nelson, 2006; Maris et al., 2000; Schneidman, 1996). 
This pain was regarded as stemming from thwarted or distorted psychological needs, 
and the desire to stop the pain led to suicidal action. He identified five main clusters 
of psychological need which when thwarted or frustrated led to psychological pain: 
needs for love, acceptance and belonging, needs for achievement, autonomy, order 
and understanding (i.e. control), avoidance of assaulted self-image (shame, defeat, 
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humiliation, and disgrace), avoidance of disruptions to key relationships and grief, 
and needs for dominance, aggression, and counteraction. 
Schneidman further identified ten elements common to all suicides: the purpose of 
suicide was to seek a solution, the goal was cessation of consciousness, the stimulus 
was unbearable psychological pain, the stressor was frustrated psychological needs, 
the emotion felt was hopelessness-helplessness, the cognitive state was one of 
ambivalence (individuals would be happy not to do it if they did not "have to"), the 
perceptual state was one of constriction where the individual saw a restricted range 
of options, the action was escape, the interpersonal act was communication of intent, 
and the pattern was consistency of lifelong styles (e.g. escape from problems) 
(Schneidman, 1996). 
Similar to the “psychache” model proposed by Schneidman, was the “cry of pain” 
model articulated by J. Williams (2000, 1997). According to this model when a 
person felt both defeated by their situation (whether an external set of circumstances 
or an internal state), and did not believe there was any possibility of escape or rescue 
from that situation, a suicidal sequence may have been initiated. Suicidal behaviour 
was seen to be an attempt to re-establish a means of escape from the unbearable 
situation by way of protest. This model explicitly focused on the escape aspect of 
suicidal behaviour, which was seen to be elicited by the sense of entrapment. The 
behaviour was not seen to be primarily motivated by a desire to receive attention or 
help, although this may have been a secondary consequence (J. Williams & Pollock, 
2000; M. Williams, 1997). 
It has further been proposed that suicidal ideation commonly arises out of two 
wishes: to escape from the problems of life and to get revenge on others. These 
thoughts and feelings have been termed “transformation drives” and may be more to 
do with changing one’s current life circumstances than actually dying (Maris et al., 
2000). 
1.2.4 Means of suicide and non-fatal suicidal behaviour 
Suicide (and suicide attempts) can employ a range of mechanisms, the most common 
of which have been found to be hanging, poisoning (including drug overdose), and 
firearms (Kreisfeld et al., 2004). The relative occurrence of different means has 
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varied across cultures and by sex. For example, firearms have been more often 
implicated in suicides in places where they are readily available, such as rural areas 
or countries with less restrictive gun-ownership regulations such as the US 
(Moscicki, 1995), and females have been found to be more likely to attempt suicide 
via drug overdose than males. Thus, an individual’s choice of method varies 
according to their accessibility to and knowledge of the means. Naturally, the more 
lethal the means employed, the more likely that death is to occur, regardless of the 
level of intention (Cantor & Baume, 1998; Maris et al., 2000). 
In considering suicidal behaviour it is important not to confuse the lethality of the 
means chosen with intent to die. A person may in fact have a high level of intent, but 
unwittingly choose a less lethal method, or vice versa. This may be particularly 
pertinent in relation to drug-related overdose where the individual may have 
insufficient knowledge to calculate a lethal dose (Fremouw et al., 1990). 
Among completed suicides in Australia in 2004, the most common method was 
hanging, accounting for 48% of deaths. Poisoning by “other”, including motor 
vehicle exhaust, was responsible for 19% of deaths, poisoning by drugs for 11%, and 
firearms 8%. All other methods including drowning and jumping accounted for the 
remaining 14% of suicide deaths (Australian Bureau of Statistics, 2006b). These 
figures are consistent with those from 2002 (Kreisfeld et al., 2004). 
Alcohol and drug use can have a significant role in suicide, either as a precursor to 
suicidal behaviour, or as the agent. A recent investigation of completed suicides 
found that single substance suicides typically implicated alcohol and were more 
likely to involve males, younger people, and those currently employed using a 
violent means of death such as firearms, hanging, or jumping. In contrast, multiple 
substance suicides tended to involve prescription medications and were more typical 
of older people, females, those not currently in the workforce, and people who died 
as a consequence of poisoning (rather than any concurrent injury) (Oei, Foong, & 
Casey, 2006) 
Much the same methods are used in non-fatal suicidal behaviour as in fatal, though 
the distribution differs greatly. During 2001-2002 in Australia, of the 22,530 cases of 
intentional self-harm resulting in hospitalisation, 85% were caused by self-poisoning 
and the majority of those cases involved females (Berry & Harrison, 2006). Eleven 
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percent of the hospitalisations resulted from self-harm using a sharp object, less than 
2% from hanging, strangulation or suffocation and less than 1% from a firearm 
wound. Those three methods were all more common among males than females 
(Berry & Harrison, 2006). Among the self-poisoning cases, the most common 
substances ingested were psychotropic medications such as benzodiazepines, 
antidepressants, antipsychotics, and non-opioid analgesics. Other forms of self-
poisoning were relatively rare with 2% of poisonings being attributed to gases and 
vapours (such as motor vehicle exhaust), and less than 1% involving the ingestion of 
pesticides (Berry & Harrison, 2006). A study in Oxford, England found a similar 
proportion (87%) of people presenting to hospital for deliberate self-harm had self-
poisoned as in the Australian study (Townsend, Hawton, Harriss, Bale, & Bond, 
2001). 
1.2.5 The relationship between suicidality and mental health problems 
One of the greatest risk factors for suicidal thought and behaviour is psychiatric 
illness. In particular, a considerable body of evidence has demonstrated that people 
with mood disorders are at elevated risk of attempted and completed suicide 
(Goldney, 2004; Hazell, 2004). This section examines the relationship between 
suicidality and some common mental health problems. 
Completed suicide 
Overall, psychiatric illnesses have been found to be present in 90-100% of suicide 
cases (Murphy, 2000). It has further been suggested that such problems are often 
insufficiently treated or unrecognised, thereby contributing to an untimely death 
(particularly depression in males) (Isacsson, Holmgren, Druid, & Bergman, 1999). 
Reviews of clinical studies of the mental health risk factors for suicide have varied 
somewhat in their estimates due to differences in the samples used, definitions 
employed, and study designs. However, it has been found that major depression, 
alcohol or other substance dependence, personality disorders, and schizophrenia are 
all over-represented among completed suicides relative to their prevalence in the 
general population (29-88%, 25-55%, 3-58%, and 2-12% respectively) (Appleby, 
2000a; Linehan, Rizvi, Welch, & Page, 2000; Lonnqvist, 2000; Murphy, 2000). An 
Australian study found that people who used heroin were 14 times more likely than 
the general community to die by suicide (Darke & Ross, 2002). 
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Another way of looking at the relationship between mental health problems and 
suicide is to consider the proportion of people with a given psychiatric diagnosis who 
eventually commit suicide. Early studies involving hospitalised samples estimated 
that up to 15% of people with major depression eventually committed suicide. 
However, reviews of more recent studies involving less severely ill participants (i.e. 
community-based samples without comorbid conditions) produced far smaller 
estimates of 1-4% (Goldney, 2004; Hazell, 2004). Therefore, the vast majority of 
people who have depression will not commit suicide. Paradoxically, partial remission 
of depression has been associated with increased risk of suicide, as individuals 
become “well” enough to actually carry out a suicidal plan (Ferrier, 1999). It has 
been estimated that the lifetime risk of suicide for an individual with other 
psychiatric disorders is approximately 3% for alcoholism (Murphy, 2000), 7-8% for 
personality disorder (Linehan et al., 2000), and 10% for schizophrenia (De Hert & 
Peuskens, 2000). Pathological anxiety has also been linked to suicide and attempted 
suicide, most often as a comorbid condition, although it can act as an independent 
risk factor (Allgulander, 2000). 
Non-fatal suicidal behaviour 
Mental health problems are also more prevalent among people who have engaged in 
non-fatal deliberate self-harm than in the general population. Beautrias et al. (1996) 
found that mood disorders were the greatest contributing factor to serious suicide 
attempts. Among people who have attempted suicide, the estimated proportion who 
are depressed ranges from 35-79% (Goldney, 2004). Suicidal ideation in the absence 
of an actual attempt has also been related to depression, with about half of those 
depressed reporting suicidal thoughts (Goldney, 2004; Lonnqvist, 2000). A study of 
South Australian adolescents found a significant positive linear relationship between 
the severity of depression and ideation (Allison et al., 2001). There was a gender 
difference, with females being more likely to report suicidal ideation at only 
moderate levels of depression compared to males.  
Regarding substance use, it has been reported that 10-24% of males and 4-17% of 
females who attend hospital for deliberate self-harm have alcohol-related problems. 
The comparative figures for other substances are 12% and 6% respectively (Murphy, 
2000). A Norwegian study of people in treatment for drug dependence found 38% 
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had a history of suicide attempt, and 42% reported suicidal ideation in the previous 
month (Rossow & Lauritzen, 2001). It has been proposed that substance use may 
function as either a pre-disposing factor or precipitating factor to suicidal behaviour, 
and that intoxication may interfere with a person’s ability to resist impulse (i.e. 
disinhibition) (Fremouw et al., 1990; Rossow, 2000). Alcohol use has often been 
associated with suicide attempts (Rossow, Romelsjo, & Leifman, 1999), with one 
research review estimating that alcohol was used during a suicide attempt in about a 
quarter of cases and with men having a higher rate of alcohol use in such 
circumstances than women (Hawton & Catalan, 1987). The same review suggested 
that about half of men and a third of women who had overdosed indicated alcohol 
use in the six hours preceding the event (Hawton & Catalan, 1987). Nevertheless, it 
has been argued that that the overall number of substances used may be more 
important in the prediction of suicidal behaviour than the specific substance, with 
poly-substance use being found to be associated with greater risk (Borges, Walters, 
& Kessler, 2000). 
Studies of attempted suicide among people with a personality disorder have yielded 
estimates of 39-90% (Linehan et al., 2000). The personality disorder with which 
suicidal behaviour has been most commonly associated is borderline personality 
disorder; although this association is hardly surprising given that suicidal behaviour 
is one of the diagnostic criteria. People with a personality disorder were also found to 
be more likely to have recurrent suicidal behaviour than those without (Linehan et 
al., 2000). 
An Australian population-based survey found that anxiety, affective, and substance 
use disorders were all associated with both suicidal ideation and suicide attempts 
within the last 12 months, and were more prevalent in those with such a history than 
among the general population (Pirkis et al., 2000). The National Co-morbidity 
Survey conducted in the United States also found elevated rates of psychiatric illness 
among those who had self-injured (Nock & Kessler, 2006). This study found that 
mental illness was even more likely among those who reported intent to die at the 
time of self-injury, than those without intent to die. Another US study using a non-
clinical sample of military recruits found those with a history of deliberate self-harm 
(without suicidal intent) showed more symptoms of various personality disorders 
(borderline, schizotypal, dependent, and avoidant), anxiety, and depression than 
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recruits with no history of self-harm (Klonsky et al., 2003). This study used both self 
and peer-reported measures. 
1.2.6 Other risk factors 
It has been argued that while a psychiatric disorder is most usually a necessary 
condition for suicide and related behaviours, it is not a sufficient one (Mann et al., 
1999). Reviews have been conducted of studies into the other risk factors for suicide 
and attempted suicide (Beautrais, 2000; Fremouw et al., 1990; Graham et al., 1999; 
Hawton & van Heeringen, 2000). A further series of articles reported on the Houston 
Case-Control Study of Nearly Lethal Suicide which compared 153 patients 
presenting at three hospital EDs with a random sample of 513 community controls 
(Ikeda, Kresnow, Mercy, Powell, Simon, Potter et al., 2001; Kresnow, Ikeda, Mercy, 
Powell, Potter, Simon et al., 2001; Mercy, Kresnow, O'Carroll, Lee, Powell, Potter et 
al., 2001; Potter, Kresnow, Powell, Simon, Mercy, Lee et al., 2001; Powell, 
Kresnow, Mercy, Potter, Swann, Frankowski et al., 2001; Simon, Swann, Powell, 
Potter, Kresnow, & O'Carroll, 2001; Swahn & Potter, 2001). Several common 
psychological, biological, and social factors emerged, many of which are strikingly 
similar to the ‘Risk factors’ for depression outlined in the previous chapter (page 20). 
As for depression, factors thought to increase vulnerability to suicidality have been 
given particular attention in this literature review due to their relevance to the current 
research aims. 
The risk factors for completed suicide and other suicidal behaviour which does not 
result in death have been found to overlap considerably, although not completely. It 
has been suggested that self-harming behaviour extends from mild suicidal thoughts 
through to fatal action (van Heeringen, Hawton, & Williams, 2000). The 
characteristics described below may be regarded as risk factors for both completed 
suicide and non-fatal suicidal behaviour unless specifically noted otherwise. 
Most people will experience some, if not many of the risk factors outlined below 
during the course of their life and will not become suicidal. Therefore, the presence 
of these risk factors does not imply that a person is or will become suicidal, however, 
they have consistently been observed as characteristic of people who are suicidal. It 
is also possible that some factors (e.g. recent losses) have increased salience in the 
aftermath of a suicide, because they help explain why a person killed him or herself, 
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and are therefore thought of as causal despite the fact that many people do not 
become suicidal in similar circumstances (Beautrais, 2000). 
Biology 
As for depression, research into the biological factors associated with suicidality is a 
complex and emerging area. This review will only briefly mention some of the 
relevant findings. Family history of suicidal behaviour has been found to be 
predictive of suicide attempts, particularly violent attempts (Roy, Nielsen, Rylander, 
& Sarchiapone, 2000). One study found almost half of a sample with a relevant 
family history had attempted suicide. It appeared that this association was not simply 
due to a shared environment (though this of course may have been a highly relevant 
factor), as monozygotic twins showed a significantly greater concordance for both 
completed and attempted suicide than dizygotic twins (Baldessarini & Hennen, 
2004). Nor was the familial link thought to be due simply to the shared inheritance of 
psychiatric disorders associated with suicide, as the increased risk remained, even 
when psychiatric disorders were controlled for. Adoption studies have also indicated 
a genetic component to completed suicides (Roy et al., 2000). Molecular genetic 
research has provided further evidence for heritability of suicidal behaviour, with the 
function of an enzyme involved in the synthesis of serotonin being partly genetically 
determined (Roy et al., 2000). 
The research literature has indicated that abnormalities in serotonin levels are more 
common in people who attempt or complete suicide than in the general population 
(Beautrais, 2000; Traskman-Bendz & Mann, 2000). Other neurotransmitters, 
including noradrenalin, dopamine, GABA, and glutamate have also been found to be 
abnormal in suicidal populations. As noted previously, low levels of serotonin have 
been established as characteristic of depression, however, in depression the 
consequences of serotonin dysfunction were apparent in a broad range of effects such 
as impaired concentration, lowered libido, and depressed mood. Among suicidal 
people, the serotonergic dysfunction was centred in the ventral prefrontal cortex. 
Serotonergic dysfunction in this area was associated with disinhibition and poor 
impulse control, a characteristic also noted in aggressive behaviours. It appeared 
likely that this was an inherited trait (Traskman-Bendz & Mann, 2000). Both human 
and animal studies have suggested that there is an interaction between cholesterol, 
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serotonin, and aggression, and that low cholesterol levels may be associated with 
suicide and other violent deaths. Evidence has also been found to suggest suicidal 
behaviours are associated with hyperactivity of the HPA axis (Traskman-Bendz & 
Mann, 2000). 
Gender 
Worldwide, males have been found to be more likely to commit suicide than females 
at a ratio of approximately 3.5 to 1 (World Health Organisation, 2001). The over-
representation of men among completed suicides has held true through recorded 
history (M. Williams, 1997). In 2004 there were four times as many male suicides as 
female in Australia (Australian Bureau of Statistics, 2006b), consistent with the 
pattern over the entire twentieth century (Australian Institute of Health and Welfare, 
2006). However, it has been established that females are over-represented among 
people who attempt suicide relative to males (Fremouw et al., 1990; Graham et al., 
1999). It is likely that the observed gender difference was partly due to the preferred 
means, with males known to be more likely to select a highly lethal method of 
attempting suicide (e.g. gunshot wound) than females. A recent analysis of National 
Co-morbidity Survey data from the United States suggested that among those who 
had engaged in non-fatal self-injurious behaviour, males were more likely to report 
an intent to die, while females were more likely to report the behaviour was a means 
of communicating with others (Nock & Kessler, 2006). In a Danish study of relapse 
and suicide risk among patients hospitalized for depression, it was found that males 
were at 2.2 times the risk of subsequently committing suicide than females, although 
there was no difference between the genders in the severity of depression at the 
index episode (Kessing, 2004). There is debate as to whether the observed gender 
differences are inherent to each sex, or the consequence of differential socialisation 
of the sexes. A detailed sociological discussion of the relevance of gender to suicidal 
behaviour may be found in Hassan (1995). 
Age 
The rate of completed suicide varies across the lifespan, though the age distribution 
differs by gender. In Australia in 2004, suicide was most prevalent among males 
aged in their twenties and thirties (approximately 26 suicides per 100,000 deaths), 
and those aged over 75 (approximately 25 per 100,000) (Australian Bureau of 
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Statistics, 2006b). Among females, death by suicide was most prevalent for those 
aged 45-54 (6.4 per 100,000). There was less variation across the life span for 
females than for males, with the lowest rate being 3.9 per 100,000 for females aged 
55-64 (Australian Bureau of Statistics, 2006b). Suicidal ideation in the last 12 
months has been found to be more common among those aged less than 45 years 
than those who are older (Pirkis et al., 2000). 
In recent years there has been growing concern about the increasing rate of youth 
suicide (particularly male), with a trebling of the rate among 15-24 year olds from 
1964 to 1997, although this trend has since declined (Australian Institute for Suicide 
Research and Prevention, 2003; Australian Institute of Health and Welfare, 2006). 
Prior to 1964 suicide was more commonly regarded as a problem in older age groups 
(Hassan, 1995).  
It seems likely that the changing trends in suicide rates seen in Australia may not be 
due to particular age-groups (e.g. 25-29 year olds) having an increased risk. Rather, 
it has been argued that particular birth cohorts (i.e. people born within certain five-
year periods) appear to be at elevated risk and the increased suicide rate persists as 
the cohort ages (Steenkamp & Harrison, 2000). It has been suggested that increased 
unemployment, especially among young males, has contributed to increased suicide 
statistics (Hassan, 1995). This finding was consistent with the cohort hypothesis of 
suicide risk, as the consequences of prolonged unemployment (e.g. damage to self-
esteem, lack of job and financial security) may persist for several years, even after 
improvement in the overall economic climate. Interestingly, given the concerns 
regarding youth suicide, the 15-24 age group had the lowest death rate for males in 
2004 (13.8 per 100,000).  
Family factors 
Both the family of origin and current relationship status have been associated with 
the risk of attempted and completed suicide. In terms of the family of origin, parental 
separation or divorce, marital discord, poor parent-child relationships, parental 
psychopathology, exposure to physical and/or sexual abuse, and family history of 
suicide have been noted to correlate with risk (Beautrais, 2000; Fergusson, 
Woodward, & Horwood, 2000; Rossow & Lauritzen, 2001). The elevated rate of 
subsequent suicide found among relatives of people who have committed suicide 
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compared to the general population has been attributed to both shared genetics and 
also the modelling of suicidal behaviour (Fremouw et al., 1990). 
With regard to current family circumstances, marital status has been demonstrated to 
be relevant, with those recently separated from their partner found to be at highest 
risk, followed by those who are divorced, widowed, or single (Fremouw et al., 1990). 
Marriage has been shown to have a protective effect for men, though not necessarily 
so for women, while having responsibility for children was found to have a 
protective effect for women to a greater degree than for men (Graham et al., 1999; 
Maris et al., 2000). At a population level, suicidal ideation and suicide attempts have 
been reported to be more common among people who were not currently married or 
in a de facto relationship than among those who were (Pirkis et al., 2000). 
Cultural background 
Indigenous populations have been found to be at greater risk of suicide and suicidal 
behaviour in Canada, USA, and Australia than non-Indigenous populations 
(Australian Bureau of Statistics, 2006b; Graham et al., 1999). Estimates of suicide 
rates among Indigenous Australians are even more inexact than among the 
population as a whole due to a number of issues relating to both ascertaining cause of 
death and identification of Indigenous status. However, from 1988-98 the rate of 
Indigenous suicide was found to be much higher than for non-Indigenous 
Australians, and was very much more prevalent in the younger age groups 
(Steenkamp & Harrison, 2000). 
It has been noted in the United States that White-Americans have higher rates of 
suicide than Afro-Americans and Hispanic-Americans (Fremouw et al., 1990). 
Evidence has also been found to suggest that suicide may be greater among migrant 
communities, possibly due to the social upheaval associated with migration (Hassan, 
1995). Studies reviewed by Hassan (1995) reported newly migrated populations had 
higher rates of suicide than the general population in both their country of origin and 
their new home. 
Personality, cognition, and hopelessness 
Studies examining the link between suicide and certain personality traits (for 
example, low self-esteem, impulsivity, and aggression) have to date provided 
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equivocal evidence for personality factors predisposing an individual towards suicide 
(Beautrais, 2000). Of all the personality variables studied, impulsivity has shown the 
strongest association with suicidal behaviour (J. Williams & Pollock, 2000). A U.S. 
case-control study of 153 nearly lethal suicide attempts found 24% of attempts were 
made with less than five minutes elapsing between the decision and the event, and 
that those making impulsive attempts were more likely to have a history of other 
impulsive behaviour and had lower levels of depression than non-impulsive 
attempters (Simon et al., 2001). Clinical wisdom points to the relevance of other 
personal characteristics in the development and maintenance of suicidal behaviour; 
with long-standing adjustment problems being frequently noted (Fremouw et al., 
1990). Neuroticism and novelty seeking have also been associated with suicidal 
behaviours in adolescents (Fergusson et al., 2000). 
The relationship between personality factors such as impulsivity and suicidal 
behaviour is thought to be mediated by maladaptive cognitive styles, such as 
dichotomous thinking, cognitive rigidity, poor problem solving skills, and irrational 
beliefs (Fremouw et al., 1990; J. Williams & Pollock, 2000). Specifically, it has been 
demonstrated that people with a history of suicidality differ in how they approach 
problem solving by being less confident, active, and systematic than control groups 
(Fremouw et al., 1990; J. Williams & Pollock, 2000).  
A sense of hopelessness or pessimism about the future has been recognised as a risk 
factor for suicidal behaviour (Hawton & Catalan, 1987). Previous research found that 
suicidal individuals showed a lack of positive expectancies and saw no hope of 
change in the future. Even when possible solutions were offered, a suicidal person 
was more likely to focus on the potential problems and negative consequences of 
implementing the solution (Fremouw et al., 1990; J. Williams & Pollock, 2000). An 
English study of 150 patients admitted to hospital for self-harm reported that two-
thirds identified at least one problem which they perceived as unable to be solved 
(most usually a relationship or financial problem) (Milnes, Owens, & Blenkiron, 
2002). Reporting unsolvable problems was found to be correlated with both 
hopelessness and severity of suicidal intent. 
As noted in the section concerning mental health problems above, suicidality has 
been found to be more common in people with a personality disorder, and suicidal 
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behaviour is one of the DSM-IV diagnostic criteria for borderline personality 
disorder (American Psychiatric Association, 2000; Lester, 2005b; Linehan et al., 
2000). Other features of the disorder include poor emotional control, fear of 
abandonment, interpersonal problems, unstable self-image, and impulsivity. 
Socio-economic status (SES) 
It has been noted that being socially disadvantaged increases the risk of suicidality 
(Beautrais, 2000; Fergusson et al., 2000; M. Williams, 1997), as does loss of social 
status (Fremouw et al., 1990). Data from the Australian National Survey of Mental 
Health and Wellbeing  revealed a linear relationship with those with the lowest level 
of education and current employment status at greatest risk of a suicide attempt, and 
those with the highest status at least risk (R. Taylor et al., 2004). A separate analysis 
of the same dataset found that among people who experienced suicidal ideation, 
being unemployed was a significant risk factor for progressing to attempted suicide 
within a 12-month period (which could also be considered an adverse life event as 
discussed below) (Pirkis et al., 2000). Evidence which linked fluctuations in the 
Australian suicide rates with economic cycles provided further support for a 
relationship between suicide and SES. That is, the suicide rate has been 
demonstrated to increase at times of economic downturn and high unemployment, 
especially among males (Hassan, 1995).  
Psychosocial stress 
Adverse life events such as loss of a partner (whether through separation or death), 
unemployment, legal issues, and incarceration have been associated with elevated 
risk of suicide (Beautrais, 2000; Hawton & Catalan, 1987). Loneliness and lack of 
social support have also been identified as a risk factor for suicidality (Hassan, 
1995), as has the loss of physical function through illness or injury (Fremouw et al., 
1990). Having moved residence within the last 12 months has been associated with 
increased risk for a suicide attempt (Potter et al., 2001). In particular, greater 
frequency of moving, a recent move, moving a greater distance, and having difficulty 
staying in touch with friends and family following a move have all been associated 
with higher risk.  
The association seen between life events and suicide may partly be due to the fact 
that in the aftermath of a suicide or suicide attempt people look for factors which 
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help explain the behaviour, even though many other people experience similar events 
without becoming suicidal. Life events on their own are unlikely to precipitate 
suicidal thought and behaviour. It is probable that it is the interaction between the 
stress level associated with a negative event and poor coping abilities that crystallize 
into a sense of hopelessness about changing the situation that then leads to suicidality 
(Fremouw et al., 1990). Even among people with severe mental illness, the 
occurrence of crises and suicidal ideation may be independent, with it being 
suggested that impulsivity, agitation, and hopelessness pose a greater suicide risk 
than a crisis event (Links, Eynan, Ball, Barr, & Rourke, 2005). 
Sexual orientation 
Sexual orientation is another factor of interest, with evidence of elevated risk of 
suicidal ideation and suicide attempts found among gay, lesbian, and bisexual youth 
(Beautrais, 2000; van Heeringen & Vinke, 2000). However, this was not been found 
to be the case for completed suicide (Beautrais, 2000). It is not clear why sexual 
orientation appeared to be associated with non-fatal suicidal behaviour, but not with 
fatal suicidal behaviour. 
A study which compared homosexual and bisexual young people with heterosexual 
young people found that homosexual or bisexual orientation was associated with a 
twofold increase in suicidal ideation, and four times the risk of a suicide attempt (van 
Heeringen & Vinke, 2000). Independently of sexual orientation (i.e. across the entire 
sample), depression was a risk factor for suicidal ideation, while low self-esteem, 
hopelessness, and previous suicidal behaviour in a person close to the individual 
were all risk factors for suicidal behaviour. An attempt was made to identify the 
mechanism by which homosexual and bisexual young people were at greater risk of 
suicidal behaviour. The most significant risk factors for homosexual and bisexual 
people were suicidal behaviour in someone close, unsatisfactory homosexual 
friendships, and being female. In contrast, the greatest risk factors for suicidal 
behaviour in the heterosexual group were suicidal behaviour in someone close, and 
hopelessness (van Heeringen & Vinke, 2000). 
Physical illness 
Physical illness has been demonstrated to be associated with an increased risk of 
both completed and attempted suicide (Stenager & Stenager, 2000; M. Williams, 
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1997). In particular, cancer and neurological disorders (multiple sclerosis, stroke, 
spinal cord lesions, and epilepsy) have been associated with elevated risk. It has been 
suggested that chronic severe pain may contribute to suicidality, though further 
research is needed (Stenager & Stenager, 2000). Survivors of nearly lethal suicide 
attempts (especially males) are more likely to have a serious medical condition than 
community controls, with the degree of risk increasing with the number of conditions 
reported (Ikeda et al., 2001). Chronic illness has been shown to precipitate or 
exacerbate depression, indirectly increasing the risk of suicide (M. Williams, 1997). 
Experiencing suicidal ideation within the last 12 months has also been associated 
with having a disability (Pirkis et al., 2000). 
Previous attempts 
A previous attempt is known to be a strong predictive factor for suicide (Rossow et 
al., 1999), and it has been estimated that between one and two-thirds of people who 
kill themselves have in fact made a previous attempt (Fremouw et al., 1990; 
Lewinsohn et al., 1996; Maris et al., 2000; Sakinofsky, 2000; van Heeringen & 
Vinke, 2000). While repeated suicide attempts have been found to increase the 
likelihood of a successful suicide occurring, the person may still have had a 
relatively low level of intent to die. Other reasons identified for repeating the 
behaviour have included the person feeling unable to cope, being overwhelmed by 
their own negative emotions, or hoping to secure the care and/or attention of hospital 
staff (Hawton & Catalan, 1987). 
Both retrospective and prospective studies in various countries have investigated the 
rate of attempted and completed suicide following an incident of deliberate harm 
(Beautrais, 2003; Cooper, Kapur, Webb, Lawlor, Guthrie, Mackway-Jones et al., 
2005; Crandall, Fullerton-Gleason, Aguero, & LaValley, 2006; Hawton, Zahl, & 
Weatherall, 2003; Owens, Horrocks, & House, 2002; Sakinofsky, 2000; Salter & 
Pielage, 2000). A systematic review of 90 observational and experimental studies 
found 14% of self-harm patients had a subsequent non-fatal occurrence of the 
behaviour within 12 months (Owens et al., 2002). Estimated rates of fatal repetition 
have ranged from 0.5% to 3.0% within 12 months (Cooper et al., 2005; Hawton et 
al., 2003; Owens et al., 2002; Sakinofsky, 2000), and increased over time with 1.7% 
to 9% of deaths within 5 years being attributed to suicide or probable suicide 
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(Beautrais, 2003; Harriss, Hawton, & Zahl, 2005; Hawton et al., 2003; Sakinofsky, 
2000). The rate of death by suicide has been found to be significantly higher among 
patients who have previously sought hospital treatment for deliberate self-harm 
(Hawton et al., 2003) or for suicide-related complaints (i.e. self-harm, suicidal 
ideation, or overdose) (Crandall et al., 2006) than among the general population or 
other hospital patients. One study found the risk of completed suicide to be greatest 
within the first six months following attendance at hospital for deliberate self-harm 
(Cooper et al., 2005). 
It is generally agreed that it is very difficult to predict which individuals with a 
history of suicidality will eventually commit suicide. A review of studies considering 
risk factors for repeated suicidal behaviour (both fatal and non-fatal) concluded that 
the research evidence indicates a large number of potential predictors, many of 
which are the same as for suicidal behaviour in general (Sakinofsky, 2000). One 20-
year longitudinal study found males were at greater risk of completing suicide at a 
subsequent attempt than females, as were older people compared to younger 
(Hawton et al., 2003). The higher the level of suicidal intent associated with an 
incident of self-harm (i.e. self-injury or self-poisoning), the greater the risk of 
subsequent suicide (Harriss et al., 2005). A recent English study found avoiding 
discovery at the time of the index episode of self-harm, not living with a close 
relative, and alcohol misuse were all predictive of subsequent fatality by suicide 
(Cooper et al., 2005). It has also been suggested that those who make an almost 
lethal suicide attempt are at particular risk for subsequently completing suicide 
(Beautrais, 2003). An interesting finding of the five-year follow-up study by 
Beautrais (2003) was that while most of the index suicide attempts were by 
poisoning or overdoses (79%), only 7.4% of subsequent suicide fatalities used this 
method, with all other suicide deaths occurring by motor vehicle exhaust or hanging. 
This finding suggested that people may shift to more lethal means if earlier attempts 
are unsuccessful. 
Help-seeking more generally may be an indicator of risk. In a retrospective study of 
Tasmanian suicides it was found that 29% had attended an ED in the year prior to 
death, 10% within the last month (Salter & Pielage, 2000). Most, but not all, attended 
for psychiatric or alcohol and drug related problems, with multiple attendances a 
particular risk indicator. 
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Environmental factors 
The context in which an individual lives may also contribute to suicide risk. Clusters 
of suicide have sometimes occurred in a particular time and place, and increased 
suicide rates have been noted after media coverage (Beautrais, 2000).17 Access to 
means of suicide such as firearms and sedatives has also been shown to elevate risk 
(Beautrais, 2000). Higher rates of completed suicide have been found in rural 
compared to urban areas of Australia, Great Britain, and North America (Australian 
Bureau of Statistics, 2006b; M. Williams, 1997). 
Intoxication 
Intoxication on alcohol and other substances increases the risk of both attempted and 
completed suicide (Dhossche, 2003; Hawton & Catalan, 1987; Powell et al., 2001; 
Rossow et al., 1999). A study comparing people attending hospital for a nearly-fatal 
suicide attempt with community controls found that being alcoholic, and consuming 
alcohol within the previous three hours were risk factors, even after controlling for 
depression (Powell et al., 2001). 
1.2.7 Treatment of suicidal behaviour 
Outlined in this section are the possible treatment interventions for people at risk of 
suicide or deliberate self-harm, or at risk of repeating such behaviour. The 
management of deliberate self-harm cases when attending hospital is then discussed, 
followed by information pertaining to the prevention of suicide. 
Types of treatment 
The efficacy of different treatments for people at risk of inflicting or repeating 
deliberate self-harm was the focus of a Cochrane review (Hawton, Townsend, 
Arensman, Gunnell, Hazell, House et al., 1999). Twenty-three randomised controlled 
trials were included using repetition of deliberate self-harm as the outcome variable. 
Most (but not all) of the studies involved some form of pharmacological or 
psychological treatment, and used standard care or placebo as the control condition. 
                                                          
17 In contrast, a U.S. case-control study of nearly lethal suicide attempts found that exposure to the suicidal 
behaviour of a family member did not increase the risk, and that exposure to suicidal behaviour of friends and 
acquaintances actually exerted a marginally protective effect (Mercy et al., 2001). The authors suggested that 
further research was necessary to identify explanatory factors for this difference. 
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The authors concluded that further research using larger samples is required before 
definitive conclusions can be drawn. The most promising results of the review and 
other studies are outlined below. 
Pharmacological treatments 
The link between psychiatric illness and suicidal behaviour is well established. It 
therefore seems intuitive that effective treatment of the underlying psychiatric 
condition should also lead to a decrease in suicidal risk. A number of clinical and 
epidemiological studies have been conducted to investigate the impact of various 
psychotropic medications on the recurrence of deliberate self-harm. Evidence for the 
efficacy of pharmacological treatments, such as some atypical antipsychotic 
medications, antidepressants, and mood stabilisers, is promising though still 
equivocal (Hawton et al., 1999; Verkes & Cowen, 2000). It is possible that some of 
the improvement noted in the latter review was simply due to the care associated 
with being in treatment, but the differential effects of medications suggested that 
there were also real pharmacological effects (Verkes & Cowen, 2000). Despite the 
potential of pharmacological treatments, the review by Verkes and Cowen (2000) 
concluded that benzodiazepines appeared to be associated with increased suicidal 
behaviour in some patients and therefore should only be prescribed with extreme 
caution. Evidence has also emerged to suggest that some classes of antidepressant 
medication may be associated with increased suicidal risk (Verkes & Cowen, 2000).  
Ecological studies conducted in Australia and overseas examining the relationship 
between antidepressant prescribing and suicide rates at a population level have 
suggested that such medications may have a positive effect in reducing suicide (Hall, 
Mant, Mitchell, Rendle, Hickie, & McManus, 2003). In Australia between 1991 and 
2000 a decline in suicide mortality was noted in those groups with the greatest 
exposure to antidepressant medication (i.e. older adults). The change could not be 
explained by other variables, such as alcohol consumption, unemployment rates, or 
means of suicide. The authors concluded that the change was most likely due to 
increased prescription of antidepressants over the study period. The causal 
mechanism was probably either through the direct physiological effects of 
medication, or through the improved experience of assessment and care received. 
The authors also suggested that the availability of newer medications with fewer side 
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effects (i.e. SSRIs) may have increased the willingness of both doctors to prescribe 
medications, and patients to take them (Hall et al., 2003). 
Psychological treatment 
As defined in one review, a psychotherapeutic approach to suicidality could be “any 
psychosocial intervention that involves repeated face-to-face contact with a mental 
health professional” (Heard, 2000, p. 504). However, that review found surprisingly 
few interventions have been the subject of randomised controlled trials, with only 
cognitive-behavioural therapies (including problem solving), and outreach/intensive 
therapies being scrutinised by such research. Few significant results were observed, 
though this may be due to methodological problems such as small sample size. The 
best evidence to date is for highly structured problem solving in combination with 
enhanced treatment (such as increased intensity by offering more sessions or an 
outreach component). Larger, multi-site studies that include high-risk participants 
may yield more conclusive results (Heard, 2000). Other related therapies which 
examine the links between cognitions and suicidal behaviour include Rational 
Emotive Behaviour Therapy (REBT) (A. Ellis & Ellis, 2006) and Dialectical 
Behaviour Therapy (DBT) (M. Brown, 2006). 
A Cochrane review also found limited evidence for the efficacy of psychotherapeutic 
approaches to deliberate self-harm (Hawton et al., 1999). Therapies with the best 
available evidence included problem solving, provision of an emergency contact 
card, and long-term psychological therapy (though the latter only applied to female 
patients with borderline personality disorder and a history of repeated self-harm). 
This review also concluded that larger studies may produce more promising results. 
Behavioural contracting has sometimes been used with suicidal clients as a 
component of therapy; although evidence as to the efficacy of “no-suicide” contracts 
has been inconclusive. It has been argued that such agreements may be more useful 
if they contain contingency plans, such as for the person to contact emergency 
support if having a strongly suicidal impulse (Kalafat & Underwood, 2005; Range, 
2005). 
Further discussion of psychotherapeutic strategies used in cases of suicidality may be 
found in Lester (2005a) and Reinecke & Didie (2005). 
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Treatment integration 
Pharmacological and psychological interventions are of course not mutually 
exclusive, and it may be that the most effective treatment response combines both 
approaches. Bertolote et al. (2003) contended that suicide is a complex problem, 
often involving co-morbidity, and a range of other psychosocial and environmental 
variables. The authors therefore concluded that the most effective treatment and 
prevention efforts were likely to be multidimensional. 
It has been argued that inadequate identification and treatment of psychiatric 
disorders such as depression can contribute to an untimely death by suicide 
(Lonnqvist, 2000). Further, evidence has been found for a positive association 
between the severity of an initial depressive episode and subsequent suicide 
(Kessing, 2004). Co-morbidity has been shown to further increase the risk of 
suicidality compared to a single diagnosis (Goldney, 2004). The rate of co-morbidity 
between depression and substance use has been demonstrated to be particularly high 
among completed and attempted suicides, with about two thirds of alcohol-
dependent people who committed suicide also being depressed (Murphy, 2000). It 
has been recommended that since depression treatment has a greater success rate 
than substance use treatment, depression should be the main focus of any 
intervention offered to those at risk of suicide, although substance use treatment may 
also be useful (Murphy, 2000). 
Hospital care for non-fatal suicidal behaviour 
It has been argued that as hospitalisation is a frequent outcome of non-fatal suicidal 
behaviour, the quality of care received may be an important element in preventing 
the recurrence of such behaviour (Hawton, 2000). That author further contended that 
elements of such care should include: emergency care, medical care, psychiatric care, 
and risk assessment. Ideally, initial emergency care would include not only an 
assessment of the immediate medical needs of the patient, but also a brief psychiatric 
assessment to determine whether the person was still actively suicidal or 
experiencing some severe psychiatric disturbance. Any possible complications of the 
attempt may be addressed during ongoing medical care (also see Medical response to 
overdose, page 83). A full psychiatric assessment may be conducted once the person 
is able to participate, for example, once any intoxicating effects of an overdose have 
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worn off. According to Hawton and van Heeringen (2000) a thorough risk 
assessment would include the lead up to the act, the act itself, motives, suicidal 
intent, ongoing risk (though prediction of this may be imprecise), and available 
coping resources and supports. It has been suggested that the process of assessment 
can be a therapeutic experience for the patient (Hawton, 2000). Some patients may 
refuse medical or psychiatric treatment, although if they are in a life-threatening 
situation it is likely that their wishes in this regard will be over-ruled and treatment 
instigated. 
As identified above, psychosocial or psychiatric assessment is an important element 
of ED care. An English matched pairs study of patients attending the Oxford General 
Hospital for deliberate self-harm found that those not given such an assessment were 
more likely to have presented between 5 p.m. and 9 a.m. (i.e. outside day time 
hours), to have had a previous history of such harm, and to engage in “difficult” 
behaviour while in the department than those who were assessed (Hickey, Hawton, 
Fagg, & Weitzel, 2001). Almost 38% of the non-assessed group had a further 
episode of self-harm during the following year, compared to 18% of those who had 
been assessed. While these outcomes may have been due partly to existing group 
differences, it was also suggested that providing a risk assessment may help reduce 
repeated self-harm. 
Hawton and van Heeringen (2000) argued that hospital care for non-fatal suicidal 
behaviour should ideally be followed by some form of aftercare. This could include 
psychiatric inpatient admission, or outpatient or community-based care. The rate of 
participation in outpatient aftercare may be increased if the same clinician is 
involved as during the hospital based treatment. Home-based treatment has also been 
demonstrated to improve participation rates in aftercare (Hawton, 2000). Provision of 
a card with emergency access to clinicians via telephone showed some promise in 
reducing repeat attempts, although the intervention appeared to be more effective for 
patients attending hospital for the first time than for those with a history of deliberate 
self-harm (Evans, Morgan, Hayward, & Gunnell, 1999). An English study involving 
enhanced GP follow-up after an episode of deliberate self-harm also had equivocal 
results, however, in contrast with Evans et al. (1999), those with a history of repeated 
self-harm showed an improvement after the intervention, while those engaging in 
self-harm for the first time apparently reacted adversely, with a greater incidence of 
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repeat attempts in the subsequent 12-month period (Bennewith, Stocks, Gunnell, 
Peters, Evans, & Sharp, 2002). The reasons for these apparently contradictory results 
between studies were not clear. 
Brown et al. (2005) conducted a randomised controlled trial with 120 adults who had 
recently attended an ED following a suicide attempt. Participants were allocated to 
either ten sessions of cognitive therapy or enhanced usual care and the rates of 
repetition of attempted suicide in each group compared over 18 months. While both 
groups continued to report suicidal ideation, that rate of repeated attempted suicide, 
self-reported depression, and hopelessness were all significantly lower in the 
intervention group (G. Brown et al., 2005). 
Research has been conducted in emergency care settings to test the utility of brief 
interventions for patients attending with problematic alcohol and/or other drug use; 
involving elements such as information provision (written and verbal), motivational 
interviewing, brief counselling while in the ED, and referral to external services 
(Blow, Barry, Walton, Maio, Chermack, Bingham et al., 2006; Crawford, Patton, 
Touquet, Drummond, Byford, Barrett et al., 2004; Helmkamp, Hungerford, 
Williams, Manley, Furbee, Horn et al., 2003). Such brief interventions generally 
aimed to reduce the rate of re-attendance to the ED, decrease the level of substance 
use, and/or encourage attendance at some other support or counselling service. The 
rationale usually given for offering a brief intervention in the emergency care setting 
is that a person may be more accepting of such assistance when faced with a crisis 
caused by their alcohol and/or other drug use (Cherpitel, 2006). While some success 
has been noted for the studies relating to substance use cited above, there have been 
few similar brief interventions delivered wholly within the ED trialled for patients 
attending following self-harm. It would be of interest to consider whether this type of 
intervention could be a feasible model for cases of non-fatal suicidal behaviour 
and/or medication overdose (with or without suicidal intent). 
Perceived needs for care 
Analysis of data from the Australian National Survey of Mental Health and 
Wellbeing was conducted to determine the perceived treatment needs of people 
reporting suicidal ideation or a suicide attempt (Pirkis, Burgess, Meadows, & Dunt, 
2001). The analysis included those who had experienced suicidality within the 
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preceding 12 months and who had used treatment services. The most commonly 
reported needs were for counselling, medication, and information. Fewer people 
reported the need for skills training or social interventions. Less than half the sample 
reported that their perceived needs for care had been adequately met (Pirkis et al., 
2001). A qualitative study of family and close friends of people who had committed 
suicide also identified a need for more well-coordinated information and education, 
as well as proactive management of suicidal individuals (for example, follow-up 
after a suicide attempt) (Nirui & Chenoweth, 1999). 
Prevention 
It has been suggested that it is unlikely that there will ever be a randomised-
controlled trial that conclusively demonstrates the efficacy of a suicide prevention 
program (Goldney, 2000). This is because completed suicide is a behaviour with a 
very low base rate, and assessment of risk factors yields a high false positive rate, 
making it very difficult to accurately predict who will eventually die by suicide, even 
amongst those identified as at-risk (Goldney, 2000). Nonetheless, prevention 
strategies have been introduced at the general population level, in primary care, and 
in psychiatric settings. 
Suicide prevention programs have been wide ranging, including initiatives to 
improve suicide awareness among professionals and the public, screening to identify 
those at-risk, treatment of underlying psychiatric conditions, restricting access to 
highly lethal means of suicide such as firearms, and by taking care in the portrayal of 
suicide in the mass media. The most promising of these appear to have been 
education programs for doctors and restricting access to highly lethal means of 
suicide, with the effectiveness of other preventative measures requiring further 
research (Mann, Apter, Bertolote, Beautrais, Currier, Haas et al., 2005). It has also 
been suggested that unemployment and substance use (particularly alcohol) could 
usefully be the target of suicide prevention strategies at a population level 
(Australian Institute for Suicide Research and Prevention, 2003; Pirkis et al., 2000; 
R. Taylor et al., 2004). In-depth discussion of suicide prevention strategies is beyond 
the scope of this literature review, however, further information may be found in the 
following works; (Appleby, 2000b; Cantor & Baume, 1999; Dhossche, 2003; 
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Diekstra, Gulbinat, Kienhorst, & de Leo, 1995; R. Jenkins & Singh, 2000; Mann et 
al., 2005; Michel, 2000; Schmidtke & Schaller, 2000). 
1.2.8 Summary 
Suicidality is a term which can be used to cover a broad spectrum of thoughts and 
behaviour from the most fleeting of thoughts of self-destruction through to 
completed suicide. It is difficult to estimate accurately the prevalence of suicidal 
thought, behaviour, and completed suicide, due to a number of issues including the 
definition used, the population under study, and sensitivity around identification. 
Nonetheless, it has been estimated that almost 2% of deaths in Australia are due to 
suicide (rising to 20% in younger age groups). Almost 4% of the Australian 
population acknowledge having made a suicide attempt in their lifetime, and 16% 
report suicidal ideation. Risk factors for suicidality include psychiatric problems, 
substance intoxication and misuse, genetics, neurobiological dysfunction, gender 
(with males at increased risk of completed suicide, and females at increased risk of 
non-fatal suicidal behaviour), family background, social circumstances, personality, 
and stress. Previous suicidal behaviour is a strong predictor of ongoing suicidality. 
Treatments, both pharmacological and psychological, often focus on underlying 
mental illness. The effectiveness of such treatments and other preventative measures 
require further research. Medication overdose is a common means of both completed 
and attempted suicide. 
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1.3 Pharmaceutical medications and overdose risk 
1.3.1 Definition 
Given that medication related overdoses account for one in ten suicide deaths and 
almost nine out of ten suicide attempts, it is worth examining such overdoses more 
closely. Hawton and Catalan (1987) provide the following definition of overdose: 
“…the deliberate ingestion of more than the prescribed amount of medical 
substances, or ingestion of substances never intended for human consumption, 
irrespective of whether harm was intended” (page 5). 
The above definition does not consider the physiological effect of the overdose event 
on the individual which may range from negligible to severe, a convention which has 
also been adopted in this thesis. Further information as to the specific definition 
adopted for the current study is contained in the Method section (Medication misuse 
or overdose, page 110). 
1.3.2 Prevalence/incidence 
Fatal medication overdose 
Due to the way in which mortality statistics are recorded in Australia, it is difficult to 
determine exactly how many deaths are due to medication overdose, and of these, 
how many are intentional. There were over 1,800 deaths due to poisoning in 2002, 
although this included both poisoning by drugs, and by other substances such as 
gases (Kreisfeld et al., 2004). Even among deaths known to be caused by drugs, both 
licit and illicit drugs were included in the figures reported, making it impossible to 
distinguish exactly how many were due to medications. 
Data from the Victorian Coroner’s Facilitation Database (VCFD)18 concerning 
poisoning deaths between 1989 and 1995 revealed that on average each year there 
were 15 deaths in the state of Victoria involving benzodiazepines, 6.5 from 
antidepressants, 5.8 from methadone, 2.0 from antipsychotics, 1.8 from codeine, and 
1.3 from paracetamol (Routley, Ashby, & Lough, 1999). From the information 
                                                          
18 The prevalence information contained in this section focuses on the state of Victoria, as this is where the 
current research was conducted. 
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provided it was not clear to what extent these deaths involved co-ingestion of more 
than one medication, or use in combination with alcohol or illicit drugs. However, it 
was highly likely that most of the benzodiazepine deaths recorded involved the 
concurrent ingestion of other central nervous system (CNS) depressants (Routley et 
al., 1999). The VCFD has since been superseded by the National Coroner’s 
Information System (NCIS).19 
Non-fatal medication overdose 
Presentations to Victorian hospital EDs for poisoning are captured by the Victorian 
Emergency Minimum Dataset (VEMD) (Routley et al., 1999). The dataset includes 
poisoning by drugs, alcohol, medicinal, and biological substances.20 In the period 
1996-1998 there were over 18,000 presentations for poisoning by adults across the 
state, accounting for almost 5% of all injury cases. Just over half of the total 
poisonings reported were for medications; primarily benzodiazepines, paracetamol, 
antidepressants, and antipsychotics (Routley et al., 1999). 
Ambulance attendances at drug-related cases in the Melbourne Metropolitan area 
have been routinely monitored by Turning Point Alcohol & Drug Centre, Inc. since 
1998 (Cvetkovski, Dietze, & McElwee, 2002). That database revealed that 
prescription and OTC medications accounted for a large proportion of drug-related 
cases attended by ambulance in Melbourne between June 1998 and April 2001. For 
example, of nearly 40,000 drug-related cases attended across Melbourne, 
benzodiazepines were implicated in 22% of attendances, antidepressants in 9%, and 
analgesics in 8% of cases. Antipsychotic drugs were involved in about 4% of 
attendances.  
1.3.3 Medications involved in overdose 
As can be seen from the prevalence data above, certain classes of medication (i.e. 
benzodiazepines, antidepressants, and analgesics) have been found to be the most 
                                                          
19 The National Coroners Information System http://www.ncis.org.au/index.htm attempted to improve the 
reporting of drug involvement in deaths. However, the Drug Module project stalled due to lack of funding. 
20 The authors caution that VEMD information contains some bias and inaccuracies, as a number of small 
hospitals were not included, and there were variable reporting practices between hospitals (Routley et al., 1999). 
However, it still provides a general picture of non-fatal medication overdose presentations to Victorian hospital 
EDs. 
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prevalent in studies of fatal and non-fatal overdose in Australia and elsewhere, 
though the order varies somewhat with location, availability, age and previous 
history (Baca-Garcia, Diaz-Sastre, Saiz-Ruiz, & de Leon, 2002; N. Buckley, Whyte, 
Dawson, McManus, & Ferguson, 1995b; Neeleman & Wessely, 1997; Schwarz, 
Ruder, Krappweis, Israel, & Kirch, 2004; Townsend et al., 2001). Despite their role 
in overdose, Baca-Garcia et al. (2002) concluded that the risk posed from an 
overdose on benzodiazepines, newer antidepressants, or antipsychotics was relatively 
low, particularly when compared to the suicide risk associated with under-treated 
mental illness, and that prescribers should be wary of withholding a potentially 
effective psychiatric medication due to fear of overdose. 
This research aimed to investigate in detail the medications consumed in overdose as 
well as the reasons for and mechanism by which they were acquired (see Research 
Questions, page 103). Therefore a brief explanation of the purpose of 
benzodiazepine, antidepressant and analgesic medications will be provided here, 
along with information about the risks and prevalence of use. 
Benzodiazepines 
Purpose 
Benzodiazepines, otherwise known as minor tranquilisers, act as a central nervous 
system depressant and are intended to be used for the short-term relief of anxiety and 
insomnia. Other purposes for which they may be used include muscle relaxation, as 
an anti-convulsant during alcohol withdrawal, for sedation during minor surgery, and 
in combination with general anaesthetics. Benzodiazepines are available on 
prescription (although there is also a black market trade) and come in a variety of 
preparations of varying strengths in both tablet and capsule form. They may have a 
short, medium, or long term duration of action, and their selection will depend on the 
desired effect (e.g. to alleviate anxiety or overcome insomnia). This class of drugs is 
intended for oral use, although some people do inject them (Ashton, 1994; Australian 
Drug Foundation, 2002; Mant & Wash, 1997; Muhleisen, 2001; National Health and 
Medical Research Council, 1991). 
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Misuse, side effects, and overdose risk 
While there are clear guidelines concerning the appropriate prescription of 
benzodiazepines (National Health and Medical Research Council, 1991; Royal 
Australian College of General Practitioners, 2000), it is clear that prescription for 
other purposes is commonplace (for example, prescription for grief, anger 
management, and depression) as is prescription over excessively long periods of time 
(Redman, 2002; Vorma, Naukkarinen, Sarna, & Kuoppasalmi, 2002). The National 
Health and Medical Research Council (NH&MRC) (1991) guidelines recommend 
that prescription be for no longer than 2-4 weeks due to declining effectiveness after 
this time and the risk of dependence, however, many people continue to use these 
medications over a period of months or even years. 
Furthermore, regardless of the medical condition for which the medications may 
have been prescribed, benzodiazepines are frequently used without medical 
supervision for a whole range of other reasons. For example, people may use 
benzodiazepines to become intoxicated, to increase the effects of heroin or other 
drugs, as a substitute for heroin or other drugs, to alleviate the symptoms of heroin 
withdrawal, or when coming down from recreational drugs such as amphetamine-
type stimulants and ecstasy (Australian Drug Foundation, 2002). 
Benzodiazepines are regarded as safer in overdose situations than many earlier 
sedative medications and tricyclic antidepressants, however, they are not without 
side effects. The potential for overdose to occur is heightened when used in 
conjunction with other CNS depressants including heroin and alcohol (Mant & 
Wash, 1997). Some types of benzodiazepine have been shown to be more toxic in 
overdose than others, for example, an Australian study demonstrated temazepam to 
be more sedating than oxazepam (N. Buckley, Dawson, Whyte, & O'Connell, 1995). 
Other negative effects may include: over-sedation and falls (particularly in the 
elderly), cognitive impairment (e.g. impairment to functions such as reasoning, co-
ordination, reaction time, and short and long term memory), increased risk of 
accidents, lowered self-protective behaviour when engaging in injecting drug use or 
sexual activity, vein damage if injected, possibly “floppy-baby” syndrome if used 
during pregnancy, depression, dependence (even at normal therapeutic doses), and an 
associated withdrawal syndrome which may be characterised by symptoms such 
rebound insomnia, rebound anxiety, panic attacks and an extensive range of other 
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symptoms (Caplehorn & Saunders, 1993; Frels, Williams, Narayanan, & Gariballa, 
2002; Holmes, 1999; Jorm, Grayson, Creasey, Waite, & Broe, 2000; Mant & Wash, 
1997; Redman, 2002).  
Benzodiazepine dependence 
As mentioned above, dependence is a significant problem in relation to the ongoing 
use of benzodiazepines. Dependence is characterised by increased tolerance to the 
effects of the medication and a withdrawal syndrome when the medication is stopped 
(American Psychiatric Association, 2000). Paradoxically, the withdrawal is often 
worse than the initial condition the medication was prescribed to treat and can 
include a variety of distressing physical and psychological symptoms. However, it is 
dangerous to stop using benzodiazepines suddenly as there is a risk of seizure. 
Withdrawal from benzodiazepine use should therefore usually involve a gradual dose 
reduction under medical supervision (National Health and Medical Research 
Council, 1991). Given the problems identified above it is preferable to manage 
anxiety and insomnia with non-pharmacological interventions where possible. Such 
techniques could include relaxation, learning good sleep hygiene, stress 
management, problem solving, exercise, diet, general counselling, and cognitive-
behavioural therapy (Andrews & Hunt, 1999; Ashton, 1994; Australian Drug 
Foundation, 2002; Mant & Wash, 1997; National Health and Medical Research 
Council, 1991; Norman, Ellen, & Burrows, 1999; Vorma et al., 2002). 
Certain groups of benzodiazepine users have been found to be at greater risk of 
dependence or abuse, including people with borderline or dependent personality 
traits, those with a history of alcohol or other drug dependencies, and older people 
(Seivewright, 1998; Vorma et al., 2002). Also, benzodiazepines with high potency 
and a short half-life have a higher associated risk of developing dependence 
(Seivewright, 1998). 
Prevalence of use 
Despite some of the problems associated with benzodiazepine use, and evidence 
which suggests there are non-pharmacologic alternatives available to treat anxiety 
and insomnia, regular benzodiazepine use among adults has been estimated to be 
between 10-20% of the population in Western countries (Norman et al., 1999). A 
recent study conducted in a Swedish city found that 5.5% of females aged 45-73 
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surveyed were currently using anxiolytic-hypnotic medication (Johnell, Merlo, 
Lynch, & Blennow, 2004). 
There is ample evidence to suggest that there is a high rate of benzodiazepine use 
within Australia. Prescription data can be accessed via the internet from the 
Commonwealth Department of Health and Aged Care, a search of which indicated 
there were approximately 7 million government subsidised prescriptions for 
benzodiazepines each year from 1992 to 2002 (Heale, 2002). In a report outlining the 
ten most commonly prescribed drugs in Australia in 1998, temazepam was ranked 
7th, accounting for over three million prescriptions nationwide, and this is only one 
medication within the benzodiazepine group (Commonwealth Department of Health 
and Aged Care, 1999). Data available from an Australian study of General 
Practitioners showed that 4.1% of all medications prescribed were 
anxiolytics/sedatives. Furthermore, temazepam, diazepam and oxazepam were 
among the top 30 most commonly prescribed drugs (Britt et al., 2001). Results of the 
Australian National Health Survey found that 4.5% of respondents reported using 
sleeping tablets within the previous fortnight, 2% used medication for anxiety or 
nerves, and 0.7% used tranquillisers (Australian Bureau of Statistics, 2006a). 
At a state level, it was estimated that in 2004 there were approximately 1.75 million 
government subsidised benzodiazepine prescriptions in Victoria, and, as for the 
national data described above, temazepam, oxazepam and diazepam accounted for 
the majority of these (36%, 20%, and 27% respectively) (Drugs and Crime 
Prevention Committee, 2006). The overall number of subsidised benzodiazepine 
prescriptions in Victoria fell by approximately 8% between 1999 and 2004, although 
there appeared to be some differences between sub-types. For example, the number 
of temazepam prescriptions fell (from 40% of total benzodiazepine prescriptions to 
36%), while alprazolam appeared to increase (from 4% of the total to 7%) (Drugs 
and Crime Prevention Committee, 2006).  
Benzodiazepines have a high potential for abuse. A project on “doctor shoppers” (i.e. 
people who see more than 15 GPs within 12 months) found that benzodiazepine 
medications account for 35% of prescriptions issued to this group (Muhleisen, 2001). 
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Antidepressants 
Purpose 
As mentioned in the section of this review concerning depression, there are several 
types of antidepressant drug which are used to treat depression, though some also 
have therapeutic effects on insomnia as well as anxiety related symptoms such as 
agitation, obsessive-compulsive behaviours, and panic attacks. 
Types of antidepressant 
This section contains information on the main types of antidepressant medication; 
the most widely used and commonly known of these are the tricyclic antidepressants 
(TCAs) and the selective serotonin reuptake inhibitors (SSRIs). Other antidepressant 
medications include the serotonin and noradrenaline reuptake inhibitors (SNRIs), 
noradrenaline-serotonin specific antidepressants (NaSSAs), monoamine oxidase 
inhibitors (MOAIs), reversible monoamine oxidase inhibitors (RIMAs), and 
tetracyclic antidepressants (TECAs). The information presented in this section is 
synthesised from several sources (Alchin & Tranby, 1995; Austin & Mitchell, 1998; 
BeyondBlue: The National Depression Initiative, 2002; T. Buckley, Parker, & 
Heggie, 2001; P. Ellis & Smith, 2002; Mitchell, 1999; Norman et al., 2004; 
Ramchandani, Murray, Hawton, & House, 2000). 
MAOIs are the oldest group of antidepressants, but due to their toxicity are less 
frequently prescribed nowadays. TCAs were also one of the earliest depression 
medications. They have reasonable action, being effective in 50-60% of cases, and 
moderate improvement being shown in a further 20% of cases. Despite their 
effectiveness in treating the target symptoms (especially depressed mood, insomnia, 
anxiety, aches and pains, and obsessive-compulsive symptoms), they have some 
serious potential side effects as outlined in the section below. RIMAs have a similar 
pharmacologic action to MAOIs, however, they are not as effective as some other 
medications (e.g. TCAs) in elevating mood. TECAs were originally promoted as 
having a faster action and fewer side effects than other antidepressants, although this 
claim has since been questioned. The SSRIs were first developed in the 1970s and 
their mode of action is by inhibiting serotonin reuptake (i.e. there is more serotonin 
available). SSRIs do not interact with alcohol and are less toxic in overdose 
situations. They are also used in the treatment of anxiety and panic disorders, eating 
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disorders, personality disorders, and substance use disorders. SNRIs may be effective 
in the treatment of severe depression, while NaSSAs may be useful for individuals 
with anxiety and insomnia associated with depression 
At present, the antidepressants of first choice are considered to be SNRIs, NaSSAs, 
and SSRIs, and others tried if these are ineffective (Norman et al., 2004). Despite the 
fact that the effects of antidepressants on noradrenaline and serotonin reuptake occur 
immediately after the medication is introduced, antidepressant medications may take 
4- 6 weeks before reaching full therapeutic effect. Further, symptoms may 
deteriorate before they improve. Due to their differential effects on 
sleep/wakefulness, TCAs are generally better taken at night and MAOIs and SSRIs 
in the morning or early afternoon. 
Misuse, side effects, and overdose risk 
MAOIs are the most toxic antidepressants and can have severe interactions with 
particular foods (e.g. red wine and cheese). If switching from an MAOI to an SSRI, 
care needs to be taken to ensure one medication is out of the system before the next 
is commenced as they cannot be used in combination. Antidepressants may not only 
interact with each other, but also other classes of medication. TCAs are potentially 
lethal in overdose situations at a lower dosage than other antidepressants and should 
not be used with alcohol. Their use is advised against in children, the elderly, and 
people with heart disease. While similar to MAOIs, RIMAs do not have the same 
interactions with certain foods and alcohol. RIMAs have no adverse cardiovascular 
effects and are less dangerous in overdose situations. TECAs are highly sedating, 
however they do not have the cardiac effects of some other antidepressants and 
therefore have a low overdose risk as well as being suitable to be prescribed for the 
medically ill. SNRIs have relatively few side effects compared to older 
antidepressants and are considered safer in an overdose. NaSSAs are less likely to be 
associated with lowered libido than other classes of antidepressant. 
The SSRIs have several side effects including nausea, nervousness, diarrhoea, 
headache, insomnia, sexual dysfunction, and weight loss (Norman et al., 2004). 
However, they are increasingly the favoured treatment because they do not interact 
with alcohol and have low lethality in overdose compared to other antidepressants 
such as TCAs. This is not to suggest that SSRIs are not implicated in overdose; 
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research has certainly found they are (Hawton, Fagg, Simkin, Bale, & Bond, 1997). 
SSRIs recently attracted controversy after evidence surfaced which cast doubt on 
their efficacy and which also suggested their use was associated with worsening 
depression and increased suicide risk via their disinhibiting effects, particularly 
among children (Geddes & Cipriani, 2004; D. Gunnell & Ashby, 2004; Lenzer, 
2004). A prospective English study found that there was a higher incidence of 
deliberate self-harm among patients prescribed SSRIs than TCAs, though this was 
not a randomised control trial and there were several other methodological 
limitations to the research (Donovan, Clayton, Beeharry, Jones, Kirk, Waters et al., 
2000). 
There may be some slight risk in using antidepressants during pregnancy (e.g. 
prematurity), but when weighed against the benefit of improving the psychological 
state of a severely depressed pregnant woman, it may still be preferable to prescribe 
antidepressant medication (Austin & Mitchell, 1998). 
A study of fatal antidepressant overdose conducted in England and Wales found that 
such overdoses were more likely to involve women and older people, and were less 
likely to involve people with a history of drug abuse (Oyefeso, Valmana, Clancy, 
Ghodse, & Williams, 2000). Five possible reasons for antidepressant overdose were 
given including: treatment resistant depression, non-compliance with prescribed 
medications, taking antidepressants in combination with other substances, under 
treatment of depression, and antidepressant toxicity (especially TCAs) (Oyefeso et 
al., 2000). 
Discontinuation reactions 
A range of psychological and physical signs and symptoms have been noted upon 
dose reduction or complete cessation of antidepressant use, especially if the 
medication is used over a period of some months, or when a high dose is being taken 
(Mitchell, 1999; Norman et al., 2004). Generally symptoms start within one or two 
days of reducing or ceasing medication use and usually subside within two weeks. 
Withdrawal symptoms include somatic complaints (for example, fatigue, headache, 
flu-like syndrome, anxiety, agitation), sleep disturbance (insomnia, vivid dreams), 
movement (unsteady gait, involuntary movements), altered affect (lowered mood, 
crying, irritability, lability), and miscellaneous other signs (for example, dizziness 
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and a sensation of electric shocks in the extremities). It is likely that some symptoms 
are more characteristic of particular antidepressant classes than others (Mitchell, 
1999; Norman et al., 2004). 
Prevalence of use 
Antidepressants are the sixth most commonly prescribed medication group by GPs, 
and account for 3.3% of all prescriptions in Australia (Britt et al., 2001). A search of 
Australian prescription data available via the Commonwealth Department of Health 
and Aged Care website found that there were approximately 9 million government 
subsidised prescriptions for antidepressants in 2000/01, though it should be 
remembered that any one individual taking antidepressant medication would most 
likely receive several scripts throughout the year (Heale, 2002). SSRIs were the most 
commonly prescribed antidepressant. Five percent of respondents to the Australian 
National Health Survey reported use of antidepressant medication within the 
previous two weeks (Australian Bureau of Statistics, 2006a). 
Analgesics 
Purpose 
While analgesics, or painkillers, do not cure the underlying cause of pain, they can 
be useful in alleviating the symptoms. There are a number of classes of analgesic, 
and the most appropriate will depend on the type of pain experienced, e.g. injury or 
inflammation of tissue (nociceptive pain), inflammation, trauma or degenerative 
disease of the nerves or axons (neurogenic pain), and pain experienced in the 
absence of any apparent injury (psychogenic pain) (Therapeutic Guidelines Limited, 
1997). 
Types of analgesic 
Analgesics are available both on prescription and OTC, with the more potent ones 
tending to be by prescription only. Non-opioid analgesic medications (e.g. 
paracetamol) have anti-inflammatory, antipyretic, and anti-platelet effects. 
Medications such as paracetamol are most appropriate for less severe pain. The non-
opioid group of analgesics includes a sub-class known as the non-steroidal anti-
inflammatory drugs, or NSAIDs (e.g. aspirin, ibuprofen), which as the name 
suggests, are useful for treating pain associated with inflammation, tissue injury, and 
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fever. Non-opioid analgesic and NSAID medications are freely available OTC and 
are the most widely used forms of pain relieving medication (Stimmel, 1997). 
Opioid analgesics activate the mu, kappa, sigma, and delta opioid receptors in the 
nervous system and are useful in cases of more severe pain, whether chronic or 
acute. Drugs in this group include morphine, codeine, methadone, oxycodone, and 
pethidine, and have application in the treatment of severe pain. Compound analgesics 
are those medications which combine two types of analgesic drug (e.g. Codeine with 
ibuprofen) (Rossi, 2003). 
Analgesic drugs may be administered by several routes (for example; oral, 
sublingual, rectal, transdermal, inhalation, injection, or epidural) though the more 
readily available and commonly used ones tend to be oral preparations (Therapeutic 
Guidelines Limited, 1997). 
Misuse, side effects, and overdose risk 
Paracetamol-based medications have few side effects if taken within the 
recommended limits. However, due to the risk of hepatotoxicity, they should not be 
taken in excess of 4g (or > 100mg/kg) daily. The liver damage caused in overdose 
situations can be severe, and sometimes fatal. Those who regularly use alcohol or 
have liver damage may be even more susceptible (Hawton, 2002; Makin & Williams, 
2000; Rossi, 2003; Stimmel, 1997; Therapeutic Guidelines Limited, 1997), although 
one study found overdose outcomes for patients with a documented history of 
chronic moderate-heavy alcohol consumption (i.e. >40g alcohol daily) were no 
worse than for other patients, provided appropriate treatment for toxicity was 
instituted (Ayonrinde, Phelps, Hurley, & Ayonrinde, 2005). 
NSAIDs have been noted to cause sodium retention have therefore been associated 
with heart failure, elevated blood pressure, and renal dysfunction in vulnerable 
people. Aspirin can cause gastro-intestinal irritation and is sometimes associated 
with tinnitus when used in high doses. Those with peptic ulcers or a bleeding 
disorder such as haemophilia should avoid aspirin due to its effect on platelet 
function (i.e. reduces congealing properties of blood). Furthermore, it should not be 
used in combination with anticoagulant medications such as Warfarin. Aspirin has 
been shown to precipitate asthma in susceptible patients. Aspirin is not 
recommended for use under the age of 12 or in pregnant females, particularly in the 
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third trimester. Occasional use of aspirin by a breastfeeding mother is thought to be 
safe (Hardman, Goodman Gilman, & Limbird, 1996; Rossi, 2003; Therapeutic 
Guidelines Limited, 1997). 
The adverse effects of opioid analgesics may include nausea, vomiting, constipation, 
respiratory depression, tolerance, and dependence (Rossi, 2003). Adverse effects 
noted with compound analgesics include increased likelihood of the side effects of 
the component drugs occurring and accumulation of drugs of different half lives in 
the system. Opioid analgesics potentiate the effect of other CNS depressants, and 
therefore are best avoided in conjunction with alcohol, other depressant medications, 
and drugs such as heroin. There may be some untoward drug interactions between 
analgesics and herbal medications (Adebe, 2002). 
Prevalence of use 
Analgesic medications such as paracetamol and aspirin are available both on 
prescription and OTC. Such medications are widely used in Western countries, with 
an estimate of 70% of the population using them regularly for pain and fever 
management (Abbott & Frase, 1998). Analgesics are the most commonly prescribed 
medications by GPs in Australia, accounting for 8% of GP prescriptions. GPs also 
frequently recommend analgesics for OTC purchase, particularly paracetamol and 
ibuprofen, and these account for more than 30% of the medications that GPs suggest 
to patients for purchase OTC (Britt et al., 2001). Between 1992 and 2002 
approximately 5 million prescriptions for opioid analgesics were subsidised 
Australia-wide under the PBS or RPBS scheme annually (Heale, 2002). As 
commonly used analgesics such as aspirin were not included in this group, it can be 
assumed that the use of analgesics was even more widespread than the prescription 
data suggest. 
1.3.4 Medical response to overdose 
Most medication overdoses attending for hospital treatment are able to be managed 
with supportive care and observation alone (Jones & Dargan, 2002). In cases where 
more active management is required, treatment may involve gut decontamination (by 
limiting the absorption of the toxin, or increasing elimination), or the administration 
of an antidote (Daly, Little, & Murray, 2006; Greene, Dargan, & Jones, 2005). 
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An oral preparation of activated charcoal is the main method of reducing absorption 
of toxins via the gastro-intestinal tract. Activated charcoal needs to be given within 
an hour of the overdose event to be effective (or slightly longer for sustained release 
medications). Other gut decontamination techniques include gastric lavage and 
inducing vomiting, however, these are no longer routinely recommended. Bowel 
irrigation is used by some practitioners in cases where activated charcoal is 
ineffective (Daly et al., 2006; Greene et al., 2005; Jones & Volans, 1999).  
Some medications and poisons have antidotes available. For example, intravenous N-
acetylcysteine may be used for paracetamol overdose, naloxone for opioid overdose, 
and sodium bicarbonate for tricyclic antidepressant overdose resulting in 
cardiovascular toxicity (Greene et al., 2005). Antidotes are not necessarily a simple 
solution to an overdose situation. For example, the administration of N-
acetylcysteine requires precise calculations of the time and amount of the overdose, 
as well as sound clinical judgement (GlaxoSmithKline, 2002). 
It is rare that cases of medication overdose that reach hospital for treatment 
subsequently result in a fatality. An English study estimated that between 1997 and 
1999 approximately 380 such deaths occurred in that country annually, accounting 
for only 0.5% of all medication overdoses treated within the hospital system (D.  
Gunnell, Ho, & Murray, 2004). This represented 29% of all overdose deaths, and 7% 
of suicide deaths. The most commonly implicated medications were paracetamol 
compounds (35%), benzodiazepines (18%) and tetra- and tricyclic-antidepressants 
(10%). The median time between admission and death was three days, with a third 
dying within one day, and 70% in the first week after admission. The most common 
conditions contributing to death were hepatic failure, cardiac arrest, pneumonia, 
cerebral anoxia, and septicaemia. At least 6% of cases were associated with 
malignant cancer (D.  Gunnell et al., 2004). 
1.3.5 Summary 
Medication overdose accounts for several hundred untimely deaths in Australia 
every year, and several thousand ambulance attendances in the Melbourne 
metropolitan area alone. The medications most commonly implicated in overdose are 
those used in the treatment of mental health conditions (particularly benzodiazepines 
and antidepressants), and for pain management (particularly non-opioid analgesics 
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such as paracetamol). The use of these medications is widespread in the Australian 
community. TCAs, paracetamol, and opioid analgesics are among the most 
dangerous medications to consume in an overdose. Medical treatment for overdose 
most usually involves supportive care, though in serious cases more active 
intervention may be required. The majority of medication overdose cases who 
receive emergency care treatment survive. 
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1.4 Medication overdose studies conducted in emergency 
care settings 
As can be surmised from the information presented earlier, there is considerable 
overlap between depression, suicidal thought and behaviour, and medication 
overdose. The findings of previous research conducted in emergency medical care 
settings of medication overdose are presented in this section. In particular, studies 
examining the intersection between medication overdose,21 depression, and/or 
suicidality are reviewed. 
Information for this section was obtained by conducting a systematic search of 
several relevant databases such as Medline, ProQuest Health and Medical Complete, 
PsychINFO, Embase, and International Pharmaceutical Abstracts. Search terms 
included suicide, self-harm, depression, medication, overdose, poisoning, hospital, 
emergency, and variants thereof. 
1.4.1 Proportion and timing of medication overdose presentations 
Many Australian and international studies examining ED presentations for 
medication overdose have reported the number of cases attending a particular service 
or group of services within a given timeframe. However, these figures have varied 
greatly, depending on the size of the hospital, the catchment area, and other 
variables, thus precluding comparison between studies. A more useful measure is the 
proportion of medication overdose or poisoning cases relative to the total number of 
patients accessing the ED service. Such estimates have ranged from 0.3-5% of all 
attendances (Aghanwa, 2001; D. Taylor, Cameron, & Eddey, 1998; Whyte, Dawson, 
Buckley, Carter, & Levey, 1997). As a proportion of deliberate self-harm cases 
attending hospital; medication overdose or self-poisoning has been found to account 
for 82-95% of presentations (Aghanwa, 2001; Colman, Dryden, Thompson, Chahal, 
Borden, Rowe et al., 2004; Haw, Hawton, Houston, & Townsend, 2001; Hawton et 
al., 1997; Horrocks, Price, House, & Owens, 2003; Townsend et al., 2001). 
                                                          
21 Some of the studies involved “self-poisoning” which may not necessarily have been confined to medications. 
However, these cases have nonetheless been included as medications accounted for the vast majority of 
substances involved. 
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Medication overdose presentations have been shown to vary by time of day. Buckley 
et al. (1993), reported that half of all admissions for deliberate self-poisoning in a 
regional area of NSW occurred in the eight hours between 6 p.m. and 2 a.m. 
Similarly, a study conducted in regional Victoria reported medication overdose 
presentations were the most common in the late afternoon and evening (D. Taylor et 
al., 1998). Ambulance data collected in metropolitan Melbourne were also consistent 
with hospital ED data; the peak time for ambulance attendance at benzodiazepine-
related cases was mid to late evening (Heale, Dietze, & Cvetkovski, 2002). 
Two studies found no variation by day of week in the rate of medication (or 
benzodiazepine) overdose (N. Buckley et al., 1993; Heale et al., 2002) (although the 
latter study found that compared to benzodiazepine overdose, heroin overdose rates 
peaked over the weekend). In contrast, D. Taylor et al. (1998) found medication 
overdose presentations were more likely to occur from Monday to Wednesday than 
during the rest of the week. Buckley et al. (1993) found no variation in the level of 
attendances across the year, however, a small but significant effect was reported for 
female presentations according to lunar cycles (i.e. fewer presentations were 
recorded at the time of a full moon). 
1.4.2 Patient characteristics 
A number of Australian and overseas studies have investigated the demographic 
characteristics of medication overdose patients. English studies have found that 49-
60% of all cases presenting to hospital for deliberate self-poisoning were female 
(Horrocks et al., 2003; Kapur, House, Creed, Feldman, Friedman, & Guthrie, 1998; 
Owens, Wood, Greenwood, Hughes, & Dennis, 2005; Townsend et al., 2001). A 
similar proportion (two-thirds) was reported in an Australian study (D. Taylor et al., 
1998), while a French study found approximately 73% to be female (Vaiva, 
Ducrocq, Meyer, Mathieu, Philippe, Libersa et al., 2006), and a Fijian study reported 
84% female (Aghanwa, 2001). In contrast, a Canadian study found 57% of hospital 
attendances for intentional medication overdose were male (Lo, Shalansky, Leung, 
Hollander, & Raboud, 2003). Ambulance attendance data collected in Melbourne 
revealed that 61% of calls to benzodiazepine-related cases from 1998 to 2001 
involved female patients (compared to 24% females for heroin overdose cases) 
(Heale et al., 2002). Therefore, while the exact figures varied, most studies reviewed 
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concluded females were over-represented relative to males by an approximate ratio 
of 2:1. 
Townsend (2001) and Taylor (1998) found that approximately two-thirds of patients 
attending for self-poisoning were aged 15-34 years, Vaiva et al. (2006) and Kapur et 
al. (1998) found the mean age of patients to be in the thirties, while Lo et al. (2003) 
found a mean age of 40 years. Horrocks et al. (2003) found that most self-poisoning 
cases in Leeds, England were aged 15-39 years. Heale et al. (2002) compared 
ambulance attendances for benzodiazepine and heroin overdoses, and found that the 
average age of those who had taken benzodiazepines was 36 years (compared to only 
27 years for heroin cases). In a Newcastle based study, 4.1% of patients attending 
hospital for deliberate self-poisoning were aged 65 or over (Ticehurst, Carter, 
Clover, Whyte, Raymond, & Fryer, 2002). As a whole, the data suggest medication 
overdose occurred across age groups, although people aged in their twenties and 
thirties predominated. 
1.4.3 Depression and other psychiatric diagnoses 
Psychiatric conditions are common among people taking medication overdose. A 
study of hospital attendances for deliberate self-poisoning in regional NSW found 
95% of patients met the criteria for a formal psychiatric diagnosis when assessed 
soon after admission (Whyte et al., 1997). In an English study of 150 people 
presenting to hospital for deliberate self-harm (96% of whom had self-poisoned), 
Haw et al. (2001) found that 92% could be diagnosed with a psychiatric disorder 
according to ICD-10 classifications. 
The most frequent psychiatric diagnoses were affective disorders (mainly 
depression) in 72% of the sample, followed by substance use disorders (alcohol 27%, 
other drugs 9%), neurotic, stress-related and somatoform disorders (mainly anxiety) 
in 23%, eating disorders in 11%, and schizophrenia in 5% (Haw et al., 2001). Forty-
six percent of those involved in a follow-up study were identified as having a 
personality disorder. There was considerable co-morbidity between diagnoses. Other 
studies also found depression to be the most common psychiatric diagnosis among 
medication overdose patients (Aghanwa, 2001; Hagedorn & Omar, 2002; Kingsbury, 
Hawton, Steinhardt, & James, 1999; Lifshitz & Gavrilov, 2002; Lo et al., 2003; 
Matthews & Fava, 2000). Regarding substance use, a different English study found a 
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somewhat lower rate of alcohol and/or drug dependence (14%) among self-poisoning 
patients, although a later study in the same region found the rates of alcohol 
dependence and drug dependence to be 20% and 7% respectively (Kapur, Cooper, 
Hiroeh, May, Appleby, & House, 2004; Kapur et al., 1998). 
An Australian study investigating the characteristics of youth attending treatment for 
deliberate self-poisoning employed the same diagnostic measures used in the 
National Survey of Mental Health and Wellbeing (Carter, Issakidis, & Clover, 2003). 
Fifty-one self-poisoning patients were compared with 31 young people who had 
previously attempted suicide, and 842 young people with no reported history of 
suicidal thoughts or behaviour. The deliberate self-poisoning group had greater 
prevalence of anxiety, affective, and substance use disorders, and a greater degree of 
mental health related disability (Carter et al., 2003). 
Age may be a relevant factor in the relationship between depression and medication 
overdose; a study comparing deliberate self-poisoning in people aged less than 65 
years with those aged 65 or over found the rate of depression was significantly 
higher in the older group (Ticehurst et al., 2002). 
1.4.4 Characteristics of hospital attendance 
An English study found that patients attending hospital following self-poisoning 
were likely to be triaged22 to be seen more urgently than those with other forms of 
self-injury (Horrocks et al., 2003). In a study conducted in regional Victoria 
information concerning the urgency of medication overdose cases, length of time in 
the ED, and disposal from the ED was recorded. Medication overdose patients were 
significantly more likely to be triaged to one of the top two most urgent categories 
(to be seen within 10 minutes of arrival) than other patients attending the ED (D. 
Taylor et al., 1998). However, those patients attending with repeated medication 
overdoses were more likely to be categorised as least urgent. Overdose patients 
                                                          
22 “Triage” refers to the process or system of ordering injured and ill patients according to medical priority. 
Those with the greatest medical need are allocated a higher priority and are therefore seen before those in lesser 
need. According to the Australasian Triage Scale used in hospital emergency departments there are 5 triage 
levels: ideally cases allocated to category 1 (red) should be seen immediately, category 2 (orange) within 10 
minutes, category 3 (green) within 30 minutes, category 4 (blue) within 60 minutes, and category 5 (white) 
within 120 minutes. Patients waiting to be seen should be continuously reassessed and if their symptoms change, 
re-triaged accordingly (Australasian College for Emergency Medicine, 2000). 
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generally also remained in the ED for longer than other patients and were more likely 
to be admitted, except for those who attended for repeated medication overdose, who 
were slightly less likely to be admitted (D. Taylor et al., 1998). A French study found 
that the average length of stay in the ED following deliberate self-poisoning was 
approximately 18-20 hours (Vaiva et al., 2006). 
A comparison of elderly (65 or more years) with non-elderly patients found that 
older patients had a significantly longer average length of stay (90 hours compared to 
29 hours), greater rate of admission to intensive care, and a higher level of mortality 
as a consequence of deliberate self-poisoning than younger patients (Ticehurst et al., 
2002). This may have been due to the greater physical frailty of the older group, or 
more severe suicidal intent leading to a more medically serious overdose. 
1.4.5 Type and number of medications 
As previously noted (see Medications involved in overdose, page 73), medications 
such as benzodiazepines, antidepressants, paracetamol, and antipsychotics are 
frequently implicated in self-poisoning in Australia and elsewhere (Baca-Garcia et 
al., 2002; Beautrais, Joyce, & Mulder, 1998; Cantor & Neulinger, 2000; Hawton et 
al., 1997; Lo et al., 2003; Neeleman & Wessely, 1997; Shah, Uren, Baker, & 
Majeed, 2002; D. Taylor et al., 1998; Townsend et al., 2001). 
An English study of presentations to hospital following deliberate self-harm found 
that the use of more than one category of medication was common, with the average 
number of medication classes consumed being 1.2 (Townsend et al., 2001). Vaiva et 
al. (2006) reported a higher mean number (1.8) of substances used in cases of 
deliberate self-poisoning attending French hospitals. Lo et al. (2003) reported that 
71% of medication overdose presentations to a Canadian hospital implicated multiple 
medications. The same study also found individuals who overdose most usually take 
their own medications (85% of cases) (Lo et al., 2003). 
Differences have been found in medications taken according to factors such as sex, 
age, and previous overdose history. One study showed females were more likely than 
males to use antidepressants, while males were more likely to use tranquillisers 
(Townsend et al., 2001). The same study found females were more likely to use 
multiple drugs, younger people were more likely to overdose on a single drug 
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(mainly paracetamol), while older people more often self-poisoned with multiple 
medications such as tranquillisers, sedatives, or antidepressants (Townsend et al., 
2001). This is consistent with findings from another study which concluded that 
elderly patients were more likely to take benzodiazepines and less likely to take 
paracetamol in an overdose than younger patients (Ticehurst et al., 2002). The 
authors suggested that the relatively high rate of benzodiazepine use in the older 
group may have been related to accessibility, with older people being more likely to 
be prescribed that group of medications. People with a diagnosis of substance abuse 
have been found to be less likely than those without to take OTC medications in an 
overdose, instead using prescription medications (Lo et al., 2003). 
1.4.6 Concurrent alcohol use 
Concurrent alcohol use has been associated with medication overdose and self-
poisoning. Data from French, English, Canadian, and Australian studies have 
implicated alcohol in 28%-40% of cases (Carter, Clover, Whyte, Dawson, & D'Este, 
2005; Lo et al., 2003; Vaiva et al., 2006). 
1.4.7 Repetition 
Repeated occurrences of medication overdose have been studied either 
retrospectively (i.e. by enquiring about a patient’s history) or, more commonly, by 
prospectively monitoring a group of patients following hospital attendance. In an 
example of the former, a Canadian study of patients attending hospital following 
deliberate medication overdose found that 74% of cases had ever had a previous 
suicide attempt and 71% a previous overdose (Lo et al., 2003). 
Longitudinal studies have generally provided a conservative estimate of repetition as 
most have not counted previous hospital attendances for medication overdose before 
the study period, or captured those who overdosed more than once during the study 
period but not attended hospital, or who attended hospital elsewhere (D. Taylor et al., 
1998). Comparisons between such studies may also be complicated by variations in 
their design, such as the length of follow-up. Kapur et al. (2002) found 15% of 
patients repeated self-poisoning within 12 weeks of the index episode. Studies 
involving 12 months follow-up have yielded estimates of 12-19% (Carter, Clover et 
al., 2005; Carter, Whyte, Ball, Carter, Dawson, Carr et al., 1999; Owens et al., 2005; 
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Vaiva et al., 2006), while a two year study found that 12% of individuals repeated 
within the study timeframe and the mean number of re-presentations was 2.3 (D. 
Taylor et al., 1998). 
Characteristics found to be associated with repetition include younger age, female 
gender, being single (i.e. being married or de facto was protective against repetition), 
greater potential lethality of the index episode, and self-discharge from the ED prior 
to assessment (Carter et al., 1999; Kapur et al., 2002). However, the findings 
regarding the association between age and repetition may be equivocal, as Townsend 
et al. (2001) found a variable proportion of repeaters versus first-time attenders 
across the age groups, while Taylor (1998) found that those patients who presented 
repeatedly were likely to be slightly older. 
A study in regional Victoria found those who attended repeatedly for medication 
overdose were more likely than those attending only once to take a single class of 
drugs, but were also more likely to have other self-inflicted trauma (though the 
overall rate of trauma in both groups was less than 11%) (D. Taylor et al., 1998). The 
finding that patients attending only once during the study period typically overdosed 
on antidepressant medication, while repeated presentations more frequently involved 
neuroleptics and paracetamol may indicate a different psychiatric diagnoses between 
groups. The former group were possibly more likely to have depression and the latter 
to have psychosis and other psychiatric disorders (assuming people overdosed on 
their own medications) (D. Taylor et al., 1998). Another study which compared first 
time overdose patients versus those who had made a previous suicide attempt found 
the group with a previous history were more likely to have experienced sexual abuse 
and exhibited more symptoms of post-traumatic stress disorder (C. Taylor, Kent, & 
Huws, 1994) 
It has been suggested that when non-fatal repetition of medication overdose or self-
poisoning occurs, the risk is greatest within the first few months after the index 
episode. One study found of those repeating within 12 months, a third did so within 
28 days, and three quarters within six months (Carter et al., 1999). Intervention at the 
time of self-poisoning has been found to be associated with reduced rates of non-
fatal repetition of self-harm. The evidence in relation to this is reviewed in ‘Models 
of care’, page 94. 
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1.4.8 Long-term fatal outcomes 
Longer-term studies have investigated the rate of completed suicide among patients 
attending hospital for medication overdose or self-poisoning. For example, all 
presentations in the ten years from 1991 to 2000 to the Hunter Area Toxicological 
Service (NSW) following deliberate self-poisoning were followed-up to determine 
the subsequent mortality rate from suicide, other causes of early death (e.g. motor 
vehicle accidents), and natural causes (Carter, Reith et al., 2005a; Reith et al., 2004). 
At the time of follow-up a total of 5.6% of cases were deceased; 1.4% as a 
consequence of suicide, 1.5% by premature accidental death, and 2.6% by natural 
causes. While the follow-up period for cases in the study was variable (the mean was 
five years), the authors estimated the probability of death by suicide after 10 years to 
be 2%, higher than would be expected in the general population. 
Analyses of risk factors in the above study revealed the following to be predictive of 
suicide: diagnosis of a psychiatric disorder arising in childhood such as conduct 
disorder (in men), involuntary admission to a psychiatric hospital from the service, 
increasing age, and previous suicide attempts (in women) (Reith et al., 2004). The 
risk factors for early deaths and natural deaths were similar, with the addition of 
male gender. Another study by the same group of authors investigating repeated 
presentations for self-poisoning found that increasing severity of overdose events, as 
measured by number of drugs involved, increased dose, increased alcohol and drug 
use, and decreased levels of consciousness upon presentation were all associated 
with elevated risk of subsequently completing suicide (Carter, Reith, Whyte, & 
McPherson, 2005b). 
The risk factors for eventually completing suicide noted above were similar to those 
previously found in an English study to be associated with higher levels of suicidal 
intent in cases of deliberate self-poisoning. These factors included being older, male, 
making repeated attempts, and using multiple substances (Townsend et al., 2001). A 
comparison of fatal and non-fatal deliberate self-poisonings in South London found 
that taking a higher mean number of substances was more likely to be associated 
with fatal outcomes (38% of fatal cases involved multiple medications [mean 1.5], 
compared to 30% of non-fatal cases [mean 1.2]) (Neeleman & Wessely, 1997). An 
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Israeli study found that ingestion of more than two different types of medication was 
associated with greater suicidal intent (Lifshitz & Gavrilov, 2002). 
1.4.9 Models of care 
Hospital presentations for medication overdose have been associated with elevated 
risk of non-fatal repetition of the same behaviour, additional pressure on limited 
health care resources, and increased risk of eventually completing suicide relative to 
the general population. Therefore, the idea of introducing an intervention at the point 
of contact with emergency services has inherent appeal. Several studies conducted in 
Australia and elsewhere have reported on the efficacy of various forms of 
intervention. These studies have employed different designs (e.g. naturalistic, 
randomised-controlled trials), and types of intervention (e.g. usual care, follow-up 
contact via telephone or postcard, comprehensive assessment and referral programs). 
As previously mentioned, mortality among deliberate self-poisoning cases that 
actually present for emergency care has been found to be very rare, and has usually 
only occurred where death was inevitable anyway (D.  Gunnell et al., 2004). It has 
been argued that it is unlikely that any intervention introduced would substantially 
alter mortality rates (Whyte et al., 1997), although the effect on other outcomes such 
as repetition or length of stay may be more readily apparent. The nature and findings 
of various studies concerning the response of emergency medical care services to 
patients presenting for medication overdose are described in this section, and the 
value of providing specialised support in addition to usual care discussed. 
A model for the hospital care of deliberate self-poisoning evolved in the Hunter 
region of NSW during the late 1980s and early 1990s (Whyte et al., 1997). The 
elements of the model included; diversion of all toxicology presentations to one 
hospital, admission of all such cases under the care of a single multidisciplinary team 
(medical, psychiatric, nursing, and drug and alcohol) with particular toxicological 
and psychiatric expertise, and 24 hours a day, seven days per week coverage (Whyte 
et al., 1997). In addition to medical management of toxicity, all patients were 
automatically given a psychiatric assessment, regardless of the seriousness of the 
poisoning, as it was recognised that any deliberate self-poisoning is a symptom of a 
problem requiring attention, and that “significant suicidal risk is present for many 
patients with toxicologically ‘trivial’ poisonings” (Whyte et al., 1997), p. 142. In 
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addition, care was expected to be non-judgemental and non-punitive, and aimed to 
maintain safety, enhance treatment compliance, provide psychological support, 
address other factors contributing to the overdose, and include follow-up services. 
While there was no apparent reduction in mortality levels as a consequence of the 
program, there was a clear reduction in the average length of stay (both pre and post 
the program, and compared to other similar locations continuing with usual care), 
and no compromise of patient care (Whyte et al., 1997). 
An intervention study based at the same site and conducted between 1998 and 2001 
involved a randomised controlled trial comparing two groups of patients treated for 
deliberate self-poisoning (Carter, Clover et al., 2005). The intervention group were 
sent eight postcards from the toxicology service over a period of 12 months 
following an attendance for self-poisoning, while the non-intervention group 
received usual care. The postcards contained a short message enquiring after the 
welfare of the patient. No significant difference was found between the intervention 
and control groups in the proportion of people who had a repeated episode of self-
poisoning within the study timeframe (15.1% compared to 17.3%). However, there 
was a significantly greater reduction in the number of repeat episodes per individual 
in the intervention group compared to the usual care group. The number of such 
episodes was reduced by almost half, and there was an associated substantial 
reduction in bed days (Carter, Clover et al., 2005). The intervention was more 
effective among females than males. 
An English randomised control trial investigated the potential of brief psychological 
therapy versus usual care following presentation to hospital for deliberate self-
poisoning (Guthrie, Kapur, Mackway-Jones, Chew-Graham, Moorey, Mendel et al., 
2003; Guthrie, Kapur, Mackway-Jones, Chew-Graham, Moorey, Mendel et al., 
2001). Six months after the overdose patients who had received the four intervention 
sessions reported significantly lower levels of suicidal ideation, higher levels of 
treatment satisfaction, and less self-harm (9% recurrence in the intervention group 
compared with 28% in the control group) (Guthrie et al., 2001). Those with lower 
levels of depression, no history of self-harm, and who had not consumed alcohol at 
the time of the overdose appeared to benefit the most from the intervention, with the 
authors concluding that a longer intervention may be useful for patients with more 
complex problems (Guthrie et al., 2003). A subsequent article pointed out the 
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limitations of the study by Guthrie and colleagues (for example, low participation 
rates, and pre-existing group differences), but nonetheless concluded that brief 
interventions addressing interpersonal conflict may have some promise in preventing 
recurrence of self-poisoning (House, 2002). 
Another study from the United Kingdom which involved a naturalistic comparison of 
psychosocial assessment versus no assessment, found patients who had received a 
psychosocial assessment were only half as likely to repeat the behaviour (Kapur et 
al., 2002). A further naturalistic cohort study by the same group attempted to 
evaluate which of two interventions for self-poisoning was associated with the lower 
rate of repetition within six months; standard psycho-social assessment after 
presenting to the ED, or referral for specialist follow-up (Kapur et al., 2004). The 
results indicated that specialist follow-up (e.g. mental health professional or self-
harm treatment service) had better outcomes than assessment alone. The authors 
cautioned that given the naturalistic design of the study the findings may partly 
reflect a referral bias. 
A French study found telephone contact one month (but not three months) after 
hospitalisation for self-poisoning was associated with fewer self-reported suicide 
attempts in the ensuing year compared to treatment as usual (Vaiva et al., 2006). 
However, there was no difference between groups in the number of deaths by suicide 
or losses to follow-up within the study timeframe. 
Despite the widely varying study designs and interventions, each of the studies 
reviewed above indicated some benefit of an enhanced response to medication 
overdose, in addition to usual care. The evidence suggested that a measure as simple 
as universal assessment of all cases attending a hospital ED service for self-
poisoning had the potential to significantly reduce the re-presentation rate. 
According to one estimate, for every twelve people so evaluated after an episode of 
self-poisoning, there was a reduction of one person among those who repeated 
(Kapur et al., 2002). Owens et al. (2005) also argued that the universal application of 
good assessment and care to all patients attending an ED following self-poisoning 
was more likely to be effective in reducing subsequent mortality by suicide than 
targeted efforts. Their 16-year outcome study found that patient characteristics had 
insufficient predictive value to be relied upon in targeting prevention strategies and 
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so there was no value in trying to specifically identify or target sub-groups at 
particular risk (Owens et al., 2005). 
Despite the above findings in favour of providing a psychosocial assessment at the 
very least, there is some evidence to suggest thorough review of medication overdose 
patients may not always occur. An English study found that 46% of cases of self-
poisoning were discharged without any psychosocial assessment at all, although this 
was in contravention of local health department guidelines (Kapur et al., 1998). It is 
possible that decisions about care may sometimes be influenced by factors other than 
clinical need. One study found patients attending hospital following deliberate self-
poisoning were less likely to be admitted or given a psychiatric assessment prior to 
discharge from the ED if they presented overnight (between 11 p.m. and 6 a.m.), or if 
they lived outside the hospital catchment area (Kapur, House, Creed, Feldman, 
Friedman, & Guthrie, 1999). These results suggest that the availability of resources 
can influence clinical outcomes, and that novel strategies may need to be employed 
to address such issues. As an example, a Welsh study found that the psychosocial 
assessment of patients attending hospital for self-poisoning could not only be 
conducted by a trainee psychiatrist, but equally well by a specialist mental health 
nurse (Griffin & Bisson, 2001). Increasing the potential pool of staff available to 
respond to patient needs through appropriate education and training may therefore 
assist in ensuring patients are thoroughly assessed. 
1.4.10 Limitations of previous studies and future directions for further 
research 
As is evident from the literature reviewed above, there have been several studies 
conducted in various countries regarding medication overdose which have shed 
considerable light on the nature and extent of this phenomenon. However, a number 
of interesting questions remain unanswered by the available evidence. 
There have been no published studies conducted in a Melbourne hospital of adult 
medication overdose. It is therefore of interest to know whether the patterns observed 
in other locations are also true of an inner-city Melbourne ED. 
Few previous studies have provided a comparison of the patients who presented 
following self-poisoning with other patient groups. Where comparisons were made, 
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it was generally with the total patient group. Colman et al. (2004) compared patients 
attending for self-inflicted injury23  with asthmatics24 and a random ED group. The 
study concluded that the self-injury group were chronic users of the ED, and had 
higher rates of psychiatric disorders than the other two groups. However, this study 
deliberately chose a primary comparison group that was very different to the self-
injury group. An English study compared patients attending the ED following self-
poisoning with patients attending as a consequence of some other form of self-injury. 
The self-poisoning groups were more likely than the self-injury group to be aged 45-
49, to be female, to be triaged as more urgent, and to receive a psychosocial 
assessment (Horrocks et al., 2003). However, few other studies of this type have 
been conducted. Therefore, it is of interest to further compare patients attending for 
medication overdose with patients who have self-harmed by means other than 
pharmaceutical ingestion or who are at-risk of self-harm to see what factors, if any, 
distinguish the groups. D. Taylor and Cameron (1998) conducted a study in regional 
Victoria in which 175 self-inflicted trauma cases were compared to 441 overdose 
cases. However, in that study, the definition of overdose was not confined to 
pharmaceutical medications, and may have involved illicit drugs, or other toxins.  It 
would be of interest to separate out patients attending with the same type of injury 
(i.e. overdose) but who had consumed two different classes of substance, namely 
illicit drugs and pharmaceutical medications. Heale et al. (2002) compared 
benzodiazepine cases with heroin overdose cases, however, this involved ambulance 
rather than ED data25, and only one class of medications and one type of illicit drug. 
While a great deal of information can be obtained from computerised patient data 
systems and other records, such sources provide only a partial understanding of the 
event. Hospital records have a limited amount of information on the personal 
circumstances of the individual and possibly none on their perspective of the 
overdose. Few studies have attempted to combine data collected from secondary 
sources such as hospital records with additional information obtained directly from 
                                                          
23 This group included all types of self-injury, not just self-poisoning, or even more specifically, medication 
overdose. 
24 The asthma group was chosen for comparison on the basis that they are also high users of ED services. 
25 While ambulance attendance data and ED data can both be considered emergency medical care datasets, they 
represent distinct although overlapping groups. Not all cases attended by ambulance are necessarily transported 
to hospital, and not all cases attending hospital arrive via ambulance. 
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the patient by the researcher. D. Taylor et al. (1998) recommended that personal 
factors such as social class, employment, marriage status, substance or alcohol use, 
and psychiatric illness be studied in a prospective setting.  
Neale (1999, 2000) conducted an ethnographic study in a Scottish hospital, though 
the focus of that study was patient experiences of illicit drug overdose rather than 
medication overdose. A Swedish qualitative study examined the perspectives of a 
small number of patients who repeatedly used the ED, focusing on life 
circumstances, and perceptions of the care received at hospital (Olsson & Hansagi, 
2001). However, the study did not specifically look at the phenomenon of overdose. 
A worthwhile direction for medication overdose research would be to combine 
inclusive patient dataset information with patient interviews, and to relate this to 
patient care. For example, to examine how patients regard the experience, and 
whether they are satisfied with the care they receive. 
It is clear that many patients attending hospital following a medication overdose 
have a psychiatric disorder, most commonly depression. However, few studies have 
investigated the severity of depressive symptomatology, either while at hospital, or 
possibly more importantly, at the time the overdose was taken. While severity of 
depression was assessed in Haw et al’s (2001) study, there has been little exploration 
in any study of medication overdose into whether the level of depression at the time 
of self-harm relates to the degree of suicidal ideation experienced, or the level of 
intent to die. 
Another drawback of studies which relied solely on information from standardised 
patient datasets is that little was recorded of the circumstances surrounding the 
overdose. For example, information contained in generic patient databases may not 
be useful in answering questions about where the medications were obtained from, 
for what purpose, how they were consumed in the overdose, and whether alcohol 
intoxication preceded or co-occurred with ingestion. The authors of a study which 
found the rate of benzodiazepine overdose was higher among population groups in 
receipt of more prescriptions for such medications suggested that the issue of 
prescription required further investigation (Ticehurst et al., 2002). It was not possible 
to tell from hospital data alone whether the medications had been deliberately sought 
with the intention of overdose, whether patients were being ineffectively treated with 
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benzodiazepines for depression, or whether the medications had a causal role in the 
overdose by precipitating disinhibition, depression, or anxiety. Such questions may 
be better answered by direct patient interviews, and may have important implications 
for prevention if improved prescribing practices lead to reduced access to a common 
means of self-harm. 
1.4.11 Summary 
ED-based studies have found that medication overdose usually accounts for a small 
proportion of the total cases (approximately 1%), but is implicated in most cases of 
self-harm (approximately 90%). The number of presentations to the ED for 
medication overdose varies considerably with time of day, with most occurring in the 
evening. Repetition is not uncommon, with Australian studies finding recurrence 
rates of about 12-14% within two years of the index episode. While the vast majority 
of medication overdose patients do not subsequently commit suicide, the risk level is 
higher than for the general population, as is the risk for early death by other non-
suicide causes. Repeated overdose events of increasing severity are a serious suicide 
risk marker. 
Most medication overdose patients are female. Psychiatric conditions, especially 
depression, are prevalent among this group and co-morbidity is common. Upon 
presentation to the ED medication overdose patients are categorised as being more 
urgent than other patients, and tend to require a longer hospital stay. 
Psychotropic medications such as benzodiazepines and antidepressants, and 
analgesic medications such as paracetamol are the most commonly used medications 
in overdose cases. Most overdoses involve only one or two different medications. 
Consuming multiple medications is associated with higher suicidal intent, and 
greater likelihood of fatality. There are some group differences in the medications 
chosen for overdose, possibly reflecting underlying psychiatric diagnoses. 
Concurrent alcohol use occurs in about a third of medication overdoses. 
In addition to medical management of overdose, there is emerging evidence that 
thorough psychiatric or psychosocial risk assessment of patients attending for care 
forms part of good clinical management. Referral to specialist follow-up services or 
intervention may offer additional protection against recurrent overdose, although 
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further research is required. Contemporary practice should avoid punitive or 
disrespectful treatment of medication overdose patients. 
Previous emergency care based studies have made a significant contribution to the 
understanding of medication overdose. However, there still remains much to be 
learned about the phenomenon, particularly as experienced in a Melbourne ED. It is 
not yet well understood how medication overdose patients differ from two patient 
groups with apparently similar presentations; patients at-risk of self-harm by other 
means, and patients who overdose on illicit substances. It would also be of interest to 
supplement hospital data sources with information provided directly by medication 
overdose survivors regarding their psycho-social history, circumstances of their 
overdose, and experience of emergency care. While depression and suicidality are 
clearly associated in some individuals, the interplay between these factors as a 
person contemplates medication overdose has not been thoroughly examined. 
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2 Aims 
2.1 Significance of Research 
Non-fatal medication overdose represents a significant public health issue. This 
study aimed to provide a description of such presentations to the ED of one major 
inner city public hospital, using a range of temporal and personal characteristics. 
Unlike most previous studies of non-fatal medication overdose which relied on a 
single source of information, this study utilised data from three sources; 
computerised hospital records, patient interviews, and observation. The study 
findings therefore have the potential to contribute to a greater understanding of the 
characteristics of medication overdose patients in comparison to other similar patient 
groups, and to also provide a description of the environmental and psychosocial 
factors which may mediate the occurrence of medication overdose. 
2.2 Specific Objectives 
1. To assess the contribution medication overdose presentations made to the overall 
patient presentations to the ED of a major inner-city public hospital in 
Melbourne, Australia. 
2. To describe who attended the ED for medication overdose, and to compare this 
group with three others: all patients who attended the ED, patients who attended 
for illicit drug overdose, and patients who attended because of potential self-
harm or actual self-harm by means other than medication overdose. 
3. To better understand the relationship between a) specific suicidal intent, b) 
suicidal ideation, and c) depression in a convenience sample of medication 
overdose survivors. 
4. To document which prescription and OTC medications were implicated in 
medication overdoses presenting to the ED, and to qualitatively document how 
the medications involved were typically acquired. 
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5. To qualitatively document individual experiences of the emergency medical 
system following medication overdose. 
6. To describe the experience of conducting research with a vulnerable population 
in a complex and sensitive environment and to comment on the feasibility of 
further similar research or of introducing a brief intervention into the ED 
environment. 
2.3 Research Questions 
A series of research questions were developed in relation to each of the stated 
objectives. 
1 To assess the contribution medication overdose presentations made to the overall 
patient presentations of a major inner city public hospital in Melbourne, 
Australia. 
 (i) How many presentations were there to the ED in a 12-month period for 
medication overdose? 
 (ii) When did presentations occur? 
2 To describe who attended the ED for medication overdose. 
 (i) What was the broad demographic profile of all patients attending for a 
medication overdose, and how did this compare to those attending for illicit 
drug overdose, or for self-harm by means other than overdose? 
 (ii) Of a sub-sample of patients, could a profile be developed to describe this 
group on a range of characteristics? (i.e. demographic, physical health, 
mental/psychiatric health, drug and alcohol use/dependence, treatment 
history, previous overdoses, personal and family history of self-harm, 
recent significant life events and social support). 
3 To better understand the relationship between a) specific suicidal intent, b) 
suicidal ideation, and c) depression in a sub-sample of medication overdose 
survivors. 
 (i) Were scores on standardised measures of depressive symptomatology 
(BDI-FastScreen) (Beck et al., 2000) and suicidal ideation (BSS) (Beck & 
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Steer, 1993) congruent with (i) each other, and (ii) with participant ratings 
of the deliberateness of their overdose and their wish to die at the time of 
overdose? 
 (ii) Were participant scores on the BDI-Fastscreen and BSS (and other 
measures) consistent with participant narratives regarding their state of 
mind and intentions at the time of the overdose? 
 (iii
) 
Did other factors appear to be systematically related to BDI and BSS 
scores? (e.g. demographic, physical health, mental/psychiatric health, drug 
and alcohol use/dependence, treatment history, previous overdoses, 
personal and family history of self-harm, recent significant life events and 
social support). 
 (iv) What was the overdose process as described within participant narratives? 
4 To document which prescription and OTC medications were implicated in 
medication ODs presenting to the ED, and to qualitatively document how the 
medications were typically acquired. 
 (i) What classes of medications were implicated in overdose presentations to 
the ED in a 12-month period? 
 (ii) In what manner were substances consumed in an OD situation? (e.g. all at 
once or gradually?) 
 (iii
) 
Were other substances usually implicated in the OD? (e.g. were participants 
intoxicated on alcohol or other substances at the time of the OD?) 
 (iv) Were the medications involved acquired specifically with the intention of 
overdosing, or for therapeutic reasons but then used in an OD? 
 (v) Where prescription medications were involved (rather than OTC), how 
were they obtained, and was this through legitimate channels or otherwise? 
 (vi) What level of understanding did medication overdose survivors have of the 
intended purpose of their medications and recommended dosages? 
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5 To qualitatively document individual experiences of the emergency medical 
system following medication overdose. 
 (i) What were the typical pathways of care through the emergency medical 
system for medication overdose patients? 
 (ii) What experiences did medication overdose patients have of the emergency 
medical system? (including ambulance attendance, while in the ED, and 
upon discharge)? 
 (iii) Were patients satisfied with their treatment in the emergency medical 
system? 
6 To describe the experience of conducting research with a vulnerable population 
in a complex and sensitive environment and to discuss the feasibility of further 
similar research or of introducing a brief intervention into the ED environment. 
 (i) What was the ED like as a research environment? 
 (ii) What was it like to conduct research interviews with medication overdose 
survivors recruited at the point of emergency medical care? 
 (iii) What did these experiences suggest about the conduct of future research? 
 (iv) What did these experiences suggest about the potential to introduce a brief 
intervention? 
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3 Method 
3.1 Research Site 
The research questions outlined in the preceding section were addressed using three 
main sources of data collected at St Vincent’s Hospital ED. St Vincent’s is a major 
public hospital and is located on the edge of Melbourne’s Central Business District. 
Access to the ED was negotiated with the Medical Director of the department. The 
Director was able to provide access to the department at all times, office space, 
computer facilities, access to the patient database, use of an interview room, and an 
introduction to ED staff. The Deputy Director, Nursing Unit Manager, Psychiatric 
Consultant Liaison and the Director’s personal assistant also provided support to the 
project. 
3.2 Data Sources 
 (1) Audit of Patient Administration System (PAS) Data - Information regarding 
every presentation to the St Vincent’s Hospital ED is entered onto the PAS database 
by ED staff. A prospective audit of relevant cases entered onto the database was 
conducted for a 12-month period from 1st November 2003 to 31st October 2004. 
(2) Patient Interview Data – In-depth semi-structured interviews were conducted 
with a convenience sample of medication overdose survivors seen in the ED. 
(3) Observational Data – Detailed observational notes were kept by the researcher 
during the 12-month data collection period on the operation of the ED and 
interactions between staff and patients, with the purpose of creating a description of 
the ED response to medication overdose. 
3.3 Explanation for the Selection of Data Sources 
As can be seen from the research questions previously listed, this project aimed to 
investigate the phenomenon of medication overdose on a number of levels. At the 
broadest level, it sought to quantify the extent of this problem as experienced by a 
single ED on a range of dimensions (e.g. number of cases, temporal patterns, broad 
demographic profile, and medications implicated). The relevant research questions 
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were therefore primarily concerned with incidence. The audit of the PAS data 
enabled the researcher to capture all medication overdose events occurring within a 
12-month timeframe, to describe the total population of medication overdose 
presentations in terms of the above-mentioned variables, and to explore the 
relationship between them via statistical analyses. However, as useful as these data 
were in describing the extent of medication overdose treated within a hospital ED, 
they explored only one dimension of the issue.  
In addition to quantifying the extent of such presentations, the study also sought to 
examine the characteristics and experiences of individuals presenting to the ED for a 
medication overdose. For example, some of the research questions concerned 
multifarious characteristics of medication overdose patients (such as mental health 
history, previous experiences of self-harm, and intentions), the manner in which 
medications were obtained and consumed, and personal experiences of the 
emergency medical care system. As suggested in Flick (2002), not all research topics 
are necessarily suitable for empirical quantitative research methods. In particular, 
when the object of interest is in some way exceptional, or the concepts involved are 
imprecise, qualitative methods may be more appropriate. Given that the research 
aimed to investigate the phenomenon of medication overdose as experienced by 
individuals, it was thought that a semi-structured format could better capture the 
complexity of this than purely quantitative methods. This approach allowed for the 
inclusion of both “theory-driven, hypotheses-directed questions” (Flick, 2002, p. 81), 
and open questions that invited participants to provide their perspective in examining 
the topic. 
The study was also intended to yield a description of the broader processes at a 
single ED for dealing with medication overdose. Such a view may not be readily 
available from the audit of all cases attending, nor is it likely that a single person 
presenting with an overdose would have a clear sense of the system more generally, 
though they may certainly be able to contribute a personal account. However, 
observational data provided a useful mechanism by which to build an overall picture 
of the workings of the ED and how the ED response might be improved upon. 
This study therefore explored the phenomenon of medication overdose by involving 
multiple data sources and various methods. By triangulating data sources and 
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methods, conclusions reached by one technique were complemented by other 
techniques (Flick, 2002). Further detail on each of the data sources, including the 
method of data collection and analytic strategy, is provided below. 
3.4 Audit of Patient Administration System (PAS) Data 
3.4.1 The PAS 
PAS is a computer database used within the ED. It has both a record keeping and 
clinical function. When a patient presents to the ED his or her details are taken by the 
triage nurse on duty. The information entered onto PAS includes both administrative 
details (e.g. name, address, next of kin), and clinical details concerning the current 
presentation. Any previous visits by the same patient can be retrieved and the new 
information added to their patient history. Each patient is assigned an identity 
number to link his or her records over time. 
Information recorded at triage includes the date and time of presentation, presenting 
complaint, age, sex, patient record number, triage level and a brief narrative of the 
case.26 Once the patient’s details have been entered and they have been triaged, their 
name, age, presenting complaint and priority level appear as an icon on a computer 
screen showing a floor plan of the ED (i.e., it is possible to tell whether a patient is in 
the waiting room or a particular cubicle within the ED. When a patient is relocated 
within the department their icon will also be moved on the map). PAS information is 
accessible by all staff on designated computers within the ED and is used throughout 
the patient’s stay in the department. 
Treating staff may add brief additional information to PAS records as they go about 
their work. For example, a clinician may record regular observations (e.g. blood 
pressure), whether any tests were conducted, or whether the person was referred for 
psychiatric assessment.27 The time the patient was seen, the time discharged, and 
discharge status28 are also routinely recorded. 
                                                          
26 For example, the narrative may say something like; “Patient brought in by ambulance complaining of headache 
and nausea. Admits to consuming alcohol and 8 serepax since 14:00. Patient history of depression and self-
harm.” 
27 This information is in addition to the more detailed information that is recorded on each patient’s hard copy 
medical file. However, only information recorded in PAS formed part of the audit. Individual, hard copy patient 
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While information is added to PAS on a real time or live basis, it is possible to 
subsequently review the records for each day. Therefore, for any given day it is 
possible to determine how many cases attended the department and to access the 
record of each patient’s stay. PAS does not contain full medical histories, however 
there is sufficient detail available to answer research questions posed via an audit of 
cases presenting within a 12-month period. 
3.4.2 Data extraction 
Process 
The daily list of patient attendances recorded on PAS was reviewed for each 24-hour 
period (midnight to midnight) for a period of one year from 1st November 2003 to 
31st October 2004. The total number of cases attending the department for any 
complaint was recorded and then the list reviewed for relevant cases (see ‘Case 
selection’ below). Where relevant cases were identified, the following information 
was noted for each patient: 
 Date and time of initial presentation to triage 
 Day of week of presentation 
 Date and time patient seen by treating staff 
 Date and time of discharge 
 Patient identity number29 
 Triage level assigned to patient 
 Presenting complaint 
 Age 
 Sex 
 Discharge status 
                                                                                                                                                                    
files were not viewed by the researcher and did not form part of the data collection process. The purpose of the 
audit was to gain an overview of the Emergency Department’s work in relation to medication overdose, rather 
than to conduct a detailed examination of individual cases via accessing medical records. 
28 Where the person was discharged to; for example, home, admitted to ward, etc. 
29 The patient identity number was recorded to enable the researcher to determine how many patients re-attended 
within the 12-month period with a similar presentation. No names or other identifying information were 
recorded. 
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 Brief case narrative as entered by triage and treating staff 
While relevant cases were often identifiable from the presenting complaint listed 
(e.g. “overdose/ingestion/poisoning”), eligible cases could be listed under a variety 
of presenting complaints. Reviewing the case narratives often revealed additional 
cases for inclusion, therefore all presentations for any given day were reviewed to 
ensure every relevant case was included in the audit. 
Case selection 
While this study specifically focused on medication-related overdoses, it was of 
interest to compare these cases with presentations for illicit drug overdose and 
deliberate self-harm on variables such as age and sex. Therefore details were 
recorded of the following types of presentation: 
 Presentations arising from misuse or overdose of medication(s), whether 
accidental or deliberate 
 Presentations arising from intoxication or overdose on illicit drug(s), whether 
accidental or deliberate, and 
 Presentations identified as involving thoughts, threats, or actions of deliberate 
self-harm. 
A single case may have qualified for inclusion on any one, two or three of these 
counts. The overlap between cases and allocation to independent groups is described 
later. 
There were times when it was difficult to determine whether to include a case on the 
basis of the information available on PAS. In such instances a decision was made on 
whether to include or exclude the case, the principle behind the decision recorded, 
and this “rule” then applied to all subsequent similar presentations to ensure 
consistency across the data collection period. These criteria are summarised below. 
Inclusion and exclusion criteria 
Medication misuse or overdose 
The focus of this study was medication overdose. The first element of this term was 
relatively simple to define; “medication” was taken to mean any pharmaceutical 
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preparation available on prescription or OTC. Therefore, it did not include 
naturopathic or herbal preparations. 
However, the concept of “overdose” in relation to medications was more difficult to 
define with precision. There is no single set of biological markers of excessive use 
(e.g. unconsciousness, shallow breathing) that apply across all medication types. 
Further, the amount of any particular medication required to have a toxic effect will 
depend on a range of variable such as the sex and weight of the individual, tolerance 
effects, substance interaction effects and so on. For example, a person who already 
has impaired liver function may be more susceptible to the effects of a paracetamol 
overdose than someone with a healthy liver. Additionally, the intention of the person 
may not be reflected in the amount of medication taken; one person may have 
consumed a harmless level of medication but regard it as an overdose, while 
someone else may consider their dangerously high level of medication consumption 
as innocuous. 
Given the impossibility of establishing inclusion criteria based on the actual level of 
medication consumed or a particular set of medical signs occurring as a consequence 
of that consumption, a more general (and therefore inclusive) definition of 
medication overdose was adopted which included the misuse of medications. For the 
purposes of this study any case in which the inappropriate consumption of 
prescription or OTC medications contributed to the presentation to the ED was 
regarded as “medication misuse or overdose” and so included in the audit. 
Inappropriate consumption included taking medication in a manner other than what 
would ordinarily be prescribed or recommended and could therefore range from 
taking a small number of tablets with nil discernible ill-effect to taking hundreds of 
tablets with life-threatening consequences. The medication was regarded as 
contributing to the presentation if there was any direct relationship between the 
inappropriate use of medication and the presenting complaint. In the simplest 
example, a patient would be triaged specifically as an “overdose” upon arrival at the 
ED. In a less obvious example, a person might present with a complaint of 
“diabetes”, but if the diabetic reaction followed a massive overdose of insulin, then it 
would be reasonable to claim the inappropriate use of medication contributed to the 
presentation. Such cases were therefore also included in the audit. 
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Although these inclusion criteria were adopted from the beginning of the project, the 
researcher continued to encounter cases in which further judgement was required as 
to whether or not a particular presentation should be included in the audit. Where 
such a judgement was made, the reasons for deciding for or against inclusion were 
noted and then this rule applied to all future cases with similar features. The 
following types of cases were excluded: 
 Cases where the consumption of pharmaceutical medications was suspected, but 
not confirmed. 
 Cases where the overdose was due to some other substance such as disinfectant or 
mouthwash (though if deliberate, the case may have been included as ‘Self-harm, 
page 114). 
 Cases where the narrative referred to the current prescription medications taken 
by the person, but where there was no implication of misuse or overdose. This 
was sometimes a difficult judgement to make in cases where a person presented 
for alcohol or other drug intoxication as it is possible that the concurrent use of 
medications, even as prescribed, may have contributed to the altered conscious 
state. In general, if a person had only taken their normal therapeutic dose (e.g. a 
single antidepressant tablet) the case was not included even if the person was 
intoxicated on some other substance such as alcohol. An exception to this was if 
the person had consumed benzodiazepine medication in conjunction with heroin, 
in which case the case was also counted as a medication overdose as the capacity 
of even small doses of benzodiazepine medication to potentiate the effects of 
heroin is well established. 
 Cases where the patient alleged they had consumed a “spiked” drink. The handful 
of such cases that presented during the 12-month period were excluded on the 
basis that there was no confirmation that the drink did in fact contain a 
medication. Had such confirmation been available the case would have been 
included. 
Occasionally a case was triaged as an overdose, but from the information contained 
in the narrative it was apparent that no overdose had occurred, although the case was 
medication-related. For example, there were a few cases where the patient was in 
fact seeking benzodiazepine medication from the ED. There was also a case triaged 
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as an overdose in which the consumption pattern (i.e. an extended period of 
excessive use of benzodiazepines followed by sudden cessation) and the physical 
symptoms described (i.e. nervousness, sweating, derealisation, seizures) were more 
consistent with a withdrawal syndrome than overdose, therefore this case was not 
included as an overdose. 
There were a small number of cases where a person was brought to the department 
by third party (e.g. friend or relative) who alleged the person may have taken a 
medication overdose but where the patient denied any such event. These cases were 
excluded unless there was other evidence such as a test result that indicated an 
overdose had in fact been taken. 
Cases where the person had taken the medication as recommended by a doctor, but 
then had an adverse reaction to the medication were not included, even if triaged as 
an overdose. (Conversely, if a patient was accidentally administered an excessive 
dose the case was included, for example, a patient in a nursing home given incorrect 
medication). 
Illicit drug intoxication or overdose 
As with medication overdose, there were two elements to the term illicit drug 
overdose, and also as with medication overdose, the definition of the substance was 
more straightforward than the definition of the outcome. Presentations involving the 
ingestion of illicit drugs were taken to be those involving substances including 
heroin, amphetamines, ecstasy, GHB, ketamine, cannabis, inhalants30, hallucinogens, 
and cocaine. 
In terms of overdose, some drug types lend themselves more readily to a tight 
definition than others. For example, an overdose of heroin might be defined as any 
case in which the person becomes unconscious, stops breathing and is cyanosed, or 
any case in which a positive response to the antidote naloxone is apparent. However, 
for many other drug types there is a much wider margin between an effective dose 
and a toxic dose (or overdose). Therefore it is unlikely that any person who has 
                                                          
30 Inhalants are not strictly speaking an illicit drug. As inhalants are generally commonly available household 
products, they are legal to possess, although it is an offence for a shop-keeper to sell such products to an 
individual if the shop-keeper believes they are to be used for inhaling (Australian Drug Foundation, 2004). 
However, due to the risks associated with inhalant use, they have been included here as an illicit drug.  
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consumed an excessive amount of a drug such as cannabis would actually stop 
breathing as a direct consequence of their drug use, nor is there any antidote which 
can be used as a biological marker of an overdose. 
Rather than try to establish different benchmarks for overdose according to each drug 
type, it was decided that any case in which recent illicit drug use (i.e. the person was 
substance-affected) was a feature of the presentation would be included in the audit. 
The rationale behind this was that any level of illicit drug intoxication warranting 
medical attention is problematic, regardless of whether it is life-threatening, and that 
in terms of understanding the contribution of illicit drug use to the patient load of the 
ED, the distinction between different levels of intoxication, or indeed defining the 
specific point at which an overdose might be said to occur, is spurious – resources 
are allocated to the patient regardless. 
As with the medication related presentations outlined above, during the process of 
conducting the audit there were a small number of cases which at first glance broadly 
met the inclusion criteria outlined above, but which were excluded on the basis of 
further detail provided in the narrative. These included: 
 Cases involving illicit drugs which were triaged as an overdose but where the 
narrative indicated the patient was in fact in withdrawal, seeking detoxification, or 
seeking medication. 
 Cases where the presentation did relate to the use of illicit drugs, but where the 
person was not intoxicated at the time of presentation. For example, there was a 
case where a person had consumed amphetamines two weeks prior and presented 
complaining of feeling anxious ever since. This case was excluded from the audit. 
Similarly, there were cases of “drug-induced psychosis” – these cases were only 
included if the person was intoxicated as well as psychotic upon presentation. If 
the psychosis was an ongoing consequence of past drug use, but without evidence 
of current intoxication, the case was not included in the audit. 
Self-harm 
All presentations to the ED for the 12-month period that involved any reference to 
deliberate self-harm or suicide were included in the audit. This could range from a 
patient acknowledging having thoughts, feelings, or wishes of deliberate self-harm or 
suicide, through to actually engaging in deliberate self-harming behaviour. In terms 
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of deliberate self-harm, cases were included whether or not the person was actually 
suicidal (e.g. cases of self-cutting to relieve tension rather than to commit suicide). 
As cases involving “medication misuse or overdose” and “illicit drug intoxication or 
overdose” were already being included in the audit, and it was not always possible to 
tell from the narrative whether such overdoses were instances of deliberate self-harm 
or accidental poisoning, such cases were not also counted as self-harm events unless 
either, (i) there was information in the narrative that made it clear that was the intent 
of the event, or (ii) there was some other self-harming behaviour undertaken in 
conjunction with the overdose. While these cases were included as self-harm for the 
purposes of data collection and calculating initial frequencies, the comparison of 
interest for the study is between medication overdose and self-harm by other means. 
Other types of self-harming behaviour included poisoning by other substances, self-
inflicted scratches/cuts/lacerations/stabbing, ingestion of foreign objects, jumping 
from height, hanging/strangulation, deliberate involvement in a car/train/tram 
accident, exhaust/gassing, and burning/electrocution. 
There were a small number of cases that were borderline for inclusion in the audit 
and the following exclusions were developed:31 
 If the narrative referred to a patient history of suicidal tendencies, but did not 
mention self-harm in relation to the current presentation. 
 If the presentation referred only to “harm”, e.g. “thoughts of harm”, but did not 
specify whether these thoughts were directed at self or others. 
 If the presentation was due to a third party reporting that the patient had suicidal 
thoughts which were denied by the patient, and there was no other evidence to 
suggest suicidal thoughts or behaviour. Similarly, if a patient was thought to be 
potentially suicidal but this was not firmly established due to a language barrier. 
 If a patient complained of hearing voices telling them to die or kill themselves, 
but the person was able to resist and not act upon the voices and had no desire or 
impulse to self-harm. 
                                                          
31 This list was developed as data collection progressed. Each time a case was borderline for inclusion, the 
researcher determined whether or not cases with that characteristic (e.g. history of suicidal tendency, but not in 
relation to the current presentation) were to be routinely included or not, and a written note made of the decision. 
Such rules were then consistently applied to all future cases identified with the same characteristic. 
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 If a person had taken an action that could potentially be regarded as suicidal, but 
the narrative gave rise to doubt about the intention of the person by the act. For 
example, there was a case of a person jumping from a dangerous height while 
intoxicated and with the police in attendance. This case was excluded as it was 
not clear whether the leap was an incident of deliberate self-harm or an attempt to 
evade the authorities. 
3.4.3 Data entry and coding 
Details for 1,475 relevant cases of the three types above were recorded by hand onto 
a daily log sheet and then transferred into a specifically designed spreadsheet. 
Information from the case narrative field was also coded to a further level of 
specificity. Where possible, the following information was extracted from the 
narrative field: 
 Whether alcohol was implicated in the presentation 
 Whether the patient was referred to “Psych Triage”32 or “Alert”33 services 
 Whether there were any security concerns arising during the presentation (e.g. did 
the person require physical restraints) 
 In regard to medication misuse or overdose cases, what medications were 
implicated 
 In regard to illicit drug intoxication or overdoses, what substances were taken 
 In regard to cases of deliberate self-harm, whether this took the form of thought, 
threat or action to self-harm and what means of self-harm were involved 
Further explanation of each of the above is provided in the relevant results section. 
The Australian Medicines Handbook (Rossi, 2003) was used as a guide in 
categorising the medication types named in the PAS narratives. In that publication 
                                                          
32 Psych triage is a team of trained staff (e.g. psychiatric nurses, psychologists, etc) based in the ED who are able 
to provide a brief psychiatric assessment of any patient referred by the treating staff. If a more intensive 
assessment is required either the psych registrar or Crisis Assessment and Treatment Team (CATT) are 
contacted. The CATT service provides urgent assessment and short term intensive treatment in the community to 
people in crisis due to a mental illness.  
33 Alert is a multidisciplinary team (e.g. social workers, occupational therapists) who are called upon to respond 
to frequent presenters to the ED with the aim of identifying appropriate alternative community support services 
for the person and facilitating access to these in order to reduce the likelihood of continued presentations. 
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medications are divided into chapters according to the organ system that the drug is 
intended to affect or the broad therapeutic action.34 Within these chapters the 
medications presented are further grouped into classes and subclasses. This structure 
guided the categorisation of medications implicated in presentations to the ED. 
However, there are some medications which have more than one possible use and 
which appear in more than one chapter in Rossi (2003). The following decisions 
were made regarding medications that could be included in more than one category; 
clobazam, clonazepam, diazepam, and flunitrazepam are all benzodiazepine 
medications (i.e. psychotropic medications), which may also be used in the treatment 
of epilepsy (neurologic): these were classified as psychotropic for this study. 
Buprenorphine and methadone are both used in the treatment of opioid dependence 
(psychotropic), but are also listed as analgesic medications: for the purposes of this 
study they were classified as psychotropic medications for the treatment of opioid 
dependence, along with naltrexone (which may also be used in the treatment of 
alcohol dependence). Non-steroidal anti-inflammatory medications (NSAIDs) are 
used for both their analgesic and anti-inflammatory effects and may therefore be 
used for a range of conditions such as osteoarthritis. They are classified as 
musculoskeletal drugs in Rossi (2003), but are also cross-referenced in the chapter 
on analgesic medications. For this study NSAIDs were categorised as non-opioid 
analgesics. There were a small number of drugs named that are usually used in the 
treatment of coughs, colds and flu, some of which act on the respiratory system and 
some on the nose. These were all included in the one category, “cough, cold, and flu 
medications”. Cases involving electrolytes35 were also included as a separate 
category. 
                                                          
34 The chapters are as follows; Allergy & anaphylaxis, Anaesthetics, Analgesics, Antidotes & antivenoms, Anti-
infectives, Cardiovascular drugs, Coagulation & blood formation, Dermatological drugs, Ear, nose & throat 
drugs, Endocrine drugs, Eye drugs, Gastrointestinal drugs, Genitourinary drugs, Immunomodulators & 
antineoplastics, Musculoskeletal drugs, Neurological drugs, Obstetric & gynaecological drugs, Psychotropic 
drugs, Respiratory drugs, Vaccines and immunoglobulins (Rossi, 2003). 
35 This includes any oral or injectable electrolyte (e.g. potassium chloride). Electrolytes may be used for re-
hydration following diarrhoea and are included in this study because highly concentrated doses may have a toxic 
effect. 
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Once all the information from PAS was entered into the spreadsheet and any 
additional coding completed, the entire 12-month data file was exported to SPSS 
13.0 (SPSS Inc., 2004) for further analysis. 
3.5 Patient Interview Data 
3.5.1 Eligibility 
To supplement data available from the PAS audit, in-depth semi-structured 
interviews were conducted with a convenience sample of medication overdose 
survivors seen in the ED. Any patient whose presentation to the ED met the criteria 
for ‘Medication misuse or overdose’ (page 110) was considered eligible for inclusion 
as an interview participant, provided they met the following additional criteria: 
 Over the age of 18 
 Capable of giving informed consent to participate in the study 
 Able to speak English36 
 Not currently in custody37 
 Actually seen for treatment38, and 
 Cleared by the medical and/or Psych Triage staff 
Each person who attended the ED in relation to medication misuse or overdose could 
only be interviewed once, regardless of how many times they presented during the 
data collection period. 
                                                          
36 Unfortunately the researcher can only speak English. The employment of interpreters was beyond the budget 
for this project, and even if such resources were available the interview covered some sensitive and complex 
subjects that may not have been suitable for translation. The standardised measures would also have needed to be 
translated, giving rise to questions of reliability. For these reasons only English-speakers were included in the 
study. This criterion excluded a small proportion of potential participants. 
37 Some patients treated in the ED for medication misuse or overdose were either currently on remand or 
imprisoned, or were accompanied by police to the hospital for later questioning. It was decided not to include 
such cases in the sample due to the difficulty accessing some of these patients (i.e. they may not have been free 
to return to the department at a later date for an interview) and also the additional security concerns associated 
with interviewing patients who are in custody. 
38 Some potentially eligible patients left the department after being triaged, but prior to being seen by a member 
of the treating staff. As referral to the study could only happen at the conclusion of treatment, it follows that 
those who left before being seen could not be included in the patient interviews. 
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3.5.2 Recruitment process 
Individuals who met the eligibility criteria were invited to participate in the research. 
The researcher was unable to approach patients directly due to privacy concerns, 
therefore treating staff were asked to assist in the referral process. Staff were 
requested to mention the study to patients and seek their permission for referral. 
As it was impossible for the researcher to be in the department at all times the initial 
plan was that there would be two methods of referral. The first method was intended 
to operate at times when the researcher was not present in the department. Staff were 
to mention the project to eligible patients and, if the patient indicated they were 
interested in referral, to give them a study card. The study cards were printed with a 
brief description of the project, a serial number, and a free-call contact number so the 
patient could telephone the researcher if they were interested in participating. Staff 
were requested to record the details of any such referrals on a log sheet kept with the 
study cards in the clinical area of the ED. However, it became apparent during data 
collection that this method of referral was not very effective, as staff were often too 
busy or simply forgot to refer eligible patients. Only a small number of referrals were 
achieved through this means, despite the researcher attending staff meetings and 
putting up signage to alert staff to the project. The lack of success via these means 
did not appear to be due to staff antipathy towards the project, but rather a case of 
having other more pressing duties to attend to.39 
The second means of recruitment was used when the researcher was actually in the 
department. Upon becoming aware that a potential participant was in the department, 
the researcher approached the relevant staff member to enquire whether referral 
might be possible once the patient was sufficiently medically and emotionally stable, 
and if so, whether the staff member could initiate this. 
Many patients who were eligible for the study were receiving both medical treatment 
by the doctors and a brief psychiatric assessment by Psych Triage staff. Where there 
was involvement by both medical and psychiatric staff the researcher endeavoured to 
seek the approval of each party before requesting the patient be approached for 
                                                          
39 When the study was originally conceived it was intended that 200 participants be recruited. However, once it 
became apparent that this target was unlikely to be attained, the sampling target and strategy was revised. See 
3.5.3, Sample size. 
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inclusion in the study. This was to ensure that all relevant treating staff were satisfied 
that the patient could safely be referred and interviewed. There were a small number 
of instances where the medical doctor cleared the person for inclusion, but the Psych 
Triage staff involved expressed some reservations about the suitability of a particular 
patient, and vice versa. In the interests of patient safety and also preserving harmony 
within the department the researcher opted not to include any patient against the 
advice of a staff member, even if another person involved in their care had given 
permission for the person to be approached. 
If the treating staff felt that the patient was well and that referral would be 
appropriate they briefly introduced the study to the patient and asked if the 
researcher could speak to them. If the patient was willing, the researcher then 
introduced herself, outlined what taking part in the project would involve, stressed 
that participation was voluntary, gave the person a study card and suggested that if 
they were interested in participating they could either make an appointment time for 
an interview or ring back later once they had time to consider the matter further. 
In cases where the person was eligible, the treating staff were satisfied of their 
suitability for inclusion, and the person agreed to take part in the study a mutually 
agreeable time within 10 days was set to conduct a full research interview. The 10-
day limit was set in order to maximise recall of the event, although in practice the 
researcher exercised some discretion in relation to this. For example, if a person 
initially made an appointment for within the 10 days but then needed to reschedule to 
a date falling outside the 10 days that request was accommodated. Verbal consent 
only was collected at initial recruitment. Full written consent was obtained at the 
time of interview. 
It was generally suggested to participants that the interview time be arranged for a 
few days after discharge from hospital to give them a chance to recuperate from the 
overdose before the interview. Seven people had their interview on the same day 
they initially attended hospital, and another seven the following day. A further nine 
were interviewed within a week of attending and another four within two weeks. The 
remaining four participants were interviewed at 15, 19, 32 and 49 days respectively, 
although all initially made contact with the researcher within 10 days of the overdose 
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as requested on the referral cards. The mean number of days to interview was 6.2, 
and the median 2.0 days. 
3.5.3 Sample size 
The purpose of the in-depth interviews was to complement the data available from 
the audit with highly personalized, qualitative information. Therefore, the sample 
size was determined with the aim of obtaining a rich description of experiences from 
a limited number of patients. These participants were recruited via a convenience 
sampling strategy (Flick, 2002). Given the nature of the research environment (i.e. a 
busy ED), and the population of interest (patients with potentially high medical and 
psychiatric care needs), it was unlikely that it would have been possible to recruit a 
representative sample. The sections concerning the ‘Recruitment process’ (page 119) 
and ‘Ethical Issues’ (page 136) describe more fully some of the issues concerning 
recruitment of participants to this study. Over the data collection period 31 patients 
were recruited to participate in the interview component of the study. 
Data collection for the patient interview component of the study commenced on 
13/10/2003 (i.e. data collection for this component of the study extended for 12.5 
months until 31/10/2004). During this time a total of 546 cases involving medication 
overdose or misuse attended the ED. Twenty-two of these left before being treated, 
19 were ineligible due to the fact that they were aged less than 18 at the time of the 
presentation, and a further 13 could not be referred to the study because they were in 
custody. Therefore there were a total of 493 cases that were eligible for referral (one 
case was ineligible of two of these grounds), and these cases were accounted for by a 
total of 396 individuals. 
Of the 493 presentations, 345 were not provided with a study card or in any way 
informed about the study, and there were a further 18 for whom it is not clear 
whether they were provided with a study card (staff may have provided these to 
patients when the researcher was not present, but if so, there was no record kept). As 
there was limited information available on patients not referred to the study at all, it 
is impossible to establish what proportion of this group may have been ineligible in 
any case due to inability to give informed consent and/or language difficulties. Most 
of these cases presented to the department at times when the researcher was not 
present to arrange referral, often overnight. There were an additional 47 cases where 
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the staff treating the patient recommended against referring the patient, generally due 
to concerns about their medical or psychiatric condition, or inability to speak 
English. Of the remaining 83 cases for whom some attempt at referral was clearly 
made, 41 patients initially accepted referral or were given a study card but did not 
recontact the researcher in order to be interviewed, 11 declined the referral 
altogether, and 31 accepted the referral and were subsequently interviewed. 
Therefore over a third of those who could be approached to participate elected to 
take part in an interview. 
3.5.4 Data collection procedures 
Location 
Twenty-six interviews were conducted in a private room within the ED itself: 16 
with patients who had already been discharged and who returned specifically to 
participate in the interview, and 10 who had already been seen by the treating staff, 
but who were awaiting discharge from the ED. The remaining five interviews were 
conducted with patients admitted to a hospital ward.  
Six participants declined to have their interview audio-taped. In these instances notes 
were written following the interview (in addition to completing the interview 
schedule). The audio-tapes of the remaining 25 participants were transcribed. 
Informed consent procedures 
When participants presented for interview, the researcher again provided a brief 
verbal explanation of the purpose and requirements of the study. Each participant 
was given a written explanatory statement about the study which included the names 
of those involved in the research team, the aims of the research, the approximate 
length of the interview, the subject matter of the interview, payment, confidentiality 
provisions, limits to confidentiality, data storage, the voluntary nature of 
participation in the research, freedom to withdraw and complaints procedures. 
Permission was also sought to audio-tape the interview for later transcription and 
analysis. In the event that the person had difficulty reading the explanatory statement 
was read aloud to the participant. Once the statement had been read by the 
participant (or aloud by the researcher), the participant was asked whether they had 
any questions. Participants willing to continue at this stage signed an informed 
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consent form. This was countersigned by the researcher. A copy of the explanatory 
statement and informed consent form may be found at Appendix E, page 333. 
Upon attending for an interview each person was required to return the numbered 
card to the researcher. The serial number on the card, rather than the person’s name, 
was then used to identify all survey forms. 
Piloting 
The first 15 interviews for the project formed a pilot phase for the interview 
schedule. This phase indicated that some modifications to the originally proposed 
survey instrument were required. In summary, the originally proposed instrument 
was longer and contained more standardised scales than the final instrument. It was 
found that many participants had difficulty with some of these structured elements of 
the survey and also that the interview was taking an excessive amount of time to 
complete (up to 2 hours). This resulted in several surveys having missing data. The 
researcher was also concerned that the interview process might unduly fatigue 
participants. Accordingly the survey instrument was modified to drop some of the 
more troublesome components, simplify the structure, and shorten the survey overall. 
No new components were added at this stage, although some elements were re-
ordered or incorporated within other sections to better reflect the flow of 
participants’ story-telling. The data from all interviews conducted during the pilot 
phase were able to be included in the final sample. 
Interview processes 
The length of interview depended on the talkativeness of the participant and ranged 
from 30 minutes to 2 hours and 10 minutes (average 73 minutes). The interviews 
followed a semi-structured format as outlined in the ‘Survey form’ section (page 
124). 
Participants demonstrated varying capacities to remain focused on specific questions 
and therefore there the interview sometimes had to be modified to suit the individual. 
For example, the questions concerning physical and mental health were intended to 
proceed sequentially with each individual area being enquired about. However, if the 
participant was repeatedly distracted by questions that were not personally relevant, 
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or inclined to give highly detailed but tangential responses, the interviewer would 
modify the questions in an effort to elicit the only the most germane information. 
There were times when participants provided information relevant to later sections of 
the interview before the specific questions had been asked. Where possible the 
interviewer allowed participants to tell their story in the sequence that arose naturally 
to them, and noted down the information on the relevant part of the form. 
There were a small number of individuals in which the interview was terminated 
before all questions had been asked. One person asked to finish early due to 
tiredness, and another was only available for one hour. There was also one referral 
back to hospital staff because the person still had concerns regarding the plan in 
place regarding discharge from hospital, which he felt would place him at-risk once 
he left the hospital and this was clearly of greater immediate concern than 
completing the interview. 
Upon completion of the interview participants were given an envelope containing a 
clean copy of the plain language statement and consent form for their records, a 
referral directory with telephone numbers for various support services (see Appendix 
F, page 338) and payment of AU$30 to cover out-of-pocket expenses and 
inconvenience. The researcher routinely checked whether the person was in need of 
immediate assistance before leaving the hospital e.g. “Do you feel safe to go now?”, 
“Would you like to speak to one of the staff here?”, “Do you want me to arrange for 
Psych Triage to see you again?”. 
3.5.5 Survey form 
Both quantitative and qualitative data were collected. The survey form comprised 
questions developed specifically for the purposes of the study and standardised 
measurement scales. The purpose of the quantitative data was to describe the sample 
and to analyse the relationship between suicidal ideation, depression, and other 
variables, while the qualitative data was intended to provide a context for the 
overdose event. For example, how the medications involved were typically acquired 
(e.g. appropriately prescribed, stockpiled, diverted, black-market), participant 
knowledge and access to information about the intended purpose of medications, 
previous responses of the health care system to help seeking behaviour, existing 
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social support networks and referral to ongoing care and support. A copy of the full 
instrument may be found at Appendix G, page 340. 
Demographic information 
Standard questions were asked concerning sex, age, living arrangements, education, 
employment, cultural background, sexual orientation and parental status. 
General health and treatment history 
Two charts were developed to briefly canvass participants’ physical and mental 
health. Their purpose was to assess general wellbeing and to establish which 
medications each person routinely took. With regard to general physical health, 
participants were asked about each body system (i.e. cardiovascular, respiratory, 
gastrointestinal, genito-urinary, musculo-skeletal, neurological, endocrinological, 
allergies, dermatological, “eyes, ears, nose and throat”, psychiatric, and “other”). 
Where necessary, a lay-persons description of these areas was provided. For each 
area, the person was asked whether they were currently experiencing a problem, to 
briefly describe that problem, the duration of the problem, whether they would rate 
the problem as mild, moderate, or severe and what kind of treatment, if any, they 
were currently receiving in relation to that problem. Notes on psychiatric problems 
were only noted briefly on this chart with fuller notes being taken on the subsequent 
chart of mental and emotional wellbeing. 
For the mental health chart, participants were asked if they had ever had each 
condition (i.e. mood disorder, anxiety, substance use disorder, schizophrenia or other 
psychotic disorder, attention deficit (hyperactivity) disorder, eating disorder, or 
“other”). It was possible that some people were unaware that they met the diagnostic 
criteria for a particular condition, while others may have self-identified as having a 
condition when in fact their symptoms would be regarded as sub-clinical if a 
diagnostic interview were undertaken. However, it was assumed that most people 
would be able to identify with some accuracy what mental health conditions caused 
them problems.40 
                                                          
40 As the focus of this study was medication overdose, suicidal ideation and depression, it was felt that there was 
already enough material to be covered in the interview without undertaking a full psychiatric diagnostic 
interview such as the Composite International Diagnostic Interview (CIDI). The use of such a tool would have 
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It should be noted that the mental health section only specifically enquired about 
DSM-IV-TR Axis 1 disorders (American Psychiatric Association, 2000). Therefore 
personality disorders (included in Axis 2) were not included, although it is likely that 
some participants met the criteria for a personality disorder. It was decided not to 
include personality disorders because (i) even when a personality disorder is 
diagnosed, not all clinicians will necessarily tell the patient, so the person may not be 
aware of the condition, (ii) it was a concern that some participants might be offended 
by the implication that their personality might be “disordered”, and (iii) most of the 
other psychiatric conditions included are understood by lay-persons, whereas the 
term personality disorder is less widely used by the general community and therefore 
potentially confusing. 
For each self-identified psychiatric condition, participants were asked to briefly 
describe the problem, the approximate date they were first diagnosed (if applicable), 
what type of treatment they received, whether they were currently medicated, and 
how they acquired their medications. Regarding substance use, participants were 
further asked to nominate any substances they may have had problems with in the 
past, any substances they were currently experiencing problems with, and whether 
they were a past or current injecting drug user. The researcher also made an 
assessment of whether the person was currently substance dependent according to 
DSM-IV-TR criteria (Appendix H, page 354). All participants were also asked 
whether anyone else in their family had been diagnosed with any of the psychiatric 
conditions listed, and if so, what relation that person was to them. 
When completing the charts, participants were prompted to provide more in-depth 
information about the medications they were taking (particularly those relating to 
psychiatric conditions) and any previous help-seeking experiences they had in 
relation to mental health and emotional wellbeing. 
Medications involved in overdose 
A chart was developed specifically for this study on which to record all medications 
and other substances consumed in the 24 hours prior to receiving emergency medical 
care for an overdose (included in Appendix G, page 340). The collection of 
                                                                                                                                                                    
considerably lengthened the interview, and therefore it was decided that self-identification of mental health 
problems would be a sufficient alternative in this instance. 
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information regarding alcohol and drug use over a 24 hour period followed a similar 
format to the data collection method described in a previous study of suicide attempt 
(Kresnow et al., 2001). 
The vertical axis of the chart was divided into 3 broad categories each made up of 
relevant sub-categories, i.e. prescription and OTC medications (antidepressants, 
benzodiazepines, antipsychotics, analgesics, methadone/buprenorphine, other), 
alcohol (spirits, beer, wine, other), and “other” drugs (cannabis, heroin, 
amphetamines, cocaine, hallucinogens, ecstasy). Along the horizontal axis, the page 
was divided into 24 columns, each representing an hour in the 24 hours preceding the 
person receiving medical attention. The chart was completed by the researcher 
asking the participant about each drug type and recording how much of each drug 
type had been consumed in each hour, or block of hours, prior to care. To improve 
the accuracy recall concerning pharmaceutical medications, a copy of the Australian 
Medicines Handbook (Rossi, 2003) was available during the interview and was 
consulted when necessary. 
The source of most medications used was generally established in the section 
concerning health. However, if any medications not already mentioned were 
implicated in the overdose, the participant was asked at this point where the 
medications had been obtained from and what they thought their purpose was. 
Medication related emergency care and the overdose event 
The questions in this section concerned the specific experience of medication 
overdose for which participants had been referred to the study and previous overdose 
experiences. 
With regard to the current overdose experience, participants were asked whether the 
word “overdose” was an “OK” term for them. Once acceptable terminology had been 
established, the date and time of the overdose for which they were referred to the 
study was ascertained.  Participants were then asked several open-ended questions 
about their experience of the emergency medical system following the overdose. For 
example, how they got to hospital, what happened to them once they reached the ED, 
their interactions with various personnel (e.g. ambulance, doctors, nurses, Psych 
Triage), what happened upon discharge, any referrals or follow-up, and whether 
there had been subsequent contact with their GP or psychiatrist. 
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The next group of questions concerned to what extent the overdose was deliberate 
and why, and to what extent the person intended to die and why. Participants were 
asked to rank the deliberateness of the overdose for which they received the study 
recruitment card on a 5-point scale where 1 equalled completely accidental/no 
intention to OD and 5 equalled completely deliberate/intended to OD. The use of the 
scale was to allow participants to report ambiguity of intent in a way that would not 
be possible with a dichotomous choice of deliberate or not deliberate. Respondents 
were also asked why they had answered as they had. This allowed respondents to 
reflect on the reasons behind their overdose. The suicidal intent of the overdose was 
examined by asking respondents to nominate on a 5-point scale how strong their 
wish to die was, with 1 equalling no wish to die and 5 equalling strong wish to die. 
Again, participants were asked to reflect on their reasons for responding as they had. 
BSS 
Suicidal ideation at the time of the overdose was assessed using the Beck Scale for 
Suicide Ideation (BSS)® (Beck & Steer, 1993). The BSS may either be self- or 
interviewer-administered and consists of 21 items; 19 contributing to the overall 
score (each with three responses options, scored 0, 1, or 2), and two informational 
items which do not contribute to the overall score. The first five items of the BSS act 
as a screen so that only those who endorse active or passive suicide attempt are asked 
the full range of questions. The subtotals from the five screening questions and 
subsequent 14 questions are added together to give a total score (0-38). For the 
purposes of the present study those who were screened in for further questioning 
were regarded as having suicidal ideation, while those screened out were considered 
to have less severe suicidal ideation (although ideation may not have been 
completely absent). The administration time for the full inventory is 5-10 minutes. 
The instrument is based upon an earlier version of the same tool, the Scale for 
Suicide Ideation (SSI; Beck, Kovaks & Weissman, 1979, in (Range & Knott, 1997; 
Reinecke & Franklin-Scott, 2005)). 
The BSS has been shown to have good reliability; and concurrent, construct, 
discriminant, factorial, and predictive validity have also been established (Beck & 
Steer, 1993). The reference period for the BSS is the past week, including the current 
day. However, the manual refers to studies where the scale was used in regard to a 
 128
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
more distant reference period and still demonstrated adequate reliability and validity. 
The reference period inquired about for the present study was immediately prior to 
the overdose. In this study the instrument was self-administered41 unless the 
interviewer decided it would be preferable to assist the participant, due to poor 
reading skills or inability to concentrate on a written task. This occurred in 20% of 
cases. 
BDI-FastScreen 
Rather than assess whether a participant was depressed or not according to standard 
diagnostic criteria it was decided instead to assess the severity of depressive 
symptomatology. This was because many in the sample were likely to have 
previously been diagnosed with depression, and therefore more new information 
would be obtained using a scale (i.e. severity), rather than a dichotomous measure 
(i.e. depressed versus non-depressed). 
The Beck Depression Inventory (BDI) FastScreen was used to assess the severity of 
depressive symptomatology (Beck et al., 2000). The BDI FastScreen is a 7-item self-
report instrument that relates to the psychological, or non-somatic criteria, of the 
Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV, 
1994). The BDI-FastScreen is a shortened version of the well-known 21-item BDI-II 
(Beck, Steer, & Brown, 1996). It was specifically developed for use with populations 
with biological, medical, or substance use problems, the somatic and behavioural 
symptoms of which may overlap with those for depression (for example, changes in 
sleep patterns or appetite). An instrument excluding such items should avoid 
spuriously elevated severity scores (i.e. reduce the likelihood of false positives). As 
the sample included in the current study were considered likely to have medical 
and/or substance use problems, the BDI-FastScreen was chosen in preference to the 
full inventory. The shortened form also has the advantage of taking only minutes to 
complete. 
The manual explains that of the seven items retained on the shortened form, the 
items relating to sadness and anhedonia were included because these must be present 
for a clinical diagnosis to be made, the item concerning suicidal thoughts or wishes 
                                                          
41 The interviewer reviewed participants’ answers to the first five questions (i.e. the screening component of the 
BSS) to determine whether the remainder of the instrument needed to be filled in by the participant.  
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was kept as an indicator of clinical risk, and the remaining four items relating to 
pessimism, past failure, self-dislike, and self-criticalness were chosen because 
previous research has found them to be especially salient to the cognitive dimension 
of depression (i.e. not overlapping with physical symptoms) (Beck et al., 2000). 
Possible scores on the BDI-FastScreen range from 0 to 21. The manual provides cut-
off scores based on medical settings where the average score is 8 and the standard 
deviation 4. Under these circumstances, the recommended cut-offs are 0-3 = minimal 
depression, 4-8 = mild depression, 9-12 = moderate depression, 13-21 = severe 
depression. The reliability, validity and clinical utility of the precursor instruments to 
the BDI-FastScreen (BDI, BDI-IA, BDI-II) have been well established in a range of 
studies (Beck et al., 1996, , 2000). The psychometric characteristics (reliability, 
content, and construct validity) of the BDI-FastScreen have also been found to be 
satisfactory (Beck et al., 2000). As with the BSS, the timeframe for the BDI-
FastScreen is the two weeks prior to interview, including the current day. Once again 
however, participants were asked to answer according to how they felt in the hours 
immediately prior to the overdose. Participants self-administered the instrument 
unless it was apparent that they had difficulty in doing so. The interviewer 
administered the instrument in 17% of cases. 
After completing the BSS and BDI-FastScreen participants were about their history 
of overdose events. For example, participants were asked how many times they had 
previously received emergency medical care as a result of taking too much 
medication, what treatment response they had received, how many times similar 
events had occurred where emergency medical care was not sought, and how many 
times, if any, the person had overdosed on illicit drugs. Participants who had 
previously overdosed (on any substance and whether or not help was sought) were 
then asked to reflect on their past reasons for so doing. 
Personal and family history of suicidal behaviour 
Participants were asked if they had ever deliberately hurt themselves without 
meaning to commit suicide (self-harm). They were also asked whether they had ever 
attempted suicide, and if so, how many times, the dates of the first and most recent 
attempts, and the method/s used (including medication overdose). Finally, 
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participants were asked whether anyone in their family or friends or close 
acquaintances had attempted or committed suicide.  
Adverse life events 
Given the established association between adverse life events and suicidal behaviour 
(Beautrais, 2000; Fremouw et al., 1990; Hawton & Catalan, 1987) it was thought 
important to gauge how many potentially stressful life events each participant had 
experienced in the 6 months prior to the overdose. To quantify the number of 
stressful events experienced (as opposed to the degree of stress objectively felt) 
participants completed a yes/no checklist of potentially stressful life experiences. 
Participants were asked “In the last 6 months, have you experienced unhappiness or 
distress as a result of any of the following issues?” and provided with a list of 29 
items (problems with parents, sexual abuse, problems with friends, unplanned 
pregnancy, anxiety about school/university performance, suicide of a friend, 
relationship break-up, own violent or criminal behaviour, financial hardship, sexual 
identity conflict, family member’s death, physical abuse, problems at work, death of 
a parent, failure at school/university, abortion, unemployment, physical illness, 
parental divorce, sexually transmitted diseases, friend’s death, physical disability, 
own alcohol consumption, homelessness, own drug use, suicide of a family member, 
violence in the home, mental illness, being bullied). Participants also had the option 
of identifying some other event they had found stressful, even if was not specifically 
included among the items. 
The list of items was obtained from the survey used in The Queensland Young 
People’s Mental Health Survey (Donald, Dower, Lucke, & Raphael, 2000), though in 
that study the timeframe was “ever”, not the “last 6 months”. This survey was chosen 
because it listed a comprehensive range of problems that have been recognised as 
risk factors for depression and suicidal behaviours such as relationship problems, 
work or study problems, financial problems and bereavement, and also because it 
was straightforward to administer. As in Donald et al. (2000), the number of stressful 
events experienced was totalled for each participant. Participants were asked which 
of the events they had experienced contributed most to feeling stressed in recent 
times and how it had affected them. This factor may not necessarily have precipitated 
the overdose itself. 
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Social support 
To assess whether participants had a supportive network interviewees were asked 
whether they felt they received much support from their friends, family, and partner 
(if applicable). 
Other considerations 
In concluding the interview, all participants were given a final opportunity to provide 
any further information about their experience which they felt it was important for 
the researcher understand. 
3.5.6 Data management 
The researcher completed the interview schedule by hand during the interview and, 
where necessary, made additional notes immediately following the interview (e.g. if 
there was too much information to capture in detail during the interview). The data 
were later entered into an SPSS 13.0 (SPSS Inc., 2004) database (i.e. all of the 
quantitative information and brief elements of the qualitative data). In addition, the 
interviews were audio-taped and transcribed by the interviewer, and then imported 
into the QSR N6 software program (QSR International Pty Ltd, 2002) for later 
content analysis of the qualitative information. Interviewer notes only were imported 
into QSR N6 in cases where the participant declined to be taped. 
3.6 Observational Data 
The researcher kept field notes during the data collection period in a daily diary 
format. The notes included: 
 days and times spent in the department 
 observations about the operation of the ED 
 interactions between staff and patients 
 conversations with staff about their work in relation to medication overdose 
presentations, and 
 recruitment of participants to the patient interviews (which staff members were 
involved - doctor, nurse, Psych Triage, etc, whether recruitment was possible, and 
if not, why not, efforts to improve recruitment). 
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Overall the researcher attended the department on approximately 230 days during the 
12-month period at various times of the day and days of the week. 
The purpose of collecting the above information was to increase the researcher’s 
understanding of the ED environment in general and enhance the description of the 
response to medication overdose presentations in particular. Observational data were 
used to contextualise information from the PAS audit and patient interviews about 
how overdoses were dealt with in the ED and how different parts of the organisation 
linked together. 
3.7 Analysis 
The three data sources were of differing relevance in addressing each of the six 
research objectives previously described. Table 1 below shows the intersection 
between the research objectives and the three data sources. It can be seen that for 
some objectives more than one source was utilised in answering the specific research 
questions. 
Table 1 Data Sources Used to Address Each Research Objective 
Objective PAS audit Interviews Observation 
1. Number of medication ODs presentations 3   
2. Characterisation of OD survivors 3 3  
3. Suicidal intent, ideation, and depression  3  
4. Medications implicated 3 3  
5. Individual experiences of the ED  3 3 
6. Conducting research in the ED   3 
 
3.7.1 PAS audit data 
Basic frequencies of each of the three types of presentations of interest (medication 
misuse or overdose, illicit drug intoxication or overdose, and self-harm) were 
calculated and expressed as a proportion of the total presentations to the ED in the 
12-month period. A Venn diagram was produced to show the overlap between the 
three. The data were then divided into three independent groups (i.e. some cases 
were dropped due to overlap between groups – see Results, page 144). Additional 
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descriptive analyses were run to determine the age and sex distribution of patients 
attending in each of the three independent groups, and to investigate temporal 
patterns such as the time of day/day of week of presentations, and total monthly 
presentations. Where data were available, analyses were also run for total 
presentations of any type to the ED in the reference period.42 Frequencies were also 
run on the types of medication consumed. 
Multinomial logistic regression was used to examine associations between several 
explanatory variables (age, sex, season, day, and time of attendance) and patient 
group. Logistic regression was used to explore the relationship between patient 
group membership and two binary treatment outcome variables (triage level and 
discharge destination). As the study focused primarily on medication overdose and 
the analyses were exploratory in relation to this group, it was necessary to nominate 
one of the remaining groups as the reference group. Given the body of evidence 
available relating to characteristics of illicit drug overdose, that group was selected 
as the reference group against which both the medication overdose and self-harm 
groups were compared. SPSS 13.0 (SPSS Inc., 2004) was used for all analyses. 
3.7.2 Patient interview data 
There were two forms of data available from the interviews; quantitative data entered 
into SPSS 13.0 (SPSS Inc., 2004), and qualitative data in the form of interview 
transcripts. The quantitative data was mainly used to generate basic descriptive 
statistics. As the BDI-FastScreen, BSS, and the two Likert-scales concerning 
intention all yielded ordinal data, correlation co-efficients were calculated as a 
measure of the association between these variables. 
The interview transcripts were searched for text concerning the acquisition of 
medications and typical stories/typologies identified. The text was also examined for 
recurring themes or patterns concerning the reasons for, and circumstances of, the 
overdose in an effort to identify particular sub-types of overdose. The qualitative 
components of the transcripts were also scrutinised for information relevant to the 
person’s experience of the emergency medical care system, such as how the person 
                                                          
42 The results for total presentations of any type to the ED include presentations for medication misuse or 
overdose, illicit drug intoxication or overdose, and self-harm as it was not possible to separate out these cases 
from the data provided. For this reason, no statistical tests were conducted using total presentations to the ED. 
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came to attend the ED (i.e. self-referred or instigated by another). A content analysis 
of individual descriptions of the treatment process from beginning to end was 
conducted (observational data were also utilised in this process). To assess the 
satisfaction of patients with the emergency medical system following an overdose, 
the transcripts were also searched for both positive and negative reflections on 
current and previous treatment experiences and the relevant comments summarised. 
Qualitative data were analysed using the QSR N6 software program (QSR 
International Pty Ltd, 2002). 
Some of the research questions posed were best answered by considering the 
quantitative and qualitative interview data in conjunction. To determine whether the 
BSS and BDI-FastScreen scores were an accurate and comprehensive reflection of 
the emotional state of each participant at the time of the overdose, individual 
participant scores on the BSS and BDI-FastScreen were compared with the 
accompanying participant narratives and inconsistencies between the two forms of 
information noted. 
The relationship of BSS and BDI-FastScreen scores to other participant factors (i.e. 
demographic variables, physical health, mental/psychiatric health, drug and alcohol 
use/dependence, treatment history, previous overdoses, personal and family history 
of self-harm, recent significant life events and social support) was also considered. 
To achieve this end the participants’ BSS and BDI-FastScreen scores were each 
dichotomised into high and low and a matrix constructed to show the relationship 
between these and the other participant factors. 
3.7.3 Observational data 
Observational data were recorded in handwritten form in a research diary. Relevant 
sections were subsequently transcribed into electronic form and grouped together 
according to relevant subheadings. The data were used in the construction of an 
account of the treatment process, including arrival at the ED, triage, medical 
treatment, Psych Triage, and discharge. The researcher’s experience in recruiting 
participants and in collecting and analysing the data were considered in relation to 
the discussion around the feasibility of future similar research or of introducing a 
brief intervention. 
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3.7.4 Handling missing data 
While every effort was made to collect comprehensive data from all interview 
participants, and this was largely achieved, there was some individual variation in 
the completeness of the information. This was partly due to the nature of the 
interview schedule which invited participants to explore their experience within a 
semi-structured format, rather than highly structured. As a consequence, many 
participants provided the most information on those topics that were of high personal 
relevance, and less information on those aspects of the interview that were not of 
current concern. For example, a participant may have been particularly forthcoming 
about the current crisis precipitating the overdose event, but have been relatively 
brief in responses about treatment history. Given the proximity of the interview to 
the overdose event this tendency in some participants is perhaps unsurprising. The 
researcher endeavoured to guide participants to respond to specific prompts, but was 
also respectful of participant inclinations where these were evident. 
There were a small number of people for whom the BDI-FastScreen and the BSS 
were unsuitable for various reasons (e.g. the person found the task of choosing 
between the different response options too difficult, the person used the response 
options as a prompt to discuss their depressive illness but did not engage in the task 
of choosing an option, the person spoke English as a second language and did not 
feel confident in responding to the items, or there was insufficient time to complete 
the forms). In these cases it was not possible to obtain BSS and/or BDI-FastScreen 
scores. 
Data from all 31 interviews were included in the analyses. Where numerical data 
based on the interviews are provided in the results section, the number of missing 
cases is noted. No imputations were made for missing data. 
3.8 Ethical Issues 
This study raised several ethical issues, both in terms of general research protocols 
and also specifically in relation to the sensitive nature of the topic. These issues were 
canvassed prior to study commencement and the project received approval from the 
Human Research Ethics Committees of Curtin University of Technology, St 
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Vincent’s Hospital Melbourne, and the Victorian Department of Human Services.43 
Submissions to these committees were prepared with reference to the National 
Statement on Ethical Conduct in Research Involving Humans (NH&MRC, 1999) and 
the principles of ethical conduct outlined in this statement were adhered to 
throughout the project. 
The ethical issues discussed below relate primarily to the patient interviews, though 
there were also ethical considerations in relation to the PAS audit and observational 
components of the study. 
3.8.1 Interviewer training 
Due to the sensitive and potentially emotionally disturbing content of the interview, 
it was recognised that the interviewer for the project needed to be appropriately 
trained in dealing with suicidal research participants. The researcher participated in a 
“LifeForce Suicide Prevention Workshop” conducted by the Wesley Mission Health 
and Counselling Services. The workshop consisted of information concerning the 
extent of suicide in Australia, an examination of some common misconceptions 
concerning suicide, the suicidal process, intervention strategies and community 
resources. The workshop included presentations, discussion, group work, written 
material, role-plays and videos. Training was delivered by a qualified counsellor 
with several years experience in delivering training on the topic of suicide 
prevention. 
The researcher also attended a number of one-day training sessions offered by a non-
government organisation specialising in the treatment of people with benzodiazepine 
dependence and anxiety disorders. The training sessions covered anxiety, depression, 
benzodiazepine medication, antidepressants and principles of cognitive behaviour 
therapy. Ongoing interview debriefing and support was available to the researcher 
from her supervisors (all of whom are qualified psychologists) throughout the data 
collection period. 
                                                          
43 Curtin University and St Vincent’s HREC reviewed all elements of the project while the Department of Human 
Services approved the Patient Interview component. 
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3.8.2 Research involving persons highly dependent on medical care 
The NH&MRC guidelines caution about the inclusion of people who are highly 
dependent on medical care, for example, those who receiving treatment in an ED 
(NH&MRC, 1999). The specific concerns raised by the guidelines are that in such 
settings consent to participate in research may need to be obtained rapidly at a time 
when the individual may be particularly vulnerable, and also that people may 
acquiesce to the research out of fear that their treatment may be compromised by 
refusal to participate. 
With regard to the first of these, there was no need to obtain rapid consent, as the 
research did not involve a treatment intervention. The purpose of basing the research 
in the ED was to recruit people known to have recently had a medication overdose 
(i.e. the ED was simply a point of referral to the study). Referral generally occurred 
at the end of the person’s stay in the department, and therefore did not interfere with 
treatment or require the person to make an important decision under pressure. 
Participants had plenty of opportunity to opt-out of the research: individuals could 
decline referral in the first instance, elect not to contact the researcher to make an 
appointment, or choose not attend for the interview appointment. 
As indicated in the NH&MRC guidelines (NH&MRC, 1999), the other potential 
problem with conducting research in a clinical environment is that potential 
participants may feel obligated to participate in return for receiving treatment. To 
avoid the possible misperception that there was an expectation they would participate 
in the study, the researcher introduced herself as being from Turning Point Alcohol 
and Drug Centre and specifically indicated she was not a member of hospital staff 
and therefore not involved in treatment. The researcher also provided assurance that 
participation was entirely on a voluntary basis. 
3.8.3 Informed consent and capacity to give informed consent 
As outlined earlier, all participants in the patient interviews were asked to provide 
informed consent before the interview commenced. Participants were provided a 
copy of the Plain Language Statement to read and were also given a verbal summary 
of the contents. The form may be found at Appendix E, page 333. Participants were 
asked to sign the informed consent form, but were told they could use a pseudonym 
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if they preferred. Confidentiality was further preserved by not recording the person’s 
name anywhere on the data collection instrument. 
Participants were considered ineligible to participate in the study unless they had the 
capacity to give informed consent. In relation to this issue, the NH&MRC guidelines 
indicate that special consideration needs to be given before including persons with 
intellectual or mental impairment in research. For the purposes of this study, any 
person who was in the active phase of a psychotic illness was regarded as being 
mentally impaired and therefore not included. Staff were also asked to consider 
capacity to give informed consent when referring patients to the study. There were 
occasions when a patient was in the ED for a medication overdose where staff and/or 
the researcher determined it was inappropriate to include the person, for example, if 
the patient was drifting in and out of consciousness. 
Therefore, determining capacity to give informed consent involved, to some degree, 
staff and/or the researcher making a judgement on behalf of a potential participant. 
That is, some potential participants were excluded from participating without being 
given a choice in the matter. This in itself raises a further ethical dilemma in trying to 
strike a balance between clinical judgement and the right of the individual to have 
opportunity to participate. In making these choices the researcher bore in mind the 
ethical principles that apply to research with humans; integrity, respect for persons, 
beneficence and justice (NH&MRC, 1999), and also tried to take a practical 
approach in terms of fitting in with the operation of the ED. 
3.8.4 Confidentiality 
While it was important to foster an atmosphere of trust between the researcher and 
participant, it was essential that the participant be made aware that there were some 
circumstances under which the researcher was obliged to reveal information to a 
third party. It was explained during the informed consent procedures that 
confidentiality might need to be broken if a person indicated an intention to harm 
him- or herself or another person, if there were any information revealed concerning 
the protective safety of children, and in circumstances where disclosure was required 
under the law (i.e. subpoena). The most relevant of these limits to the participant 
group in this study was the threat of self-harm. 
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Particular care was taken to ensure participants understood the limits to 
confidentiality regarding self-harm. For example, while obtaining informed consent 
the researcher would specifically say something like “Before we start the interview it 
is important for you know that if I am concerned during the interview that you might 
be at immediate risk of hurting yourself, I will need to tell someone here at the 
hospital.” 
If the participant gave any indication during the interview that they were at-risk of 
self-harm, such as a particularly elevated score on the Beck Scale for Suicidal 
Ideation (BSS), the researcher followed the matter up directly. The response included 
expressing concern for the well-being of the client, screening to assess the degree of 
risk (e.g. emotional state, frequency/intensity of suicidal thoughts, asking about any 
suicide plans or methods the person may have in place), enquiring about what 
resources and supports the person might have had in place, and offering to refer the 
person back to the hospital staff. The researcher also reinforced the supports 
available to the participant and encouraged them to access such supports (e.g. if the 
person had an appointment booked with their psychiatrist in the near future this was 
reinforced as a support). 
Extracts of text from the transcripts have been used as illustrative examples in the 
Results section of this report. However, to preserve the anonymity of participants, no 
transcripts have been reproduced in full. Furthermore, where quotes are used, any 
details that might identify an individual have been omitted or altered in a way that 
does not diminish the meaning of the text (for example, details of where the person 
works or lives might have been changed). 
3.8.5 Distinction between treatment and research 
It is possible with research of this nature that some participants may confuse the 
purpose of the interaction with the researcher, mistaking it for a therapeutic or 
treatment relationship. Where necessary during the interview process the researcher 
indicated she was not in a position to provide advice or ongoing support and 
encouraged the person to access the treatment options available to them. 
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3.8.6 Potential risk to participants 
The interview included questions on sensitive topics that had the potential to distress 
some participants (e.g. medication use, overdose and suicidal thoughts and 
behaviour). Given that the study was specifically concerned with these issues, such 
questions were impossible to avoid. To reduce the risk of unduly upsetting 
participants the study information sheet and informed consent form alerted potential 
respondents to the topics covered in the interview. The right of participants to choose 
not to discuss personally sensitive or distressing issues was respected in that 
participants were assured that they could refuse to answer any or all of the questions, 
even after giving informed consent. Participants were also informed that they could 
withdraw from the study at any time without prejudice and procedures were put in 
place for ensuring the participant was aware of available supports after the interview. 
3.8.7 Age limit for participation in interviews 
Participants had to be over the age of 18 years. 
3.8.8 Participant payment 
As mentioned previously, participants were paid AU$30 for taking part in the 
research. This was in accordance with standard practice at Turning Point Alcohol 
and Drug Centre and was regarded as fair recompense for the time and 
inconvenience of attending an interview, and travel expenses incurred, and in 
recognition of the vital contribution participants make to such research. It was felt 
that the amount of money offered as reimbursement was not sufficiently great in 
itself to be an inducement to participate. 
3.8.9 Data storage 
All consent forms and survey data are currently kept under secure conditions 
accessible only by the researcher. No identifying information was recorded on the 
survey forms. Consent forms are stored separately from data. All data will be 
destroyed seven years after the final publication of results. Audio tapes were wiped 
once analysis of the patient interview data was complete. 
The security of the data is the responsibility of the researcher. The data are stored 
under locked conditions in a designated room at Turning Point Alcohol and Drug 
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Centre. Electronic data does not include any identifying information. Computer files 
are stored within a limited access network. 
3.8.10 Epidemiological research 
The PAS audit was a form of epidemiological research and is therefore covered 
under the NH&MRC guidelines (NH&MRC, 1999). There were two ethical issues 
arising from the use of the PAS data: the potentially identifiable nature of the 
information, and obtaining individual patient consent to use it. 
Regarding the potential for the data to be identified, no names, addresses or other 
personal information were recorded. The patient identity numbers are potentially 
identifiable only to those people who already have access to PAS (i.e. hospital staff 
who are already in a position to access patient information). The identity numbers 
were gathered with the sole purpose of determining re-attendance rates in the 12-
month period, allowing the data to be analysed according to number of individuals 
presenting, as well as instances. The only person with access to the audit database 
was the researcher. 
The NH&MRC guidelines (NH&MRC, 1999) recommend that where possible the 
consent of participants be obtained for the use of such data. However, the guidelines 
also state such data may be accessed without individual consent under particular 
circumstances, for example, if collecting consent would be impracticable. Given the 
nature of the ED it would have been impossible to obtain consent from all people 
who attended to access the data. Furthermore, the audit yielded valuable information 
that could not be gained by any other means. 
3.8.11 Observational research 
The ethics committee of the hospital approved the observational component of the 
study. It was impractical to obtain informed consent from staff-members every time 
the researcher asked them a question or observed them in their work, however, as the 
researcher had been introduced at relevant staff meetings and the project explained, it 
was thought ethically sound to proceed with observational data collection without the 
written consent of every staff member. Further, as the purpose of the observation was 
not to assess or evaluate individual staff, but to describe the usual processes involved 
in responding to overdose, there was no risk of individual staff being disadvantaged 
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as a consequence of the observation. Further, the observations were intended to 
inform a description of ED processes, rather than a critique, therefore the risk of the 
ED as a whole being disadvantaged was also minimal. 
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4 Results 
The Results section has been structured so that data are presented in the order that 
relates to each of the six objectives, rather than according to the data source from 
which they were derived. 
4.1 Objective 1 - Number of medication misuse or overdose 
presentations to the ED 
Data to address Objective 1 were available from the PAS audit. The cases of primary 
interest were those involving medication overdose, with information on self-harm, 
illicit drug overdose, and all presentations to the ED during the 12-month study 
period also collected for comparative purposes. 
4.1.1 Medication misuse or overdose presentations to ED 
Number of cases 
PAS data were collected on the number of presentations to the ED of (a) any kind, 
and (b) for medication misuse or overdose, illicit drug intoxication or overdose, and 
self-harm. There were a total of 32,139 presentations in the sampling frame. Of 
these, 521 cases involved medication misuse or overdose (1.6% of all presentations), 
477 involved illicit drug intoxication or overdose (1.5%) and 732 self-harm (2.3%). 
However, presentations for each of these were not necessarily independent; a 
presentation may have involved more than one category (Figure 1). 
Overall 1,475 (4.6%) of all ED presentations for the year fell into one or more of the 
three categories. Table 2 shows the overlap between the groups; with the greatest 
commonality occurring between self-harm and medication misuse or overdose (10% 
of relevant cases). 
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Illicit drug overdose 
(n=477) 
 
Figure 1 Overlap between Self-harm, Illicit Drug Intoxication or Overdose, 
and Medication Misuse or Overdose Presentations 
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Table 2 Overlap between Self-harm, Illicit Drug Intoxication or Overdose, 
and Medication Misuse or Overdose Presentations 
Group 
number 
Medication 
misuse or 
overdose 
Illicit drug 
intoxication or 
overdose 
Self-harm 
 
N % of cases 
 (n= 521) (n= 477) (n= 732) (1,475)  
1. 2 2 3 545 36.9 
2. 2 3 2 386 26.2 
3. 3 2 2 296 20.1 
4. 2 3 3 23 1.6 
5. 3 2 3 157 10.6 
6. 3 3 2 61 4.1 
7. 3 3 3 7 0.5 
 
A sizeable proportion of the medication misuse or overdose presentations were 
probably in fact also attempts at self-harm, even though they were not recorded as 
such in the triage notes. Therefore a second estimate of self-harm cases was 
calculated including medication misuse or overdose cases, excepting those instances 
where the PAS information clearly indicated the event was not one of self-harm. The 
estimated rate of self-harm when both self-harm and medication misuse or overdose 
cases were combined, and excluding the 42 cases where there was specific indication 
of an accidental medication overdose or denial of self-harm by the patient, was 3.3% 
of total presentations to the ED in the 12 month period. 
Selection of cases for analyses 
There was overlap between the above groups in 16.8% of cases. To allow statistical 
analyses to be conducted it was necessary create independent groups by collapsing 
some groups and excluding others. Group 1 (self-harm only, n=545) was retained as 
an independent group. Group 2 (illicit drug intoxication or overdose only) and Group 
4 (illicit drug intoxication or overdose AND self-harm) were combined into a single 
group (n=409). Groups 3 (medication misuse or overdose only) and 5 (medication 
misuse or overdose AND self-harm) were also combined into a single group 
(n=453). Therefore the primary comparisons presented in this section are of cases 
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involving medication misuse or overdose (MOD, n=453)44 illicit drug intoxication or 
overdose (DOD, n=409)45, and self-harm by means other than medication or drug 
overdose (SH, n=545). Therefore a total of 1,407 cases were retained in the analyses. 
The cases in the remaining two groups were considered more closely to determine 
whether they could be reasonably re-classified into another group, or whether it was 
better to exclude them from the analyses. Group 7 included the few cases (n=7) that 
involved all three factors of interest. The narratives for these cases implicated a 
range of illicit drugs and medications. As it was impossible to determine which 
factor predominated (i.e. self-harm, medication overdose, or illicit drug overdose) in 
the presentations, the cases could not be assigned to a single category and were also 
excluded. 
It was particularly difficult to decide whether to re-categorise or exclude cases in the 
final overlapping group (Group 6), where the overdose involved both illicit drugs 
and medications. The PAS narratives revealed that about two-thirds of these cases 
involved heroin in combination with benzodiazepines. This is a common 
combination (Gerostamoulos, Staikos, & Drummer, 2001) and in illicit drug research 
would typically be regarded as a heroin overdose. However, as some of these cases 
involved very large doses of benzodiazepines (i.e. much larger quantities than some 
cases that only involved medications) it cannot really be argued that all these 
overdoses were primarily heroin. The other cases in this group ranged across various 
different medications and drug types (e.g. cannabis, amphetamines, ecstasy). As the 
recording of quantities consumed was inconsistent on PAS, it was impossible to 
judge in many instances whether these overdoses were mostly related to the illicit 
drug, or the medication. Therefore it was impossible to devise a consistent rule by 
which to reclassify these cases as either medication overdoses or illicit drug 
overdoses, and case-by-case allocation would have been arbitrary in many instances. 
For these reasons it was decided to exclude these cases from the analysis (n=61). 
                                                          
44 Therefore this category includes all medication related overdoses regardless of suicidal intent (i.e. deliberate 
or accidental), but excludes those cases known to also involve an illicit drug. 
45 Therefore this category includes all illicit drug related overdoses regardless of suicidal intent (i.e. deliberate or 
accidental), but excludes those cases known to also involve any medication. 
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Number of individuals 
The PAS audit data shown in the Results section generally refers to the number of 
presentations, rather than the number of individuals. However, it is also important to 
know how many individual people account for the 1,407 presentations of interest in 
the 12-month data collection period. This was calculated by aggregating cases 
according to identification number. Altogether, there were 1,158 people who 
presented once or more in each of the three categories (361 individuals for MOD, 
367 for DOD, and 430 for SH). Most individuals attended the ED only once, 
however, 11% of people who attended for MOD attended more than once, as did 
17% for SH, and 7% for DOD (Table 3). Regarding all presentations to the ED in the 
12-month period, the mean number of attendances was 1.4, with a maximum of 69 
visits by one individual. 
Table 3 Number of Individuals Presenting and Number of Presentations per 
Individual for MOD, DOD, SH & ED Total 
Statistics MOD 
(n=453) 
DOD 
(n=409) 
SH 
(n=545) 
ED Total 
(n=32,139) 
 Number of individuals 
 361 367 430 22,516 
 Number of presentations per individual 
Range 1-16 1-8 1-10 1-69 
Mean 1.3 1.1 1.3 1.4 
Standard dev. 1.2 0.6 0.8 1.4 
 Number of presentations by individuals in 12 months (%) 
1 88.6 92.6 83.7 78.6 
2 7.2 6.0 10.7 13.1 
3 2.2 0.8 3.0 4.3 
4 0.8 0.0 2.1 1.6 
5 0.3 0.0 0.0 0.9 
>5 0.9 0.5 0.4 1.5 
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4.1.2 Time of presentations 
Information from PAS was used to identify temporal patterns of MOD presentations 
to the ED. Comparative data are presented for DOD and SH, and for presentations to 
the ED as a whole. 
Season 
Seasonal figures are expressed as a proportion of the yearly total for each group.46 
Presentations for MOD occurred most frequently in summer (Figure 2), as did those 
for DOD. The pattern of presentations for the ED as a whole appeared to be 
relatively stable across the year, as were SH presentations. 
0
5
10
15
20
25
30
35
Summer Autumn Winter Spring
Season
Pr
es
en
ta
tio
ns
 (%
)
MOD (n=453) DOD (n=409)
SH (n=545) ED total (n=32,139)
 
Figure 2 Season of Presentations for MOD, DOD, SH & ED Total 
There was no consistent association between season and group membership (Table 
4). The only significant results were that the SH group were about one and a half 
times as likely as the DOD group to present to the ED in the winter and spring. 
                                                          
46 Data collection commenced in November 2003 rather than at the beginning of a season, therefore that month 
was grouped with September and October 2004 as “Spring” although these months were not contiguous. 
 149
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
Table 4 Group Membership and Percent Attending the ED per Season 
Group n Season % OR 95% CI 
MOD 453 Autumn 23.8 0.861 0.60-1.23 
  Winter 20.5 1.065 0.72-1.57 
  Spring 24.7 1.064 0.74-1.53 
  Summer 30.9 REF  
SH 545 Autumn 24.4 1.076 0.76-1.53 
  Winter 23.1 1.463+ 1.01-2.12 
  Spring 27.2 1.426+ 1.00-2.03 
  Summer 25.3 REF  
DOD 409 Autumn 27.4 REF  
  Winter 19.1 REF  
  Spring 23.0 REF  
  Summer 30.5 REF  
ED Total *  32,139 Autumn 24.6   
  Winter 23.8   
  Spring 25.7   
  Summer 25.9   
+ Result significant at the 0.05 level 
* Data for ED Total were not included in the logistic regression analyses 
Day of week 
MOD cases were spread relatively evenly across the week, with a low of 12% on a 
Tuesday and a high of 17% on a Saturday (Figure 3). For SH cases, the day of lowest 
attendance was Sunday (13%) and the highest Monday (16%). For both of these 
types of presentation the percentage range was small (about 3%). In contrast, 
presentations for DOD ranged from a low of 10% on Monday, to 21% on Saturday, a 
spread of nearly 11 percentage points. Total presentations to the ED did not differ 
across the week (14% on Thursday to 15% on Sunday). The data on which the graph 
is based may be found in Appendix I, page 355. 
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Figure 3 Day of Week of Presentations for MOD, DOD, SH & ED Total 
As initial inspection of the data revealed few patterns in the data, with the exception 
of elevated weekend attendances, day of presentation was recoded as either 
“Weekday” (Monday to Friday) or “Weekend” (Saturday and Sunday) for analysis of 
difference between groups. Weekday attendances were 1.4 times more likely to be 
for MOD and 1.7 times more likely to be for SH than to be for DOD (Table 5). 
Table 5 Group Membership and Percent Attending the ED on a Weekday 
Group n % Weekday 
attendance 
OR 95% CI 
MOD 453 68.0 1.436+ 1.09-1.89 
SH 545 71.7 1.717+ 1.31-2.25 
DOD 409 59.7 REF  
ED Total * 32,139 70.7   
+ Result significant at the 0.05 level 
* Data for ED Total were not included in the logistic regression analyses 
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Time of day 
The proportion of presentations for MOD, DOD, SH and total presentations to the 
ED by 6-hourly blocks is presented graphically in Figure 4. There was an increase in 
the number of MOD presentations across the course of the day, with few 
presentations between 6 a.m. and midday, and then an increase between midday and 
6 p.m. The peak time for attendance was between 6 p.m. and midnight, gradually 
decreasing again from midnight to 6 a.m. A similar pattern existed for DOD and SH 
cases, although the increase in SH cases appeared to start somewhat earlier (midday 
to 6 p.m.), while for DOD it finished later (midnight to 6 a.m.). For total 
presentations to the ED, the quietest time of day was from midnight to 6 a.m., and 
the busiest from midday until 6 p.m. 
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Figure 4 Time of Day of Presentations for MOD, DOD, SH & ED Total 
The MOD and SH groups were each only about half as likely as the DOD group to 
attend between the hours of midnight and 6 a.m., and the same applied to the MOD 
group between 6 a.m. and 12 noon (Table 6). There were no significant differences 
noted for other times of the day. 
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Table 6 Group Membership and Percent Attending in 6-hourly Blocks 
Group n Time 
attended 
% OR 95% CI 
MOD 453 00:00-05:59 19.0 0.567+ 0.39-0.82 
  06:00-11:59 11.5 0.536+ 0.35-0.82 
  12:00-17:59 30.5 0.927 0.66-1.30 
  18:00-23:59 39.1 REF  
SH 545 00:00-05:59 16.5 0.553+ 0.38-0.79 
  06:00-11:59 13.9 0.730 0.49-1.09 
  12:00-17:59 34.7 1.182 0.85-1.64 
  18:00-23:59 34.9 REF  
DOD 409 00:00-05:59 26.4 REF  
  06:00-11:59 16.9 REF  
  12:00-17:59 25.9 REF  
  18:00-23:59 30.8 REF  
ED Total * 32,139 06:00-11:59 13.5   
  12:00-17:59 23.5   
  18:00-23:59 35.3   
  06:00-11:59 27.5   
+ Result significant at the 0.05 level 
* Data for ED Total were not included in the logistic regression analyses 
 
4.1.3 Summary 
Altogether medication misuse or overdose cases accounted for approximately 1.6% 
of cases attending the ED in a 12-month-period. Most medication overdose patients 
(88.6%) presented only once within a year. Presentations were most frequent in 
summer (30.9%), on Saturdays (17%), and between 6 p.m. and 12 midnight (39%). 
Compared to the other two groups, DOD cases were more likely to attend on the 
weekends and from midnight to 6 a.m. (and from 6 a.m. to midday in comparison to 
MOD). 
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4.2 Objective 2 - Characterisation of MOD patients at the ED 
This objective was met by considering two sets of data: the information available 
from PAS was used to broadly characterise cases of medication overdose, and patient 
interview data were used to examine the psychosocial circumstances of individuals 
attending the department. The intentions of this objective were to determine whether 
medication overdose patient characteristics in this study were similar to those found 
in previous studies, and also to explore whether these cases differed systematically 
from self-harm and illicit drug overdose cases. The purpose of the patient interviews 
was to obtain additional information regarding the profile of medication overdose 
patients that was not otherwise available from the computerised hospital records 
accessed. 
4.2.1 Broad demographic profile and summary of ED attendance 
Basic demographic information (e.g. sex, age) was available from PAS, along with a 
range of other details such as triage level, presenting complaint and discharge 
destination. 
Sex 
While females accounted for 64% of MOD presentations, a greater percentage of 
males attended for DOD (68%) and SH (56%) (Table 7). The SH group most closely 
resembled the gender distribution for all attendances at the ED.47 Females were 3.8 
times more likely to be in the MOD group and 1.7 times more likely to be in the SH 
group than the DOD group. 
                                                          
47 There were a very small number of cases where sex was listed as indeterminate (i.e. approximately 0.2% of all 
attendances). These cases have been dropped from the analysis concerning sex 
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Table 7 Group Membership and Percent Female 
Group n % Female OR 95% CI 
MOD 452 63.6 3.769+ 2.84-5.00 
SH 545 44.0 1.689+ 1.29-2.21 
DOD 409 31.8 REF  
ED Total * 32,083 44.1   
+ Result significant at the 0.05 level 
* Data for ED Total were not included in the logistic regression analyses 
 
Age 
MOD presentations ranged from 14 to 94 years of age, with a mean of 36 years and a 
median of 34 years (Table 8), with a comparable age distribution evident for SH 
presentations. Presentations for DOD covered a smaller age range (15 to 61 years), 
with a mean of 27 years and a median of 25 years. The average age for all three 
groups was somewhat lower than the average for the ED overall (48 years). 
Table 8 Age of Presentations for MOD, DOD, SH & ED Total 
Statistics MOD 
(n=453) 
DOD 
(n=409) 
SH 
(n=545) 
ED Total 
(n=32,081) 1 
Mean 36.2 27.2 34.8 47.8 
Median 34.0 25.0 33.0 44.0 
Std. Deviation 13.9 8.4 12.3 21.3 
Minimum 14 15 15 1 
Maximum 94 61 85 102 
1 Age data were missing in 58 cases 
 
The age distribution of patients attending for MOD, DOD, and SH is presented 
graphically below (Figure 5). In all three groups, most attendances to the ED were by 
individuals aged in their twenties or thirties. This was also true for total ED 
presentations, although a flatter distribution existed across all age groups, with a 
concentration of cases above the age of 75 years. 
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Figure 5 Age Group of Presentations for MOD, DOD, SH & ED Total 
Initial inspection of the age data (as presented above) suggested different patterns of 
attendance between groups, primarily driven by the younger age groups. Age was 
therefore recoded into four categories: <20, 20-29, 30-39, and 40+, for analysis of 
group differences. Age group was a significant predictor of group membership, with 
DOD cases ten times as likely to be aged less than twenty than either MOD or SH 
cases, approximately five to six times as likely to be aged in their twenties, and 
approximately three times as likely to be aged in their thirties (Table 9). This 
suggests that the MOD group were on the whole older than DOD patients and more 
similar in age to SH patients. 
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Table 9 Group Membership and Percent Attending by Age Group 
Group n Age group % OR 95% CI 
MOD 453 <20 6.6 0.100+ 0.06-0.17 
  20-29 30.7 0.168+ 0.11-0.25 
  30-39 27.2 0.310+ 0.20-0.48 
  40+ 35.5 REF  
SH 545 <20 6.1 0.098+ 0.06-0.17 
  20-29 34.7 0.205+ 0.14-0.30 
  30-39 26.4 0.327+ 0.21-0.50 
  40+ 32.8 REF  
DOD 409 <20 17.8 REF  
  20-29 49.1 REF  
  30-39 23.5 REF  
  40+ 9.5 REF  
ED Total * 32,139 <20 4.1   
  20-29 22.4   
  30-39 17.2   
  40+ 56.3   
+ Result significant at the 0.05 level 
* Data for ED Total were not included in the logistic regression analyses 
 
Presenting complaint 
While information from PAS was used to allocate cases to the three groups: MOD, 
DOD, or SH, triage nurses nominate a single “presenting complaint” for each patient 
from a large pre-determined computerized list of complaints.48 Given the great 
number of different presenting complaints assigned to cases in the audit, only the 
most common ones for each group (MOD, DOD, and SH) have been listed here. For 
MOD cases, the most common presenting complaint was ‘OD/ingestion/poisoning’ 
(86%), followed by ‘Altered consciousness’ (3%), ‘Psych behaviour’ (3%), and 
                                                          
48 “Presenting complaint” for cases in the PAS audit included; Alcohol intoxication, Allergic reaction, Altered 
consciousness, Amputation, Arrest (cardio/pulm), Cellulitis, Collapse, CVA? TIA?, Diabetes, Dizzy, Foreign 
body, Haem & melaena, Hypotension, Hypothermia, Inhalation, Laceration, LOC, Malaise, Nausea, 
OD/ingest/poisoning, Other, Pain abdomen, Pain back, Pain chest, Pain limb, Pain neck, Palpitations, 
Parasthesia, Poisoning, Psych behaviour, Psych harm, Psych mood, Psych relationships, Psych thoughts, Review, 
Seizure – atypical, Seizure – post ictal, Short of breath, SOB - Asthma, Social/placement problem, Trauma 
abdomen, Trauma hand, Trauma head, Trauma limb, Trauma multiple, Trauma neck, Violent behaviour, 
Vomiting/diarrhoea, Vomiting/nausea, Weakness. 
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‘Psych harm’ (3%). Similarly, for DOD, the most commonly listed complaints were 
‘OD/ingestion/poisoning’ (68%), ‘Altered consciousness’ (15%), and ‘Psych 
behaviour’ (3%). In relation to SH, the most frequent complaints assigned by the 
triage nurse were ‘Psych mood’ (23%), ‘Psych behaviour’ (23%), ‘Psych thoughts’ 
(21%), ‘Psych harm’ (15%), and ‘Laceration’ (9%).49 
Triage level 
The most common triage category for all three types of presentation was “3” (Table 
10), which is assigned to cases to be seen within 30 minutes of attending the ED. 
However, the remainder of the MOD cases tended towards the more urgent end of 
the spectrum. This was also true for DOD cases. In contrast, two-fifths of SH 
presentations were assigned a “4” (i.e. to be seen within 60 minutes). Triage 
categories “3” and “4” were the most frequently used across all ED presentations. 
Table 10 Triage Level Assigned to MOD, DOD, SH & ED Total Presentations 
Triage level % 
 MOD DOD SH ED Total 
 (n=453) (n=409) (n=545) (n=32,139) 
1 3.8 19.3 3.9 1.5 
2 20.1 15.6 9.4 9.3 
3 63.8 39.4 44.0 40.1 
4 11.7 23.0 39.8 41.6 
5 0.7 2.7 2.9 7.5 
 
To determine whether group membership predicted urgency, triage level was 
dichotomised into two groups; those to be seen immediately “Triage 1”, versus those 
not to be seen immediately “Triage 2-5”. When compared with DOD, both the MOD 
group and SH group were approximately six times as likely to be categorised as 
Triage 2-5 (Table 11). It therefore appears that MOD and SH patients were 
                                                          
49 The various psychiatric categories (e.g. psych behaviour, psych thoughts, psych mood) are applied to patients 
attending with primarily psychiatric symptoms. The specific one chosen depends upon the predominating 
features of the presentation, for example, someone presenting hearing voices would be assigned psych thoughts, 
while some found acting in a bizarre manner would be psych behaviour. 
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significantly less likely to be assessed as requiring immediate attention (as denoted 
by allocation to triage category 1) than DOD. 
Table 11 Group Membership and Percent “Triage 2-5” 
Group n % Triage 2-5 OR 95% CI 
MOD 453 96.2 6.140+ 3.57-10.57 
SH 545 96.0 5.973+ 3.62-9.85 
DOD 409 80.7 REF  
ED Total * 32,139 98.5   
+ Result significant at the 0.05 level 
* Data for ED Total were not included in the logistic regression analyses 
 
Length of time between being triaged and being seen by treating staff 
The length of time waited between triage and being seen by treating staff was 
calculated for the three groups (Table 12). Among the MOD cases, 17 people left 
after triage but prior to treatment, as did 26 DOD cases and 20 SH cases. No data 
were available concerning how long such people stayed in the waiting room before 
leaving. Of those who remained, 5% of MOD cases were seen immediately, 
compared to 23% of DOD and 4% of SH. Cumulatively, 87% of both MOD and 
DOD cases were seen within an hour of being triaged, compared to 76% of SH cases. 
The median waiting time for each of the groups was 17 minutes for MOD cases, 9 
minutes for DOD cases and 24 minutes for SH cases.50 These data were not available 
for the ED as a whole. 
                                                          
50 Median waiting times were calculated rather than mean waiting times due to skewed data and the presence of 
outliers. 
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Table 12 Length of Time between Triage and Being Seen by Treating Staff for 
MOD, DOD, SH & ED Total 
Time waited MOD DOD SH 
 (n=436) (n=383) (n=525) 
 % Cumulative % Cumulative % Cumulative
Seen immediately 5.0 5.0 22.7 22.7 3.8 3.8 
1-10 minutes 36.0 41.1 29.8 52.5 24.2 28.0 
11 to 30 minutes 26.4 67.4 20.6 73.1 27.8 55.8 
31 to 60 minutes 19.5 86.9 14.1 87.2 19.8 75.6 
1 to 2 hours 11.5 98.4 8.9 96.1 15.8 91.4 
More than 2 hours 1.6 100.0 3.9 100.0 8.6 100.0 
 
Length of time between being seen by treating staff and being discharged from the ED 
The length of time between commencing treatment and being discharged was also 
calculated for the three groups. Ten percent of MOD patients remained an hour or 
less in the department, 21% were discharged within two hours, 42% within four 
hours, and 88% within 12 hours. After 24 hours, less than 3% of MOD patients 
remained in the ED. Approximately 25% of patients treated for DOD (n=383) were 
discharged from the ED within an hour, 41% within two hours and 95% within 12 
hours of being seen by a member of the treating staff. Of the 525 SH patients who 
remained for treatment, 31% were discharged within an hour, and 51% within two 
hours and over 96% within 12 hours. The median time as a patient of the department 
was 4 hours 47 minutes for MOD patients, 2 hours 44 minutes for DOD patients and 
1 hour 56 minutes for SH patients. The data table relating to the above may be found 
in Appendix J, page 356. Figure 6 shows the proportion of cases remaining in the 
department at each time interval (please note the scale used on the X axis is not 
directly proportional). These data were not available for the ED as a whole. 
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Figure 6 Proportion of Cases Remaining in the ED at Each Time Interval for 
MOD, DOD, SH & ED Total 
Discharge destination 
Almost 70% of MOD and SH patients were discharged home, compared to over 80% 
of DOD patients (Table 13). Relatively fewer DOD patients required admission (6%) 
than for MOD and SH (about 20%). Approximately 7-9% of patients in all three 
groups left at their own risk prior to the completion of treatment. Other discharge 
destinations accounted for relatively few patients. 
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Table 13 Discharge Destination for MOD, DOD, SH & ED Total 
Discharge % 
 MOD DOD SH ED Total 
 (n=453) (n=409) (n=545) (n=32,139) 
Home 66.7 82.4 69.4 65.7 
Admitted 21.6 6.8 19.1 24.5 
Own risk 4.0 2.7 2.4 1.1 
Own risk – no tx 3.5 6.4 4.8 4.9 
Another hospital 2.4 1.0 2.9 2.6 
Other* 1.8 1.7 1.4 1.2 
* “Other” discharge destinations included; return to ward, mental health, left after advice, residential 
care, correctional facility, died in emergency. 
 
For the purposes of determining whether group membership predicted outcome, 
discharge destination was recoded as a dichotomous variable. The categories of 
“Admitted” and “Home” were retained, while all other categories of destination were 
recoded as missing (approximately 10% of cases across all groups). The MOD group 
were almost four times as likely to be admitted in comparison to the DOD group, and 
the SH group were 3.3 times as likely to be admitted (Table 14). 
Table 14 Group Membership and Percent Admitted 
Group n % Admitted OR 95% CI 
MOD 400 24.5 0.256+ 0.16-0.40 
SH 482 21.6 0.302+ 0.19-0.47 
DOD 365 7.7 REF  
ED Total * 32,139 27.2   
+ Result significant at the 0.05 level 
* Data for ED Total were not included in the logistic regression analyses 
 
Other information 
Additional information about presentations was recorded in many (but not all) of the 
PAS narratives. Other data available included alcohol consumption, referral to Psych 
Triage or Alert, whether a Code Grey51 was called, and if the person was in custody 
                                                          
51 In the case of an emergency a “code” may be called. These may occur in a range of situations, e.g. smoke/fire, 
evacuation, patient aggression, police attendance required, medical emergency, personal threat, etc. In case of an 
emergency, a staff-member called a central number and stated the nature and location of the emergency to the 
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at the time of presentation. These factors did not form mandatory fields within PAS, 
so if there was no mention of alcohol (for example), it did not mean that alcohol was 
not involved, simply that it was not recorded. Therefore the data presented below can 
be taken as a minimum estimate of each of the factors and for this reason no 
statistical comparisons were conducted between groups (Table 15). 
A case was included as “Alcohol-related” if alcohol was mentioned in the triage 
notes (e.g. ‘has been drinking today’, ‘intoxicated’, ‘blood alcohol level = 0.05+’). 
“Mental health assessment” was recorded if the triage notes indicated the person was 
referred to or seen by Psych Triage, the psychiatric registrar, or CATT, or if the 
person was admitted to the psychiatric unit. “Social work assessment” was recorded 
if the notes said the person had been seen by a member of the Alert team or an 
alcohol and drug worker. Cases were recorded as a “Code Grey - Actually called” 
when the PAS notes made any reference to a Code Grey or Code Black being called, 
or if the person was restrained, listed as involuntary, or sectioned under the Victorian 
Mental Health Act 1986. A case was listed as a “Code Grey – Warning” if the notes 
instructed that a Code Grey was to be called if the person tried to abscond from the 
department. “In police custody/imprisoned” applied to cases where the person was in 
the custody of police while in the ED, or was brought to the ED from the police cells, 
the remand centre, or a prison.  
A greater proportion of MOD cases involved alcohol (at least 24%) than DOD or SH 
(18%). The group most likely to receive a mental health assessment was SH (at least 
77%), followed by MOD (59%), with relatively few DOD cases (10%) being 
assessed. Likewise, SH were the group most likely to have a reference made to Code 
Grey in the PAS notes (at least 12%). Frequencies for all ‘other information’ 
obtained from the PAS narratives are presented in Table 15. 
                                                                                                                                                                    
operator. This was then broadcast on loudspeakers throughout the hospital. Staff were trained to respond to the 
emergency, and once resolved, an all clear was broadcast. Each type of code had a particular colour attached to 
it. The most relevant code to this project was Code Grey which meant an incident of patient aggression was 
occurring. Code Black meant the police were to be called. 
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Table 15 Other Information Derived from PAS for MOD, DOD & SH 
Other information % 
 MOD DOD SH 
 (n=453) (n=409) (n=545) 
Alcohol-related 24.3 17.6 17.8 
Mental health assessment 58.9 10.0 77.2 
Social work assessment 4.4 4.2 4.0 
Code Grey 7.9 6.1 12.3 
Actually called 4.4 5.4 9.7 
Warning 3.5 0.7 2.6 
In police custody/imprisoned 2.4 2.7 1.2 
 
4.2.2 Summary 
The PAS data suggest that patients attending the ED for medication misuse or 
overdose may broadly be characterised by female gender (64%), being aged in their 
thirties, being listed as a case of “overdose/ingestion/poisoning” at triage, and being 
assigned to triage category 3. In addition, a mental health assessment was conducted 
in at least 60% of cases, and alcohol was implicated in at least a quarter of cases. In 
contrast, more illicit drug overdose cases were male (68%), and aged in their 
twenties. Illicit drug overdose cases were also likely to be listed as an overdose, and 
assigned to triage category 3. Relatively few received a mental health assessment (at 
least 10%). Patients presenting for self-harm (not including medication or illicit drug 
overdose) approximated the ratio of males to females attending the ED as a whole 
(56% male). Most were in their thirties. The presenting complaints most often 
assigned to this patient group were psychiatric (i.e. psych mood, psych behaviour), 
and they were generally triaged at level 3 and below. At least three quarters of these 
cases received a mental health assessment. Statistical comparison of the three groups 
confirmed that both the MOD and SH groups were more likely to be female than 
DOD, but that DOD patients were on the whole younger. While DOD patients were 
also more likely than MOD or SH to be assigned to triage category 1 (denoting that 
the patient requires immediate treatment), this group was also the least likely to be 
admitted to hospital, suggesting that their care, while acute, is most usually managed 
within the ED. 
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4.2.3 Profile of interview sample 
In addition to the information available on medication overdose attendances from 
PAS, the profile of this group was further developed with information from patient 
interviews. The data presented below is from a small sub-sample and therefore may 
not be representative of all medication overdose patients attending hospital EDs. 
However, it gives a rich description of 31 patients who attended the ED within the 
study period who were able to be interviewed. 
Thirty out of the 31 interview participants were classified in the MOD group. All of 
these participants had clearly had an incident of medication overdose or misuse in 
the lead up to their presentation to hospital. Further, the PAS record of nine of these 
made specific reference to self-harm in association with the event in the narrative, 
though other cases may have also involved some suicidal intent, even if not 
mentioned. There were three cases where the PAS report indicated the medication 
overdose was not an instance of self-harm. There was only one case not classified as 
MOD for the purposes of the PAS audit. This case involved concurrent medication 
misuse or overdose, and overdose or intoxication on an illicit substance, and was 
therefore one of the few cases excluded from the audit by the process of creating 
independent groups (see Selection of cases for analyses, page 146). 
Demographic information 
Age and sex 
Of the 31 participants interviewed, 55% were male and 45% female. The youngest 
participant was 20 and the oldest 76. More people aged in their twenties and thirties 
were interviewed (42% and 29% respectively), compared to older people (13% of 
people were in their forties, 13% in their fifties, and one person in his/her seventies). 
The age distribution of the interview sample was similar to that for the total 
presentations for medication overdose. There were slightly more males interviewed 
than would be expected on the basis of the PAS audit data.  
Living circumstances 
Participants generally had stable accommodation; with 83% reporting they currently 
lived in a private residence (either rental or privately owned). However, 16% were in 
marginal housing circumstances; 10% were residing in boarding house style 
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accommodation, one (3%) was staying in a refuge, and one person (3%) was 
homeless. In keeping with the catchment area for the hospital, about two-thirds of 
participants resided in the northern and eastern suburbs of Melbourne (including 
inner suburban areas). About half the participants were from inner urban areas, 
including the CBD. 
Most people interviewed lived with others. Clearly those in transitional housing 
shared their accommodation, although not necessarily with friends or relatives. 
Among the 26 in private residences only five (19%) lived alone. Nineteen percent 
were living with friends/housemates at the time of the overdose, 19% were living 
with their partner (without children), one person (4%) was living with a partner and 
housemates, 15% were living with their parents, 15% with other relatives, and 8% 
with their children (one with a partner and one without). While only two people (6%) 
were actually living with children, 26% participants indicated they had a 
child/children, although in half of these cases someone else had custody. 
Education and employment 
In terms of educational background, 58% of participants had completed secondary 
school, another 23% had completed Year 10 or 11, and the remainder had a less than 
Year 10 education. Fifteen people (48%) had completed further education since 
leaving school; 16% had undertaken a short course (e.g. certificate in horticulture), 
3% had completed a trade qualification, and 29% had completed a university degree. 
Most people interviewed were not currently working. Twenty-nine percent were 
unemployed, while another 29% were on a pension (generally a disability pension). 
Eight people (26%) were currently working (19% in full-time employment), 13% 
were students and one person had a job, but was taking extended leave due to her 
mental health (3%). 
Cultural background 
All but one participant indicated that English was the main language they spoke at 
home. When asked what cultural or ethnic background they identified with, 84% said 
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“Australian”, 10% people indicated European heritage, one person (3%) was of 
Asian heritage, and one person North American.52 
Sexual orientation 
Most participants identified themselves as heterosexual. Two people (6%) 
interviewed were bisexual and one gay/lesbian (3%). 
Physical and mental health 
Physical health 
Participants indicated whether they currently (i.e. at the time of the interview, but not 
necessarily as a consequence of the overdose) experienced any significant medical 
problems in any of the body systems (Table 16). The most common area in which 
people experienced a problem was the musculoskeletal system, followed by the 
cardiovascular and gastrointestinal systems. A fifth of the sample indicated 
significant problems concerning respiration, glands and hormones, and skin 
conditions. As may be seen, data were missing in a small number of cases. 
Table 16 Physical Health Problems Currently Experienced (n=31) 
Physical health problems % 
 
 
Yes No Unable to 
determine 
Musculoskeletal 32.3 67.7 0.0 
Cardiovascular 22.6 77.4 0.0 
Gastrointestinal 22.6 77.4 0.0 
Respiratory 19.4 80.6 0.0 
Endocrinological 19.4 77.4 3.2 
Dermatological 19.4 74.2 6.5 
Neurological 16.1 83.9 0.0 
Eyes, ears, nose & throat 16.1 74.2 9.7 
Allergies 12.9 80.6 6.5 
Genitourinary 6.5 93.5 0.0 
Other 3.2 90.3 6.5 
 
                                                          
52 More specific information on cultural heritage was provided by participants (other than those identifying as 
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Only 16% of people said they experienced no physical health problems, 32% people 
had problems in only one area, 23% people had problems in two areas and the 
remainder had three or more body systems in which they experienced problems. The 
greatest number of physical health problem areas for any one person was six. On 
average, participants indicated they had two significant current medical problem 
areas. 
The musculoskeletal problems described by participants were generally either 
arthritic pains or related to an old injury or surgery. Participants suffering from 
musculoskeletal problems had generally been troubled by their complaint for a 
number of years and found it to have a moderately severe impact on their life. Of the 
half currently being treated for their musculoskeletal problems, the most common 
response was to take prescription analgesics. 
Most cardiovascular problems identified by participants were described as a “heart 
murmur”, except for two participants who said they had high blood pressure. Two 
people had experienced cardiovascular problems for 10 or more years, the remainder 
only recently. In every case the problem was rated as only mild or moderate, and 
there was only one person currently on medication.  
The most common respiratory problem mentioned by participants was asthma, which 
most reported having had since childhood. Not all reported current treatment, but 
those who did were using antiasthmatic medication. Only one person regarded their 
respiratory health problem as severe, the rest rating it mild to moderate. 
Reported gastrointestinal problems related mainly to digestion (such as Irritable 
Bowel Syndrome or constipation), though one person reported severe pancreatitis 
and another person reported a peptic ulcer. In most cases the problem was of some 
years’ duration. Only two people were on medication, while others indicated they 
managed their problem by avoiding triggers (e.g. alcohol). 
Of those identifying themselves as having endocrine problems, the types of 
conditions included diabetes, menopause, glandular fever, and hyperthyroidism. 
Most often the person had suffered for a year or more, and rated the impact on their 
                                                                                                                                                                    
“Australian”), but to protect anonymity, general terms are used here. 
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lives as moderate to severe. The two diabetic participants were both currently treated 
with insulin. 
Participants mentioned a range of skin conditions, including eczema, cirrhosis, acne, 
and general rashes. In general, participants reported that these conditions were 
intermittent, and were of only mild importance. A number of people commented that 
their dermatological conditions were exacerbated by stress and worry. 
Four participants (13%) indicated that they had Hepatitis C, only one of whom was 
currently being treated for the condition. 
While physical and mental health complaints were separated for the purpose of data 
collection, it was clear from a number of participant responses that problems in one 
area sometimes exacerbated or even caused problems in the other, therefore physical 
and mental wellbeing were not necessarily distinct. In particular, cardiovascular 
symptoms, dermatological conditions and digestive disorders seemed to be related to 
mental health. For example, concerning Irritable Bowel Syndrome one participant 
noted; 
Interview 11 I think it’s a combination of my diet and my alcohol intake and 
also I am a bit of a perfectionist and I worry a lot, so I would 
say yes definitely, it’s all of those factors 
Therefore, poor physical health in some cases had a deleterious effect on the mental 
wellbeing of the participant, just as poor mental health sometimes resulted in 
physical symptoms. 
Mental/psychiatric health 
This section reports on psychiatric disorders (self-identified and/or diagnosed)53 
described by the interview participants. Thirty of the participants indicated they had 
experienced psychiatric problems (either past or current). It may be seen from Table 
17 that the most commonly identified problems were mood disorders (e.g. 
depression, dysthymia, bipolar), anxiety disorders (e.g. generalised anxiety, panic 
disorder, obsessive-compulsive disorder), and substance-related disorders 
                                                          
53 Participants were asked, “Would you say you have/had X?” for each psychiatric condition, and if so, when first 
diagnosed, if ever. Inclusion as a case for each condition in this section was based on either self-identifying as 
having that condition, and/or having been formally diagnosed by a relevant professional. 
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(dependence, abuse). A quarter of people reported an eating disorder (e.g. anorexia 
nervosa, bulimia nervosa), 19% indicated a psychotic disorder (e.g. schizophrenia) 
and 10% indicated they had been diagnosed as having an attention 
deficit/hyperactivity disorder as a child. Two people identified as having some 
“other” psychiatric disorder; one a gambling problem, and the other indicating 
problems in relation to sexual identity which were causing psychological distress. 
Table 17 Mental Health Problems Ever Experienced (n=31) 
Mental health 
problem 
% 
 Yes No Unable to 
determine 
Mood disorder 87.1 12.9 0.0 
Anxiety disorder 80.6 9.7 9.7 
Substance use 74.2 19.4 6.5 
Eating disorder 25.8 61.3 12.9 
Psychosis 19.4 74.2 6.5 
ADD/hyperactivity 9.7 80.6 9.7 
Other 6.5 83.9 9.7 
 
Of the 30 participants who indicated they had experienced mental health problems, 
the average number of conditions identified was three. Most participants (87%) 
identified themselves as having experienced between two and four mental health 
problems (Table 18). 
Table 18 Number of Mental Health Problems Identified (n=31) 
Number of problems N % 
0 1 3.2 
1 2 6.5 
2 6 19.4 
3 9 29.0 
4 12 38.7 
5 1 3.2 
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Further information on specific mental health problems is presented below. As 
mentioned earlier, due to individual differences in responding to the survey, not all 
participants necessarily provided information about every topic of interest in this 
section, although a vivid picture of the mental health of participants was still evident 
from the information provided. 
 Mood disorders 
Most participants (87%) indicated they had a mood disorder. The majority of these 
had been formally diagnosed, although there were a small number who said that 
while they had never been officially diagnosed, they believed that they were in fact 
depressed. Considering the duration of depressive symptoms described, the fact that 
most had been treated with antidepressants (see below), and that scores obtained by 
many participants on the BDI-FastScreen were indicative of depressive 
symptomatology (see BDI-FastScreen, page 190), it seemed reasonable to conclude 
that this was an accurate diagnosis in most cases. There were three participants who 
indicated they had been diagnosed with a Bipolar Disorder. 
Almost all participants could trace their first feelings of depression back to their 
teens or early childhood, with some saying they had “always” felt depressed. The 
most common age of onset seemed to coincide with puberty. Only two or three 
people had their first experience of depression in their twenties or later. Therefore 
among the older participants it was common to have felt depressed for more than 30 
years. For most people, formal diagnosis seemed to lag some years behind the initial 
onset of the problem. Although most participants said they now recognise they were 
depressed in their teens, most were not diagnosed or treated until their twenties or 
beyond. 
Interview 21 I think basically when I was about 14, 15 I started to notice 
things that were different and I lost interest in everything and 
um, sort of no care for any consequences (…) it gradually got 
worse. I think I didn’t realise I had depression, you know, till I 
think 27 (when) I went to get help for it (…) Whenever I feel 
depressed I feel like my body is all bruised. 
*** 
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Interviewer OK, so you’ve mentioned that you think you’ve got depression, 
but have never been diagnosed. Yep, how long would you say 
that’s been…? 
Interview 9 Oh, years. I’ve had it on and off for years. I’ve had it for a long 
time, a very long time. Since pretty much since I went, I left 
home at 14, so, and I haven’t had anything to do with my family 
since (…) A lot of the time I have abused the medications and 
there’ve been times when, I’ve been suicidal a couple of times 
that way, with pills. 
Past or current experience of depression treatment was common, with only three 
people who said they had a history of depression never having received any 
treatment for it. The treatments people mentioned fell into two main groups; 
medication and counselling (although a small number of people also mentioned the 
use of telephone help lines). As alternative treatments such as yoga, acupuncture, and 
St John’s Wort were not enquired about directly, it is not possible to tell how many 
participants had ever tried such methods. 
The most commonly prescribed medications were antidepressants. Fourteen people 
(45%) indicated they were currently taking antidepressant medication. Seven of these 
were taking an SSRI, six people an “other” antidepressant and one person a TCA. 
However, of those taking an antidepressant, about half mentioned one or more other 
medications they were on that they believed were prescribed to assist with their 
depression. The most frequently used additional medications were benzodiazepines, 
antipsychotics, and antiepileptics (the last of which may be prescribed for Bipolar 
Disorder where other treatments have not been effective) (Rossi, 2003). Most people 
indicated that they currently took their antidepressant medication on a regular basis 
as prescribed, although there were a small number of participants who expressed 
difficulty in maintaining a consistent pattern. 
Very few participants had only ever taken one type of antidepressant. Most had 
previously tried several antidepressant medications (up to 12 in one case), but had 
stopped for a range of reasons such as poor efficacy, thinking they were no longer 
required, or being recommended to change to something else. Many participants who 
were prescribed medication also received some level of counselling from their 
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prescribing GP or psychiatrist. This apparently ranged in nature from brief, relatively 
directive counselling through to long-term psychotherapy. Few participants 
commented on the usefulness of undertaking counselling or psychotherapy with their 
doctor. 
Many participants had also tried counselling with a psychologist or other trained 
professional, aside from their doctor. Some regarded this support as very valuable, 
but there were a greater number of participants who had found the experience to be 
unsatisfactory in some way. Problems identified included the counselling focussing 
on the wrong issues, difficulty in establishing rapport, the person feeling they did not 
need to discuss their problems, and the counsellor leaving the service. Those who 
had the most positive experiences of counselling were able to point to some tangible 
gain made or skill learnt through the process, such as the ability to distract oneself 
from negative thoughts. 
Of the 27 people with mood disorders, 89% were able to provide information on 
their family history. Of these, 63% indicated at least one relative suffered from a 
depressive illness, and 38% of these identified multiple relatives with depression. 
Forty-two percent of those providing a family history said one or both of their 
parents were depressed. 
Interviewer And has anyone in your family got depression? 
Interview 25 Um yes, my dad. All of them, everyone’s, my mum, and my 
brother have all been diagnosed with depression. And my 
brother’s the only one who takes antidepressants regularly, and 
that’s mostly been to sleep though… We think on my Dad’s side 
that his dad suffered from depression, but he’s gone now. 
  
 Anxiety disorders 
Most participants (25/28, 89%) indicated they had an anxiety disorder. Many of 
these recognised they had in fact had anxiety problems extending back into 
childhood or teen years, although this may not have been identified as such until 
some years later (either by formal diagnosis, or through the increased awareness of 
the individual). A smaller number of participants developed anxiety in their twenties. 
For most participants, anxiety has remained an active problem several years after the 
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initial onset. Here is one participant’s description of her first panic attack at the age 
of fifteen, a problem that she has continued to experience into her thirties: 
Interview 21 That was the first one I had, when I was fifteen actually (…) I 
was at school and the whole school just span, like it was 
spinning, and um, I felt really queasy and um I started crying 
and um I just was standing in the middle of the courtyard at 
school. All of a sudden I couldn’t move, I just stood there. 
Some participants provided greater detail on their anxiety problems. At least 48% of 
those with anxiety said they had experienced panic attacks, some on a daily basis. 
Twenty percent were particularly prone to anxious feelings in social situations, 12% 
of those with anxiety described symptoms of agoraphobia, and 8% indicated a 
diagnosis of Post-Traumatic Stress Disorder (PTSD) associated with past sexual 
abuse (although it is possible a larger number would actually meet the diagnostic 
criteria). 
In discussing depression and anxiety, many participants (14) spontaneously 
commented that they consider them to be the same thing or have found one condition 
leads to the other. Therefore, in terms of personal experience of psychological 
distress, the distinction between the two was not always relevant. Similarly, in 
discussing medications used for the treatment of one condition, participants 
frequently listed drugs more commonly associated with the treatment of the other 
(for example, benzodiazepines used to combat depression). 
Interview 25 Anxiety is probably my major one. Anxiety is what causes me to 
become to be depressed because I wear myself out with it. 
That’s my main problem, and so, just generalised anxiety. If 
anxiety is left untreated too long it can turn to sort of a 
combination of depression and very high anxiety at the same 
time which can lead to sort of social phobia problems. There’s 
panic attacks. 
*** 
Interviewer So with the [antidepressant medication], was it mainly 
prescribed for your panic attacks or do you think your doctor 
also prescribed it for depression? 
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Interview 19 Both. Yes, the psychiatrist said, “You’ll have the benefit of, 
these will control your panic attacks, you shouldn’t even get 
them, and they’re actually an antidepressant, so I think they’re 
excellent for you.” 
It was established that 17 participants (68% of those with anxiety, and 55% of the 
total sample) were currently taking medication for anxiety. The majority of these 
were taking either one or two types of benzodiazepine medication (typically 
alprazolam or diazepam). A number of people were on antidepressants (mainly 
SSRIs and “other” antidepressants) in conjunction with benzodiazepines. There were 
two participants who were only taking antidepressant medication specifically 
prescribed for its anxiolytic properties. The majority of people had been prescribed 
their medication by a GP or psychiatrist, although at least six people (19%) described 
“doctor shopping” in order to obtain scripts for benzodiazepines and one person used 
other peoples’ medication. 
There seemed to be a wide range of recommended dosing regimes among those who 
had their medication prescribed, and variable adherence to them. Some were 
prescribed regular doses at set times of the day, while others were instructed to take 
them “as needed” which for many participants appeared to be varying amounts 
several times a day (one person up to 12 times per day). Many participants appeared 
unaware of the dependence-inducing potential of benzodiazepines, despite having 
taken them under medical supervision for an extended period of time. However, 
there were a small number of participants whose doctors were currently encouraging 
them to withdraw from benzodiazepine medication, and/or switch to an 
antidepressant. Here is an extract from the interview transcript of one participant 
taking three different types of benzodiazepine under medical supervision, who also 
experienced frequent “anxiety attacks”: 
Interview 23 I use the [oxazepam] to help me sleep, [diazepam] because I 
have anxiety attacks and the [nitrazepam] helps, my body has 
just become immune to [nitrazepam], so it’s just sometimes I 
can just take, instead of being in a massive comatose sleep I 
might just take two of those just to wind down, instead of taking 
maybe you know four [diazepam] or something like that (…). 
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Interviewer And the [diazepam], you would take at a regular time, or…? 
Interview 23 I take two in the morning and two at night. Unless I feel like I’m 
having an anxiety attack, and then I’ll take more. 
Interviewer And how many (more) do you normally need to… 
Interview 23 Two, I don’t abuse them. They’re too bloody hard to come by. 
Interviewer The [oxazepam], you take to sleep at night, how many do 
you…? 
Interview 23 Just two. 
Interviewer How often do you have an anxiety attack? 
Interview 23 Every day. 
Interviewer Are they predictable? 
Interview 23 They are predictable because I can feel them coming on. It’s like 
I get really edgy, and I can feel it get any further than that I’ll 
take, you know, a couple of [diazepam] (…). 
Interviewer With the [diazepam] and [oxazepam], are they prescribed by 
your GP, or…? 
Interview 23 All through my doctor, everything from one doctor. I don’t 
doctor shop or anything like that, so. 
Interviewer OK, and how often does (your GP) issue you scripts? 
Interview 23 Well, whenever I go there and I need it, he will issue it. Knowing 
now, now when he finds out that I’m suicidal he will issue it per 
weekly, not, he won’t let me have scripts… 
A number of people who indicated they had an anxiety disorder have had counselling 
from a psychologist or other professional “counsellor”, although it seemed in many 
cases this did not specifically address anxiety, but was of a more general nature (e.g. 
for depression, relationship issues, substance use, etc). There were certainly a 
number of people on anxiolytic medication who had not received counselling. 
Participants’ experiences of counselling were mixed, with many people feeling that 
the counselling process was of limited assistance, for reasons such as finding it 
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difficult to discuss their problems openly or having to change counsellors. Only a 
couple of participants mentioned being taught specific anxiety reduction techniques 
(such as relaxation and breathing exercises), and even then these were not perceived 
as especially helpful. The most positive experiences of counselling seemed to be 
associated with liking the counsellor, rather than any substantial improvement in 
anxiety levels. Other forms of assistance for anxiety accessed by a small number of 
people included telephone help lines, an anxiety support group and personal research 
and reading into the problem, all of which were regarded as helpful. 
Anxiety disorders were also common among the family members of participants. Of 
the 23 people who provided information regarding this, 57% said they had at least 
one family member with an anxiety disorder, and in 35% of cases one or both of the 
person’s parents were regarded as anxious. 
 Substance use disorders 
Although only one person interviewed was specifically identified on PAS as having 
had an illicit drug involved in the medication overdose for which they attended 
hospital (see Profile of interview sample, page 165), this should not be taken to 
suggest the interview participants were primarily a non-drug using group. Most 
participants (23/29, 79%) indicated they had current or previous substance use 
problems. The majority of these recalled that their problematic alcohol and/or drug 
use commenced in their teens, although there were also a smaller number who 
commenced using in their twenties. Many people described a variable pattern of 
consumption over the years, with periods of using more heavily, or “bingeing” (often 
as a coping mechanism in times of stress), interspersed with periods of relatively low 
levels of use. A number of people continued to struggle with dependence (see 
below). The most commonly mentioned substances were heroin, alcohol and 
cannabis, although some participants also made reference to amphetamines and 
inappropriate use of medications. 
An effort was also made to determine whether each participant could be regarded as 
meeting the criteria for substance dependence. It was only possible to establish this 
for 24 participants, half of whom met the criteria for dependence. Of those meeting 
the criteria, 42% were poly-substance users, 25% were alcohol dependent and 17% 
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were heroin dependent. Two people indicated they were currently dependent on 
prescribed methadone, but also had extensive histories of poly-substance use. 
Information was available from 25 participants regarding injecting drug use. Of 
these, 56% said they had never been an injecting drug user, 24% had been in the past 
but were not at time of interview, and 20% were currently injecting drug users. 
All of the participants who indicated a substance use problem provided some 
information on their treatment history. Six of the 23 people (26%) had never had any 
substance-related treatment at all (two had ceased use on their own). The remaining 
74% had accessed a wide range of treatment types, with varying outcomes. 
Treatment types accessed by these 17 people included seeing a community-based 
counsellor/psychologist (59%), doctor/psychiatrist (other than for pharmacotherapy, 
47%), residential detoxification (41%), pharmacotherapy (methadone or 
buprenorphine, 29%), a therapeutic community or residential rehabilitation service 
(24%), Alcoholics’ Anonymous (18%), services provided through the justice system 
(both in and out of prison, 18%) and telephone help lines (6%). The number of 
different treatment types ever accessed ranged from one to five, with most people 
having tried two or three types at least once, sometimes several times. Participant 
experiences of treatment were variable, with both positive and negative comments 
made. Among the good things people mentioned about treatment were that they liked 
the counsellor/s and felt supported, a sense of structure, and learning about their 
problem. 
Interview 6 You know it’s absolutely fantastic, (…) someone just to help you 
see the structure, to create a structure in my life, and to help me 
see it, basically create a framework in which to operate and 
then sort of manage that  (…) 
However, negative experiences – some treatment centred and some client centred - 
outnumbered positive ones. The following difficulties were each mentioned by at 
least one participant; barriers to accessing treatment (such as waiting lists, travel 
distance, and cost), lack of structure within the program, not fitting in with other 
program participants or being asked to leave, side effects of pharmacotherapy, not 
being able to maintain change, missing drug use, and treatment focusing on the 
wrong problem. 
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Interview 11 In the end I really, I was miserable not ever having a drink (…) 
I would rather be dead than like not, be stopped forever (… ) in 
the end it just wasn’t, it wasn’t going to be the answer (…) 
*** 
Interview 26 Well it’s good, but it’s sort of like, it can’t do anything for me if 
I’m not willing to do the work as well, and I always do the same 
thing. After a while I start feeling better, I feel like I’m safe, and 
I just fall back in the shit again. Yeah, it’s a really powerful 
disease and sometimes I feel like I’m wasting their time, you 
know what I mean, these people are getting paid and they could 
be seeing someone who is going to recover, you know what I 
mean. Whereas I sort of, I get these times when I’m feeling 
really positive and I feel like, yeah, I will recover, but then, you 
know, I just fuck it all up again and get to a point where I just 
feel like yeah, the possibility of recovery for me doesn’t exist, 
you know. 
Twenty-two people provided information on their family history of substance use 
problems. Of these, only three people (14%) indicated they were not aware of 
anyone else in their family who had problems in this area. Fifty-five percent named 
only one other person who had substance use problems and the remainder had 
multiple relatives with problems. At least 68% of participants providing a family 
history indicated a relative had problems with alcohol dependence (some with other 
drugs also), while most of the others were injecting drug users (especially heroin). 
Approximately half of those with a family history identified that one of their own 
parents (or a primary caregiver during childhood) had a substance use problem.  
Interview 3 Ah yes, my sister was a heroin addict and is now on the 
methadone program. She’s an alcoholic and yeah, the family all 
drink too much. 
 Eating disorders 
Eight people (8/27, 30%) said that they had experienced an eating disorder either in 
the past or currently. This included both male and female participants. Half of the 
participants who self-identified as having an eating disorder described a restrictive 
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eating pattern typical of Anorexia Nervosa, while the rest mentioned binge eating 
followed by purging (via vomiting or laxatives), typical of Bulimia Nervosa. Most 
had first experienced disordered body image and eating during their teens, and for 
many this issue had since resolved itself, although a couple were still susceptible to 
the problem. For example: 
Interview27 I still don’t feel right, … I don’t throw up, I just don’t eat that 
much, maybe once about 5 or 6 o’clock. 
Most people who had experienced anorexia or bulimia had discussed it at some stage 
with a counsellor, though not in the context of specialist treatment for eating 
disorders, but rather while engaged in general counselling addressing a range of 
other issues. Two participants said they had never previously discussed their problem 
with anyone. None of the eight reported having ever been hospitalised specifically in 
relation to an eating disorder. 
Many of those who had suffered from eating disorders spontaneously commented on 
the close association that existed for them between disordered eating and depression: 
either negative thoughts and feelings about body weight precipitated an episode of 
self-starvation or bingeing/purging, or their depression was exacerbated by poor 
eating habits. Some even described their disordered eating or purging behaviour as a 
form of self-harm or self-abuse, akin to other self-harming behaviours. One person 
found that treatment for depression paradoxically made her eating disorder worse as 
weight-gain was an unwanted side effect of the medication. 
Four interviewees indicated they had a relative with an eating disorder. 
 Psychosis 
While six people (6/29, 21%) self-identified as ever having had a psychotic disorder 
(and were therefore counted as such), there were in fact ten people (34%) altogether 
who described an experience of psychosis; three non-substance-induced and seven 
substance-induced. Three participants (10%) indicated they had been previously 
diagnosed with either schizoaffective disorder or schizophrenia. All three were 
currently under the care of a psychiatrist and had additional support workers, and 
two were currently taking antipsychotic medications. All described difficulty in 
taking their medications as prescribed and/or seeking additional medications 
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elsewhere (i.e. one person found it difficult to comply with a routine regime of 
medication, and two sought additional medications via doctor shopping and/or using 
other people’s medications). The remaining seven participants said they had 
previously had at least one substance-induced psychotic episode associated with 
intoxication or withdrawal (three of these were related to the use of medications, and 
four to the use of illicit drugs). For some this had been a once off event, while others 
had experienced multiple episodes. Only one participant was aware of a relative with 
a psychotic illness. 
 ADD/ADHD 
Three participants (3/28, 11%) self-identified as having a history of ADD/ADHD, 
although only one was formally diagnosed as such and medicated during childhood 
(but not currently). One person reported a family history of ADD/ADHD. 
 Other 
In addition to the two people who self-identified as having some “other” psychiatric 
disorder (gambling and sexual identity), there were two reported cases of family 
members having some “other” mental health problem. One participant mentioned a 
sibling with a personality disorder and one reported a parent with a gambling 
problem. 
Acceptability of the word “overdose” 
In order to check whether the main concept of the study was meaningful to 
participants, and the language appropriate, participants were asked whether the term 
“overdose” was “OK” for them. The majority thought it was acceptable (27/29, 
93%), one person (3%) gave an unclear response and one person (3%) rejected the 
term. This person believed the term “overdose” should only be applied to situations 
where a person stops breathing, is unconscious, and does not respond to stimulation. 
With regard to the events for which he was referred to the study, this participant said 
he showed none of these signs, instead describing his state as “being severely stoned, 
being too stoned”. However, as this person also believed he had taken too much 
medication and had required medical attention as a consequence, it was possible to 
include him in the study even though he rejected the term overdose. Given the 
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general acceptability of the term “overdose” to participants it was thought possible to 
use it throughout the study. 
Previous overdoses 
Information was gathered concerning the previous history of overdose among 
participants. Two-thirds of the interview participants (20/31, 65%) had received 
emergency medical care (i.e. ambulance attendance and/or hospitalisation) as a result 
of taking too much medication on at least one previous occasion. Two of these (10%) 
were unable to say how many times they had received medical care for a medication 
overdose. Of those who had overdosed, a quarter reported only one previous 
overdose requiring medical care, half had required care on up to five occasions, and 
the remainder had emergency care on more than five previous occasions. The person 
with the greatest number of occurrences reported in excess of 60 medication 
overdoses for which medical care had been sought. 
A small number of people had a history of medication overdose extending back into 
their teenage years (for two people their first overdose occurred more than 30 years 
previously), though others had first overdosed in their twenties or later. About a third 
of those with prior overdoses had sought emergency medical care at least once 
within the last 6 months for the same reason. On the whole, previous medication 
overdoses had been taken deliberately, whether as active suicide attempts, or to 
temporarily escape from negative feelings. Only a small number were accidental. 
In terms of treatment received for previous medication overdoses, the range of 
interventions described was similar to those for the current overdose (see Medication 
overdose patients’ experiences of the emergency medical care system, page 235). For 
example, aspects of care mentioned included ambulance attendance, monitoring in 
the ED, psychiatric assessment, sometimes hospitalisation (medical or psychiatric) 
and psychiatric follow-up. Several people mentioned having previously being 
administered charcoal or having their stomach pumped, which was a comparatively 
rare treatment experience in relation to the presentation for which people were 
referred to the study. In general, people felt they had been well-treated on previous 
occasions: 
Interview 11  No, I’ve only had good, from what I can remember, I’ve only 
had good care 
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*** 
Interview 13 The hospital staff were just the same, just as good 
In addition to those occasions where the medication overdose actually resulted in 
ambulance attendance and/or hospitalisation, several participants (12/25, 48%) 
reported that there had been times in the past when they had consumed too much 
medication but where they had not sought emergency medical care. Half of these had 
only one such previous experience, but one person reported 20 medication overdoses 
and another person “hundreds”. 
Interview 22 Yeah, I’ve taken too much morphine before. My friend just drove 
me home and put me to bed. That’s about it. 
It was possible to establish from the interview data that at least 11 people (35%) had 
previously experienced an illicit drug overdose. Most of these were accidental heroin 
overdoses, the most common treatment received was the administration of naloxone, 
and in some cases, transportation to hospital. Two participants (6%) reported 
previously overdosing on amphetamines and one (3%) on ecstasy. 
Personal and family history of self-harm 
Participants were asked about their own history of self-harming behaviour, and also 
whether there was a family history of suicidal behaviour.54 More than half of (15/28, 
54%) indicated they had previous history of deliberately hurting themselves, but 
without meaning to commit suicide (for example, cutting or burning). Of these, about 
half had done so only once or rarely, while the rest indicated a history of more 
regular self-harm, mainly involving self-laceration. One participant described how 
occasional self-laceration relieves tension as follows: 
Interview 21 I have done it when I think, when my brain goes on overload, it 
sort of again, it sort of takes away the pressure in my brain for 
some reason 
Information was available from 25 participants on whether they had previously 
attempted suicide. Twelve (48%) indicated a history of attempting suicide (excluding 
                                                          
54 This examination of personal history of self-harm excluded the current overdose event, which is dealt with 
under 
, page 190). Objective 3 - Specific suicidal intent, suicidal ideation, and depression
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the overdose for which they were included in the study); a quarter of these had only 
attempted once previously, and the remainder had multiple attempts. Most had five 
or less previous attempts but one person estimated they had attempted suicide about 
50 times. All had previously attempted suicide by overdose, three people had 
attempted by cutting/slashing themselves, and one person had previously tried to 
hang herself. 
Further information concerning history of attempted suicide was available from the 
BSS, which was completed by twenty-four participants. Thirteen (54%) indicated a 
previous suicide attempt (which may have included the most recent medication 
overdose). Of these, three (23%) reported their wish to die during the last attempt as 
low, five (38%) as moderate and five (38%) said they had a high wish to die during 
their most recent suicide attempt. Greater detail concerning the BSS is provided in 
the results relating to Objective 3, page 190. 
Regarding family history of suicide, four people (4/27, 15%) indicated at least one 
member of their family had committed suicide (one person had multiple suicides 
within the family), and a further 11% said someone in their family had attempted 
suicide. None of these events had occurred recently. Suicide among friends and 
acquaintances was more common; with 11 (n=25, 44%) people saying they had a 
friend or acquaintance who had committed suicide, and a further four (16%) 
knowing someone who attempted suicide. Again, most of these events had occurred 
some years previously, although one person had received news of a friend suiciding 
within the last 6 months. 
Recent significant life events 
Nineteen participants were able to provide information on whether they had 
experienced unhappiness or distress as a result of particular life events in the last six 
months. Most participants indicated problems arising from their mental health and/or 
problems with their parents (Table 19). About half the group had experienced stress 
related to a relationship break-up, financial hardship, problems at work, and/or 
problems with friends. The number of different stressful events reported by 
participants ranged from 4 to 12, with an average of 7. 
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Table 19 Number of Recent Significant Life Events in Last 6 Months (n=19) 
Significant life events Experienced in the last 6 months 
 N % 
Mental illness 14 73.7 
Problems with parents 13 68.4 
Relationship break-up 10 52.6 
Financial hardship 10 52.6 
Problems at work 10 52.6 
Problems with friends 9 47.4 
Own alcohol use 8 42.1 
Being bullied 8 42.1 
Physical illness 7 36.8 
Unemployment 5 26.3 
Own drug use 4 21.1 
Anxiety about school/university performance 3 15.8 
Violence in the home 3 15.8 
Own violent/criminal behaviour 3 15.8 
Physical abuse 3 15.8 
Homelessness 3 15.8 
Failure at school/university 2 10.5 
Parental divorce 2 10.5 
Death of a friend 2 10.5 
Physical disability 2 10.5 
Sexual abuse 1 5.3 
Suicide of a friend 1 5.3 
Sexual identity conflict 1 5.3 
Other* 11 57.9 
* Other sources of stress identified included illness in family (n=3), interpersonal conflict/anger 
(n=3), death of pet, release from jail, self-harming behaviour, feeling suffocated, and having a new 
partner 
 
Participants identified the biggest contributing factor to feeling stressed lately 
(although some nominated more than one factor which they saw to be of equal 
importance, or the factors were interrelated).55 Six people (n=19, 32%) nominated 
                                                          
55 Participants were not asked about the relative contribution of each life event to the overdose, nor should it be 
assumed that the biggest contributing factor to feeling stressed necessarily precipitated the overdose (although in 
some cases a causal relationship was mentioned by the participant). However, these data provide some 
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work or study: for some this was about issues of workload, while others indicated 
they had been subject to workplace bullying. Disruption to key relationships 
(including separation from partner, removal of children, and family conflict) was the 
greatest stress for six participants (n=19, 32%). Problems relating to mental health or 
substance use were of greatest importance to five people (n=19, 26%). Financial 
difficulties and/or unemployment were particularly concerning to three people 
(16%). 
Interview 11 I feel threatened that I could lose my job, and I’ve been assured 
I’m not going to lose my job, right, but I feel threatened that 
these particular people at work could help me out the door, you 
know what I mean, (…) 
*** 
Interview 4 Oh just the booze and the alcohol and, you know, the way I treat 
people. It’s getting worse, each year it seems to be getting 
worse. I have less and less close friends, I used to have heaps, 
play all sports, I had friends everywhere, but now they’re just 
dwindling away, because they know what I’m like when I get 
drunk, so if they have a party, don’t invite (participant), because 
he’ll end up doing…something stupid. 
*** 
Interview 25 (…) probably the mental illness I guess (...) because um, it kind 
of takes over, it can take over. 
*** 
Interview 15 Um, I haven’t had money and it’s like a kick in the guts for 
pretty much anyone, walking around, can’t go out, get to see all 
these people go out with money buying all these things, and not 
being able to buy anything. 
                                                                                                                                                                    
information regarding the general level and nature of stress experienced by the sample. Information specific to 
events precipitating the overdose may be found in the section ‘The overdose process’ page 206). 
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Social support 
Participants were asked whether they felt as though they received much support from 
their friends, family and partner. Only eight people indicated no support was 
forthcoming from any of these sources. However, this did not necessarily mean such 
people had no support, as some had a caseworker or other professional support 
person available to them. 
Family 
Of the 16 participants who provided information on whether their family was 
supportive, only six (38%) indicated that encouragement or assistance was 
forthcoming, and even then, four qualified this by saying their family was supportive 
only “sometimes”. The remainder of participants who commented on family were 
either estranged from their relatives, were in touch but found them to be 
unsupportive, or were in active conflict. It therefore seems that a sense of being in a 
supportive family environment was rare amongst this group. 
Interview 13 No, because I don’t talk to my mother, or any of my other 
relatives. I live with my father but he’s got depression and he 
just can’t relate to anyone. 
Friends 
Eighteen participants provided comment on the support received from friends. In 
contrast to perceptions of family, friendships were seen to provide more support. 
Two-thirds indicated they had a friend or friends from whom they could get help or 
could talk to, although some further commented that they did not like to trouble 
friends with their problems. The remaining participants had no friendships, had 
fallen out with friends, or were avoiding drug-using friends while trying to give up 
drug use. 
Interview 13 My psychiatrist has actually pointed out how wonderful my 
friends are, not using that word, but how exceptional they are 
because of their loyalty. 
*** 
Interview 23 I find it very hard to talk to people that aren’t on the same 
wavelength that I’m on, like being through a heroin addiction, 
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you know, all this, a lot of people haven’t been, wouldn’t even 
know about it. When I take my son to the day care, no one even 
talks to me, because they think I’m the biggest laugh in the 
world, where they look at me like I’ve got leprosy. I’m always 
neatly dressed and I always neatly dress my son, so I feel like 
I’m really isolated and… I don’t know why. 
Partner 
Of the 18 people who commented on this, about half had no partner (three of these 
had very recently separated, although ten people altogether had earlier indicated a 
relationship break-up within the last six months). Among those with partners, 
perceptions of support were evenly divided, between those who found their partner 
supportive and those who did not. Therefore, simply having a partner did not 
necessarily imply a support mechanism. 
4.2.4 Summary 
From the interviews conducted it is apparent that while most of the participants were 
currently in stable accommodation, and the majority had attained a Year 10 or higher 
level of education (both of which might be considered protective factors), many were 
experiencing a range of other problems in terms of current functioning. For example, 
the majority were either unemployed or on a disability pension, and a number of 
those currently engaged in work or study indicated they were experiencing problems 
related to that role. Financial problems were also common. A number of people 
indicated they had recently experienced problems in relationships with their families, 
and to a lesser extent with friends. Many had a primary relationship end within the 
preceding six months. Almost all participants described mental health issues, the 
most common of these being mood disorders, anxiety disorders, and problematic 
substance use, all of which affected more people than not. A quarter also had a 
history of eating disorders. Most mental health problems described were of many 
years duration and experiences of unsuccessful treatment (both pharmacological and 
psychological) were frequently mentioned. Previous overdoses and other self-
harming behaviours were widespread, although not universal. The majority of 
participants were currently prescribed psychotropic medications for their mental 
health condition. Participants tended to have at least one or two current physical 
 188
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
health problems, although these varied in severity. However, a number of 
participants commented on the capacity of physical health problems to impact 
negatively on their mental health, and vice versa. 
A case-by-case summary of the personal characteristics of participants as they 
related to severity of depressive symptomatology and suicidal ideation is presented 
in the next results concerning Objective 3 (page 200). 
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4.3 Objective 3 - Specific suicidal intent, suicidal ideation, 
and depression 
Data from the patient interviews were used to further explore the relationship 
between depression, suicidal ideation, and suicidal intent among survivors of 
medication overdose, and are divided into four parts. 
Firstly, the findings relating to instruments intended to measure the main variables of 
interest are presented. Depressive symptomatology at the time of the overdose was 
measured using the BDI-FastScreen, the level of suicidal ideation among participants 
at the time of the overdose was measured with the BSS, and the deliberateness and 
intentionality of the overdose were assessed using two 5-point Likert scales. An 
analysis of the correlation between these measures is also provided. 
Next the relationship between the scores obtained and participant narratives 
concerning the overdose is examined. This was to determine whether depressive 
symptomatology, suicidal ideation, and suicidal intent as measured by the scales 
were reflected in participant descriptions (i.e. do the scales appear to have content 
validity), and also to further explore these concepts. 
Thirdly, BDI-FastScreen and BSS scores were considered in relation to a range of 
other variables to assess whether any consistent pattern emerged between participant 
characteristics and levels of depression and suicidal ideation. 
The section concludes with a description of the overdose process based on 
participant narratives. 
4.3.1 Measures of depression, suicidal ideation, and intent of overdose 
BDI-FastScreen 
The mean score on the BDI-FastScreen was 11.1 (median = 10.5, range 3-21, n = 24, 
20 self-completed, and 4 interviewer administered). BDI-FastScreen scores can be 
divided into minimal (0-3), mild (4-8), moderate (9-12), and severe (13-21). In this 
sample 4% scored in the minimal range (1 person), 42% in the mild range (10 
people), 12% in the moderate range (3 people) and 42% in the severe range (10 
people). Therefore over half those interviewed reported moderate to severe 
depressive symptomatology at the time of the overdose. 
 190
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
BSS 
The mean score on the BSS was 11.2 (median = 8, range = 0-27, n = 25, 20 self-
completed, and 5 interviewer administered).56 Unlike the BDI-FastScreen, there are 
no suggested cut-off scores relating to severity for the BSS. However, the first five 
questions of the BSS serve as a preliminary screen, and those who answer in a way 
that suggests no significant suicidal ideation do not go on the answer the remaining 
questions. Eleven people were screened out after the first five questions. Seven 
people scored zero on the BSS. 
Likert scales 
When asked how deliberate the overdose was on a scale of one to five, where one 
equalled completely accidental, no intention to OD and five equalled completely 
deliberate, intended to OD, the mean score was 3.4 (median = 4, range 1-5, n = 30). 
In terms of the intention at the time of the overdose, where one equalled no wish to 
die and five equalled strong wish to die, the mean score was 2.7 (median = 2.5, range 
1-5, n = 29). 
Correlation between measures (BDI-FastScreen, BSS, and Likert scales) 
Correlation co-efficients were calculated to determine whether scores on 
standardised measures of depressive symptomatology (BDI-FastScreen) and suicidal 
ideation (BSS) were congruent with each other, and with participant ratings of the 
deliberateness of their overdose and their wish to die at the time of overdose. The 
results indicated that these participant scores on these measures were correlated with 
one another (Table 20). 
                                                          
56 The mean score was calculated using all participants who completed the BSS, regardless of whether individual 
participants answered only the first five screening questions, or the entire inventory. 
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Table 20 Correlation Matrix for Measures Regarding Suicidal Ideation, 
Depression, Intentionality, and Wish to Die 
Measure  BSS BDI 
FastScreen 
Accidental v 
deliberate 
Wish to die 
BSS Pearson 1.00 .80* .66* .85* 
 Sig (2 tail) - .000 .000 .000 
 n 25 23 25 25 
BDI Pearson  1.00 .62* .74* 
FastScreen Sig (2 tail)  - .001 .000 
 n  24 24 24 
Accidental v Pearson   1.00 .68* 
deliberate Sig (2 tail)   - .000 
 n   30 29 
Wish to die Pearson    1.00 
 Sig (2 tail)    - 
 n    29 
*  Correlation is significant at the 0.01 level (2-tailed). 
 
Summary 
Current mild, moderate, or severe depressive symptomatology was common among 
the interview sample. Almost half of those who completed the BSS were screened 
out after the first five questions, suggesting either low or no suicidal ideation in 
relation to the overdose. The responses given by the remainder of the group to the 
screening questions qualified them to complete the entire instrument, suggesting they 
experienced suicidal ideation preceding the overdose. Most participants reported the 
overdose to be more deliberate than accidental (i.e. >3). However, most also rated 
their wish to die as being closer to no wish than strong wish (i.e. <3). 
4.3.2 Consistency between scale scores and participant narratives 
Participant narratives about the overdose were firstly considered in conjunction with 
scores obtained on both standardised instruments (BSS and BDI-FastScreen), and 
then the two Likert scales concerning the deliberateness of the overdose and wish to 
die. 
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BDI-FastScreen and BSS 
BDI-FastScreen scores were separated into two groups, with those scoring 0-8 
classified as low, and those scoring 9-21 as high. The low group corresponded to 
scores indicative of minimal or mild depression, while the high group corresponded 
to moderate or severe depressive symptomatology (Beck et al., 2000). 
Similarly, BSS scores were divided into low’ and high scoring groups. As there are 
no set cut-offs between levels of severity of suicidal ideation suggested for this 
instrument, the decision was made to include those participants who were screened 
out after answering the first five questions as low in suicidal ideation, and those who 
were screened in to answer the full BSS as high (though it should be noted that not 
all those who were screened out were necessarily free of any suicidal ideation, nor 
that those screened in were highly suicidal) (Beck & Steer, 1993). It was then 
possible to divide participant narratives into four groups depending on the scores 
obtained on both instruments (i.e. High BSS/High BDI-FastScreen, High BSS/Low 
BDI-FastScreen, Low BSS/High BDI-FastScreen, and Low BSS/Low BDI-
FastScreen). Altogether, 23 participants were classified on this basis, while there 
were 8 people for whom scores were missing on one (n=3) or both (n=5) 
instruments, and who could therefore not be classified. The number of participants in 
each group is presented in Table 21. 
Table 21 Number of Participants Scoring ‘High’ or ‘Low’ on the BSS and The 
BDI-FastScreen 
 High BSS Low BSS Total 
High BDI-FastScreen 10 2 12 
Low BDI-FastScreen 4 7 11 
Total 14 9 23 
 
Once participants had been classified the accompanying participant narratives were 
considered. The purpose of this was to determine whether the standardised scores 
obtained were congruent with the participants’ narrative descriptions of their 
emotional state and intentions at the time of the overdose.  
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High BSS/High BDI-FastScreen 
The High BSS/High BDI-FastScreen group was the most frequently occurring 
classification, with 10 people classified in this way. According to BDI-FastScreen 
scores, nine of these people showed evidence of severe depressive symptomatology, 
and one of moderate depressive symptomatology. Participant narratives concerning 
life circumstances and perceptions of self at the time of the overdose were consistent 
with high levels of depression. These included descriptions of severe stress such as 
prolonged insomnia, poor health, significant problems with substance use and 
gambling, interpersonal conflict (in intimate relationships, with family and friends, at 
work, etc), separation from children, and sexual identity issues. A number of 
participants described other distressing emotional states in conjunction with 
depression, saying they felt angry, abandoned, empty, useless, and unable to control 
their feelings. These feelings appeared to be compounded by the highly self-blaming 
view many participants took of their situation and frustration at their inability to alter 
it. For example: 
Interview 26 I think there’s got to be some learning in there for me 
somewhere, and I’m just not learning it, you know. I’m hard 
headed, and it’s like it just keeps on going and going because 
I’m not seeing the lesson, I’m not grasping what I’m supposed 
to grasp out of this. 
*** 
Interview 23 I don’t want to die like I said, but I’m not in a hurry to live 
either. If I could change my life and be happy, no problem, I’ll 
live until I’m a hundred and fifty, but I’m not happy, and that 
makes it hard to live when you’re not happy, and I don’t have 
any self-confidence in myself, I’m not happy with myself and 
who I am, I’m not happy about the mother I am because I’m 
suicidal, like I constantly think about having suicidal thoughts, 
and then I feel guilty because I don’t want to leave my son 
without a mother, he hasn’t got a father. 
*** 
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Interview 11 I’m not out to hurt anyone, it’s just I have this overwhelming 
feeling of worthlessness, you know. 
In almost all of the cases classified as high BSS the participants saw little hope for 
their future and had given consideration to death as a solution to their problems. 
Therefore the overdose was regarded as a suicide attempt by most in this group. 
However, many also mentioned protective factors that suggested some ambivalence 
about death, such as not wanting to hurt others, or being afraid of death. Three 
people, while scoring highly on the BSS, then provided reasons for the overdose that 
suggested a desired outcome other than death. One person wanted to go to sleep and 
not wake up, and two others indicated the main reason for overdosing was that they 
wanted help, although they also saw death as a possible consequence of the 
overdose. 
Interview 2 I think I just wanted to go to sleep and never wake up, but not 
really die. 
This group was the one most likely to think frequently about suicide, and many had a 
history of previous serious suicide attempts. 
Low BSS/Low BDI-FastScreen 
Seven people interviewed were categorised as low on the basis of both their BSS and 
BDI-FastScreen scores. However, six of these scored in the mildly depressed range 
(one was minimally depressed). Therefore this group was not depression free, just 
less severely so than some of the other groups. Participant narratives concerning the 
lead up to the overdose made reference to problems consistent with mild depression, 
such as insomnia, stress, erratic moods and feeling isolated, but lacked some of the 
more extreme experiences noted in the groups with higher levels of depressive 
symptomatology.  Participant comments regarding suicide were largely consistent 
with the low BSS scores obtained, with most stating that they did not want to die at 
the time of the overdose. A number commented on the capacity of pills to help them 
escape unpleasant cycles of thinking and to make them feel better, but their intention 
in taking them fell short of a wish to permanently escape via death. However, this 
group was not completely devoid of suicidal ideation, with about half saying that 
they had thoughts about death and dying, even though they were not actively 
suicidal. Other comments indicative of relatively low suicidal ideation included 
 195
Non-fatal pharmaceutical medication overdose, suicidality, and depression 
taking the medications to sleep, by accident, to get high and, in one case, to get 
attention. 
High BSS/Low BDI-FastScreen 
The High BSS/Low BDI-FastScreen group included four participants. This group 
might be regarded as the most curious because it is counter to common 
understandings of suicide that a person who is not at all or only mildly depressed 
would have high levels of suicidal ideation.57 All four had mild depressive 
symptomatology as measured by the BDI-FastScreen. One of the participants 
described life circumstances and emotions leading up to the overdose that were 
similar to those of people in the High BSS/High BDI-FastScreen group, such as 
current family conflict, a history of abuse, and feeling angry, unhappy and 
abandoned. However, her depressive symptomatology at the time of the overdose 
was only rated as mild. This participant had a particularly high score on the BSS, 
which was consistent with other information she provided. For example, she 
indicated that she planned the overdose and wrote a suicide note (although she also 
said she thought about reasons for living at the time of the overdose). A possible 
explanation for the apparent inconsistency between mild levels of depression and 
high levels of suicidal ideation may be found in her comment that she was drunk and 
therefore possibly not rational at the time of the overdose.  
Two participants in this group did not mention any particular feelings of depression 
prior to the overdose in the interview, which was consistent with their BDI-
FastScreen scores. However, both regarded the overdose as deliberate, which is in 
keeping with their allocation to the high BSS group. The first of these participants 
indicated that he often felt suicidal, and that this was in someway a comfortable state 
for him to be in. In discussing suicidal thoughts the participant said the following: 
Interview 6 The certainty is probably driven by the fact that I am suicidal, 
so I don’t know, but you’re that suicidal that you’re quite happy, 
and quite happy to be mad, you know. Generally after you know, 
70 percent of the time you feel fairly good, relatively, so. 
                                                          
57 Although there is evidence to suggest that partial remission of depressive symptomatology may be associated 
with increased risk of suicide in some individuals (Ferrier, 1999). 
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The second participant whose narrative lacked mention of depression indicated that 
at the time of the overdose he wanted to sleep, shut out the world, and thought his 
whole life was a delusion. This last comment suggests he was possibly in a psychotic 
state when the medications were taken. It is interesting to note that the last two 
participants reported a history of psychosis, while the first participant mentioned in 
this section has a history of bipolar disorder. This more complex psychiatric history 
may in part account for the apparent paradox of relatively low depressive 
symptomatology in conjunction with suicidal ideation. 
The final participant in this group provided an account of her current life 
circumstances that was consistent with her score on the BDI-FastScreen (i.e. 
symptomatic of mild depression). However, while she was screened in to complete 
the full BSS, her overall score on this instrument was in fact quite low and she 
showed few other indications of suicide risk. 
Low BSS/High BDI-FastScreen 
There were only two participants who were rated as having moderate depressive 
symptomatology but who indicated low levels of suicidal ideation. In both these 
cases the participants identified feeling stressed, worried, and unhappy about 
difficulties in their primary relationship at the time of the overdose, as well as other 
life concerns, which was consistent with their BDI-FastScreen scores. However, the 
low scores on the BSS indicated minimal suicidal intent. This was further evident 
from the narratives around the overdose. One had primarily “wanted to get that shit-
faced”, rather than die, and stated that “suicide is a coward’s way out”. The other 
participant was somewhat ambivalent about his intentions, but in the end was 
concerned about the impact of harming himself on others, and also actively sought 
help immediately following the overdose. 
Summary 
There was a high level of consistency between scores obtained on standardised 
measures (BDI-FastScreen and BSS), and participant narratives regarding depressive 
symptomatology and suicidal ideation. Even where an individual scored highly on 
one instrument and not the other, this differentiation was generally also apparent in 
the accompanying narrative. Among this sample a low score on the BSS was not 
necessarily indicative of a complete absence of suicidal thoughts. Many participants 
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with such scores reported thinking about death and dying, even in the absence of an 
active suicidal wish or plan. 
Likert scales 
As mentioned earlier, participants rated the deliberateness of the overdose and their 
wish to die at the time on a 5-point scale. To further explore the concept of intent, 
participants were then asked why they had rated the overdose as such, and the 
responses were considered in light of the rating selected. 
“Deliberateness” of overdose 
As reported earlier, the median rating for the “deliberateness” of the overdose was 
“4” (n=30), indicating in most cases the overdose was more deliberate than 
accidental. Of those who answered “1”, indicating the overdose was completely 
accidental, only one had actually been unaware of the amount of medication being 
consumed (i.e. the person was accidentally administered an excessive dose of 
methadone by someone else as part of a supervised pharmacotherapy program). 
Others who rated the deliberateness of the overdose as “1” or “2” had intentionally 
consumed the medications, but from their comments it was apparent that the outcome 
(i.e. an overdose) was unintentional. These nine participants said they wanted to 
sleep, get high, make a statement, or thought it would be OK to take the medication 
in that quantity. The six participants who rated the deliberateness of the overdose as 
“3” or “4” acknowledged they had taken the medications, and therefore that it wasn’t 
accidental, but professed some ambivalence about what outcome they wanted. For 
example: 
Interview 15 “I didn't want to deliberately hurt myself, and it wasn't 
completely an accident, because I mean, 15 tablets don't 
accidentally pop down your throat.” 
Fourteen people rated the deliberateness of the overdose as “5”. These responses 
were divided between those who said that they knowingly took the medications, and 
therefore that the overdose was by definition “deliberate”, regardless of the intended 
outcome, and those who went on to give some further explanation for why they 
overdosed.  These reasons included being down or depressed, wanting help, and 
wanting to escape intolerable inner states. 
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“Wish to die” at time of overdose 
The median rating by participants of their “wish to die” at the time of the overdose 
was 2.5 (n=29), indicating a slight preference towards the not wishing to die end of 
the scale. The nine who rated their wish to die as “1” generally supported this rating 
with a statement that made clear their desire to live, and/or was a rejection of suicidal 
intention at the time of the overdose. Fifteen participants rated their intention to die 
as somewhere in the middle (2-4), and many supported this rating with a statement 
indicating ambivalence about the outcome of the overdose. For example, some said 
they did not know whether they wanted to die, or did not care whether they died, 
others wanted to escape from their present reality without actually dying, and a 
couple of people who were considering suicide also cited reasons for living, 
mitigating the strength of their wish to die. 
Interview 11 I didn’t really want to die, but I thought that “I’m useless in this 
world”, and that the world would be better off if I went, you 
know what I mean, but I didn’t really want to die because I’m 
frightened of death. I’ve got a fear of death. I mean, that’s like 
so stupid, you know what I mean? 
*** 
Interview 8 Um, I’d started to write a suicide note and I planned where I 
was going to go in the car. I had taken all my pills out and they 
were all in front of me on my bed, I was sitting on my bed with 
them all there. I started to write a note and I guess trying to 
explain myself, to myself, you know, and then I decided that I 
couldn’t leave my Dad. 
Five people selected “5”, indicating a strong wish to die. All of these participants 
provided a comment about their strong wish to die that was consistent with their 
rating. Most indicated a sense of hopelessness; believing their problems were too big 
to solve and there was no prospect of a better future. One person said she did not feel 
worthy of living at the time of the overdose. 
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Summary 
As for the BSS and BDI-FastScreen, participant stories concerning the circumstances 
surrounding the overdose were congruent with Likert scale ratings of the 
deliberateness of the overdose and the participants’ wish to die. It was also clear that 
the concepts of “deliberateness” and “wish to die” were not interchangeable, with 
many of those who considered their overdose to be deliberate expressing 
considerable ambivalence about the intended outcome, and relatively few 
unambiguously wishing to die. 
4.3.3 Other factors related to suicidal ideation and depressive 
symptomatology 
Scores on the BDI-FastScreen and BSS were considered in relation to a range of 
other variables. As there were only a limited number of non-representative cases in 
the sample, and a number of these contained missing data on various survey items, 
statistical analyses of relationships between variables were not considered 
appropriate. Descriptive statistics for various factors under study were included in 
previous sections; however, it was also of interest to investigate how some of these 
variables related to scores on the standardised measures of suicidal ideation and 
depressive symptomatology. 
As an alternative to statistical analysis as a means of synthesising the data on 
participant characteristics as they relate to BSS and BDI-Fast Screen scores, a case 
matrix was constructed. This involved plotting participants’ responses on a range of 
variables on a case-by-case basis, and then grouping cases according to their BSS 
and BDI-FastScreen scores. This gives a visual representation of the patterns of 
responding according to symptom severity, although of course this does not 
determine levels of statistical significance. Table 22 shows the pattern of responding 
on a range of variables on a case-by-case basis, with individual cases represented in 
rows and the variables of interest in columns. The presence of an asterisk in a row 
means that the individual case possessed the characteristic identified in the column 
heading. 
The following variables were included in a matrix (Table 22); age, sex, physical 
health, mental health, history of medication overdose, personal history of deliberate 
self-harm or attempted suicide, family or friend who has committed suicide, recent 
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significant life events, and level of wish to die. Some of these have been simplified, 
for example, by converting a continuous variable into a dichotomous one. A 
definition of how each of these has been operationalised is provided under the 
subheadings below, along with a description of how the data appear to relate to the 
four groups; High BSS/High BDI-FastScreen, High BSS/Low BDI-FastScreen, Low 
BSS/High BDI-FastScreen, and Low BSS/Low BDI-FastScreen. The matrix relates 
to the 23 participants who completed both measures, and each row represents a 
single case (grouped according to BSS and BDI-FastScreen scores). Case numbers 
have not been included as the information used in conjunction with direct participant 
quotes may render individuals potentially identifiable. 
A number of variables were excluded on the basis that there was low variability in 
participant responses, and as such their inclusion in the matrix would add little 
information. For example, living circumstances, cultural background, sexual identity, 
education and employment were all excluded. Social support from family, friends, 
and partner were also excluded, as there was a considerable amount of missing data 
for these items. 
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Table 22 Relationship between Other Variables and Scoring ‘High’ or ‘Low’ on the BSS and the BDI-FastScreen (n=23) 
 
Group 
Variables of interest 
 Wish to die 
(>=3)1 
Self-harm 
and/or 
suicide 
attempt2 
Previous 
emergency 
care for OD3 
Family/friend 
committed 
suicide4 
Life 
problems  
(>= 7)5 
Mental health 
conditions 
(>=4)6 
Physical 
health 
conditions 
(>=2)7 
Female Age (>=30) 
* * *  * *  * * 
* * * * *  *  * 
* * *    * *  
* * *  *  * * * 
* * * * * *   * 
* * * * - * * * * 
* * * * * *  *  
* *  * *  *  * 
* *    *  * * 
High BSS 
High BDI 
*   * * * *  * 
* * *  - *    
 * * * * *   * 
* *   - * * *  
High BSS 
Low BDI 
   * *   * * 
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 Variables of interest 
Group Wish to die 
(>=3)1 
Self-harm 
and/or 
suicide 
attempt2 
Previous 
emergency 
care for OD3 
Family/friend 
committed 
suicide4 
Life 
problems (>= 
7) 5 
Mental health 
conditions 
(>=4)6 
Physical 
health 
conditions 
(>=2)7 
Female Age (>=30) 
*    *     Low BSS 
High BDI     - *     
 * * *      
 * * *   *   
 * *     *  
  *  - * *  * 
  *  *   * * 
 *  *   *   
Low BSS 
Low BDI 
   *      
1 This relates to the “Wish to die” Likert-scale scores (range 1-5), where * denotes a score >=3  
2 This item combines participant responses on previous deliberate self-harm and attempted suicide, where * denotes a positive response to either or both items 
3 This concerns participants who have previously sought emergency medical care following an overdose, where * denotes a positive response 
4 This item combines responses on whether a family member or friend of the individual has committed suicide, where * denotes a positive response to either 
or both items 
5 Participants with >=7 life problems in the last 6 months denoted by *, missing cases denoted by -  
6 This relates to the number of mental health problems endorsed by the participant, where * denotes >=4 mental health problems  
7 This relates to the number of physical health problems endorsed by the participant, where * denotes >=2 physical health problems 
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Wish to die 
Participants who scored greater than or equal to “3” on the five-point Likert scale 
concerning “Wish to die” are denoted in Table 22 with an asterisk. This selection 
appears to have a strong relationship to scoring highly on the BSS, although not the 
BDI (unless in conjunction with a high BSS score). This is consistent with the 
correlation analysis presented earlier and suggests the five-point scale is in itself a 
reasonable indicator of suicidal ideation. 
Previous self-harm or suicide attempt 
Participant responses concerning whether the individual had ever deliberately 
harmed themselves but without meaning to commit suicide (e.g. cutting, burning) 
and/or whether they had ever attempted suicide were combined into a single variable. 
Almost all participants who were categorised as high BSS (whether high or low on 
the BDI-FastScreen) had a history of self-harming or suicide attempts. This was also 
true for some people who had low ideation at the time of the overdose (as measured 
by the BSS), but as a lesser proportion overall. 
History of emergency care for medication overdose 
A relatively high proportion of positive responses were evident in both the High 
BSS/BDI group and the Low BSS/BDI group. Therefore, there was no clear 
relationship apparent between having previously sought or required emergency care 
for a medication overdose from the ambulance service or an ED and scores on the 
BSS and BDI-FastScreen. 
Family or friend committed suicide 
Having a family member or a friend who had committed suicide was collapsed into a 
single variable. This appeared to be a common experience among participants, and 
no clear relationship to BSS and BDI-FastScreen scores emerged from these data. 
Recent significant life events 
Participant responses were dichotomised into those who reported experiencing seven 
or more life problems in the six months prior to interview, and those who reported 
less than seven problems. The pattern of responding was indicative of those with 
more severe suicidal ideation and depression reporting more recent stressful life 
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events, although there were several instances of missing data in relation to this item. 
If a relationship between life stress and suicidal ideation existed, it is not clear what 
direction this took. That is, whether those participants with the most problems 
became the most highly suicidal, or whether those who were most suicidal and 
depressed had a tendency to perceive their lives as being filled with stress, or were 
more likely to report such events. 
Mental health 
All participants who identified themselves as having four or more mental health 
conditions are denoted with an asterisk in Table 22.58 All participants included in 
this table had at least two or three mental health conditions, therefore the unmarked 
cases were not free of psychiatric problems, they just had fewer than the others. Self-
identification as having four or more mental health conditions was most common 
among those with high BSS scores. Participants categorised as low on the BSS and 
BDI-FastScreen only rarely indicated the presence of four or more problems in this 
area. 
Physical health 
Participants nominating two or more physical health problems are marked with an 
asterisk in Table 22. No clear pattern emerged from the data in relation to the 
presence of physical health problems and scores on the BSS and BDI-FastScreen, 
with participants in all four groups having two or more conditions. 
Sex 
There were approximately equal number of males and females in the groups 
categorised as high BSS. However, there was a tendency for males to outnumber 
females among the groups based on low BSS scores. 
Age 
Participants were dichotomised according to age. Those aged 30 or more appeared to 
be over-represented in those groups based on high BSS scores relative to those in 
                                                          
58 Problems relating to the use of alcohol and other substances were included in this total, and therefore substance 
dependence is not presented as a separate variable in the case matrix. 
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their twenties, who were more frequently characterised by low scores on both 
instruments. 
Summary 
While the information presented in the case matrix does not represent a statistical 
analysis of factors associated with elevated BSS and BDI-FastScreen scores, nor 
model how these factors interact, it does provide a preliminary indication of the 
variables which appear to be related to the scale scores. Having a wish to die of “3” 
or greater, a history of self-harm or suicide attempts, seven or more recent life 
problems, four or more mental health problems, and being aged over 30 all appear to 
be somewhat more common among participants categorised as high BSS, and to a 
lesser extent high BDI-FastScreen. 
4.3.4 The overdose process 
This research aimed to uncover and document the overdose experience. Participant 
narratives were therefore examined to identify the process of taking an overdose, and 
common themes noted. The means by which people acquired and consumed their 
medications are covered in ‘Acquisition of medications involved’, page 226. 
Three common elements were noted in participant stories surrounding the overdose: 
the events leading up to the overdose, the feeling-state of the individual at the time, 
and finally, the desired outcome of the overdose. Participant narratives may not have 
necessarily followed a chronological progression through these elements (for 
example, some people mentioned the intended outcome first, and then provided the 
context for that), but some mention of each was typically made as the person 
recounted the overdose. Furthermore, many people mentioned more than one point 
relevant to each element. Texts of the overdose story were examined and examples 
of the relevant elements identified for each case. The range of precipitating events, 
feeling states and intended outcomes found in the data are described separately 
below. 
Participants differed greatly in their eloquence; some provided highly detailed 
accounts of what had occurred in the lead-up to the overdose, had a wide vocabulary 
with which to describe the nuances of their own emotions at the time, and could 
reflect on the sometimes contradictory nature of their intentions. Others provided 
 206
Non-fatal pharmaceutical medication overdose, suicidality and depression 
rather more straightforward accounts of what occurred and how they felt (for 
example, “angry”). In a small number of cases it was quite difficult to identify what 
precipitated the overdose, how the person was feeling and/or what they hoped the 
outcome would be, though it is not clear whether such scant accounts were due to the 
inability of the person to articulate what had occurred, or unwillingness to discuss 
this with the researcher. Therefore, the information presented below does not 
necessarily capture the whole experience of all participants, but is reflective of the 
information provided to the researcher.  
Precipitating events 
Participant stories about the lead up to the overdose included descriptions of a 
number of precipitating or activating events and situations. These were grouped 
together according to common themes. Most people mentioned one or two events or 
situations that appeared to have a contributory effect to the overdose, and some 
mentioned up to three distinct events. Broadly speaking the most common 
precipitating events were alcohol and drug use, unpleasant memories, and 
interpersonal conflict. The events described generally occurred immediately prior to 
(or at least within several hours of) the overdose, or represented an ongoing problem 
for the individual (but one that had troubled them in the 24 hours prior to the 
overdose). 
Eight participants mentioned problematic alcohol or drug use (e.g. bingeing, being in 
withdrawal) as contributing to their overdose. That is, from the point of view of the 
individual concerned, this factor was not simply associated with the overdose, but 
had a causal influence. In one instance the substance use was also associated with 
gambling problems.  
Eight people reported being troubled by unpleasant memories from the past 
(remembering traumatic incidents, for example) or had been ruminating on earlier 
events (such as previous disappointments) in the lead up to the overdose. In some 
cases these memories were triggered by external events such as contact with a family 
member, but in other cases the distressing memories surfaced without any obvious 
prompt. In these cases the emotional impact of past events was clearly as significant 
to the person as events occurring in the present. 
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Interpersonal conflict was a theme mentioned by many. There were three main areas 
in which interpersonal conflict was most apparent: primary relationships, family 
relationships, and/or work. Eight people described having a major dispute or 
misunderstanding with their partner/spouse prior to the overdose, in some cases 
culminating in the relationship ending. Seven people mentioned significant conflict 
with family member/s prior to the overdose (this includes one case where the 
participant was separated from children). Work related problems included both 
actual conflict and general stress in the context of employment or study and were 
experienced by five people. While some of these conflictual events occurred in the 
days or weeks prior to the overdose, all participants who raised this theme reported 
being troubled by the conflict in the 24 hours prior to overdose. 
Four people reported being unemployed, experiencing financial problems, or being 
homeless as a significant issue at the time of the overdose, and three were distressed 
about the loss of a support person or lack of help available to them. The following 
excerpt is from a participant who had learned her counsellor could no longer 
continue to see her on the morning preceding the overdose: 
Interview 2 (…) I felt very alone and I knew that the only person that was 
very stable and always had been since I’ve been here was my 
counsellor and the thought of losing her was really frightening. 
“Other” events were also mentioned, though each by relatively few people. Two 
participants were greatly troubled by insomnia, two participants remarked upon poor 
health/health concerns in the lead up to the overdose, one person discussed being 
troubled by issues of sexual identity, one person could not give a clear account of 
events, other than going out with friends and being upset by “something”, and 
finally, one person was accidentally administered a methadone overdose by their 
pharmacist. 
Feeling states 
Participant narratives were closely examined for text concerning how the person was 
feeling in the time immediately before overdosing, and passages concerning 
emotional and physical states highlighted, for example “I was worried sick”, and 
“feeling down”. While there were almost as many different words used to describe 
feeling states as there were participants, these were grouped into six broad themes; 
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‘anxious/stressed’, ‘depressed’, ‘unworthy’, ‘negative interpersonal emotion’, 
‘physical state’, and ‘unclear’. Most participants could be included in one or two of 
these categories, although some descriptions fitted three. 
A number of adjectives were included under the broad umbrella term of 
‘anxious/stressed’ (e.g. worried, overwhelmed, confused). Nine participant narratives 
included reference to being under stress or feeling anxious in some way. Six 
participant narratives made direct reference to feeling depressed and/or hopeless and 
were included within the theme ‘depressed’ (though from the BDI-FastScreen scores 
discussed earlier, it is reasonable to suggest that depression, or at least a depressed 
mood, was a feature of more than these six overdoses). The theme ‘unworthy’ related 
to at least six participants. In these cases participants expressed that they felt 
worthless, unloved, or were self-castigating. 
‘Negative interpersonal emotion’ was noted for overdoses occurring in situations of 
interpersonal upheaval that resulted in the person experiencing feelings such as 
frustration, anger, or a sense of being undervalued. This theme was relevant to eight 
of the narratives. For example: 
Interview 20 Yes, yeah, I just had the pip because she was telling me, saying 
“I still love you heaps”, and all that sort of stuff, just the more I 
thought about it, thinking about her with another bloke I was 
just getting angrier and angrier. I just wanted to, I didn’t give a 
shit really. 
In the above quote the participant specifically linked the content of his cognitions 
with his emotional state (i.e. his thoughts intensified his feelings). However, many 
participants did not articulate awareness of any such connection. 
Many participant narratives made reference to the physical condition of the person at 
the time of the overdose. Altogether 17 narratives made reference to a physical state: 
in 13 cases the person was intoxicated, in three the person referred to extreme 
tiredness or exhaustion, and one person reported experiencing withdrawal symptoms 
in the lead up to the overdose. While these are not emotional states, it is reasonable 
to conclude that physical sensations such as ‘feeling drunk’ or ‘feeling exhausted’ 
were associated with the overdose event, possibly as an additional causal factor. 
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Finally, the participants’ state of mind in the lead up to the overdose was not clearly 
articulated in four cases. 
Desired outcomes 
Desired outcomes were primarily considered in terms of whether or not the person 
wished to die as a consequence of the overdose (or was ambivalent about this), but 
other intended outcomes are also discussed below. In discussing the overdose event 
only five people expressed that they had a clear and unambiguous wish to die at the 
time of the overdose, though none of these indicated they still wished to die at the 
time of the interview. This was consistent with the results of the “Wish to die” Likert 
scale. Nine people were equally clear that they had not wished to die as a 
consequence of the overdose. The remainder expressed ambivalent intentions. 
Among the nine people with no wish to die, the intentions of the overdose were 
varied (most stated only one desired outcome, though one person mentioned two). 
Three people primarily wanted to get stoned, two people were trying to get some 
sleep, two wanted to escape from thinking/consciousness but were also clear that 
they did not want to die, and one person wanted to make a statement to his partner. 
There was also one person who did not want to die, but for whom the intention was 
unclear, and another who had no intention at all, as a third party had administered the 
medication to them, and had accidentally given enough to cause an overdose. 
Among the 17 participants with ambiguous intentions, uncertainty about desired 
outcomes was manifested in two main themes within participant narratives: ‘apparent 
contradictions’ and ‘escape’. Some narratives contained elements of both. ‘Apparent 
contradictions’ were those narratives where the participant expressed intentions that 
could be regarded as competing or contradictory. Examples of such pairings are 
listed below and occurred in about half the narratives.59 
 I thought the world would be better off without me/I didn’t want to die 
 I thought these medications might kill me/I knew they probably wouldn’t 
 I wanted to die/I sought help immediately afterwards 
 I wanted to sleep and not wake up/I am not sure about dying 
                                                          
59 Please note, while these examples are based on actual narratives they are not direct quotes. 
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A desire to “escape” or shut out the world was also noted in about half the narratives 
where the person was ambiguous about their desire to live or die. Participants 
generally wanted to escape from their problems and/or the strain of continuously 
thinking about them. It was as though many participants needed a rest from whatever 
difficulties were consuming them in the lead up to the overdose. Death, or at least 
prolonged unconsciousness, seemed to offer a possible solution in this regard, 
manifesting in a sense of ambivalence about dying. 
Interview 27 I have suicidal thoughts, but that day especially (…) so I don’t 
know, so it was a little bit, but not, not a definite “I wanna die” 
it was just, I just wanna go away for a bit, have a rest (…) I 
don’t want to hurt my body in anyway, like a train or anything 
like that, but if there was euthanasia I’d have it right away, so I 
don’t know, I don’t know. 
Other desired outcomes articulated by a small number of people in the ambiguous 
group included getting some sleep (i.e. overcoming insomnia), to get intoxicated, or 
to get help and/or attention. These were generally secondary to the other two desired 
outcomes noted above. 
Interview 25 (…) I started just thinking that maybe all these diagnoses were 
right and there was something seriously mentally wrong with 
me, and I’d better get myself to hospital, and I’ve tried to like 
admit myself to mental health facilities before believing that I 
was very ill, and being told that I wasn’t, and so I thought 
“well”, it was sort of like me going, “well, I’ll show you all that 
I really am”. 
Relationship between precipitating events, feeling states, and desired outcomes 
An attempt was made to formally explore how the sub-themes within precipitating 
events, feeling states, and desired outcomes related to one another. That is, were 
there particularly strong associations between sub-themes across these three 
domains? A hypothetical example of such a relationship would be conflict with a 
partner being consistently related to negative interpersonal emotions, which in turn 
might be consistently related to a wish to die. 
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The software used to analyse the participant interview data, NVIVO, allows searches 
to be conducted between different elements of the data.60 However, an exploration of 
the intersections between the various sub-themes yielded little information. In many 
cases there seemed to be no particular relationship between the sub-themes. There 
were a few instances where an association appeared to emerge, but the number of 
cases involved was too small to report with any confidence. 
Because the large number of sub-themes within the precipitating events and feeling 
states categories resulted in complex matrices, it was thought that any patterns in the 
data might possibly be obscured. Therefore the theme structure within these 
categories was simplified by collapsing some sub-themes into broader categories on 
the basis of like content (e.g. grouping together conflict with partner, conflict with 
family, and work conflict). However, no consistent patterns emerged even when the 
simplified matrices were generated. 
Despite the insufficient evidence to explore links between sub-themes within 
precipitating events, feeling states, and desired outcomes, it was still possible to 
propose a relationship between these themes at the broadest level. The overdose 
process as described by most participants suggested that it was the interaction of 
feelings and events that led to the overdose being seen as a desirable outcome. 
Summary 
Three themes consistently emerged in relation to the overdose process: precipitating 
events, feeling states, and desired outcomes. Common precipitating events included 
problematic drug use and interpersonal conflict. Precipitating factors were not 
necessarily confined to present day experiences; current memories of past events 
were clearly relevant to the overdose in a number of cases. A lack of resources 
(including employment, money, and emotional support) was also significant in some 
instances. 
                                                          
60 Matrices of co-occurring data elements can be constructed in NVIVO that are similar to a cross-tabulation 
procedure within standard quantitative data analysis packages. Searches were conducted for the sub-themes of 
Precipitating events x Feeling states, Precipitating events x Desired outcomes, and Feeling states x Desired 
outcomes. This type of search returns a table showing the total number of documents coded to each cell of the 
matrix. It should be noted that for both Precipitating events and Feeling states, some participants were coded to 
more than one sub-theme. 
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The feeling states described by participants were generally negative, and related to 
both the interpersonal and internal emotional worlds of participants (for example, 
feelings of anger and frustration with others, as well as feelings of depression, 
worthlessness, and self-hatred within the individual). Physical states such as 
intoxication, and to a lesser extent, extreme tiredness were also common. 
Only a few participants had a clear desire to die at the time of the overdose, and a 
slightly larger number were definite that they had not wanted to die. The majority of 
overdose survivors interviewed were ambiguous about their intentions. Among those 
who seemed ambivalent in this regard were many who expressed a wish to escape 
their current problems. Ambivalence was also noted in the tendency of some 
participants to articulate competing or contradictory thoughts about the overdose. 
The main contributory precipitating events and feeling states identified here (i.e. 
problematic substance use, interpersonal conflict, and negative emotions such as 
depression and anxiety) are similar to the recent significant life events earlier 
identified by participants as causing unhappiness or distress in the previous six 
months (Recent significant life events, page 184). 
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4.4 Objective 4 - Medications implicated in medication 
misuse or overdose 
Objective 4 was addressed with reference to both PAS audit data and patient 
interviews. The information from PAS was used to broadly describe the range of 
prescription and OTC medications implicated in overdoses presenting to the ED over 
a 12-month period, whereas the interview data were used to describe actual patterns 
of consumption in the lead up to overdose, as well as any concurrent alcohol or drug 
use. Patient interview data were also used to address the questions concerning the 
acquisition of medications implicated in the overdose. 
4.4.1 Medications implicated in overdose presentations to the ED 
The PAS narratives for most medication misuse or overdose presentations included 
enough information to categorise the medications into drug classes and subclasses. 
However, more detailed information concerning the specific brand and/or the actual 
quantity of medication taken was not recorded with sufficient consistency to be able 
to judge from PAS whether individual events were medically serious. Other relevant 
factors in determining the likely seriousness of presentations were also unknown 
(such as the tolerance and body weight of the person). 
As noted at the beginning of the results section, there were a total of 521 cases 
during the 12-month data collection period where the misuse of medications or 
medication overdose contributed to the presentation to the ED. Of these, there were a 
small number (22/521) for whom no information concerning the specific medications 
involved was recorded (e.g. the narrative may simply have referred to the event as a 
“polypharmacy OD”). Table 23 shows the medications used in the 499 cases where 
the medication type was known and recorded. The left hand data column shows the 
medications used by the MOD group (i.e. those presentations where only 
medications were implicated in the overdose, not illicit drugs, and excluding 21 
cases with missing data). The middle data column contains information relevant to 
cases presenting at the ED with an illicit drug overdose that also involved 
medications (i.e. this column corresponds to groups 6 and 7 in Table 2, less one case 
with missing data). The far right data column is the total of the previous two columns 
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(i.e. all presentations to the ED for medication misuse or overdose for which data on 
the specific medications used were available). 
Medications involved in medication misuse or overdose presentations to the ED in 
the 12-month period fell into nine of the broad categories described in Rossi (2003); 
allergy/anaphylaxis, analgesics, anti-infectives, cardiovascular, coagulants 
/anticoagulants, endocrine, gastrointestinal, neurological, and psychotropic, as well 
as the “cough, cold, and flu medication” and “electrolytes” categories described in 
the Method (page 106). 
The most commonly implicated broad group of medications were psychotropic 
medications (75%), followed by analgesics (23%), and neurologic medications (6%) 
(Table 23). Within each of these categories there were a number of subcategories. 
Column percentages sum to more than 100% as patients may have consumed more 
than one broad class of medication (for example, a psychotropic and an analgesic 
medication). 
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Table 23 Medications Implicated in Medication Misuse or Overdose 
Presentations to the ED 
Medication % 
 MOD Medication & illicit 
drug overdose 
Total 
 (n=432) (n=67) (n=499)1 
Psychotropic 72.5 88.1 74.5 
Benzodiazepines 49.3 74.6 52.7 
Antidepressants 19.4 10.4 18.2 
Antipsychotics 14.2 6.0 13.0 
Other anxiolytics/hypnotics 2.7 3.0 2.8 
Opioid dependence treatment 2.3 9.0 3.2 
Bipolar medication 0.7 0.0 0.6 
Analgesic 26.4 4.5 23.4 
Non-opioid 17.6 3.0 15.6 
Combination 7.4 0.0 6.4 
Opioid 3.9 1.5 3.6 
Neurologic 6.8 1.5 6.0 
Antiepileptic 5.8 1.5 5.2 
Anticholinergic 0.9 0.0 0.8 
Cardiovascular 5.5 4.5 5.4 
Endocrine 3.9 1.5 3.6 
Allergy & anaphylaxis 2.1 0.0 1.8 
Gastrointestinal 1.6 1.5 1.6 
Anti-infective 1.6 0.0 1.4 
Cough, cold & flu 1.6 0.0 1.4 
Coagulation & blood formation 0.7 0.0 0.6 
Electrolytes 0.7 0.0 0.6 
Medication not otherwise listed 0.9 1.5 0.8 
1 22 out of 521 cases had no information on medication type consumed.  
 
The average number of medications involved was 1.6 (Table 24). However, the 
median (1.0) is probably a better measure of central tendency as the data are skewed. 
The highest number of medications taken in any one case was seven. Across the 
range of relevant presentations recorded, about two-thirds involved only one 
medication, while the remainder implicated two or more. Where more than one 
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medication contributed to the presentation, this may have involved medications from 
the same class or different classes. 
Table 24 Number of Medications Implicated in Medication Misuse or Overdose 
Presentations to the ED 
Statistics Group 
 MOD Medication AND 
illicit drug overdose 
Total 
 (n=432) (n=67) (n=499)1 
 Statistics 
Mean 1.6 1.4 1.6 
Median 1.0 1.0 1.0 
Std. Deviation 0.9 0.6 0.9 
Minimum 1 1 1 
Maximum 7 3 7 
 Number of medications implicated per presentation (%) 
1 63.2 70.1 64.1 
2 22.0 23.9 22.2 
3 10.0 6.0 9.4 
>3 4.8 0.0 4.3 
1 22 out of 521 cases had no information on medication type consumed. 
 
Commonly implicated medications 
Benzodiazepines, antidepressants, non-opioid analgesics, and antipsychotics all 
made a substantial contribution (14-49% each) to the overall number of 
presentations. 
Benzodiazepines 
Of the 213 MOD patients (49%) whose hospital attendance implicated 
benzodiazepines, 82% had taken only one type, 16% two types, and 2% more than 
two types (mean =1.2 types, range 1-4). The most frequently mentioned 
benzodiazepines among the MOD group were diazepam (46%), alprazolam (26%), 
temazepam (20%), nitrazepam (10%), and oxazepam (6%) (Table 25). The 50 cases 
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of illicit drug overdose that also involved benzodiazepines were also examined.61 An 
apparently greater proportion of these cases involved diazepam, alprazolam, and 
oxazepam than in the MOD group (i.e. no significance testing was undertaken of 
group differences). Other types of benzodiazepine were infrequently mentioned in 
this group. 
Table 25 Specific Medications Implicated in Benzodiazepine-Related Misuse or 
Overdose 
Benzodiazepine Group 
 MOD Medication & 
illicit drug 
overdose 
Total 
 (n=213) (n=50) (n=263)1 
Diazepam 46.0 58.0 48.3 
Alprazolam 25.8 34.0 27.4 
Temazepam 20.2 2.0 16.7 
Nitrazepam 9.9 2.0 8.4 
Oxazepam 6.1 20.0 8.7 
Clonazepam 3.8 0.0 3.0 
Unspecified benzodiazepine 3.8 4.0 3.8 
Flunitrazepam 2.8 0.0 2.3 
Bromazepam 1.4 0.0 1.1 
Lorazepam 0.5 0.0 0.4 
1 The sum exceeds 100% because some individuals had taken more then one benzodiazepine type. 
 
Antidepressants 
Eighty-four people in the MOD group (19% of those patients for whom the 
medication involved was known) attended the ED in relation to antidepressant 
misuse or overdose in the 12-month period. In all of these cases but one, the event 
had involved the ingestion of a single antidepressant. In the MOD group, the most 
commonly used antidepressant sub-class were the SSRIs, accounting for 52% of 
antidepressant-related attendances (n=44: 10 paroxetine, 10 sertraline, 8 citalopram, 
7 fluoxetine, 5 fluvoxamine, 3 escitalopram, 1 unknown SSRI). “Other” 
                                                          
61 Comparable data on the specific sub-types of medication taken in conjunction with illicit drug overdose are not 
presented for other categories of medication (e.g. antidepressants, non-opioid analgesics) due to the small number 
(<10) of relevant cases in each category. 
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antidepressants were taken by 25% of the group (n=21: 11 mirtazepine, 10 
venlafaxine, 1 reboxetine). The next most often mentioned group were the tricyclic 
antidepressants (23%) (n=19: 5 amitriptyline, 5 dothiepin, 3 doxepin, 1 
clomipramine, 1 imipramine, 1 trimipramine, 4 unknown TCA). There was one case 
involving an unspecified antidepressant. No overdoses attending the department 
involved tetracyclic or MOAI use. The data described above do not include the seven 
people who had taken antidepressants in conjunction with illicit drugs. 
Non-opioid analgesics 
Seventy-six MOD cases (18%) involved the ingestion of a non-opioid analgesic. As 
described earlier, the non-opioid analgesic group included aspirin, paracetamol and 
other NSAID preparations. Most of the presentations related to paracetamol (78%, 
n=59), 18 were for other NSAIDs, and five for aspirin. 
Antipsychotics 
Of the 61 MOD cases (14%) whose attendance at the ED concerned the use of 
antipsychotics, 56 had taken only one type, while in five cases two different 
antipsychotic medications had been used. Most of the presentations (75%) related to 
atypical antipsychotics (n=46: 23 olanzapine, 15 quetiapine, 5 amisulpride, 3 
clozapine, 2 respiridone, 1 aripiprazole), while a quarter involved conventional 
antipsychotics (n=16: 15 chlorpromazine, 1 fluphenazine decanoate, 1 
trifluoperazine). The four people who had taken antipsychotic medication as well as 
illicit drugs are not included here. 
Less commonly implicated medications 
The remaining medications listed below each accounted for less than ten percent of 
MOD cases. 
Combination analgesics 
This class included a range of medications (e.g. aspirin/codeine, aspirin/morphine, 
codeine/ibuprofen, paracetamol/codeine, paracetamol/dextropropoxyhene). However 
of the 32 cases of combination analgesic misuse or overdose (7% of MOD cases), 
only three different types were implicated. Thirty involved paracetamol with 
codeine, one case involved codeine with ibuprofen, and the remaining case was 
paracetamol with dextropropoxyhene medication. 
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Anti-epileptics 
Twenty-five MOD cases (6%) implicated anti-epileptic medications. Twenty-one 
involved only one type, while the remainder involved two or three anti-epileptic 
medications. One case involved the barbiturate anti-epileptic primidone, while the 
rest were medications classified as “other antiepileptics” (Rossi, 2003) (11 
Valproate, 10 carbamazepine, 2 gabapentin, 3 lamotrigine, 1 levetiracetam, 1 
phenytoin, 1 topiramat). 
Cardiovascular 
Cardiovascular medications were involved in 24 of all MOD presentations (6%). 
These generally involved only one cardiovascular medication, but in one case two 
medications were used and in another four different cardiovascular medications had 
been taken prior to hospitalisation. The majority of cases (n=21) involved drugs used 
in the treatment of hypertension, including 16 cases involving the centrally acting 
antihypertensive clonidine. Most of the cases of overdose implicating this medication 
were attributable to a single individual with a pattern of frequent overdose. 
Therefore, this sample may overestimate the contribution of cardiovascular 
medications to total overdose statistics relative to other samples. Antiarrhythmic 
medications and lipid lowering drugs each accounted for two cases and drugs for 
heart failure for one case.  
Opioid analgesics 
Of the 17 MOD presentations (4%) relating to opioid analgesics, six involved 
tramadol, six codeine, three oxycodone, and two morphine. This group excluded two 
opioid analgesics, buprenorphine and methadone, which are covered separately 
under opioid dependence treatment medications. 
Endocrine 
Over the 12-month period there were 17 MOD presentations (4%) relating to 
medications affecting endocrine function. In one case the person had taken three 
endocrine medications. Antidiabetic medication (e.g. insulin) was used in 15 cases, 
two cases involved thyroid hormones and one involved a medication affecting 
calcium homeostasis. 
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Other (non-benzodiazepine) anxiolytics and hypnotics 
There were 12 MOD cases (3%) related to other (non-benzodiazepine) anxiolytics 
and hypnotics. Most of these were zolpidem (10 cases), one person had taken 
zopiclone, and one person had taken both zolpidem and buspirone. There were also 
another two people who had taken a medication from this group in combination with 
illicit drugs 
Opioid dependence treatment medications 
Ten MOD cases (2%) implicated medications used in the treatment of opioid 
dependence. Of these, nine involved methadone, and one naltrexone (which is also 
used in the treatment of alcohol dependence). There were an additional six cases 
where the person had taken a medication from this class, as well as illicit drugs. 
Allergy & anaphylaxis 
Nine MOD cases (2%) involved medications used in the treatment of allergy. Eight 
of these were of a “sedating antihistamine” such as promethazine hydrochloride and 
one was of a “less sedating antihistamine” (Rossi, 2003). 
Gastrointestinal 
Seven MOD presentations (2%) followed the ingestion of gastrointestinal 
medications. Four were for a medication used in the treatment of peptic ulcers and 
reflux, one was a medication used in the treatment of nausea, one an antidiarrhoeal, 
and one a laxative. 
Anti-infective 
Medications used in the treatment of infection were used in seven MOD cases (2%). 
Six presentations involved an antibacterial (e.g. penicillin), and in one case an 
antiprotozoal had been taken. 
Cough, cold & flu 
Seven MOD presentations (2%) involved the ingestion of medications intended to 
treat coughs, colds and/or flu. Dextromethorphan (a cough suppressant) was used in 
two, psueudoephedrine products in a further two (used for rhinitis and sinusitis), and 
non-specific cough/cold medications in the other three. 
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Anticholinergics 
Four presentations implicated anticholinergic medication; three benztropine and one 
benzhexol. 
Bipolar medication 
Three medication cases involved lithium. 
Electrolytes 
Potassium chloride had been taken in all three cases involving electrolytes. 
Coagulation & blood formation 
There were two MOD cases in which oral anti-coagulants had been taken, and one 
involving a haemopoietic agent (iron tablets). 
Other medications 
The four MOD presentations involving medication not elsewhere classified involved 
an immunosuppressant, adrenaline, diet pills and dexamphetamine. 
Age and sex 
Age and sex frequencies were calculated for cases involving benzodiazepine, 
antidepressant, antipsychotic, and non-opioid analgesic use, as these were the four 
medications types for which there were the greatest number of attendances. These 
data were generated for the MOD group only. In considering these data it should be 
remembered that the groups were not independent, as over a third of patients took 
more than one type of medication and hence may be included in multiple categories. 
For this reason, no statistical analyses have been conducted to determine whether the 
age and sex distributions differ according to medication type.62 
Females accounted for most presentations in each medication category, ranging from 
62% of antipsychotic presentations to 78% of non-opioid analgesic presentations 
(Table 26). The medication types for which males were most highly represented 
were the antipsychotics (38%) and benzodiazepines (36%). In all four groups the 
average age of patients was between 32 and 37 years. 
                                                          
62 When independent groups were created, some medication types retained as few as 40% of the original cases. 
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Table 26 Age and Sex of MOD Cases Involving Benzodiazepines, 
Antidepressant, Non-Opioid Analgesics, or Antipsychotics 
Medication Age  Sex 
 N Mean Median Std Dev Range  % Female 
Benzodiazepines 213 37.0 35.0 13.3 16-90 64.0 
Antidepressants 84 34.8 33.5 12.1 17-76 69.9 
Non-opioid 
analgesics 
76 32.2 27.5 13.3 14-52 77.6 
Antipsychotics 61 37.2 35.0 15.2 18-94 62.3 
 
Summary of medications used in cases of medication misuse or overdose 
Psychotropic medications were the broad class of drugs most frequently implicated 
in MOD attendances to the St Vincent’s Hospital ED, with benzodiazepines (49%), 
antidepressants (19%) and antipsychotics (14%) typically involved. Analgesics were 
the next most commonly implicated class, typically non-opioid analgesics (17%) 
such as paracetamol. Small proportions of cases involved neurologic medications 
(7%), cardiovascular medications (6%), and endocrine medications (4%). A variety 
of other medications were named within the 12-month data collection period, but in 
even smaller numbers. It therefore appears that medications prescribed for mental 
health conditions, and/or painkillers (especially those available OTC), are the most 
likely to be used in cases of medication misuse or overdose, and that involvement of 
medications for other physical ailments is comparatively infrequent. 
4.4.2 Manner of consumption 
While the PAS audit provided a good overview of medications commonly consumed 
in overdose, more detailed information on how these were consumed and what other 
substances were implicated was available from the participant interviews. 
Participants were questioned regarding the medications and other substances used in 
the overdose (i.e. the 24 hours prior to receiving emergency medical care). In the 
couple of cases where the person had delayed seeking medical care until the 
following day, the 24 hours up until the overdose were considered. 
Most people used only one or two different medications in the 24-hour period (with 
an average of 1.8), but there was one person who had taken five different 
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medications. The most commonly used medication types were benzodiazepines (14 
participants, particularly diazepam, temazepam and alprazolam), antidepressant 
medications (12, predominantly SSRIs, and “other” antidepressants), analgesics (7, 
mainly paracetamol), atypical antipsychotics (4), and antiepileptic medication (3). 
Other types of medications taken by only one or two people included methadone, 
lithium, cardiovascular medication, dexamphetamine, gastro-intestinal medication, 
and antihistamines. For those taking more than one medication, there seemed to be 
no particular pattern in terms of combinations. 
While the medications described above were all taken in the 24-hour reference 
period, not all necessarily formed part of the “overdose”. For example, there were a 
couple of cases each where the person had taken their benzodiazepine or 
antidepressant medication as prescribed earlier in the 24-hour period (and one case 
involving methadone), and then later taken some other medication/s in an overdose 
situation. However, on the whole, the medications taken in the reference period were 
taken in quantities exceeding the recommended dose and therefore can be considered 
to have contributed to the person’s presentation to the ED. 
It is difficult to make a general statement about the quantities of medication 
consumed, as some participants were able to give more specific information about 
this than others. Further, the toxicity of the dose would have varied considerably 
between cases, depending on the class of medications involved, the dose-strength, 
the tolerance of the individual, and whether there were other medications, alcohol or 
illicit drugs consumed within the relevant timeframe. However, it can be said that the 
quantities taken were wide ranging, from approximately 10 benzodiazepine 
tablets/capsules, through to in excess of 100 analgesic tablets/capsules. Consumption 
of smaller amounts (e.g. less than 50 tablets/capsules) was far more typical among 
interview participants than larger amounts (e.g. greater than 50 tablets/capsules). 
The most common pattern of consumption was for the medications to be consumed 
all at once, rather than spaced out over time. In a few cases participants described 
spreading the medication consumption out over two or three hours, particularly 
where larger quantities were involved. There were very few cases where the 
medications were taken over a longer time frame than that. Further information 
concerning the 24 hours prior to receiving medical attention, including the length of 
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time waited until seeking assistance is outlined in ‘Medication overdose patients’ 
experiences of the emergency medical care system’, page 235.  
4.4.3 Concurrent alcohol and illicit drug use 
Of the 31 participants, at least 16 had used alcohol and/or illicit drugs in the 24 hours 
preceding or concurrent with the medication overdose. Of the 13 people who 
discussed their alcohol use, the most commonly consumed alcoholic beverages were 
spirits (6), followed by beer (5), and wine (5). One person consumed fortified wine 
and another person did not specify what type of alcohol they had drunk (participants 
may have had more than one type of alcohol). In terms of the pattern of drinking and 
quantity consumed, most had drunk alcohol over several hours, with two or three 
describing having been on a “bender” over the previous two or more days prior to the 
overdose. Most continued drinking up until taking the medications, and almost all of 
those who consumed alcohol would have been intoxicated at the time of the 
overdose. At least ten of those who had been drinking had consumed well in excess 
of the recommended daily limits, with many describing drinking very large quantities 
(e.g. most of a two litre cask of wine, or an entire bottle of sherry followed by four 
longneck bottles of beer). The rate of alcohol involvement revealed by participant 
interviews was greater than that indicated by PAS, which recorded alcohol 
involvement in only a quarter of cases. 
In contrast, relatively few people reported the use of illicit drugs in the 24 hours 
leading up to their medication overdose. Only five people had used any such 
substance. Three of these had smoked cannabis, and in each case the amount taken 
was typical for that person in any 24-hour period and appeared to be unrelated to the 
overdose. The amount smoked ranged from a “couple of tokes” on a joint to “a few 
cones”. One person reported having a hit of heroin in combination with large 
quantities of tricyclic antidepressant medication both on the morning of the 
overdose, and over the preceding days (i.e. 50 x 50mg tablets over a four day period, 
including a large quantity on the day of the overdose). One person had taken 
amphetamines during the previous day, and then being unable to sleep, took 
excessive quantities of a sleeping medication and attended hospital as a consequence. 
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4.4.4 Acquisition of medications involved 
Reasons for acquiring medications 
For the vast majority of participants, the medications involved in their overdose had 
originally been acquired for therapeutic reasons, such as depression, anxiety, 
insomnia, or pain relief. In a small number of such instances the medication had been 
prescribed (or bought OTC) some time previously, and was not routinely taken by 
the person at the time of the overdose. In such cases the participant had generally 
stopped taking their medication without medical advice, but may have kept it for 
over a year before it was used in the overdose (although in such cases the medication 
did not appear to have been kept with the purpose using it in an overdose in mind). 
The following participant had ceased taking a tetracyclic antidepressant medication 
that was subsequently used in an overdose; 
Interview 26 That was the one that Dr X prescribed me a long time ago, and 
because I’d gone off them I stuck them in the cupboard. OK, I’ll 
use them if I couldn’t sleep but I’ve only done that a couple of 
times over time. 
There were five cases where the reason for acquiring the medications appeared to be 
that the person used the medications recreationally. For example, one person liked 
the “buzz” associated with the use of a combination analgesic, another person sought 
the hallucinogenic effect of antihistamines, and a third enjoyed “getting smashed” on 
benzodiazepines. 
There were only two people who specifically acquired medications with the express 
intention of self-harm via overdose; one person bought OTC analgesics and the other 
acquired a range of medications via doctor shopping and stealing a relative’s 
medication. There was one case where it was not clear whether the purpose of 
acquiring their medication was therapeutic, recreational, or in order to overdose. 
Method of acquisition 
Transcripts of the participant interviews were searched for information concerning 
the source of medications used in the overdose. Stories concerning acquisition were 
divided into four groups; obtained from the participant’s “regular doctor”, obtained 
by “doctor shopping”, bought “OTC”, and “other”. In most instances the medication 
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used in the overdose had been acquired from only one of these sources, but in six 
cases there were two sources. As would be expected given the finding above that 
most people originally acquired their medications for therapeutic purposes rather 
than for recreational use or self-harm, the most common method of acquisition was 
prescription by the individual’s “regular doctor” (either a GP or psychiatrist). Six 
people referred to “doctor shopping” in order to obtain prescriptions, usually because 
they found it impossible to acquire the medications they felt were required through a 
single doctor. In general, such behaviour appeared to be in the context of an ongoing 
pattern of regular over-use of medication, rather for the purposes of obtaining 
enough medication to overdose. Six people had obtained their medications from a 
chemist without requiring a prescription (i.e. “OTC” medications such as non-
prescription analgesics). In terms of “other” sources of medication, CATT had given 
one person their medication, one person had stolen medication from a relative, a 
friend had given one person a free sample pack, and one person did not provide any 
information on the source. 
Interview 5 At one stage I had about 12 doctors, you know, and I thought, 
“I’d better give this up because if the health department catches 
me I’ll be stuffed mate”, so (…) that’s why I’ve cut right down 
to two doctors (…) 
Participant understandings of purpose of medication and recommended dosages 
Almost all participants were able to articulate what condition each of the particular 
medications they were taking was intended to treat. There was only one person who 
was not sure of all the medications he was currently prescribed; his relatives and 
pharmacist managed this person’s medications for him. Participants generally had no 
trouble recalling the dosage recommended to them by their doctor and could recall 
other relevant information where that had been given, for example, interaction 
effects, side effects, and length of time until onset of action. It was not possible to 
check the veracity of participants’ responses regarding recommended dosages 
against actual prescriptions, but the information provided was plausible and there 
was no apparent reason to doubt individual stories. While many participants 
indicated they most usually took their medications correctly (with the exception of 
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the overdose), some participants acknowledged they did not always take them as 
prescribed even though they were aware of the instructions for use.  
It was difficult to reach any conclusion regarding the appropriateness of prescribing 
for any given participant. Such an assessment would require a full case review of the 
person’s diagnosis and treatment history by a trained psychiatric specialist, and was 
beyond the scope of this project. However, as a number of participants were 
currently being encouraged by their doctor to reduce their use of benzodiazepines, 
and others were continuing to take these medications over an extended period of 
time, despite national guidelines that recommend otherwise (National Health and 
Medical Research Council, 1991; Royal Australian College of General Practitioners, 
2000), it is possible that a number of participants had in the past or were currently 
experiencing dependence problems connected with the use of benzodiazepines. This 
was consistent with the findings regarding doctor shopping presented above; in 
relevant cases the most commonly sought medication type was benzodiazepines. 
4.4.5 Summary 
The data from the participant interviews were consistent with that from the PAS 
audit in terms of the medication classes consumed. That is, benzodiazepines, 
antidepressants, and analgesics dominated, with an important contribution also being 
made by antipsychotic and antiepileptic medications. However, these were by no 
means the only types of medications used, and many cases involved a wide range of 
other substances. The mean number of medications used by the interview sample was 
also very similar to that revealed by PAS (1.8 and 1.6 respectively). Consumption of 
the medications most often took place over a discrete time period (up to 3 hours if 
large quantities were involved). Intoxication on large quantities of alcohol prior to 
the overdose occurred in approximately half the cases, and may be considered a 
contributing factor to the overdose, but other drug involvement was comparatively 
rare. In general, participants had generally acquired the medications used in the 
overdose through legitimate channels, and for genuine conditions. Deliberately 
acquiring medications in order to overdose was comparatively rare. 
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4.5 Objective 5 - Individual experiences of the emergency 
medical system 
The literature concerning treatment for self-harm generally, and medication overdose 
in particular, recommends that various treatment elements be included in any 
comprehensive response to these issues (see literature review). The treatment of 
medication overdose patients at St Vincent’s ED is therefore described here both to 
provide a detailed picture of how such cases are managed, and to later discuss this in 
comparison with identified best practice. The information presented in this section is 
derived from both patient interviews and observational data. 
4.5.1 Typical pathways of care through the emergency medical system 
An understanding of the pathways through the emergency medical care system was 
developed on the basis of observing staff and patient interactions during the period of 
data collection, and also via informal conversations with ED staff regarding the 
process in individual cases. For example, if there were a person eligible to be 
included in the study within the department, the researcher would speak to treating 
staff to establish whether referral was appropriate at that time. This would depend on 
factors such as whether the person was yet medically clear, or had been assessed by 
Psych Triage. By discussing these considerations with staff the researcher was able 
to begin conceptualising typical treatment processes. By the end of the data 
collection period the researcher was able to anticipate in most cases when referral 
might be appropriate relative to other activities, signalling that an understanding of 
the typical progression had been reached. This conceptualisation of the process was 
further confirmed by treatment descriptions contained in interview transcripts, 
presented in a later section – ‘Medication overdose patients’ experiences of the 
emergency medical care system’, page 235. 
The outline provided here covers arrival in the ED, triage, medical treatment, 
psychiatric assessment, referral to other support mechanisms, and discharge, and is 
depicted in a flow chart (Figure 7). While the information is presented in a linear 
fashion, the pathway through care observed was not necessarily sequential, as certain 
process may have occurred in tandem, such as medical observation and psychiatric 
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assessment. Events varied somewhat from patient to patient depending on the details 
of the individual case. 
Arrival in the ED and triage 
Medication overdose patients arrived at the ED either by ambulance, in which case 
they were delivered via the ambulance bay63, or by other means, in which case they 
walked into the waiting room. A triage nurse briefly assessed each patient as soon as 
possible after arrival. On the basis of the patient’s description of the reason for 
attending, further questioning by the nurse, and any clinical measures such as heart 
rate, blood pressure, and Glasgow Coma Scale score, a triage score from 1 to 5 was 
assigned to prioritise the person relative to other patients. The nurse may also have 
asked to see the packaging of any medications the patient took. 
Patients arriving by ambulance generally remained on a trolley or were transferred to 
a cubicle within the department after triage. Patients arriving on foot usually waited 
in the waiting room until called by the doctor, although patients triaged as a high 
priority were more quickly moved into the clinical area. Occasionally a medication 
overdose patient arrived in a highly agitated state, posing a risk to either themselves 
and/or others. In such instances a Code Grey was called upon arrival to ensure the 
safety of the individual, staff and other patients. 
Once triaged, patients received medical care in the order of greatest need. There were 
a small proportion of individuals who chose not to wait and left the department at 
their own risk prior to being seen by a doctor. There were also a very small number 
of cases presenting for medication overdose that the triage nurse referred directly to 
Psych Triage (an example of a case where this may happen is a person who 
frequently presented to the ED with psychiatric and social issues, but who also said 
they “overdosed” on a non-toxic dose of a regular medication, e.g. 3 diazepam 
tablets, by way of giving a reason for their presentation). 
Medical treatment 
Once patients were called through to see the doctor they were again questioned about 
the amount, type, and time of medications consumed. The medical response varied 
depending on the medication(s) taken and severity of overdose. The more medically 
                                                          
63 A small number of patients in police custody or from jail are also delivered via the ambulance bay. 
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serious the overdose the greater the level of intervention warranted. The response 
ranged from immediately giving the person medical clearance, monitoring only 
while the person recovered (e.g. heart rate, blood sugar levels, etc), giving activated 
charcoal64, through to administration of an antidote, for example, N-acetylcysteine 
for paracetamol overdose (Jones & Volans, 1999). In addition to the medical 
requirements arising from the medication overdose, other aspects of the presentation 
were also managed (for example, tending cuts in a person who had self-harmed). 
Where the person progressed to from this point depended on two factors; whether 
they were medically clear, and whether or not there were any psychiatric issues 
requiring further attention. With regard to medical clearance, most medication 
overdose patients recovered sufficiently to be discharged home from the ED without 
requiring admission to the hospital (as found by the PAS audit). If there were no 
ongoing medical complications and no need for psychiatric assessment, the person 
was typically discharged home. However, if it was apparent the person was still too 
ill to go home, an inpatient admission was arranged, either to the short stay 
Emergency Medical Unit (an extension of the ED), or to a general ward. Whatever 
the medical status of the patient, further assessment was typically arranged if there 
was the possibility of psychiatric or social issues requiring attention (see below). 
Psychiatric assessment 
If there was any indication the overdose may have been intentional or if there were 
other concerning signs such as high levels of distress, refusal to speak, agitation, or 
bizarre behaviour, a psychiatric assessment was arranged. Responsibility for 
conducting the assessment depended upon the medical status of the patient. If the 
patient was likely to be medically clear for discharge, Psych Triage was responsible, 
whereas if the patient was likely to require medical admission to the hospital, a 
member of the Consultation-Liaison Psychiatry Service (CL) generally conducted 
the assessment (see below). 
As with admission on medical grounds, inpatient admission to a mental health 
service did not occur in most cases of medication overdose, even among those people 
                                                          
64 Activated charcoal is given as it helps absorb toxins in the stomach, preventing them from being absorbed into 
the blood stream. It is best used within an hour following ingestion of the toxic substance, after which time it is 
less effective (Jones & Volans, 1999). 
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who had some degree of suicidal intent at the time of the event. The Victorian 
Mental Health Act 1986 (and subsequent amendments to April 2005) outlines ten 
principles of treatment and care that should apply in the provision of health care 
services to people with a mental disorder (reproduced in Appendix K, page 357). The 
second of these is that “wherever possible, people with a mental disorder should be 
treated in the community”. Therefore, unless the person continued to be at immediate 
risk of harming themselves or others, both legislation and current clinical practice 
favoured the least restrictive treatment option available. 
Psych Triage 
The Psych Triage team conducted brief psychiatric assessments in the ED when 
requested by a member of the medical team. As suggested by the word “triage”, the 
Psych Triage service determined the risk and urgency of the presenting case, rather 
than providing a full assessment. If the person appeared to be at low immediate risk 
of self-harm, they were generally discharged home. This sometimes involved 
ongoing mental health support such as CATT follow-up or referral to community-
based services. 
Crisis Assessment and Treatment Team (CATT) 
In cases where the Psych Triage brief assessment indicated the patient was at 
ongoing risk, CATT was generally called to attend the ED to conduct a more 
thorough assessment. Depending on the outcome of the assessment the person may 
have been discharged home or, if there were no ongoing medical complications, 
admitted to the psychiatric unit. Some privately insured patients were transferred to a 
private clinic. 
Consultation-Liaison (CL) Psychiatry Service 
The CL psychiatry service is part of the St Vincent’s Mental Health Service. Among 
the services provided by CL is the responsibility for assessing and treating hospital 
inpatients referred with psychiatric conditions. Therefore any medication overdose 
patient likely to become an inpatient on medical grounds who also required 
psychiatric care was seen by a member of this team. 
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Other support mechanisms - Alert and A&D clinician 
A multidisciplinary team called Alert had the role of assessing frequently attending 
patients in an effort to address some of the social circumstances that may have 
contributed to the recurrence of visits (for example; finances, accommodation). 
There was also a specialist drug and alcohol clinician available to assess and refer on 
patients with drug and alcohol related problems. When the treating doctor or Psych 
Triage worker identified the need for additional social support or alcohol and drug 
assessment, a medication overdose patient may have been referred to the Alert team. 
The diagram on the following page is a flowchart depicting how a medication 
overdose case might progress through the ED (Figure 7). The unshaded boxes 
represent assessment or treatment processes, while the shaded boxes represent 
endpoints in terms of the ED involvement with the patient. The points at which 
decisions need to be made regarding the person’s progression through the system are 
posed as questions. 
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4.5.2 Medication overdose patients’ experiences of the emergency 
medical care system 
Participants were asked to describe the care received from the ambulance service (if 
applicable), while in hospital, and upon discharge from the ED. A content analysis of 
the interview transcripts was undertaken to identify common stories. As some 
participants were interviewed while still a patient of the ED, or while an inpatient of 
a ward, not all had necessarily experienced the later parts of the process (e.g. 
discharge and referral), and therefore could not comment on these aspects of care. 
Length of time until help-seeking initiated 
It was difficult to arrive at a precise estimate of how long after the overdose event 
emergency medical care was sought. Participants generally did not know exactly 
what time they had commenced and finished taking the medications involved in the 
overdose, when an ambulance had been called and how long it took to arrive, or what 
time they arrived at the ED. However, patient arrival times at the ED were 
consistently recorded on the PAS system, therefore this information was used as a 
surrogate measure for the time at which emergency medical care was sought 
(although some participants were in the care of ambulance staff prior to that time). 
Twenty-four participants were able to provide an approximate estimate of the time at 
which they ceased using medications involved in the overdose (at least to the nearest 
half hour, but some with greater accuracy than that). This was subtracted from their 
arrival time in hospital to give a proxy measure of the length of time until emergency 
medical attention was received. 
It appears that half the sample sought medical attention within 4 hours of finishing 
taking the medications (6/24 in under 2 hours, and 6/24 within 2-4 hours). Four 
people arrived at the ED within 4-6 hours, four within 6-12 hours, and three within 
12-24 hours. One person arrived at the ED just over 24 hours following the overdose. 
Therefore three-quarters of those attending the ED who could estimate the time of 
their overdose arrived at hospital within 12 hours. 
Mode of transport to the ED 
Participants were also asked about means of transport to the ED. There were only 
two participants who did not provide any information regarding how they had arrived 
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at hospital. Of the 29 who did discuss this topic, most (20) had been transported to 
the ED by ambulance. Only three of these had actually called the ambulance 
themselves; in two of these cases the call had been made fairly promptly following 
the overdose, while in the third case the call was made a few hours later, but at the 
onset of symptoms caused by the overdose. 
Among the participants who did not call the ambulance themselves, there were a 
range of other people who made the call: these included a relative of the participant 
(5 cases), friend (4), partner/spouse (2), police (2), hotel/hostel staff (2), and GP or 
psychiatrist (2). Although these seventeen people did not make the call to the 
ambulance themselves, many can be regarded as having initiated care by alerting 
someone else to their state. Most people actively alerted someone else to the fact that 
they had overdosed, who then arranged for the ambulance. Of the seven who did not 
actively let someone else know they had overdosed, five participants were found at 
home by others who lived in the house (and in some cases who had also been home 
at the time of the overdose), and two were witnessed in an intoxicated state in a 
public place, prompting others to call for assistance. 
There were nine people who arrived at the ED by means other than ambulance. Four 
people were driven to hospital by a relative or partner, and one person by a friend. In 
most of these cases the participant had asked that they be taken to hospital. Four 
participants were referred to the ED by a health care worker (pharmacist, counsellor 
or doctor) who upon seeing the person for their regular appointment had become 
concerned about their state. In most of these cases the person arrived on their own at 
the ED with a referral letter from their worker. For example; 
Interview 27 …and then I went (to) counselling and my counsellor seen that 
something wasn’t right and called the doctor (…) Yeah, I went 
to the GP in X St, and um, she rang Poisons, and they said that 
I’d have to go to hospital to have my heart monitored, and she 
couldn’t do anything, so she wrote a letter and I had to go up to 
St Vincent’s. 
From the results above it seems that while very few of the participants had actually 
called the ambulance themselves, it was quite common among this group of 
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medication overdose survivors to initiate help-seeking or alert others to their 
condition, even if someone else then arranged for transport to hospital. 
Arrival at the ED 
Most people were triaged fairly rapidly upon arrival at the ED (arrivals by 
ambulance are most usually triaged first, but all patients are triaged at the earliest 
opportunity). Patients were generally placed in one of the cubicles closest to the 
doctors and nurses station, for easy observation. 
A number of participants commented in the interview that they had limited memory 
of both transportation to hospital and arrival in the ED. A couple of participants were 
unconscious when they arrived, but most were intoxicated on medications (and in 
some cases alcohol). Therefore, while their memory of the ambulance trip and triage 
was hazy, they had been moderately aware of their surroundings at the time. At least 
two people realised at the time that they had been transported to hospital but were 
not sure which one, while one person described being completely disoriented and 
frightened by the experience of arriving at hospital. 
Interview 3 Yeah, I remember vaguely arriving, waking up and feeling 
cross, and them asking me where I was. I knew I was in hospital, 
but I wasn’t sure which one, whether it was Western General or 
St V’s. 
*** 
Interviewer Do you remember the ambulance arriving? 
Interview 4 No. 
Interviewer Do you remember anything about the trip, or arriving at 
hospital? 
Interview 4 All I remember was getting here and the worst thing that ever 
happened in my life, I was screaming out for my mother and my 
brother and I couldn’t move and no-one could hear me. 
Interviewer Did you know where you were? 
 237
Non-fatal pharmaceutical medication overdose, suicidality and depression 
Interview 4 No. I thought I was in bed. I just couldn’t get out of bed and I 
couldn’t talk and you know, no-one could hear me, and I was 
trying to pick something up to throw against the wall. 
Interviewer Did you gradually realise where you were, or…? 
Interview 4 After a while I started to think maybe I’m at the hospital, but I 
was still yelling out, then when I started to come good and I, you 
know, seeing these faces, and I realised where I was. 
Interviewer And how did you feel then, when you realised where you were? 
Interview 4 Oh, I felt safe. I wasn’t where I thought I was. It felt like I was 
drowning and no-one could hear me, and I was yelling out to my 
mother, “help me”, and my brother (…). Yeah, once they started 
(…) saying you’ll be all right, I could hear em, but I couldn’t 
see, I thought I was blind. 
The experience described above was an exceptional one, but serves to demonstrate 
how confused a patient in an altered conscious state might be, and how this may in 
some cases translate into apparently aggressive or violent behaviour, although the 
person is actually feeling scared. 
Medical treatment 
Given the altered conscious state of most participants when they arrived in hospital it 
followed that many had limited memory of being in the ED, although there were 
others who had clear recall. According to participant descriptions of their treatment, 
the majority of cases were handled with only observation and minor intervention. A 
number of people described being left to sleep off the effects of the medication, 
although with active monitoring of their condition by the ED staff. Blood pressure 
and heart rate was routinely recorded for most, and a number of people also had a 
blood test performed to check for dangerously elevated paracetamol levels. 
Occasionally participants were asked to provide an alcometer reading. A small 
number of people said they were given intravenous fluids, and one person was given 
glucose to counteract an insulin overdose. Only a very small number of participants 
experienced more interventionist treatment such as being given activated charcoal or 
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being administered parvolex, which is the antidote used in cases of paracetamol 
poisoning. 
For the majority of those who stayed in the ED for monitoring and to sleep off the 
effects of the medication, the experience of being in hospital did not appear to be 
particularly upsetting (over and above the emotional impact of the overdose), even if 
the person had a disturbed night’s sleep: 
Interview 21 What do I remember of it? I remember different people that 
came in and (…), these vague people pop up. I’d doze off and 
then someone would wake me up for something, so I remember 
things like that. I remember being very sleepy, but I felt 
comfortable. I felt like um, there was one time that I got really 
uncomfortable, I got twitchy and I had to sit up and then I 
remember being nauseous and vomiting. 
*** 
Interview 22 I just sort was feeling bad for a while, I just sort of slept it out, 
woke up in the morning still a little bit dizzy, but I was pretty 
good. 
However, one person had arrived in a conscious state subsequently took a turn for 
the worse, required restraining for her own safety, and then woke up not knowing 
what had happened to her: 
Interview 23 It didn’t have any effect until I got into hospital, and then I woke 
up, and I was restrained. I didn’t even know what the hell went 
on, so I didn’t have, I thought I was fine, and then when I fell 
asleep, I woke up and I had restraints on my arms, my legs, and 
a catheter in me, so I don’t remember anything about that, so I 
don’t know what I did, I’ve got no idea (…) I don’t want to 
know! (…) I did crack it, because I didn’t know what the hell 
was going on, you know, all I remember is falling asleep in a 
nice state and waking up in restraints, so, I didn’t know what the 
hell had gone on. 
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There was one other instance where the person found the experience of medical 
treatment quite traumatising because it brought to the forefront pre-existing issues 
about being violated and out of control, even though intellectually she understood the 
necessity of what the treating staff were doing to her. 
Interview 2 Um, no, just it’s a horrible experience, the overdose, it’s a 
horrible experience (…) It was dreadful, it was horrible. It was 
horrible being awake and not being able to do anything because 
I was…that was awful. Having to have things taken off you…it 
was all really traumatic to me, it was traumatic, like having 
ECGs, you know, being exposed like that. Having no control 
over having to use a bedpan. It’s just traumatic for me because 
it brings up issues from my past. 
Interviewer About loss of control? 
Interview 2 About loss of control of my body. Obviously they’re doing a job 
and trying to help but it feels like being violated. It felt like it 
that night because I didn’t have control because I wasn’t 
physically and mentally capable of saying I don’t want you to do 
that or no, I tried, but I couldn’t. And I knew they were doing 
their job, but it just brought back feelings of violation from the 
past, so I found it really traumatic having no control and just 
the fact that I had actually done what I had done.65 I found it 
quite traumatic that I had done that. I thought, “Why did I do 
that?” 
Aside from the very few cases where the person was no longer able to provide 
consent for him or herself (such as described above), participants generally agreed to 
the treatment provided. However, one person removed their drip, another disputed 
the need for him to take activated charcoal, and a third discharged himself without 
telling anyone after becoming tired of waiting to be cleared to go. One person’s 
request to be given more diazepam (following a benzodiazepine overdose) was 
refused. 
                                                          
65 That is, the overdose. 
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Three-quarters of the patients interviewed were medically fit to be discharged home 
from the ED after a period of observation, and the rest required admission. 
Psychiatric assessment 
Over two-thirds of the people in the interview sample received some form of 
psychiatric or social work assessment while in hospital (22/31, 71%), a rate of 
assessment similar to that earlier indicated by PAS (63.3%). Eighteen were assessed 
psychiatrically, while four people were referred to Alert. Participants with only 
short-term medical needs were initially seen by a member of the Psych Triage team 
(13), though in six of these cases the person was then referred on to CATT for a 
more detailed review. The psych registrar from the CL Psychiatry Service saw five 
people. In most cases the participant was assessed to no longer be at acute risk of 
self-harm, though two people specifically said in the interview that while they were 
not currently in crisis, they had informed the person conducting the psychiatric 
assessment that they could not guarantee their safety at other times in the future. 
Participants generally seemed to regard the interaction with psychiatric services as 
neutral or positive, although one person said it was of no help. 
Of the four people referred for Alert or alcohol and drug assessment, two people 
received help in relation to accommodation issues (though one of these requested 
referral back to Alert during the interview to discuss these further), and two were 
referred to other alcohol and drug services. 
Eight people were not seen by either a psychiatric worker or Alert. Two of these 
people said their overdose was not deliberate, and there was no risk of self-harm. 
Two people declined to see Psych Triage, one because she had an appointment with 
her private psychiatrist and the other because she was tired. One person left before 
being seen and it is not clear why the remaining three people were not assessed. 
There was only one person for whom no information on psychiatric assessment was 
available. 
Admission to hospital 
Of the people interviewed who were admitted to hospital, seven were patients of the 
Emergency Medical Unit or a general ward, while one was admitted to the Mental 
Health inpatient unit. Those admitted on medical grounds had all consumed very 
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large quantities (for example, several dozen tablets) of medication compared with 
those who did not require admission. At least three of these people were at-risk of 
sustaining liver damage through paracetamol poisoning and were placed on a 
parvolex drip. Most stayed in hospital about three days, though this ranged up to a 
week. There was one person who was on the methadone programme at the time of 
the overdose and she continued to receive this medication regularly while an 
inpatient. Neither positive nor negative comments were forthcoming about the 
experience of being a medical inpatient. 
It was usual for the medical inpatient group to be seen by a psychiatric registrar 
while in hospital, though subsequent Mental Health admission was not required. The 
person who was admitted to the Mental Health unit had also taken a substantial 
quantity of medication, but not enough to require ongoing medical care once 
transferred from the ED. However, he was deemed to be at continued psychiatric 
risk, hence his admission. When interviewed this person was pleased to have been 
admitted, regarding it as an opportunity to “take some time out” for a week or two. 
The proportion of people interviewed who were admitted to hospital (25.8%) was 
similar to the overall rate of admission to hospital among MOD patients described 
earlier (21.6%). 
Discharge and referral 
As mentioned at the beginning of the results section, there were ten patients 
interviewed while in the ED awaiting discharge, and a further five interviewed while 
still an inpatient of a hospital ward. Therefore only 16 of the 31 interview 
participants had already been discharged at the time of interview. As a consequence, 
the information presented in this section only describes the full experience of 
approximately half the sample. However, information from cases not yet discharged 
has also been included as some these participants were aware of the arrangements 
being made on their behalf for discharge and referral. 
Aside from those participants mentioned above who were admitted as an inpatient, 
the most common discharge destination was home (one person was transferred to a 
private psychiatric hospital, and another person left before formal discharge after 
being refused further diazepam). People either made their own way home or were 
picked up by a friend, relative, or worker. In at least one case where the person lived 
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a considerable distance from the hospital a cab charge was provided to cover the 
journey. 
Of the thirty-one interviewees, 15 participants indicated their GP and/or psychiatrist 
knew about the overdose (or the person anticipated they would be informed by the 
hospital if they had not already been discharged), 11 said their prescribing doctor did 
not know about the OD, and five people did not provide any information regarding 
this. Among the cases where the person’s doctor was aware of the overdose, four 
patients had told their doctor themselves, and in at least three cases the doctor knew 
of the overdose because they had referred the person to the ED in the first place. 
There were only six cases in which the hospital informed the prescribing doctor 
about the overdose, and this was often done by way of a letter given to the patient to 
pass onto their GP or psychiatrist. At the time of the interview at least ten people had 
seen their doctor, spoken to them on the telephone, or made a future appointment 
with them since being discharged from the ED. In the few instances where people 
commented on their doctor’s reaction to hearing about the overdose, most often 
participants felt that their doctor responded in a supportive way, although there were 
a couple of cases where the person said their prescribing doctor was angry with them 
about the overdose. 
Aside from follow-up with the participant’s GP or psychiatrist, referrals were also 
made to other sources of assistance in a small number of cases, including CATT, 
alcohol and drug treatment, and accommodation services. In some cases this 
involved referring a person back to an existing support, while in others a new link 
was made. There were some cases in which the person was discharged from hospital 
without their doctor being informed or any other referral being made. However, in 
such cases it was most likely that a psychiatric assessment had been conducted while 
the person was in the ED, and that the person was regarded as being at low ongoing 
risk. 
Feelings afterwards 
Sixteen people reflected on how they felt about the overdose experience afterwards. 
Most expressed regret and/or guilt about the overdose event, wished that it had never 
happened, or viewed themselves negatively for having taken an overdose. 
Interviewer And how do you feel about the overdose now? 
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Interview 17 Pretty stupid really, yeah, it won’t happen again. 
*** 
Interview 13 I regret it, but I don’t think I would have done anything else. I 
feel, like I feel regret that I abused the hospital system and I 
abused my psychiatrist and I stuffed my boyfriend around for the 
day and worried my friends. You know, I have regret, and bit of 
guilt, that I did that. Yeah, yeah, regret and guilt, that’s how I 
feel. Guilty. Guilty, yeah I feel guilty 
At least six participants said they were relieved to be alive and to have avoided any 
long-term damage from the overdose, and/or that they would not overdose again. 
This sense of relief was true even of people who reported higher levels of suicidal 
ideation at the time the overdose was taken (although five of these had a previous 
history of at least one overdose). Four people saw the overdose as a learning 
experience from which they could think about other more constructive ways of 
dealing with their problems. Finally, two people described going home and using 
illicit drugs to relax themselves after the experience. 
No participants indicated a wish that the overdose had been successful as a means of 
killing themselves, or regret at having received emergency medical care. However, it 
should be remembered that anyone still actively suicidal after being treated in the ED 
would be unlikely to have been referred to take part in the study. 
4.5.3 Patient satisfaction with treatment 
Participants were specifically asked whether there was anything they had wanted to 
happen in hospital that had not occurred. Most participants did not identify any gaps 
in the care that they had received. Responses varied from non-committal, “there’s 
not much they can do”, to enthusiastic “I think this is a wonderful hospital.” A small 
number of people who were happy with their treatment commented that as they were 
drowsy while in hospital discussing the overdose with anyone at that point would 
have been of limited use, while others had valued the opportunity to speak to Psych 
Triage or CATT. The particularly distressing experiences some participants 
described above were in the minority, and in all cases the person also recognised that 
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the hospital staff had actually acted in accordance with the patient’s needs, even 
though they may not have been aware of this at the time. 
In terms of gaps in the treatment received, there were four people who made 
suggestions in relation to follow-up and/or referral. Two people thought some form 
of debriefing or follow-up organised by the hospital may have been useful. One 
person had been recommended to seek psychotherapy by a hospital psychiatrist, but 
was having trouble accessing a bulk-billing psychiatrist in the community. Another 
person thought referral to a Cognitive Behaviour Therapy practitioner would have 
been useful, though he had since arranged this for himself. 
In general, participants had few other complaints about any aspect of their treatment 
(including their contact with the ambulance system), and many in fact expressed 
satisfaction. However, there was one instance each of people feeling a police officer, 
an ambulance officer, or an ED doctor involved in their case treated them poorly by 
being rude to them. 
4.5.4 Summary 
There are a number of common pathways through the emergency medical care 
system for people presenting with medication overdose. The specific pathway of care 
taken depends on both the medical seriousness of the event and the mental health 
status of the individual. 
Most people included in the study sought assistance within six hours of the event, 
and initiated care themselves either by calling for help directly or alerting someone 
else to their condition. The most common mode of transport to the ED was 
ambulance, followed by being driven by a friend or relative. Medication overdose 
patients were generally at least somewhat intoxicated upon presentation to the ED. 
Common treatment in the ED included routine observation and screening tests, with 
administration of antidotes and activated charcoal being reserved for the more 
medically serious presentations. Most participants were physically well enough to be 
discharged home from the ED after the effects of the medication had time to wear 
off, though the majority were also given at least a brief psychiatric review before 
discharge, which may or may not have involved referral to community-based 
services. In a minority of cases the person’s doctor (GP or psychiatrist) was 
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informed. It was common for participants to express regret and guilt about the event, 
as well as relief at having recovered from the overdose. Few complaints about the 
emergency medical care system emerged. A very small number of participants found 
the treatment experience to be traumatic at the time, though afterwards 
acknowledged the necessity of what had occurred. 
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4.6 Objective 6 - The research experience 
In this section the researcher’s experience in conducting a project in the ED will be 
discussed with reference to all components of data collection (i.e. the PAS audit, 
patient interviews, and observation). This experience will be used to inform a 
commentary (see Discussion) on the feasibility of future research into medication 
overdose in the ED, or of introducing a brief intervention for medication overdose 
survivors. 
4.6.1 The ED as a research environment 
In considering what the ED is like as a research environment, a brief description will 
first be given of the operation of the ED, followed by a summary of some of the 
challenges posed and advantages offered by conducting a study within this setting, as 
experienced by the researcher. 
Nature of the ED 
In conceptualising the ED it is useful to bear in mind three elements; function, 
physical environment, and staffing, and further, how these three relate to a fourth 
element, the patient.  There is no doubt that the primary function of the ED is to 
provide an emergency medical response to people requiring acute care. In a sense, 
the ED is intended as a “clearinghouse” for the acutely sick or injured (over half 
those triaged during the data collection period were allocated to level “3” or above). 
Patients are prioritised according to need, have an assessment made of their medical 
and psychiatric needs, are treated and/or stabilised where possible, and then 
dispatched to an appropriate destination with further care arranged elsewhere if that 
is required, such as by transfer to the intensive care unit, or a referral back to the 
patient’s GP. Approximately 90 cases are triaged at the hospital ED each day and the 
intention is that these people should only remain within the department for a short 
length of time, that is, until they are stable enough to go home, or until transfer to an 
appropriate ward can be arranged. Any other activities occurring in the ED, such as 
research, need to be undertaken with an understanding that the primary role of the 
department must always take precedence. 
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The physical environment of the ED reflects its function; it is primarily set up as an 
acute clinical area. On the outer are the waiting room and ambulance bay, and once 
inside, most of the floor space is devoted to beds. The areas not used for beds are 
used as a station for medical and nursing staff, triage and administrative functions, 
storage for equipment, preparation rooms, and toilets and showers. There is one 
interview room available, which is used for some psychiatric assessments, as a 
waiting room for family members of patients, and other similar functions. Separated 
from the clinical area are the staff room, some small offices and a training room. 
Therefore, while the ED itself is a reasonably sizeable department, there is little 
room for activities and people not directly related to the care of patients and the 
function of the department. Patients are only allowed two visitors at a time, and they 
are usually encouraged to sit with the patient or in the waiting area, rather than move 
around the department. While patient beds are separated into individual cubicles, and 
these can be screened off with curtains if necessary, there is limited privacy. The 
beds holding the sickest patients need to be within clear view of the medical and 
nursing station for ongoing observation. Even with the curtains drawn cubicles are 
not soundproof, especially if the treating staff need to speak in a loud voice for a 
patient to hear, or if the patient is making a lot of noise. 
Staff numbers are large because the department is one of Melbourne’s major EDs, 
the staff-to-patient ratio required in an acute medical setting is high, and the service 
operates 24 hours a day, 7 days a week. The diverse workforce includes medical, 
nursing, allied and mental health staff, administrative workers, and Support Service 
Associates (SSAs).66 Because the ED is situated within a major teaching hospital 
there are also groups of medical students who rotate through the department on a 
regular basis. 
Challenges 
The very nature of the ED poses some challenges to researchers choosing to conduct 
a project within that environment. As just mentioned, the function of the ED is to 
provide care and therefore it has a primary clinical orientation. The systems within 
the ED are all geared towards the provision of treatment, the physical layout is 
                                                          
66 This is a role equivalent to what used to be called an orderly, i.e. assist with patient transport, cleaning duties, 
etc. 
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designed to facilitate this, and staff are oriented towards clinical outcomes. While an 
ED may readily accommodate researchers wishing to locate their project at that site, 
it is up to the researcher to adopt a research design that fits around the primary 
function of the ED. A small number of illustrative examples are provided below. 
The PAS database provides a record of every patient attending the ED. It provides a 
brief, real-time summary of each presentation, and therefore represents a potentially 
useful source of data regarding patient attendances. Information on PAS is not as 
comprehensive as the associated paper-based patient files, particularly in so far as 
clinical observations, test results, and so on, are concerned. However, it has the 
advantage of being more readily accessible than hard copy files, is searchable on a 
daily basis, and consistently provides certain basic data items such as age, sex, time 
of arrival, triage level, and presenting complaint. Nonetheless, PAS is primarily a 
clinical tool, designed to assist staff in their management of patients while they are in 
the department (for example, current status, location, etc), and to provide a record of 
attendance. While basic searches can be conducted and summary reports are 
routinely produced from PAS for internal purposes, undertaking a non-routine search 
(such as that required for this study) is more difficult. For example, to audit cases 
involving medication overdose it was not enough to simply run a search on 
“overdose”. Such a search would return many irrelevant cases, and could also miss 
potentially relevant ones in which the search term does not appear. Similarly, using 
the presenting complaint to select cases could return an incomplete data set. The only 
solution was to manually search through every case presenting to the ED on a daily 
basis in order to find those matching the audit criteria (see Method), and to record 
the relevant data items for those cases in a separate spreadsheet. The advantage of 
this was that the researcher could be assured of capturing all cases, but the process 
was time intensive. 
The physical space of the ED also presented particular challenges to the researcher. 
While office space was made available for the project, the need to conduct 
observation of ED processes and to promote awareness of the study by discussion 
with staff required the researcher to spend time in the clinical area of the ED. With 
space at a premium and everyone aside from the researcher having a clearly defined 
role contributing to the overall functioning of the ED, it was at times difficult for the 
researcher to find an unobtrusive position from which to observe. Staff were 
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generally accepting of the presence of the researcher once the project was explained, 
but there were times when the department was at its most frenetic that the researcher 
felt “in the way” (this is not meant in the literal sense, as the researcher was careful 
to be physically unobtrusive, and avoided interrupting clinical staff in the middle of 
their work, but taking on the role of observer for an extended period of time amidst 
such a hive of immediately required activity was at times an uncomfortable contrast). 
Another challenging aspect of the physical layout of the ED was in ensuring privacy 
during the referral process. In briefly introducing the study, the researcher 
necessarily had to make reference to the main topic of the research (i.e. medication 
overdose), which flagged the reason for the patient’s attendance. As the initial 
referral often took place within the cubicle, any loud conversation would possibly be 
heard from adjoining beds. The researcher was always very careful to ensure other 
patients and visitors did not hear the conversation with the patient about the study. 
There were times when the patient wanted to take part in the study and initially 
expressed a preference to be interviewed within the cubicle rather than the interview 
room. In these instances the researcher explained the impossibility of this given the 
need for a private and confidential space. 
Related to this sense of being out-of-place is the contrast between the strong clinical 
orientation of ED staff where evaluation of a situation is geared towards choosing an 
immediate course of action to optimise treatment outcomes, and the more removed, 
contemplative orientation required for research. Although many staff undoubtedly 
had previously been connected with research in the ED, and/or studied research 
subjects during their clinical training, it was apparent that the role of the researcher 
was not necessarily clearly defined in minds of all staff. Despite the project being 
introduced at staff meetings, and written material being placed on notice boards and 
in the staff room, there were times when it became evident a staff member was not 
sure why the researcher was there. For example, the person may have known the 
researcher was interested in “overdose” cases, but thought this involved some type of 
clinical intervention. The researcher dealt with such misapprehensions by giving 
further information about the project. 
Provision of information to staff about the project was complicated by the fact that 
staff work according to a roster, and therefore there was never a time at which all, or 
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even most staff were likely to be present at once in order to discuss the project. As 
mentioned above, the ED is multidisciplinary, and the different professions tended to 
have different meeting schedules. At the commencement of the project the researcher 
attended meetings with medical, nursing, allied and mental health staff to present 
information about the study, request assistance and respond to any queries or 
concerns. It is not clear what percentage of the relevant workforce were in 
attendance at these meetings, and in any case, over the 12-month period there were 
changes in staff (for example, new employees, people returning from leave). The 
researcher attended another meeting of medical staff mid-way through the data 
collection process to remind people about the project. 
Communication about the study was supplemented by a variety of other mechanisms. 
Where possible, use was made of staff notice boards (including the posting of regular 
updates once the project commenced), a communication book located in the staff 
room, and the ED newsletter, published on an occasional basis. A project folder was 
placed in the clinical area and information sheets in the administration area. Towards 
the end of the data collection period an internal ED website was developed on which 
an article about the study was also posted. In addition, the researcher also spent 
considerable time speaking to individual staff members, particularly medical and 
Psych Triage staff (who were the most involved in referral) about the project. 
Despite these mechanisms, it was difficult to ensure all staff were aware of and 
interested in the study. In practice, there were a small number of staff members who 
particularly took on board the role of referring patients to the project at times when 
the researcher was absent from the department. 
Advantages 
While the challenges outlined above at times made the experience of data collection 
in the ED difficult, there were several advantages to situating the project within the 
department. Being located within the ED for a period of 12 months allowed the 
researcher to develop an understanding of how the department functions, and how 
the different elements of the treatment team work together (for example, at what 
point the medical staff might involve Psych Triage). Close observation of the system 
in action enabled the researcher to become far more familiar with it than would have 
been possible through the verbal descriptions of staff and/or patients alone. The 
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observations made provided a useful context in which to situate participant narratives 
about experiences of the ED, as the researcher had no difficulty in “imagining” the 
physical locations and personnel described, and could clarify the narrative against 
knowledge both parties shared (for example, the participant may have been unsure 
whether the person they had spoken to was a member of Psych Triage but would 
give a name or physical description that confirmed this for the researcher). 
Some of the challenges associated with communication were outlined above. The 
flipside of those difficulties was that by being regularly present in the ED the 
researcher was available to discuss the research with staff, clarify referral procedures 
as necessary, and, as was often the case, remind staff about the project when an 
eligible patient attended. Without this presence, it is unlikely that as many patients 
would have been interviewed, as staff did not always remember to mention the 
project without prompting. 
By being present in the ED, the researcher was also able to gain a greater 
understanding of the response to medication overdose patients, as staff would explain 
events as they were occurring. For instance, the first time the psychiatric registrar 
was called to assess a patient rather than the Psych Triage, a staff member was able 
to explain that this was because it was anticipated the person would be admitted as a 
medical inpatient (see Objective 5 for an explanation of pathways through care). By 
being exposed to the day-to-day operations of the ED the researcher was able to pick 
up on many of the details of typical patient care, which may have been overlooked if 
the information concerning treatment pathways was obtained via some other means, 
such as a brief interview. 
A presence in the department also meant that the researcher had greater access to 
information as to why a certain person might not be suitable for interview. As has 
already been stated, not all potentially eligible patients were necessarily referred, 
particularly when the researcher was not physically in the ED. However, simply by 
observing the researcher was able to clearly see that there was a sizeable proportion 
of patients for whom referral to the study would be inappropriate. Examples of such 
cases included people who were highly agitated, or conversely, badly drug affected, 
people who were extremely emotionally upset, refusing to talk, requiring transfer to 
the inpatient psychiatric unit, able to speak only limited English, and a range of other 
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circumstances that made introducing the study at that time unfeasible. The researcher 
was also able to see that this group of patients is only one small part of the overall 
ED work, and that treating staff are often working between several patients at a time 
with a range of needs. 
Being witness to some of the complexities of different cases allowed the researcher 
to shift in focus from endeavouring to maximise recruitment, to an acceptance that 
attempting referral would not always be reasonable for either the individual or for the 
smooth functioning of the ED. Therefore while the selection criteria for the study 
were reasonably broad, in practice, the group of people interviewed reflects a 
convenience sample of patients for whom both the treating staff and the researcher 
believed inclusion would not have an adverse impact. If the reason for non-referral 
was temporary (such as being drug affected), it was sometimes possible to ask that 
the person be referred at a more suitable time. The complexity of some cases, and the 
implications of this for recruitment, may not have been as clear to the researcher 
without the observational component of the study, as this information was not readily 
apparent from PAS. 
Another advantage of conducting the research within the ED was that it was a 
supported environment. Although patients were only referred with the approval of 
treating staff, and patients further had to provide their informed consent to 
participate, it was considered an advantage for the interviewing to take place in a 
location where there was immediate psychiatric support on hand should it be 
required. As it turned out, such back up was not needed, but having additional 
support on hand represented sound risk management given the sensitive nature of the 
project. 
4.6.2 The experience of being an “external” researcher 
Some of the issues raised in the section above could suggest that having an external 
researcher enter the ED to investigate an issue may be a disadvantage (for example, 
initial unfamiliarity with local processes, being unknown to staff, having no other 
“role” in relation to the patient). However, while a researcher new to the ED 
environment has much to learn before the information gathered can be made sense 
of, the independence of this position also conferred its own advantages. Being new to 
the situation meant asking a lot of questions and having many informal discussions 
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with a range of people in order to reach an understanding of how the system worked, 
rather than being informed by one’s own previously held perceptions and 
assumptions. An internal staff member conducting a similar research project may 
have had easier access to patients (as there would be valid reasons besides the 
research for speaking to a patient which could assist with recruitment). However, this 
would have come at the cost of a dual relationship, requiring careful balancing. As an 
external researcher there was no role conflict to negotiate. Similarly, the researcher 
was able to provide an assurance to participants that as she was not a hospital 
employee, the information they provided concerning the overdose or their treatment 
would not be discussed with the ED staff (with the usual exception of ongoing risk of 
self-harm). 
4.6.3 Conducting research interviews with survivors of very recent 
medication overdose 
The rationale for recruiting participants at the point at which they received 
emergency medical care and interviewing them shortly thereafter (preferably within 
10 days) was to maximise the accuracy of recall. The study sought to examine the 
specifics of the medications used, and also patients’ experiences of care, memories of 
which may become less reliable with time. The individuals who took part all 
appeared to be suitable for interview at the time, though there were some factors that 
required special consideration in accessing this group, particularly at the point of 
recruitment. 
There were some instances where a member of hospital staff was of the opinion that 
an eligible patient was in a suitable condition to be interviewed. However, when the 
researcher then went to approach the person it was occasionally apparent that 
readiness for interview means different things to different people. For staff used to 
dealing with sick and injured patients, an individual being alert and oriented when 
roused might signify capacity to give informed consent and participate in an 
interview, even if the person is still connected to an intravenous drip, somewhat 
drowsy, and unable to get out of bed. After all, ED staff are accustomed to 
interacting with patients in such states; patients who are “well” do not need to be in 
the ED. However, for a social researcher wishing to conduct an interview taking an 
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hour or more, recruiting a patient in this condition, let alone interviewing them, is 
unlikely to be regarded as satisfactory or ethical. 
Because the researcher was reliant on the assistance of staff in introducing the study 
to patients, such precipitous offers of referral had to be handled carefully. It was up 
to the researcher to decline to proceed with recruitment at that stage, while still 
encouraging the staff member to make a referral at a more appropriate time. As 
patients often remained in the department for several hours the researcher could not 
always wait for a suitable moment for the referral to take place (the most suitable 
moment generally occurring just before the patient was ready to be discharged). In 
such cases the researcher would ask the staff member to pass on a study card to the 
person before they left, or to ask the next person on duty to do so if their shift 
finished before the patient could be referred. Alternatively, if the person was well 
enough to consent to referral, but not well enough to immediately participate in a 
lengthy interview, the researcher would introduce the project and arrange to speak to 
the person again at a later date. 
On the whole it was the preference of the researcher that participants return to do the 
interview at least a couple of days after the overdose occurred, as it was felt this may 
give the person an opportunity to have some rest, shower, change clothes, and 
possibly review their decision to participate. However, as mentioned earlier in the 
results, a number of people opted to participate in the interview before leaving the 
hospital. Reasons people gave for wanting to participate immediately included 
anticipated difficulties in returning on another day (e.g. due to travel time, other 
commitments, etc), and wanting to do the interview while they were waiting for 
something else to occur (e.g. someone to arrive to take them home). Provided the 
researcher felt the person was truly able to provide informed consent and was in a 
condition to be interviewed, and treating staff were happy for the interview to take 
place, every effort was made to accommodate patient inclinations in this regard. 
The researcher was at all times mindful that the interviews were being conducted at 
very close temporal proximity to the overdose. In many cases the life circumstances 
contributing to the overdose were unlikely to have changed in the time the patient 
had been in hospital (though their thoughts and feelings about these circumstances 
may have). Throughout the interview the researcher remained alert to the possibility 
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that the person remained at-risk, even if Psych Triage had assessed them as low risk. 
Therefore it was essential that the researcher have the capacity to conduct a risk 
assessment as needed. This involved knowing when to stop the interview in order to 
follow up any indication of ongoing suicidal thoughts or feelings. As it happened, 
there were no participants who were assessed to be at acute suicidal risk during the 
course of the interview, though there were a few who could be regarded as at 
ongoing chronic risk, which is not surprising given the study population. In such 
instances the researcher reinforced any supports mentioned by the participant during 
the interview, such as an upcoming appointment with the person’s counsellor or 
psychiatrist. 
While all research involving humans must allow participants the opportunity to opt 
out at any stage, it was thought particularly important in this study to reiterate the 
point at any stage where there was the slightest concern that the participant might be 
finding the interview taxing. For example the researcher might say “How are you 
doing? Let me know if you’ve had enough.” There was only one case (as mentioned 
previously) where the interview was terminated early. 
At the conclusion of each interview the researcher again enquired whether the person 
was feeling OK and ready to go home. Participants were routinely asked if they 
would like to speak to someone from the hospital (i.e. a member of Psych Triage) 
before leaving or returning to their cubicle. However, no participants took up this 
option. 
4.6.4 Summary 
The ED presented a challenging environment in which to conduct a sensitive 
research project. Nevertheless, the project yielded rich information about medication 
overdose, particularly patient experiences thereof, not readily available by other 
means. Factors impacting on the research included the nature of the ED, staffing 
changes and communication, the clinical rather than research orientation of hospital 
data systems, the importance of maintaining patient confidentiality, the perceived 
role of the researcher, and patients’ capacity to provide informed consent. The 
implications for future research into medication overdose or for introducing a brief 
intervention within the ED are considered in the Discussion. 
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5 Discussion 
5.1 Objective 1 - Number of medication misuse or overdose 
presentations to the ED 
This study aimed to assess the contribution of medication overdose cases to the 
work-load of a single inner-Melbourne ED over a period of one year, and also to 
compare these presentations to cases of illicit drug overdose and self-harm. 
5.1.1 Number of presentations 
The proportion of cases due to medication overdose (1.6%) fell well within the upper 
limit (5%) found by previous studies (Whyte et al., 1997). The expansive definition 
of medication overdose employed in the present study may partly account for the 
higher proportion of medication overdose cases recorded compared to Taylor et al’s 
(1998) study conducted in regional Victoria (0.7%). The present study found that 
illicit drug and medication overdoses made an approximately equivalent contribution 
to ED presentations. However, this may have been influenced by the study setting, a 
busy inner-city hospital. It would be of interest to examine the relative contribution 
of such cases in hospitals with differing catchment areas in other parts of 
metropolitan Melbourne, and across Victoria. 
A small proportion (22%) of the 432 cases categorised as self-harm involved 
medication overdose as the agent, although this figure only included those 
medication overdoses in which the PAS information specifically indicated an 
intention of self-harm. However, even once all cases of medication overdose were 
included in the calculation (on the basis that most are likely to be self-harm events), 
the proportion increased to 50%, still lower than previous studies which have found 
85-95% of self-harm cases to be via medication overdose. Again, this most likely 
reflects the definitions employed in this study, with self-harm including not just 
actual self-injury, but also suicidal ideation, thoughts, and threats. A less inclusive 
definition would result in a smaller denominator and therefore a larger proportion of 
medication overdose cases relative to total self-harm cases. 
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5.1.2 Temporal patterns 
The temporal pattern of MOD presentations to the ED was consistent with earlier 
studies, with the evening being predominant (N. Buckley et al., 1993; D. Taylor et 
al., 1998). A similar pattern was also evident for both SH and DOD cases; although 
in the latter cases the peak time for arrival extended into the early morning. There 
was a distinct difference between the daily pattern for all cases attending the ED and 
the pattern for the three study groups. In contrast to MOD, DOD, and SH cases, 
overall presentations to the ED in general peaked in the late morning and early 
afternoon. The findings regarding temporal patterns in presentation-type across the 
course of the day have implications for the staffing of the ED, as those cases likely to 
involve elements of toxicity and/or a requirement for psychiatric assessment are most 
likely to attend overnight. Rostering in EDs should ensure there are staff members 
with relevant specialist expertise available on duty overnight. This would avoid the 
potential danger identified by Kapur et al. (1999) of sub-optimal psychosocial 
assessment services being available to those patients attending the ED overnight 
following a medication overdose. 
The present study replicated the findings of previous studies in demonstrating only 
minimal or no variation in MOD attendances according to the day of week (N. 
Buckley et al., 1993; D. Taylor et al., 1998). In addition, this study found MOD and 
SH presentations both follow a similarly even pattern across the week (as do ED 
presentations overall), while DOD presentations clearly differed by day of week, 
with a greater number of attendances on the weekend. This differential pattern of 
attendances is consistent with ambulance attendance data which found calls to 
benzodiazepine-related cases were spread across the seven days of the week, while 
heroin attendances showed a distinct spike at the weekend (Heale et al., 2002). 
While the greatest number of MOD presentations occurred in summer, there was no 
strong evidence of variation across a 12-month period. DOD presentations also 
peaked in summer, while SH presentations and total ED presentations appeared 
relatively evenly distributed across the year. Given that data were collected for only 
one year, it may be that any underlying seasonal trends in attendance rates were 
unable to be detected by this study. Extended data collection over several years may 
reveal cyclical patterns for one or more of the groups in question, or a relationship 
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with other external events, such as changes in the availability of medications or illicit 
drugs. Ongoing monitoring of ED overdose presentations that clearly distinguishes 
between medication, illicit drug, and other poison overdose cases would assist in this 
regard. 
5.1.3 Repetition 
Eleven percent of MOD cases attending the ED returned at least once with the same 
complaint within the 12-month data collection period. This is consistent with 
previous research which found a rate of repetition of approximately 14% within two 
years, and even higher rates over a lifetime (Carter et al., 1999; D. Taylor et al., 
1998). While medication overdose is recognised as an oftentimes recurrent 
behaviour, few previous studies have actually compared the rate of repetition from 
medication overdose with other types of presentation. In this study, recurrent MOD 
presentations were less common than recurrent presentations for SH (16%), and 
more common than for illicit DOD (7%). However, recurrent presentations for all 
three types of case were less than for the ED overall; 21% of all individuals attended 
more than once in the 12-month data collection period, although some of those 
repeated presentations may have been for entirely separate complaints (for example, 
asthma on the first occasion and a soft tissue injury on the second). The mean 
number of attendances for all four groups ranged from 1.1 to 1.4. It may therefore be 
that the tendency for medication overdose patients to repeatedly attend the ED for 
the same reason is somewhat overstated in the literature when other types of 
presentation are also considered. As with previous studies, the data on repetition 
included here do not take into account attendances to other EDs during the data 
collection period, overdose events for which the person did not seek help or attend 
the ED, or events occurring before or after the defined data collection period, all of 
which would inflate the rate of repetition. 
5.2 Objective 2 - Characterisation of MOD patients at the ED 
This study sought to characterise medication overdose patients in two ways; at a 
broad level in comparison to illicit-drug overdose patients and self-harm patients 
using patient information routinely collected by ED staff, and more specifically via 
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in-depth interviews with a sub-sample of medication overdose patients to obtain 
information that would not otherwise be available. 
5.2.1 Broad demographic profile using PAS data 
The audit of PAS data enabled MOD presentations to be described on a range of 
variables including sex, age, presenting complaint, triage level, waiting time, and 
discharge destination. This discussion will compare the findings on these factors 
with previous research. The audit also allowed the three study groups to be compared 
with each other and the total ED attendances on the variables of interest, allowing a 
differential profile to be built. Where relevant, reference is also made to the patient 
interview data, although this is more thoroughly discussed in a subsequent section 
Sex and age 
The finding that 64% of MOD patients included in the audit were female was highly 
consistent with previous studies of medication overdose conducted in various 
settings (including the ED, ambulance attendances, and elsewhere), which have 
found the female to male ratio to be approximately 2:1 (Heale et al., 2002; D. Taylor 
et al., 1998; Townsend et al., 2001; Vaiva et al., 2006). The proportion of MOD 
cases that were female was substantially higher than for all cases presenting to the 
ED during the study period, again suggesting that female sex is particularly 
associated with this complaint. Further, MOD patients were significantly more likely 
to be female than DOD patients, which accords with previous ambulance attendance 
data comparing benzodiazepine and heroin-related cases (Heale et al., 2002). 
Previous research suggests that non-fatal self-harming behaviour is far more 
prevalent among females than males (and fatal behaviour more prevalent among 
males than females) (Australian Bureau of Statistics, 2006b; Graham et al., 1999). In 
contrast, this study found 56% of SH cases were male. However, it should be 
remembered that in creating the three independent groups for comparison, any cases 
involving SH by way of medication overdose were assigned to the MOD group. 
Were these cases included as SH cases, it is likely that the female proportion would 
have been greater. Horrocks et al. (2003) also considered self-poisoning and self-
injury as separate groups and found females to be over-represented in the former 
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group (54.7%) and males in the latter (54.4%). These groups can be regarded as 
similar to the MOD and SH groups in the current study. 
While the preponderance of females among MOD patients was clear, it should also 
be remembered that about a third of such cases were male, which in this study 
equated to more than 160 men over the 12 months in which data were collected, or 
one man presenting to the ED every two or three days following a medication 
overdose. If these figures were to be extrapolated across the state the overall number 
would be in the thousands per annum. Therefore prevention and intervention efforts 
concerning medication overdose should not overlook men, and there may need to be 
differential targeting according to gender. Given that medication overdose is widely 
perceived as a female phenomenon, further research specifically investigating 
medication overdose among males may yield important data to inform gender-
specific interventions. 
The age of MOD patients spanned nine decades from 14 years to 94 years, although 
the average age was in the mid-thirties. Previous studies have also found a wide 
range of ages represented among medication overdose patients, with a concentration 
in the lower age groups. A very similar pattern was found for the SH patients. In 
comparison, DOD cases were more tightly concentrated from 15 years to 61 years, 
and were significantly younger than MOD patients, with an average age of 27 years. 
All three groups were more skewed towards the younger age groups than the ED 
patients overall. This difference could partly be because younger people are more 
likely to be at-risk of these behaviours, or because older people are at greater risk of 
other health problems necessitating an ED visit. 
Characteristics of hospital presentation 
The most commonly used presenting complaint for both MOD and DOD was 
‘OD/ingestion/poisoning’, which identified 86% and 68% of relevant cases 
respectively. The next most common complaint for both types of overdose was 
‘Altered consciousness’. As these presenting complaints give no indication of the 
agent involved, it was not possible to use this information to categorise cases, and 
further information from the narrative field was required. While overdose cases most 
usually had a presenting complaint which reflected the physical state of the patient, 
SH cases were more typically assigned a presenting complaint which referred to their 
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mental state. Over 80% of presenting complaints for this group were psychiatric (for 
example, ‘psych thoughts’, ‘psych mood’). The most frequently mentioned physical 
state of patients presenting for SH was ‘laceration’ accounting for only 9% of the 
group. 
Although the presenting complaint labels assigned were generally accurate, they may 
in part explain why the rate of psychiatric assessment appeared to be somewhat 
higher among SH cases (at least 77%) compared to MOD cases (at least 59%), even 
though most of these could also be assumed to be self-harming. It may be that cases 
given a psychiatric label were flagged in the minds of staff as requiring mental health 
attention more so than medical attention. In contrast, for cases of 
‘OD/ingestion/poisoning’ the physical risk may have been the focus of treatment, 
with psychiatric care being less routinely instigated. The apparent difference in the 
rate of psychiatric assessment between SH and MOD cases appears to be the reverse 
of that found by Horrocks et al. (2003) who noted that self-poisoning cases were 
more likely to receive a psychosocial assessment than self-injury cases. The reasons 
for the difference between studies are unclear. It would be of interest to know 
whether staff believe deliberate medication overdose patients should universally 
receive a mental health assessment during their stay in the ED. It would also be of 
interest to know why such a small proportion of DOD cases (10%) were 
psychiatrically assessed. For example, do medical staff members simply assume such 
cases occur because the individual mistakenly took too much of the relevant 
substance, or do they choose not to request an assessment only once they have 
established that the overdose was definitely not deliberate? 
Almost nine out of ten MOD cases were categorised to triage category three or 
higher (to be seen from immediately to within 30 minutes), suggesting that these 
cases are regarded as relatively urgent. In comparison, only half of all cases 
attending the ED were assigned to the same degree of urgency. This is consistent 
with the findings of Taylor et al. (1998). SH cases tended to be triaged somewhat 
more urgently than the ED total, but less so than MOD, which is consistent with the 
findings of Horrocks et al. (2003). DOD cases were triaged as significantly more 
urgent than the other groups. The average length of time each group was required to 
wait was consistent with triage status (i.e. DOD were seen the most quickly, 
followed by MOD, and then SH). 
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The greater urgency with which DOD patients were triaged and seen is most likely a 
reflection of the medical seriousness that may be associated with illicit drug toxicity. 
For example, overdoses on substances such as heroin and gamma hydroxy-butyrate 
(GHB) may leave the patient comatose, with a very low respiratory rate, or requiring 
an antidote or intubation.  Furthermore, illicit drug users may be less likely to attend 
hospital at lower levels of intoxication because the purpose of use is to be somewhat 
intoxicated anyway, and hospital attendance generally only occurs when the risk 
from toxicity is high. This could account for the significantly greater likelihood of 
being categorised to the highest triage level, requiring immediate attention. In 
contrast, medication overdose is less likely to be recreational, and more likely to be 
in order to self-harm, and/or to seek care. Care-seeking behaviour may result in 
attendance at the ED with a lower level of medical need compared to illicit drug 
intoxication, although the psychiatric needs of the individual may of course be acute. 
Nonetheless the triage system will necessarily prioritise someone in extreme physical 
danger (for example who has stopped breathing) ahead of all others, no matter how 
psychiatrically distressed those others may be. 
Among the three patient groups MOD cases spent the longest average time in the 
department; over two hours longer than DOD patients and almost three hours longer 
than SH patients. Previous research has found that medication overdose patients have 
a longer length of stay compared to the overall patient group (D. Taylor et al., 1998). 
Such a comparison was not possible in this study. The differences noted in length of 
time in the ED are most likely due to the relative complexity of presentations. Most 
MOD cases required a medical assessment, followed by treatment which may have 
simply involved monitoring and supportive care, but which may have also included 
blood tests, the administration of an antidote, and occasionally gut decontamination 
techniques. Once the patient was medically stable, a psychiatric assessment may 
have also been warranted. Given that benzodiazepines (the most common medication 
involved in overdose) are CNS depressants, some patients remained too drowsy to 
allow for psychiatric assessment for a considerable period of time. These factors 
would all contribute to lengthening a patient’s stay in the ED. 
DOD patients may have also required resuscitation, supportive care, and the 
administration of an antidote if appropriate, but were relatively less frequently 
referred for a mental health assessment. As the SH group in this study excluded 
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medication overdose patients, and included those with suicidal thoughts and ideation 
as well as suicidal action, only a relatively small proportion would have required 
medical attention for an injury, such as suturing a laceration. However, the majority 
of SH cases required a psychiatric assessment. It seems likely that those deemed to 
be at ongoing high suicide risk would have been admitted fairly promptly, while 
those not at high risk tended to be discharged fairly rapidly as the current legislation 
governing mental health treatment, the Victorian Mental Health Act 1986, specifies 
that patients should be attended to in the “least restrictive environment”. These 
treatment differences between groups may in part account for the shorter length of 
time between being seen and being discharged for both DOD and SH compared to 
MOD. 
For all three groups of interest, and for total ED presentations, the most common 
discharge destination from the ED was home (66-82%), followed by admission to 
hospital (7-25%). However, there were some group differences, with about a fifth of 
both MOD and SH cases being admitted, compared to less than a tenth of DOD 
patients. It was not clear from the data available what proportion of admissions were 
for medical versus psychiatric reasons, though it is likely that a number of patients in 
the SH group in particular would have been admitted for further psychiatric 
monitoring. 
The results of the present study differed somewhat from those of Taylor et al. (1998) 
who found overdose patients were more likely to be admitted than other patients. In 
that study, 47% of presentations for a single overdose and 32% of recurrent 
overdoses were admitted to a general ward or intensive care (compared to 35% of 
general patients). A further 7-8% of overdose patients were admitted to the 
psychiatric ward. While not tested for statistical significance, the MOD patients in 
the present study had a lower rate of admission than ED patients in general (22% 
compared to 25%). It is not clear why there appears to be a lower rate of admission 
in the present study, but as this seems to apply to all types of presentation, not just 
medication overdose, it may be due to different practices or bed availability between 
locations, or changes in these factors since the previous study was conducted. 
It is significant to note that 7-9% of the three comparison groups and 6% of ED 
patients overall left at their own risk and without being formally discharged; a 
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number of whom had not been seen by a member of the treating staff. It is not 
possible to determine how long such patients waited prior to deciding to leave, what 
motivated them to leave without being treated, and what psychiatric and medical risk 
they were at when they left. These questions could be the focus of future studies. 
Information available on PAS regarding alcohol involvement, the need for a 
psychiatric or social work assessment, security issues, and custodial status point to 
the complexity of some patient presentations. As indicated in the results section, data 
concerning these factors are a minimum estimate only, as it was not compulsory to 
complete the relevant fields. It has previously been found that about a third of 
medication overdoses involve concurrent alcohol use (Lo et al., 2003), somewhat 
higher than the one quarter of MOD cases according to the PAS audit. The likelihood 
of the latter figure being an underestimate was reinforced by patient interviews; just 
over half the interview participants indicated alcohol played a role in the lead up to 
their overdose on medications. The discrepancy is most likely because the PAS data 
was largely based on rapid triage assessment, which may have overlooked some 
details of presentation that later become apparent during the treatment process, and 
during an in-depth interview. MOD cases appeared more likely to involve alcohol 
compared to either SH or DOD, but once again, the likely inaccuracy of the data 
limits the conclusions that can be drawn about this. 
A mental health or social work assessment is currently recommended by some as an 
integral part of thorough ED care for people at-risk of self-harm or self-poisoning 
(Hawton, 2000; Hickey et al., 2001; Whyte et al., 1997). In this study, such 
assessment was recorded as having been conducted for over 60% of MOD cases and 
over 80% of SH cases (DOD cases are discussed below). Further, the patient 
interview data revealed that two-thirds of that sub-sample had been given a mental 
health or social work assessment. Among that group there were instances where an 
assessment was deemed unnecessary (for example the overdose was accidental, or 
the person had an imminent appointment with their psychiatrist). Therefore, while it 
appears that the rate of assessment was reasonably high for both MOD and SH cases, 
there is room for further improvement. It would be of interest to further investigate 
the small proportion of cases for which there was no record on PAS of an assessment 
having been done. It is likely that some of these cases were in fact assessed, but the 
information was not recorded on PAS (although it may have been recorded on the 
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limited access information system used by the Psych Triage staff, which the 
researcher did not have permission to view). 
DOD cases had a relatively low rate of mental health or social work assessment (at 
least 14%). It not clear whether this is because DOD cases were seen by staff as less 
likely to require such intervention and were therefore not offered it, whether such 
offers were generally refused, or whether other services were regarded as more 
appropriate for this patient group. At the time the data were collected, the Alert 
Team included a specialist alcohol and drug worker, although the position was 
relatively new at the time. A greater proportion of DOD cases may be referred for 
assessment as other ED staff members become more familiar with the alcohol and 
drug expertise available. 
A Code Grey or Code Black may be called for the protection of the patient, staff, and 
other people in the ED. The group with the highest rate of such codes being called or 
warned was SH (12%). This probably reflects the duty of care owed by the hospital 
towards patients deemed to be at-risk of self-harm to protect them from further 
suicidal behaviour. Observation of ED operations revealed that very few patients 
were physically restrained while in the department, but in some cases a notation was 
placed on the PAS record of patients at high risk of self-harm to alert staff to 
intercede if the person tried to leave before formal discharge. 
It is not clear from the results of this study whether the proportion of patients in the 
three groups in police custody or from prison (1.2-2.7%) was high relative to other 
hospitals. However, this seems likely given that one of the main hospital buildings at 
St Vincent’s was constructed with a secure ward to provide acute inpatient facilities 
for Victoria’s prison system. 
5.2.2 Interview sub-sample 
The circumstances surrounding recruitment precluded the inclusion of a 
representative sample of medication overdose patients. The sample was necessarily 
limited to those deemed to be capable of providing informed consent by medical and 
psychiatric staff, and was further limited by the patient’s own interest in participating 
in a voluntary interview about a potentially distressing personal event. Nonetheless, 
the interviews provide a detailed first hand account of the experience of medication 
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overdose among a diverse group of individuals. The information obtained from 
patients regarding their background, physical and mental health, previous experience 
of overdose and self-harm, recent significant life events, and social supports was not 
contained within PAS. The interview data therefore represent an important additional 
means of understanding the characteristics and experiences of medication overdose 
survivors. 
Demographic characteristics 
The ratio of males to females in the interview sample was somewhat higher than 
would be expected from either the literature or the information from the PAS audit. It 
is not clear why more males participated than females. It may be that more males 
were deemed suitable for interview by staff than females, and were therefore over-
represented in the number referred to the study, or that males were more likely to 
agree to take part when approached to participate. 
As a whole the group were reasonably well educated, with over 80% having at least 
a Year 10 level of education, and 58% having completed Year 12. Almost a third had 
university qualifications. However, it is not clear whether the education levels of the 
interview sample would hold true for all medication overdose cases, or whether there 
was a self-selection bias operating. Of all the demographic characteristics 
investigated, employment was the area in which impaired functioning was most 
apparent, with about two-thirds of the group not currently in paid work. A substantial 
number of these were on a disability pension, generally as a consequence of their 
mental and emotional problems, rather than physical disabilities. It may of course be 
that patients not currently in work were more likely to have the time available to 
participate in the interview and that a representative sample of medication overdose 
patients would show less work-related impairment. However, even among those who 
were employed, most reported that problems at work were a significant source of 
stress. These findings regarding unemployment and job-related stress are consistent 
with the literature relating to risk factors for self-harm (Australian Institute for 
Suicide Research and Prevention, 2003; Pirkis et al., 2000; R. Taylor et al., 2004). 
Participants on the whole reported stable living circumstances, although the 16% in 
marginal living conditions was higher than what would be expected among the 
general community. This may be a reflection of, as well as a contributor to, the 
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psychiatric and social difficulties reported by many of the participants. Similarly, the 
fact that four out of the eight parents in the sample did not have custody of their 
children could be regarded as both a consequence and a cause of the mental health 
issues experienced by some individuals. 
Health 
The literature identifies physical illness and disability to be risk factors for 
suicidality (Pirkis et al., 2000; Stenager & Stenager, 2000; M. Williams, 1997). The 
present study found that almost all participants identified themselves as having 
current health problems, with an average of two per person. While it was not possible 
to assess the contribution of each and every physical health complaint to the 
subsequent medication overdose, it was clear from the patient narratives that many 
participants were aware of an ongoing relationship between their physical and mental 
health, with fluctuating symptoms in one being related to changes in the other. From 
patient descriptions, it appeared that cardiovascular, dermatological, and digestion 
related symptoms were particularly sensitive indicators of mental health. Exploring 
the link between current physical and emotional states may be a fruitful area for 
those working with people at-risk of medication overdose or other forms of self-
harm, and the use of such symptom awareness as an early warning system of 
deteriorating mental health should be further explored. 
Most participants described complex and longstanding psychiatric problems in both 
themselves and among family members. All but one person said they currently or 
previously had experienced a psychiatric problem, with the vast majority self-
reporting multiple diagnostic categories. The high prevalence of mood disorders, 
anxiety, and problematic substance use was entirely consistent with previous 
evidence regarding psychiatric diagnoses among medication overdose survivors and 
people at-risk of self-harm, as was the high prevalence of co-morbidity (Aghanwa, 
2001; Beautrais et al., 1996; Carter et al., 2003; Goldney, 2004; Hagedorn & Omar, 
2002; Haw et al., 2001; Kingsbury et al., 1999; Lifshitz & Gavrilov, 2002; Lo et al., 
2003; Lonnqvist, 2000; Matthews & Fava, 2000; Murphy, 2000; Nock & Kessler, 
2006; Pirkis et al., 2000; Rossow & Lauritzen, 2001; Whyte et al., 1997). 
In general, participants indicated that their mental health problems were of long-
standing duration. It was striking to note that many had lived with such problems 
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from adolescence or earlier, although diagnosis and treatment may not have occurred 
until some years later. The finding that mental health problems first emerged in 
adolescence was consistent with previous research which found that initial episodes 
of depression most commonly occur from 15-19 years of age (Hazell, 2004). The 
long delay between symptom onset and diagnosis typical of many participants in the 
present study was true even though similar problems were also evident among 
parents and other first degree relatives of participants, suggesting that a family 
history of psychiatric illness did not necessarily contribute to early detection. It is 
possible that early exposure to the psychiatric problems of other family members 
normalised the experience of psychological distress for many, making diagnosis and 
help-seeking less rather than more likely. The role of family history in the emergence 
and detection of mental health problems is an important area for future research. 
Specifically, earlier detection and management of mental health problems may be 
important for the prevention of medication overdose, to help reduce the cumulative 
effects of such illness on the social and emotional development of at-risk individuals. 
Many participants had experienced ineffective treatment of their psychiatric 
disorders, although it was not clear to what extent this was due to inappropriate 
treatment, low levels of compliance with suggested treatments, or the condition not 
responding to conventionally available treatments. For depression and anxiety, the 
most common treatments were medication and/or counselling. Antidepressants and 
benzodiazepines appeared to be the most commonly prescribed medications for these 
conditions, although the patient narratives raised some questions about the efficacy 
and appropriateness of their application. It seemed than many participants had 
previously tried a number of antidepressant medications without experiencing 
significant and sustained improvement in their mood. Similarly, many participants 
reported taking various combinations of benzodiazepines over the years but were still 
experiencing functional impairment due to their feelings of anxiety and depression at 
the time of the overdose. Over half the participants had sought treatment for alcohol 
or drug use (approximately a third of these had tried pharmacotherapy for heroin 
dependence), with mixed results. 
The extensive use of long-term benzodiazepine treatment to manage anxiety-related 
symptoms in this group was a matter of concern. Australian guidelines available for 
over 15 years specifically caution against prolonged use of benzodiazepines for more 
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than 2-4 weeks, even at a normal therapeutic doses because of the high risk of 
inducing dependence, and the decline in effectiveness with extended use (National 
Health and Medical Research Council, 1991). While some participants were aware of 
this and indicated their prescribing doctor was actively trying to assist them in 
reducing their benzodiazepine intake, a greater proportion of those being prescribed 
benzodiazepines were unaware of their side-effects. The question remains as to 
whether the doctors of participants in this study and the medical profession more 
generally are also unaware of current prescribing guidelines, the risks associated 
with extended benzodiazepine use, appropriate gradual withdrawal techniques, and 
other alternative forms of treatment for anxiety, depression, and insomnia. Although 
there were a number of participants with a history of substance use problems, none 
indicated their current use of benzodiazepines was primarily to assist in either 
alcohol or heroin withdrawal (another common application for these medications), 
therefore the high level of use cannot be attributed to this. 
Counselling for various mental health problems also appeared to be of variable 
assistance to the interview participants. Factors that appeared to reduce the 
effectiveness of counselling included both internal and external barriers (for 
example, not wanting to discuss problems, changes in counselling personnel). 
Overall, participants did not strongly endorse counselling as having been particularly 
helpful in overcoming their problems with depression, anxiety, and substance use, 
although as participants were interviewed shortly after a medication overdose it is 
possible that the unhelpful elements of the process may have been more readily 
recalled than the helpful ones. Factors identified by participants as being associated 
with positive counselling experiences included liking the counsellor, and in a small 
number of cases, learning specific techniques to assist them in coping with their 
difficulties such as cognitive restructuring. The importance of a good therapeutic 
alliance is widely accepted in the helping professions, but that alone may not be 
sufficient to bring about therapeutic benefit. The use of more structured, evidenced-
based psychological strategies with groups at-risk of medication overdose, other 
forms of self-harm, and depression more generally has been well canvassed in the 
literature (Guthrie et al., 2001; Hawton et al., 1999; Heard, 2000; McKenzie et al., 
2004), and should be more widely available to at-risk individuals than the data 
available from this study suggest. 
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The high rate (at least 80%) of past or current problematic substance use in the 
interview sample was of particular interest, as was the finding that approximately 
half were substance dependent (where this was able to be established). The episodic 
pattern of use in response to stress described by many suggests a maladaptive coping 
strategy in some instances, though it is also possible that in some cases substance 
dependence caused stress, rather than being used as a solution to it. At least a third of 
the sample had ever injected illicit drugs, five currently. It was not anticipated that 
there would be such a substantial proportion of injecting drug users among the 
sample, and it is not clear whether this would be true of medication overdose patients 
in general, or whether the finding was specific to this sample. If the relationship were 
to hold true across a larger sample, it may indicate that injecting drug users are at 
elevated risk for medication overdose, as well as illicit drug overdose, and that 
treatment programs aimed at this population should address mental health issues 
generally, and overdose risk in particular (whether from illicit drugs, medications, or 
a combination of both). 
About a quarter of the interview sample indicated they currently or had previously 
suffered from an eating disorder; a somewhat higher rate than the 11% found by Haw 
et al. (2001). However, that study could be expected to yield a more conservative 
estimate as it measured symptomatology at the time of interview via a standardised 
diagnostic instrument, rather than self-reported lifetime experience of various 
psychiatric disorders used in this study. Many interview participants drew a link 
between their eating and/or purging habits, mood-related symptoms, and desire to 
self-harm (or at least desire not to self-nurture). As such, eating disorders in this 
sample can be seen as part of a constellation of behaviours ranging from neglecting 
one’s own health through to outright self-harm, both impacting on, and being 
impacted by the level of depression experienced by the individual.  
Only three (10%) of the participants in the present study indicated they had a 
psychotic illness, which was low compared to the other psychiatric conditions. This 
is comparable to the rate of 5% reported in Haw et al. (2001), although that study 
involved more stringent assessment of psychiatric symptomatology using 
standardised diagnostic criteria, while the present study employed self-report. A 
further seven participants in the present study said they had experienced psychoses 
as a consequence of drug intoxication or withdrawal. An unknown number of 
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medication overdose patients presenting to the ED were excluded from the study on 
the basis that their active psychotic state prevented them from being able to give 
informed consent. Therefore it is likely that the interview data collected do not 
adequately address the experience of overdosing on medications as a direct 
consequence of a psychotic episode (for example, obeying an auditory hallucination 
to overdose). A sensitively designed study could usefully address the experience of 
suicidal impulses and commands among psychotic patients provided the issues of 
informed consent were adequately addressed (for example, by retrospective report 
once the psychotic episode was over, or by interviewing significant others). 
Previous history of overdose and self-harm 
Previous estimates of repeated overdose have been limited by the fact that they have 
generally only counted repeated presentations to the same hospital (or hospitals 
within the same region) in a given time frame, and cannot capture the lifetime 
prevalence of repetition. A greater proportion (2/3) of the interview participants in 
this study acknowledged at least one previous deliberate overdose than would be 
predicted on the basis of earlier research (e.g. (Carter et al., 1999; D. Taylor et al., 
1998)), or from the PAS data discussed above. While studies based on hospital data 
collected for a limited period of time may underestimate the true rate of repetition, it 
is also unclear to what extent people who had overdosed multiple times self-selected 
into the present study, resulting in an overestimate of the rate of recurrence. The 
finding that a third of the interview participants had previously experienced an illicit 
drug overdose is perhaps unsurprising, given the substantial proportion of 
participants with a history of problematic substance use, as discussed above. 
About half of those participants able to provide information on whether or not they 
had any past episodes of self-harm indicated they had previously tried to kill 
themselves. As the proportion of participants who had previously overdosed on 
medication exceeded the proportion reporting a prior suicide attempt, it appeared that 
many of the overdoses described above, while deliberate, were not taken with the 
intention of committing suicide. However, medication overdose was still the main 
method chosen for previous attempts, with other methods relatively infrequently 
used. While the entire participant group can be regarded as at-risk, those reporting 
multiple earlier suicide attempts via medication overdose may be at particular risk. 
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Repeated presentations for medication overdose with increasing severity is a 
recognised risk factor for fatal outcome (Carter, Reith et al., 2005b). 
As noted by Maris et al. (2000), suicidality encompasses a broad range of thought 
and action, and therefore includes self-mutilation, even in the absence of a true wish 
to die. About half of the study participants interviewed acknowledged ever engaging 
in behaviour such as self-cutting and burning. This behaviour can be viewed as a 
strategy used to cope with stress. It did not necessarily appear to be the case that 
individuals progressed from such forms of self-harm onto more life-threatening 
behaviour such as a medication overdose. Rather, participants with a history of self-
harm, both with and without suicidal intent, reported moving in and out of different 
states characterised by fluctuating levels of suicidal ideation, rather than following a 
linear trajectory. 
Completed suicide has a very low base rate in the general community. Therefore to 
find four people in a relatively small group with at least one family member who had 
committed suicide, and another three with relatives who have made a serious suicide 
attempt, suggests that this group of medication overdose survivors had a greater level 
of exposure to suicide within their families of origin than the general population. 
This is consistent with the suicide literature which indicates such a family history is a 
significant risk factor for suicidal behaviour (Beautrais, 2000; Fergusson et al., 2000; 
Rossow & Lauritzen, 2001). The present study noted the presence or absence of such 
a family history, but did not explore the meaning of this history to participants in the 
experience of their own suicidality. Greater understanding of individual’s 
perceptions of suicides within their own family could help inform prevention and 
intervention strategies aimed to assist those also showing risk of suicide via 
medication overdose or other means. 
Recent significant life events 
Life events were measured in this study using the same instrument as employed by 
Donald et al. (2000) in their mental health survey of young people from the 
Queensland general population. In their sample, the average number of life events 
endorsed was four, while in this study the average number was seven, indicating the 
present sample of medication overdose patients had more life stressors than a general 
population sample. This difference is even more striking when one considers that in 
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the previous study, participants were asked about their lifetime experience of each of 
the events, while in this sample, the timeframe was confined to the past six months. 
Psychosocial stress is a well recognised risk factor for both depression and 
suicidality (Alchin & Tranby, 1995; Beautrais, 2000; Becker & Kleinman, 1991; 
Hawton & Catalan, 1987; Paykel, 2004), and it appears that the present sample was 
consistent with the literature in this regard. 
The direction of causality between life stress and mental illness is an interesting 
question. It makes intuitive sense that experience of stress may contribute to 
depression, or even self-harm. However, almost three-quarters of participants who 
completed the life-events checklist for this study said that their mental illness was 
itself a source of stress, and for many, the most important stressor in their life during 
the past six months. Therefore the experience of stress may equally be regarded as a 
consequence of poor mental health, as well as a cause. In addition to mental illness, 
the two other important sources of stress identified by this sample were disruption to 
key relationships, and work or study-related issues. The ability to cope in these areas 
(i.e. mental well-being, work/study, interpersonal relationships) can be regarded as 
central to being able to function effectively in the culture in which the participants 
live. These data suggest that the stress experienced in these areas by participants 
represented a significant challenge to their coping skills, and by extension, their 
ability to enjoy life. 
Social support 
In general, the participants in this study identified few reliable sources of social 
support. Almost without exception, the medication overdose patients interviewed did 
not see their families as supportive. Given the high rate of mental health problems in 
first degree relatives of participants discussed earlier, it is likely that the capacity of 
many families to give support was limited by their own difficulties. Similarly, among 
those participants with partners, these relationships were often regarded as a source 
of stress rather than a source of support. Where participants had friendships, these 
appeared to offer more emotional sustenance than either family members or partners, 
however, many people reported having few or no friendships, and therefore this 
cannot be relied upon as a source of support among people at-risk of overdose. 
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Being without meaningful sources of social support and feeling lonely increases the 
risk of suicidal thought and behaviour (Hassan, 1995). The findings of the present 
study highlight that simply counting the number of people in the lives of those at-risk 
of self-harm may be a poor indicator of the level of support a person has, as a 
number of participants experienced many of their closest interpersonal relationships 
to be deleterious rather than helpful. It is therefore important to consider the quality 
of relationships, as well as the quantity. It may in some cases be unrealistic to hope 
that a network of positive relationships will arise naturally, especially if the person 
has little experience of being in a supportive, healthy relationship with anyone. 
Therefore, community members without any source of social support, and who are 
at-risk of suicide or self-harm may benefit from formal helping structures designed to 
link them into social networks that can offer a sense of encouragement and 
companionship (for example, support groups).  
5.3 Objective 3 - Specific suicidal intent, suicidal ideation, 
and depression 
The advantage of including an interview component in a hospital-based study of 
medication overdose was that it allowed an exploration of patient perspectives on the 
overdose not possible through examination of ED database information alone. In 
particular, the interviews allowed a sub-sample of the relevant patient group to 
provide information regarding their level of depression and suicidal ideation at the 
time of the overdose, and to discuss their intentions in taking an overdose. 
5.3.1 Assessment of suicidality and depression, and participant 
narratives about the overdose 
This study found a wide distribution of scores on the scaled measures used to assess 
depression, suicidal ideation, wish to die, and deliberateness of overdose. The broad 
range of scores suggest a highly heterogeneous group, even though the study 
included only a limited sample of patients who had all attended an ED following a 
medication overdose, and who therefore might be expected to show a more 
standardised profile. These findings suggest that no assumptions can be made about 
the severity of either depression or suicidal ideation in people who have recently had 
a medication overdose and that these should be routinely assessed as part of 
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psychiatric care within the ED, as should the intention of the overdose, and whether 
it was accidental or deliberate. It does appear however, that these four factors are 
correlated, with a high score on any one of these measures likely to be associated 
with high scores on each of the others. 
The strongest association found was between the BSS and the Likert-scale 
concerning the strength of the person’s wish to die at the time of the overdose. While 
the former obviously provides far more specific information about the suicidal 
thinking and behaviour of an individual, and is therefore a superior instrument to use 
in a formal assessment or for treatment planning, simply asking someone to indicate 
on a five point scale the strength of their wish to die at the time they self-harmed 
could be used as a rough indicator of suicidal intent in a situation where thorough 
assessment is not possible. On average, participants rated the deliberateness of the 
overdose more highly than the strength of their wish to die, suggesting that other 
factors besides suicidal intent contribute to the decision to overdose. 
As would be expected given the correlation found in this study between measures of 
depressive symptomatology and suicidal ideation, most participants could be 
classified as either high scorers on both measures, or low scorers on both measures. 
On the whole narratives were consistent with numerical scores on standardised 
measures, with those at the higher end describing far more severe depression and 
being more likely to regard death as a solution to their problems. This finding is 
perhaps unsurprising, as it makes sense that most people will give an account of 
events that confirms the responses selected on formal measure. As would be 
expected, those who had lower scores on the BDI-FastScreen and BSS generally also 
described milder symptoms of depression and identified reasons for the overdose 
other than wishing to die. However, this group were not free of all suicidal ideation, 
and therefore could still potentially benefit from interventions aimed at people at-risk 
of deliberate self-harm. 
A small number of participants presented the apparent anomaly of being classified as 
high on the BSS and low on the BDI-FastScreen. It was not clear why some people 
with signs of mild depression would apparently be suicidal, although this study 
suggests psychiatric complexity, in particular psychotic symptomatology, may be a 
factor worthy of further consideration in any study of suicidality in the absence of 
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significant depression. Specific features of psychotic disorders, such as delusional 
thinking, could drive suicidal behaviour, rather than the sense of hopelessness and 
constricted pattern of thinking regarded as typical of depression. As mentioned 
earlier, any such study of medication overdose or deliberate self-harm would need to 
be specifically designed to take into account issues such as capacity to consent. 
5.3.2 Characteristics associated with high levels of depression and 
suicidal ideation 
The current study design precluded statistical analysis of the ability of various 
participant characteristics to predict scores on the BSS and BDI-FastScreen. 
However, it can tentatively be concluded that certain factors appeared to have a 
relationship with high scores on BSS and BDI-FastScreen in the interview sample. 
These factors included; wishing to die, a history of suicide attempts or self-harm, life 
problems, mental health problems, older age, and being female. The identified 
factors were consistent with the literature regarding depression and suicidality. 
However, it is still not clear how these factors relate to one another in their 
association with depression and suicidality. Future research involving a large 
representative sample could examine the interaction effects between these variables 
in cases of medication overdose or other forms of deliberate self-harm. An 
understanding of the primacy of the risk factors in their contribution to suicidal 
thought and behaviour would have significant implications for the design of 
intervention and prevention efforts. 
5.3.3 Overdose process 
This study identified three elements to the overdose process; precipitating events, 
feeling states, and desired outcomes. Events of particular significance in this study 
included being troubled by unpleasant memories, interpersonal conflict (with partner, 
family, or at work), alcohol and drug use, and being without adequate resources 
(unemployed, homeless, without emotional support). An interesting finding was that 
memories played such an important role in the overdose process for many. The fact 
that an emotionally charged memory could significantly contribute to the decision to 
self-harm, even in the absence of any other precipitating event, suggests that the 
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connection between unhappy ruminations and subsequent self-harming actions could 
be a useful target for psychological therapies for people at suicidal risk. 
The three elements of the overdose process identified in this study have much in 
common with Beck’s cognitive-behavioural orientation to suicide (G. Brown et al., 
2006). Activating events were clearly identified, as were the participants’ emotional 
responses and behavioural consequences. What did not emerge strongly from 
participants’ narratives was a conscious awareness of a cognitive element to the 
process which, according to cognitive-behavioural theory, mediates the relationship 
between events and emotional responses. If the premise that cognitions influence 
feelings and behaviour is accepted to be true, the frequent absence of a well-
articulated “thinking” component from participant narratives may be highly relevant. 
Even where participants engaged in “unhappy ruminations” as described above, few 
seemed to regard this potential precipitant of suicidality as being within their control. 
Therapeutically, encouraging greater awareness of the contribution of thought 
processes to emotional responses and providing coaching in strategies for 
counteracting negative thinking to people at risk of medication overdose may be of 
assistance in interrupting the overdose process. 
As would be expected, negative feelings such as anxiety, depression, and 
unworthiness were commonly articulated by the interview participants. These 
internally focussed emotions were experienced by many, while some were more 
likely to regard the source of their negative feelings to be outside themselves (for 
example, being frustrated, angered, or undervalued by others). This distinction may 
be useful in working with a person at-risk of medication overdose; that is, the 
approach taken may be guided by whether the person perceives their emotions as 
arising internally (within the self) or externally (within the relationship). People at-
risk of medication overdose may also be particularly susceptible to physical states 
such as exhaustion and intoxication. The importance of maintaining good physical 
health and trying to get adequate sleep should be emphasised as part of any 
prevention efforts. Use of alcohol and other drugs should also be kept to a minimum, 
both because they can have a depressive effect, making already negative emotions 
worse, and also because of their potential disinhibitory effect. 
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Although organised differently, the precipitating events and feeling states identified 
in this study are also somewhat similar to the psychological needs identified by 
Schneidman (1996), including (briefly) love, control, avoiding assaults to one’s self-
image, maintaining key relationships, and dominance/counteraction. Schneidman 
argues that if those needs are not adequately met, or are distorted, such significant 
psychological pain may be caused that suicidal thinking is stimulated. The 
participants’ narratives in general, and stories regarding the events and feelings 
associated with the overdose in particular, suggest these needs were frequently 
unmet in the lives of those interviewed. 
Regarding the desired outcomes of the overdose, relatively few participants included 
in this study reported an intention to die at the time of taking the medication. 
Participants were more commonly ambivalent about what they hoped would happen 
as a consequence of their actions. The predominant theme was that of escape (from 
problems, negative emotions, and so on), although many also expressed 
contradictory wishes such as to die, and simultaneously to not die. The finding that 
most instances of medication overdose were associated with a desire to escape is 
entirely consistent with the theoretical perspectives on suicide and suicidal ideation 
offered by authors such as Schneidman (1996), Williams (1997), and Maris (2000), 
who all suggest that one of the primary drives of suicidal behaviour is to escape. The 
finding that relatively few participants indicated that they overdosed in order to 
obtain help, receive attention, or communicate their distress to significant others is 
also consistent with previous work on suicidality which suggest such aims are 
generally only secondary to the primary goal of escape (J. Williams & Pollock, 2000; 
M. Williams, 1997). A small proportion of the participants in this study indicated 
their overdose had no suicidal component at all, and in such instances the 
motivations included wanting to become intoxicated (which could also be regarded 
as form of escape) or to sleep. 
The description of the overdose process developed from participant narratives can be 
regarded as a preliminary schema for the interaction between precipitating events, 
feeling states, and intended outcomes. A future study could investigate this model 
further, both to determine whether it holds true for other forms of self-harm, and also 
to investigate more closely how the three elements relate to each other. For example, 
are certain types of events and/or emotional states more likely to be associated with 
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some types of intended outcome than others? While some effort was made to explore 
such relationships in the present study, a study specifically focussed on the overdose 
or self-harm process could collect more detailed and targeted information, allowing 
the description to be further refined. 
5.4 Objective 4 - Medications implicated in medication 
misuse or overdose 
The information obtained from PAS allowed for a complete audit of all medication 
types involved in medication overdose and misuse presentations to the ED over a 12-
month period, while the interview material provided additional information on how 
the medications were actually consumed, and how, where, and why they were 
acquired. 
5.4.1 Medications implicated in overdose 
The data obtained in this study were consistent with previous findings regarding the 
most commonly implicated medications in overdose; that is, benzodiazepines, 
antidepressants, and analgesics were the main classes of medications involved (Baca-
Garcia et al., 2002; N. Buckley, Whyte et al., 1995b; Cvetkovski et al., 2002; 
Neeleman & Wessely, 1997; Routley et al., 1999; Schwarz et al., 2004; Townsend et 
al., 2001). The finding that psychotropic medications accounted for the greatest 
proportion (75%) of cases is not surprising, as the issues of psychiatric illness and 
overdose are inextricably linked; those with mental health problems are clearly at 
greater risk of overdose than those without. In addition, many psychotropic 
medications act as a sedative which, as can be seen from the discussion above 
regarding reasons for overdosing, is an effect many people overdosing may 
specifically be looking for (i.e. the wish to escape consciousness). 
The finding that two-thirds of cases in this study involved only one medication type 
was consistent with the non-fatal medication overdose cases investigated by 
Neeleman & Wessely (1997), but was greater than the proportion of single 
medication overdoses (30%) noted by Lo et al. (2003). The mean number of different 
medications consumed in this study (1.6, range 1-7) was also similar to previous 
studies (Neeleman & Wessely, 1997; Townsend et al., 2001; Vaiva et al., 2006). As 
it is thought that taking a greater number of medications in an overdose is indicative 
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of a higher level of suicidal intent (Lifshitz & Gavrilov, 2002), it may be that the 
wish to die was not very strong in many of the cases included in the audit, although 
this was of course only assessed in the interview sub-sample. The quantity of 
medications taken may have also be an important indicator of suicidal intent; 
however, it was not possible in most cases included in the PAS audit to assess the 
actual volume of medications taken, or other relevant details, such as individual 
tolerance levels. Current computerised patient information systems most likely do 
not contain enough information to systematically study the quantity of medications 
consumed in all relevant presentations, or to assess the associated toxicity. However, 
these questions may be of interest to future research. 
The finding that benzodiazepines, antidepressants, and analgesics were commonly 
used by patients presenting with medication overdose was also consistent with the 
prescription data (and the recommendations of medical practitioners in the case of 
OTC analgesics), outlined in the literature review. In particular, diazepam and 
temazepam are two of the most commonly prescribed benzodiazepines and were the 
most frequently implicated in medication overdose in this study. However, while 
diazepam accounted for approximately a quarter of benzodiazepine prescriptions in 
Victoria in 2004 (Drugs and Crime Prevention Committee, 2006), it was over-
represented among medication overdoses in this study, being implicated in almost 
half the cases. Also of interest was the finding that the relatively short-acting 
benzodiazepine alprazolam was used in approximately a quarter of benzodiazepine 
overdoses, a rate higher than the prescription data reviewed would suggest (7%) 
(Drugs and Crime Prevention Committee, 2006). The extent of use and misuse of 
these particular medications may therefore warrant further attention. The most 
commonly prescribed or used antidepressants and analgesics (SSRIs and paracetamol 
respectively) were both implicated in the greatest number of overdoses within their 
class of medications.  
5.4.2 Patient descriptions of the consumption process 
The findings of the participant interviews regarding the type and number of 
medications consumed mirrored those of the PAS audit. However, the interviews 
provided additional information regarding the manner in which medications were 
consumed in an overdose. 
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Alcohol or illicit drug intoxication appeared to play a role in the medication overdose 
of about half of those interviewed. Excessive alcohol use in particular seemed to be 
key part of the spiral towards overdose, perhaps through reduced inhibition, and the 
depressant effect of this substance. The majority of those who had drunk alcohol in 
the 24 hours prior to the overdose consumed very large quantities that can be 
assumed to have severely impaired the person’s judgement. The rate of alcohol use 
within the interview sample was higher than either that estimated by the PAS audit 
(25%), or the third of OTC overdose patients found to have consumed alcohol in an 
earlier study employing a chart review method (Lo et al., 2003). It is possible 
therefore that the individual patient interview method utilised in this study uncovered 
a higher rate of alcohol use than studies relying on hospital data alone. 
As intoxication is a recognised risk factor for attempted and completed suicide 
(Dhossche, 2003; Hawton & Catalan, 1987; Powell et al., 2001; Rossow et al., 1999), 
persons at-risk of medication overdose and other forms of self-harm may need 
assistance in identifying and implementing other coping strategies besides alcohol 
and drug use. Doctors prescribing medications to people with psychiatric illness also 
need to be aware that binge drinking may increase the risk of overdose, and to 
modify their prescribing practices and general care accordingly. For example, by 
limiting the number of repeat prescriptions provided during those periods when a 
person is engaging in substance use, or encouraging patients to develop other non-
harmful crisis plans, such as contacting a support service. 
While impaired judgement associated with intoxication was a relevant feature of 
approximately half the overdoses closely examined in this study, the remainder made 
the decision to overdose when sober. Examining the differences between cases of 
intoxicated versus non-intoxicated medication overdose was beyond the scope of this 
study, however, it would be useful to know whether various patient characteristics, 
such as level of suicidal ideation or psychiatric diagnoses have any predictive 
capacity in this regard.  
The interview data revealed that in most cases the medications involved in overdose 
were consumed within a fairly short space of time; generally all at once for smaller 
quantities, or in several batches over two or three hours where larger quantities were 
involved. Therefore in contrast to the extended period of alcohol use which may have 
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preceded the overdose in many cases, the actual overdose event itself appears to have 
been quite short. 
5.4.3 Medication acquisition 
The data about why medications were initially obtained, their source, and participant 
understandings of their intended uses give rise to several possibilities for reducing 
the risk of medication overdose. Significantly, the acquisition of medications with 
the specific intent of using them in an overdose was rare among this sample, with 
people primarily overdosing on medications they had previously acquired for 
therapeutic purposes. This finding suggests that prevention efforts could usefully 
focus on reducing the risk associated with medications people have in their 
possession as a matter of course. 
A number of interviewees overdosed on medications prescribed some time 
previously, which they had ceased to use but still kept in their possession (although 
not with the intention of subsequently using them in an overdose). Encouraging the 
community in general, and those at-risk of overdose in particular, to dispose of 
unused medications in a safe way may assist in reducing the ready availability of 
medications as a means of self-harm. Another way of reducing the risk potential 
would be for prescribing doctors to consider the quantities of medications they 
prescribe at a single time to those at-risk (for example, not providing repeat 
prescriptions to those with a previous history of overdose), and by routinely 
reviewing patient progress. This could include not only monitoring the mental health 
status and ongoing life stressors of vulnerable patients, but also their compliance 
with medication and other forms of treatment, storage of unused medications, and 
current alcohol and other drug use. At times of elevated risk it may be appropriate to 
consider dispensing only small amounts of medication every two or three days to 
prevent large quantities building up and to put in place additional supports such as 
counselling or arranging for an inpatient admission. Such strategies do have potential 
disadvantages, such as being perceived as punitive, controlling or patronising; 
however the evidence from this study clearly suggests that it is legitimately 
prescribed or acquired medications that account for the greatest amount of harm. 
While this study was not designed to address the appropriateness of the prescribing 
practices of participants’ doctors, there was some evidence to suggest that more 
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conservative dispensing of medications, particularly benzodiazepines, could assist in 
the prevention of overdose. The information provided by several of those 
interviewed suggested they may have been prescribed an excessive quantity of 
benzodiazepines over a lengthy period of time without any apparent improvement in 
their psychiatric condition, and with these same medications then being used as a 
means of self-harm. As discussed in relation to Objective 2 above there are clear 
guidelines for the prescribing of these medications which do not appear to have been 
followed in many instances. It is not clear whether this was due to a lack of 
awareness among prescribers (of the guidelines, the dependence-inducing potential 
of benzodiazepines, and treatment alternatives), or whether some doctors disagreed 
with the guidelines and therefore chose to disregard them. It is also possible that 
doctors are under pressure to prescribe these medications because they do in fact 
provide some immediate symptomatic relief (notwithstanding their long-term risks), 
or are unwittingly involved in their over-prescription by patients who engage in 
“doctor-shopping”, as was acknowledged by a small number of participants in the 
present study. These issues are all important areas for further investigation. 
5.5 Objective 5 - Individual experiences of the emergency 
medical system 
The research questions concerning typical pathways through care following a 
medication overdose, and patient experiences of, and satisfaction with their treatment 
were answered with reference to both the patient interviews and observational data. 
These are discussed in relation to the pre-existing evidence base. 
5.5.1 Treatment processes 
Treatment of medication overdose patients presenting to the ED generally followed a 
somewhat predictable route depending on the individual features of the case, such as 
medical seriousness, and ongoing suicidal risk. As recommended in the literature 
concerning emergency treatment of medication overdose and other forms of self-
harm (Hawton, 2000; Whyte et al., 1997), it appeared that St Vincent’s had a 
comprehensive treatment model in place that included both the requisite medical 
attention, and appropriately qualified staff available to conduct psychiatric 
assessment. As suggested elsewhere (Jones & Dargan, 2002), patients in general 
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received supportive care and observation, with more serious intervention such as 
decontamination or antidotes only being used where medically necessary. However, 
an area where treatment may be strengthened would be to ensure at least a brief 
psychiatric risk assessment is universal for medication overdose patients. As 
discussed earlier it was not absolutely clear from the PAS data what proportion of 
medication overdose cases were provided with a psychiatric assessment, although the 
Psych Triage service certainly was available and well-utilised. At the time the study 
was conducted there was no standardised follow-up or aftercare of medication 
overdose patients following discharge, though in many cases referral was made to 
external sources of support such as the patient’s GP, community-based psychiatric 
services, and alcohol and drug treatment. Previous authors have stressed the 
importance of ongoing support post discharge (Guthrie et al., 2003; Hawton, 2000; 
House, 2002; Kapur et al., 2004). 
5.5.2 Active help-seeking 
There were several indications from the data regarding patient experiences of 
emergency medical care that most of the patients interviewed experienced some 
hesitation about the desired outcomes of their self-harming behaviour. The majority 
of participants actively sought assistance on their own behalf, most by alerting 
someone else to their condition who then called an ambulance. Help was also sought 
fairly rapidly, generally within six hours of the overdose, suggesting many 
participants had decided by that time that they did want to recover from their self-
poisoning. Participants were frequently regretful about the overdose, and many 
readily acknowledged their relief at being alive. Taken together, these findings 
provide further support for the notion that suicidal or self-harming behaviour is often 
accompanied by ambivalent feelings, and is often prompted by a temporary sense of 
having run out of other options, rather than a fixed and unequivocal wish to die 
(Schneidman, 1996; J. Williams & Pollock, 2000; M. Williams, 1997). 
5.5.3 Staff-patient interactions 
Whyte et al. (1997) caution against treatment practices which are judgemental or 
punitive in responding to patients who have taken a medication overdose. 
Participants in this study were generally positive or neutral about their treatment 
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experience, suggesting that disrespectful or punishing treatment was rarely an issue 
in this setting. It is possible that this finding was influenced by selection and 
reporting biases, with those people who had a bad experience being less likely to 
volunteer for the study, or those who did participate feeling uncomfortable about 
criticising the care received. However, responses regarding this topic seemed to be as 
genuine as for other parts of the interview, the use of the more unpleasant 
interventions such as activated charcoal appeared to be confined to those cases where 
it was medically warranted, and observation of ED practices did not indicate any 
antagonism towards medication overdose patients among staff, all of which were 
consistent with a non-judgemental, non-punishing treatment environment. 
Participant experiences of being frightened or out of control while in the ED 
represented only a small minority of cases, but naturally gave rise to more explicit 
narratives than for the other cases. The intention in including these non-
representative narratives in the Results section was to highlight that while such 
unpleasant experiences are rare, they have a great impact on the patient. Therefore if 
it is known that a patient has required restraining while in the ED, part of the later 
psychiatric assessment could usefully include debriefing about why this was 
necessary. This would also provide an opportunity for the patient to have their 
experience acknowledged and understood, and should the patient want it, to have the 
treatment staff assist to fill in any gaps in the patient’s memory of the event. 
5.6 Objective 6 - The research experience 
This section utilised the researcher’s experience in conducting a research project into 
medication overdose within the ED to consider two questions; “What do these 
experiences suggest about the conduct of future research regarding mental health 
issues in the ED environment?”, and “What do these experiences suggest about the 
potential to introduce an ED-based brief intervention relevant to medication 
overdose and other forms of self-harm?” 
5.6.1 Implications for future research 
Upon reflection of the 12 months spent in the ED, a number of suggestions emerge 
that may assist in the planning of future ED-based research regarding the data 
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sources used, key relationships to be established, and recruitment strategies to be 
considered. 
Given that the ED is a challenging setting in which to undertake a study, and the 
particular sensitivities associated with interviewing an at-risk population such as 
those with mental health problems or who have self-harmed, it is undoubtedly worth 
minimising the amount of data that needs to be collected from individuals. In 
conducting such a study it is important to take the time to establish what secondary 
data sources may be available to answer some of the research questions posed. In this 
instance PAS was used, although other potential sources of information for future 
research could include de-identified paper-based records and possibly even the state-
wide psychiatric database, though of course such data sources are becoming 
increasingly (and rightly) difficult to access as a consequence of more stringent 
privacy legislation. Use of secondary data sources helps define the parameters of the 
research topic, and may assist in refining the specific research questions to be 
addressed via any client interviews. There is a wealth of data routinely collected in 
health care settings, not all of which are in a format immediately suitable for research 
purposes, but that when reviewed systematically can yield an enormous depth and 
breadth of information. Clinicians working in such settings may well have a sense of 
patterns in patient presentations from their own experiences (for example, which 
medications predominate in medication overdose cases); however, it is of great 
benefit to be able to support these impressions with comprehensive data analysis. 
Similarly, direct observation of the operation of the ED can contribute significantly 
to a researcher’s understanding of the processes associated with particular types of 
presentations, and also the likely impediments to undertaking research in an acute 
health care setting and/or with at-risk populations. Such knowledge can assist in the 
design of any subsequent primary data collection mechanisms. For example, what 
recruitment techniques might be appropriate, when and where could interviewing 
occur, and at what alternative locations, if any, could the study be situated. Another 
strategy (not employed in the development of this particular study but which could 
be useful for similar research in the future) would be to conduct a series of key 
informant interviews with various ED staff members, such as the director, Psych 
Triage, and senior medical and nursing personnel. While the researcher undertook 
several preliminary discussions with some key individuals prior to the 
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commencement of the project, a formalised process of interviewing would help 
solidify the researcher’s understanding of the most crucial issues to be considered 
before embarking on patient interviews, and also yield a valuable data source in its 
own right. In addition, this process could be useful in the establishment of 
relationships with relevant staff members who have a particular interest in the topic 
and who may be able to act as a liaison for the project. A snowballing approach 
could be adopted, with each person interviewed being asked “who else” would be 
useful to speak to, until all relevant personnel have had an opportunity to be heard. 
Such preliminary work is essential, not only in building a picture of the issue under 
study and potentially answering some of the research questions, but also in 
determining what interview method is likely to be the most suitable for the 
population of interest. On the basis of the experience gained while conducting this 
study, the researcher has formed the opinion that when studying a difficult to access, 
potentially at-risk population, it is crucial that the demands of participation be very 
carefully considered. If a large, representative sample of patients providing 
standardised information is believed to be required, the demands of the study on 
those patients should be kept to a minimum (for example a very brief interview or 
paper-based survey), for both pragmatic and ethical reasons. However, if detailed 
personal information is of particular interest, such as a personal account of events or 
psychosocial history, it may be better to adopt a qualitative research design involving 
a limited sample. A possible drawback of this approach is that such a method may 
selectively sample relatively “well” patients. However, in a population of people 
who have recently overdosed this could be considered a responsible bias, and does 
not necessarily detract from the relevance of the information obtained. Care would 
need to be taken to ensure that findings from a select sub-group were considered with 
caution in relation to other groups not adequately represented in the research. 
Finally, recruitment and interviewing in this setting with this specific population is 
difficult, time consuming, and involves many practical and ethical considerations. 
Therefore other recruitment options should also be thoroughly canvassed. This study 
was originally designed to include recruitment via the Metropolitan Ambulance 
Service, which would have allowed potential participants to make contact with the 
researcher several days after the overdose. The proposed recruitment method was 
passive in the sense that the researcher made no contact at all with the potential 
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participant; rather it was up to the individual to opt-in by contacting the researcher. 
In some ways this could be regarded as a less intrusive form of recruitment than 
relying solely on the ED. However, one of the ethics committees reviewing this 
proposal before the commencement of the project was concerned that all interviews 
should take place within a highly supported facility, and therefore restricted 
recruitment to within the ED only. It is of course unknowable whether this was a 
necessary precaution, and the researcher acknowledges that a duty of care exists for 
both the researcher and any ethics committee approving study protocols. All 
concerned want to minimise the risk of a hypothetical worst case scenario becoming 
reality. Ongoing research in this area must continue to grapple with the difficult 
question of how to best to extend our knowledge of depression, self-harm, and 
suicide in order to reduce their personal and social impact, while not exposing those 
most affected by them to any further risk. 
5.6.2 Implications for introducing an intervention 
One purpose of conducting this study was to investigate the possibility of 
introducing some form of intervention at the point of contact with the ED that may 
be of value to medication overdose patients in order to reduce the likelihood of 
future presentations of this type. Such programs have been introduced with some 
success for patients attending the ED with problematic alcohol and/or other drug use, 
on the basis that a time of crisis represents an excellent opportunity to intervene 
(Blow et al., 2006; Cherpitel, 2006; Crawford et al., 2004; Helmkamp et al., 2003). 
These programs have tended to involve the provision of information or brief 
counselling within the ED, or encouragement to attend external services. The 
experiences outlined above suggest that there may be limited potential to introduce 
an intervention designed to be delivered wholly within the ED due to both the 
intended purpose of the service, and the relative complexity of medication overdose 
presentations. However, this point of contact in the care system may be an especially 
significant opportunity for assessment and referral. 
As mentioned earlier, the ED is designed to respond to the acute medical and 
psychiatric needs of patients, and therefore provides a rapid response, rather than 
ongoing care. It is therefore questionable whether it would be appropriate to resource 
the ED to conduct ongoing therapeutic work of the type likely to be required to 
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address the often complex mental health and social needs of medication overdose 
patients. Given that the ED is only a brief point of contact, it lends itself more readily 
to the conduct of high quality psychiatric assessment and liaison work. Any 
additional resources provided to the ED could usefully be put to ensuring these 
functions are as comprehensive as possible. 
In order for assessment and liaison to be effective, however, it needs to be supported 
by community-based services that are able to follow through with the after care of 
the patient. There are several examples in the literature review of patients attending 
the ED for self-harm being enrolled for follow-up, rather than discharged home with 
no further care. It is contended here that while such interventions may potentially be 
useful to the patient, and represent good continuity of care, it may be more suitable 
for this type of intervention to be delivered by a community-based agency able to 
maintain an ongoing relationship with the patient at non-crisis times. The ED could 
undoubtedly play a significant role in referring medication overdose patients to such 
a service, but may not be best placed to actually deliver it. Nor would a system of 
this nature preclude the ED from developing a case management plan to guide the 
response to a particular patient with special needs (for example, a frequent presenter) 
to ensure consistency in their treatment. 
While it is argued here that it would be more suitable to locate any program of 
ongoing care and support elsewhere, the experience of care received whilst in the ED 
may still be pivotal. In addition to ensuring any assessment and referral process is 
both thorough and effective, patient perception of treatment is also crucial. For a 
vulnerable and possibly marginalised population, receiving respectful care may help 
alleviate some of the distress associated with the overdose event. From the 
participant narratives reported in relation to Objective 5, it appears that on the whole 
patients were satisfied with the treatment received. This climate of non-judgemental 
care should continue to be fostered; even among the small proportion of patients who 
behave disruptively while in the ED (maintaining a respectful style of interaction 
with the patient is unlikely to make matters worse and may make them better). 
Although it was not systematically enquired about, several participants 
spontaneously commented that they found the research experience to be a positive 
one, as they found it “good” to talk to someone about the event. The interaction itself 
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was not intended to be therapeutic, but these comments suggest that for some people 
simply being listened to can assist. While staff may have limited time to spend with 
each patient, ensuring whatever interaction does occur is positive may confer some 
therapeutic benefit in its own right, and may increase the likelihood of the patient 
taking up any referral options offered. 
5.7 Study limitations 
The design and scope of the study reported here imposed some restrictions on the 
wider applicability of the data. The data collection period extended for 12 months, 
which was sufficient to obtain a sample of several hundred patients from PAS, to 
recruit 31 medication overdose patients for interview, and to conduct an extended 
period of observation. However, a longer period of data collection, particularly of the 
computerised hospital records would allow for investigation of trends over time in 
attendances for medication overdose, illicit drug overdose, and self-harm which may 
reveal greater seasonal variation than the current study. Such prolonged data 
collection could also show changes in the pattern of attendances which may be 
related to external factors (for example, an increase or decrease in the prevalence of a 
particular type of medication following changes in prescribing practices). Similarly, 
extending data collection to include other hospitals in inner city Melbourne, or 
across the metropolitan area or state-wide, may uncover differences related to the 
geographic and demographic catchments of each setting. Furthermore, extended 
geographic and temporal coverage would allow for repeated presentations to be more 
accurately estimated, provided cases could be linked across sites. 
The current study was unusual in that it included comparator groups (illicit drug 
overdose, actual or potential self-harm by means other than overdose, and total 
presentations to the ED) against which to assess medication overdose presentations. 
However, comparisons were only made using the PAS data, with the interviews 
being restricted to medication overdose patients. There were some important 
elements of the interview data that were simply not available from PAS, such as 
recent life events, mental health history, and levels of social support. These factors 
may also be relevant to the presentations of the other groups. Future studies could 
include comparison groups to see to what extent these factors contribute to the ED 
presentations of other types of cases, as it is possible that significant problems in 
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these areas are not exclusive to medication overdose cases and that some of the 
circumstances identified here as preceding treatment-seeking behaviour have wider 
applicability. 
As already discussed in detail, the interview component of the present study was 
limited to 31 patients with both the capacity to consent, and an interest in 
participating in an extended interview about their experiences. There were a number 
of patients deemed by hospital staff to be inappropriate to interview, and an even 
greater number whose capacity to and interest in participating were unknowable, due 
to the limited resources available for recruitment. As it was, more than a third of 
those approached to participate agreed to take part, which is a reasonable response 
rate when the location of the study and the nature of the interview are considered. 
However, the sample included cannot be regarded as representative of all medication 
overdose cases, as there were likely to be some important biases in who was 
included. For example, those excluded by ED staff on the basis of high, ongoing 
suicide risk may have had a different profile on a number of dimensions from those 
who were included. Participants in this study also reported high levels of current 
and/or past alcohol and other drug use, and it is not clear whether this characteristic 
would be as evident among a representative sample. It may be that truly 
representative study designs are not appropriate when dealing with at-risk groups as 
caution will always need to prevail over such methodological imperatives. Were 
future studies to investigate those patients known to be excluded from this study, 
such as those without capacity to give informed consent, alternative research designs 
would need to be employed, for example by interviewing significant others such as 
friends, family and treatment providers, or delaying recruitment to such time as 
informed consent to participate is able to be obtained. 
There were specific instances in which the detail of data able to be collected was 
limited for reasons beyond the researcher’s control. For example, while information 
as to the type of medication involved was almost always recorded on PAS, the 
quantity was only noted in some instances. Therefore it was not possible in this study 
to accurately estimate the amounts of different medications taken. The patient 
interview data provided more information regarding quantity of medications, but the 
participants had highly variable recall of this even a few hours post overdose. 
Greater accuracy in estimating the amount taken may be possible by combining data 
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sources such as self-report, witness accounts, and blood testing (in cases where such 
information was available). Some of the information obtained from PAS, such as 
whether or not alcohol was implicated, was recorded in a free-text field, and can 
therefore only be taken to be a minimum estimate, as it is not known in how many 
cases relevant information was not recorded. Likewise, not all participants were able 
to complete every section of the interview due to factors such as inability to choose 
between response options provided, disinclination to discuss certain issues, and time 
constraints. The last of these issues led to the decision to shorten the interviews after 
the pilot phase (i.e. the first 15 interviews), which meant not all information 
collected from these interviews could be included. Nonetheless, the majority of the 
final 31 participants provided information for most of the survey questions included 
in the revised version, allowing group responses to be reported. 
Rather than use a standardised psychiatric diagnostic or screening measure, 
participants were asked to self-report current and past mental health problems. The 
rates of various psychiatric conditions reported may have therefore been influenced 
by factors such as participants’ recall, accurate knowledge of their condition, and 
willingness to disclose sensitive personal information. Self-report was considered 
sufficient in the present study, due to its focus on the phenomenon of medication 
overdose rather than prevalence of various psychiatric disorders, the use of the BDI-
FastScreen to measure depression symptom severity, and the already lengthy nature 
of the survey form. However, future research could benefit from objective 
verification of psychiatric conditions. Diagnoses of particular interest could include 
psychotic disorders (which may have been under-represented in the present study 
due to issues with informed consent), and personality disorders, which although 
previously shown to be associated with suicidal behaviour, were not reported by any 
participants. 
There were some potential sources of data that may inform understandings of 
medication overdose that were beyond the scope of this study. For example, various 
professionals involved in the care of medication overdose patients such as ambulance 
officers, ED doctors, nursing staff, Psych Triage and CATT members may have all 
had insights to offer about the management of these presentations had they been 
interviewed. While observational data contributed to knowledge of the role of each 
of these groups in patients’ pathway through care, there was no formal opportunity to 
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seek their opinion on the appropriateness of the treatment offered, or what alternative 
models of care should be considered. Other important personnel who could also be 
included in future studies would be doctors and pharmacists who have prescribed or 
dispensed medications to people who have subsequently overdosed. This would 
assist in determining whether current practices could be modified to reduce the 
likelihood of such outcomes. Finally, representatives of those agencies to which 
medication overdose patients are referred following discharge from hospital could 
also be interviewed to determine to what extent such services are utilised, and how 
these referral opportunities could be maximised. 
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number and severity of previous medication overdoses or other forms of self-harm, 
and levels of social support available. If differences do exist, these may have 
implications for treatment, suggesting that a differential response could be required. 
Psychiatric assessment and follow-up is acknowledged in the literature as an 
important element of care for medication overdose patients. This study revealed a 
reasonably high level of assessment being conducted within the ED; however, such 
assessments were not universal. The reasons for this warrant further investigation. 
For example, was the lack of psychiatric assessment in some cases due to patient 
refusal to participate, the treating doctor deciding that assessment was not required, 
or Psych Triage being too busy to respond immediately and the patient leaving prior 
to being seen? The data suggest that ongoing suicidal risk was highly variable among 
medication overdose patients, and should therefore always be carefully assessed, 
rather than assumed. 
Also with regard to the provision of psychiatric services, there is a state-wide 
database in existence used by mental health clinicians based in the ED. This 
represents a significant untapped data source about the movement of patients 
between hospitals, changes in their patterns of attendance, and usual pathways 
through care. The database in question is strictly limited in terms of accessibility to 
those directly concerned with the patients’ psychiatric care (i.e. even other non-
psychiatric ED treatment staff do not have access). However a researcher with the 
appropriate permission, and taking into account privacy concerns, could extract 
valuable information about patterns of service utilisation among medication overdose 
patients. This could be particularly powerful if cross-linked with PAS data, and 
would allow for the relevant cases to be examined by psychiatric diagnosis, thereby 
overcoming a potential limitation of the current study which used unconfirmed self-
reported mental health problems. Another possible use of the psychiatric database 
would be to gather preliminary data for further research examining the relationship 
between psychosis and ED presentations for actual or potential self-harm (by 
medication overdose or other means), the nature of which was only partially captured 
by the present research. 
Medication overdose patients included in this study were most commonly discharged 
home. An interesting extension study would be to look at what follow-up, if any, is 
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offered to the majority of patients, and to what extent this is engaged with. In 
instances where follow-up falls through it would be of interest to know whether this 
is due to systemic problems (for example, a patient wants assistance, but the support 
system fails to deliver), individual issues (the required services are readily available, 
but are rejected by the patient), or a combination of both. Such an extension study 
could also include investigation of the clinical management of repeated presentations 
for medication overdose to determine the most effective responses for reducing their 
occurrence and severity. 
The main life problems identified by patients in this study were mental health issues 
(including delayed diagnosis, poor response to treatment, and problematic substance 
use), work-related issues such as unemployment or job-related stress, and disruptions 
to key relationships. These findings suggest that intervention and prevention efforts 
which specifically target these problem areas may be of benefit to at-risk individuals. 
For example, earlier detection of psychiatric problems in conjunction with better 
treatment monitoring may reduce some of the ongoing difficulties patients 
experience in relation to their mental health, and ameliorate the accumulation of life 
disappointments and chronic stress which appeared to contribute to the current 
circumstances of so many study participants. Again, in this study these issues were 
only canvassed among the medication overdose group via semi-structured interview. 
Future research could consider also including comparison groups (such as illicit drug 
overdose and self-harm patients) in an interview component of a study of ED 
presentations to determine whether these problems are particular to medication 
overdose patients, or more widespread among those accessing ED services. The 
theme of escape noted in many participant narratives may also have broader 
applicability among illicit drug overdose and other self-harm cases, and is a notion 
which could be incorporated into intervention strategies, that is, strategies that assist 
people to find alternatives coping strategies rather than escaping via self-harm or 
substance use. 
Problematic substance use was the rule rather than the exception among the 
medication overdose patients interviewed for this study. Four out of five indicated 
they had previously or were currently experiencing difficulties in this area (primarily 
in relation to heroin, alcohol, and cannabis), and at least half were intoxicated at the 
time of the overdose. It is not clear whether the interview group were representative 
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of all medication overdose patients in this regard. The PAS data gave only limited 
insight into the extent of alcohol or other drug use at the time of medication 
overdose. Concurrent ingestion of such substances was sometimes, but not always 
recorded, and the extent to which this represented under-recording by ED staff was 
unknown. Furthermore, little or no information about an individual’s history of drug 
use was given. Improved recording of concurrent substance use at the time of 
presentation (where possible) may better inform immediate treatment, ensure referral 
to appropriate on-going support services upon discharge, and also shed light on the 
true proportion of medication overdose cases involving co-ingestion of alcohol and 
other drugs. 
Among the most significant findings of this study was the high rate of 
benzodiazepine involvement in medication overdose presentations. While the PAS 
data were not surprising in the light of previous ED-based research, ambulance data, 
and rates of prescription, the additional information obtained from the patient 
interviews strongly suggests that this is an issue of great concern and one which 
warrants further investigation. Of particular concern was the apparent over-
representation of certain classes of benzodiazepine medication relative to their rate of 
prescription (e.g. alprazolam). The reasons for this unexpectedly high contribution to 
medication-related harm need to be established, and action taken to reduce it. 
A substantial number of interview participants provided information which indicated 
they may have been prescribed benzodiazepines inappropriately, for example, to treat 
depression, over an extended period of time (years in some cases), in excessive 
quantities, or in combination with several other types of benzodiazepine medication. 
A smaller number of participants described seeking these medications from multiple 
sources, indicating some doctors may unwittingly be over-prescribing 
benzodiazepines to patients with dependency issues. While a full investigation of the 
prescribing practices of the doctors of patients included in this study was beyond the 
scope of the project, the preliminary evidence suggests that prescribers and 
dispensers of such medications could be involved in addressing the issue of 
benzodiazepine misuse generally and benzodiazepine overdose in particular. This 
could occur through increasing awareness of the current prescribing guidelines, the 
risks associated with long-term use of benzodiazepines, and alternative forms of 
evidence-based treatment for depression such as antidepressants, and cognitive-
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behavioural therapy. It may be that some patients respond poorly to any form of 
treatment offered, in which case the focus may shift from alleviating symptoms to 
the management of ongoing chronic depression or anxiety. This could include crisis 
planning to provide the person with a realistic alternative to overdose at times of 
great distress. Given the information concerning the acquisition of medications used 
in overdose, it would also be beneficial to encourage prescribers and dispensers to 
discuss the appropriate disposal of unused medications with patients, and to strongly 
advise against concurrent alcohol use. These issues may require closer monitoring in 
high risk cases. 
The data also suggest that people at-risk of medication overdose may require 
particularly skilful psychological or psychiatric interventions. Patient interviews 
revealed generally poor outcomes from counselling, which of course could be 
expected from a group who have all recently overdosed. Nonetheless, the counselling 
experiences described did not indicate widespread use of highly-structured, 
evidence-based techniques, with most people appearing to have had generalist 
counselling. Such non-directed, short-term counselling may simply not be sufficient 
to meet the needs of some members of this group. Long-term structured 
psychological work with ongoing monitoring, goal-setting, and additional social 
support may be required for many, particularly those with longstanding mental health 
and social issues, and a history of self-harming behaviour. Given that most of the 
patients interviewed had very limited means, such assistance would need to be 
available at low or no cost. Changes introduced to Australian Medicare funding in 
November 2006 may assist in making services more accessible, with up to 12 
sessions with an eligible psychologist per calendar year attracting a government 
rebate, although it is still too early to comment on the effectiveness of this scheme in 
improving treatment uptake. 
Finally, the experience of undertaking this research has potential implications for 
both the conduct of similar research involving sensitive topics and/or vulnerable 
populations in the ED setting, and for introducing a brief intervention aimed at 
reducing medication overdose. It is recommended that any research conducted within 
an ED setting take full advantage of any other data sources available prior to 
introducing patient interviews, both to reduce the level of involvement requested of 
patients, and to minimise the impact on the workload of the ED. It can be difficult to 
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achieve representative recruitment when relying on the goodwill of a large and 
mobile workforce. Therefore study designs which require large representative 
samples need to take a whole of ED approach, and may be better supported by 
having senior staff members as an integral part of the research team. Smaller scale, 
non-representative recruitment is more readily achieved, but again may be assisted 
through the involvement of one or two key members of the ED staff with a 
commitment to the project. Where patient interviews are regarded as necessary to 
answer the research questions posed, the information collected should be kept to a 
minimum, and alternative sources of recruitment also considered where possible. 
It was further concluded from the findings of the research and the experience of 
collecting data within the ED for a period of 12 months that while this setting was 
ideally suited to dealing with the acute medical and psychiatric needs of medication 
overdose patients, and for providing a risk assessment and referral to ongoing 
services elsewhere, it was not well resourced for ongoing care. Therefore while the 
ED could be a referral source for participants to an intervention aimed at reducing 
the risk of medication overdose or other forms of self-harm, the actual delivery of 
such a program would be better located within another community-based support 
service. An external treatment agency may be able to offer continuity of care over an 
extended period of time, or to provide linkages to other support services such as 
crisis accommodation, that could not routinely be made available through the ED. 
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Appendices 
 
Appendix A  DSM-IV-TR Criteria for Major Depressive Disorder 
The criteria for a Major Depressive Disorder, with either a single or recurrent 
episodes are as follows (American Psychiatric Association, 2000): 
A The presence of a single Major Depressive Episode (to be categorised as a single 
episode), or the presence of two or more Major Depressive Episodes (to be 
categorised as recurrent) 
B The episode is not better accounted for by Schizoaffective Disorder and is not 
superimposed on Schizophrenia, Schizophreniform Disorder, Delusional 
Disorder, or Psychotic Disorder Not Otherwise Specified 
C There has never been Manic Episode, a Mixed Episode or a Hypomanic Episode 
(except if related to substance or treatment induced or due to direct physiological 
effects of a general medical condition) 
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Appendix B  DSM-IV-TR Criteria for Major Depressive Episode 
The criteria for a Major Depressive Episode are as follows (American Psychiatric 
Association, 2000): 
A Five or more of the following criteria have been present for 2 weeks, and at least 
one of the symptoms is either depressed mood or loss of interest/pleasure 
 (1) Depressed mood most of the day, nearly every day 
 (2) Markedly diminished interest or pleasure in all, or almost all, activities 
most of the day, nearly every day 
 (3) Significant weight loss when not dieting or weight gain (i.e. > 5% of body 
weight in a month), or decrease or increase in appetite nearly every day 
 (4) Insomnia or hypersomnia nearly every day 
 (5) Psychomotor agitation or retardation nearly every day 
 (6) Fatigue or loss of energy nearly every day 
 (7) Feelings of worthlessness or excessive or inappropriate guilt (which may 
be delusional) nearly every day 
 (8) Diminished ability to think or concentrate, or indecisiveness, nearly every 
day 
 (9) Recurrent thoughts of death, recurrent suicidal ideation without a specific 
plan, or a suicide attempt or a specific plan for committing suicide 
B The symptoms do not meet the criteria for a Mixed Episode 
C The symptoms cause significant clinical distress, or impairment in social, 
occupational or other important areas of functioning 
D The symptoms are not due to the direct physiological effects of a substance or a 
general medical condition 
E The symptoms are not better accounted for by bereavement (unless symptoms 
persist for longer than two months, or involve functional impairment, 
worthlessness, suicidal ideation, psychotic symptoms or psychomotor retardation 
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Appendix C DSM-IV-TR Criteria for Dysthymic Disorder 
The criteria for Dysthymic Disorder are as follows (American Psychiatric 
Association, 2000): 
A Depressed mood for most of the day, for more days than not 
B The presence of two or more of the following: 
 (1) Poor appetite or overeating 
 (2) Insomnia or hypersomnia 
 (3) Low energy or fatigue 
 (4) Low self-esteem 
 (5) Poor concentration or difficulty making decisions 
 (6) Feelings of hopelessness 
C During the 2 year period, the person has never been without the symptoms in 
Criteria A and B for more than 2 months at a time 
D The disturbance is not better accounted for by Major Depressive Disorder 
(chronic or in partial remission) 
E There has never been a Manic Episode, a Mixed Episode, or a hypomanic 
Episode, and the criteria for Cyclothymic Disorder have never been met 
F The disturbance does not occur exclusively during the course of a chronic 
Psychotic Disorder 
G The symptoms are not due to the direct physiological effects of a substance or a 
general medical condition 
H The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning 
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Appendix D DSM-IV-TR Criteria for Substance-Induced Mood Disorder 
The criteria for Substance-Induced Mood Disorder are as follows (American 
Psychiatric Association, 2000): 
A A prominent and persistent disturbance in mood predominates in the clinical 
picture and is characterised by either (or both) of the following; 
 (1) Depressed mood or markedly diminished interest or pleasure in all, or 
almost all, activities 
 (2) Elevated, expansive, or irritable mood  
B There is evidence from the history, physical examination, or laboratory findings 
of either; 
 (1) The symptoms in Criterion A developed during, or within a month of, 
Substance Intoxication or Withdrawal 
 (2) Medication use is aetiologically related to the disturbance 
C The disturbance is not better accounted for by a Mood Disorder that is not 
substance-induced. Evidence that the symptoms are better accounted for by a 
Mood Disorder that is not substance-induced might include the following: the 
symptoms precede the onset of the substance use (or medication use); the 
symptoms persist for a substantial period of time (e.g. about a month) after the 
cessation of acute withdrawal or severe intoxication or are substantially in excess 
of what would be expected given the type or amount of the substance used or the 
duration of use; or there is other evidence that suggests the existence of an 
independent non-substance-induced Mood Disorder (e.g. a history of recurrent 
Major Depressive Episodes) 
D The disturbance does not occur exclusively during the course of a delirium 
E The symptoms cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning 
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Appendix E Explanatory Statement and Informed Consent Form 
St Vincent’s Health 
__________________________________________________________ 
 
Participant Information Sheet and Consent Form 
Medication Project 
Version 3 Dated 13 October 2003  
 
Protocol No:   70/03 
 
Name of Participant: 
 
U.R. number: 
 
Full Project Title:  Medication Overdose Project 
 
Principal Investigator:  Dr Paul Dietze (ph. 8413 8413) 
    Penny Heale (ph. 8413 8445) 
 
Associate Investigators:  Dr Alison Ritter 
    Professor Sandy Gifford 
    Mr Steve Burgess 
Dr Andrew Dent 
Mr William Barger    
 
This Participant Information and Consent Form is 5 pages long. Please make 
sure you have all the pages. 
 
1 Your Consent 
You are invited to take part in this research project.  
This Participant Information contains detailed information about the research 
project. Its purpose is to explain to you as openly and clearly as possible all 
the procedures involved in this project before you decide whether or not to 
take part in it.  
Please read this Participant Information carefully. Feel free to ask questions 
about any information in the document. 
Once you understand what the project is about and if you agree to take part 
in it, you will be asked to sign the Consent Form. By signing the Consent 
Form, you indicate that you understand the information and that you give 
your consent to participate in the research project. 
You will be given a copy of the Participant Information to keep as a record. 
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2 Purpose and Background 
Turning Point Alcohol and Drug Centre, Inc., in conjunction with Deakin 
University, Curtin University, St Vincent’s Hospital and the Melbourne 
Metropolitan Ambulance Service is conducting a study of the experiences of 
people who have recently received emergency medical treatment in relation 
to experiences of prescription and/or over-the-counter medication(s) use. 
The purpose of this project is to explore the factors contributing to the 
treatment, including the thoughts and feelings people have just before 
medical care was needed. We are also interested in what happens once 
emergency medical services are involved. The findings of this research will 
contribute to our understanding of medication overdose and how to best 
respond to it. 
A total of 200 people will participate in this project. 
You are invited to participate in this research as your experiences will 
provide important information for the project. 
This research is part of the ongoing research programme of Dr Paul Dietze, 
and is also towards the PhD Penny Heale. 
3 Procedures 
Participation in this project will involve being interviewed today. The 
interview will take about 60 minutes and will include questions about your 
living arrangements, family background, health, personal circumstances and 
any previous similar experiences with medications. I will also ask you some 
specific questions about the event for which you received the card such as 
your use of medications around that time. You will receive $30 for your time 
and travel expenses after the interview. We would also like to tape record 
parts of the interview. 
4 Possible Benefits 
Possible benefits of this research include an increased understanding of the 
factors contributing to the event. This will help in the development of 
strategies to prevent overdose and to better respond to people who do 
experience medication related harm. There may not be any benefit to you 
personally. 
5 Possible Risks 
A possible risk of participating in this research is that you will be asked to 
talk about personal experiences which may distress you. Should you be 
upset by the interview, you will be referred to an independent counsellor. 
Further, if you wish, the interview can be stopped at any time. 
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6 Privacy, Confidentiality and Disclosure of Information 
All the research information you provide will be confidential. However, a 
serious and imminent threat to harm yourself or others may be subject to 
reporting to a third person. Any information concerning the protective safety 
of children is subject to reporting to relevant authorities. Confidentiality of 
the information you provide in respect of yourself or others will be safeguarded 
except where the disclosure is required, authorised or permitted under law. 
The information you provide will be kept in a locked cabinet at Turning Point for 7 
years and then destroyed. Only the researchers directly involved in the project will 
have access to this information. 
In any publication, information will be provided in such a way that you 
cannot be identified. No findings that could lead to the identification of any 
individual will be published. The vast majority of the data will be presented 
in aggregate form to protect the identification of individuals. However, in 
rare cases, direct quotes may be made from interview notes. In such cases, no 
information will be used that may identify the participant from whom the 
quote is taken. 
7 Participation is Voluntary / Freedom to withdraw 
Your involvement in this research is completely voluntary. You are not 
required to answer any questions that you feel uncomfortable with, even 
after giving informed consent. If you change your mind about taking part in 
the research you are free to withdraw at any time prior to the analysis of the 
data, and this will not affect your access to any services. 
8 Results of Project 
If you are interested in the findings of the research you will be able to have a 
copy of the final report. This should be available within 6 months of the final 
interviews being conducted. Please call either of the principal researchers (Dr 
Paul Dietze or Ms Penny Heale) on 8413 8413. 
9 Further Information or Any Problems 
If you require further information or if you have any problems concerning 
this project, you can contact the principal researchers. The researchers 
responsible for this project are Dr Paul Dietze and Ms Penny Heale, 
telephone 8413 8413. 
10 Complaints and Research Participant Rights 
If you have any complaints about any aspect of the study or the way in 
which it is being conducted, you may contact the Patient Representative at St 
Vincent’s Health on Telephone: 9288 2211. You will need to tell the Patient 
 335
Non-fatal pharmaceutical medication overdose, suicidality and depression 
Representative the name of the person above who is named as principal 
investigator. 
12 Ethical Guidelines 
This project will be carried out according to the National Statement on Ethical 
Conduct in Research Involving Humans (June 1999) produced by the National 
Health and Medical Research Council of Australia. This statement has been 
developed to protect the interests of people who agree to participate in 
human research studies. 
The ethical aspects of this research project have been approved by the 
Human Research Ethics Committee of the Victorian Department of Human 
Services and by the Human Research Ethics Committee of Curtin University.  
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St Vincent’s Health 
__________________________________________________________ 
 
Consent Form 
Medication Project 
 
Version 3 Dated 13 October 2003 
 
I have read (or have had read to me), and understood the Participant 
Information version 3 dated 13 October 2003. 
I freely agree to participate in this project according to the conditions in the 
Participant Information.  
I will be given a copy of the Participant Information to keep  
The researcher has agreed not to reveal my identity and personal details if 
information about this project is published or presented in any public form.   
I understand that part of this interview will be tape-recorded and give 
permission to the researchers to do so. 
 
Participant’s Name (printed) …………………………………………………… 
 
Signature        Date 
 
 
Researcher’s Name (printed) …………………………………………………… 
 
Signature        Date 
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Appendix F Referral Directory 
REFERRAL DIRECTORY 
 
These services try to answer every call, but during very busy periods you may not be able to get through the first 
time. If you need to talk to someone, please don’t give up – either wait in the queue until your call is answered, leave 
a message, try to call again a few minutes later, or try one of the other numbers on the list. 
 
 
SERVICE NUMBER HOURS OTHER INFORMATION 
EMERGENCY 
Police/Fire/Ambulance 000   
Poisons Information Centre 13 11 26 24 hours/day, 7 days/week  
TELEPHONE HELP LINES 
Suicide Helpline 1300 651 251 24 hours/day, 7 days/week  
Care Ring 9326 8522 24 hours/day, 7 days/week  
Lifeline 13 11 14 24 hours/day, 7 days/week  
DirectLine 1800 888 236 24 hours/day, 7 days/week Alcohol & drug info and referral  
Kids Help-Line 1800 55 1800 24 hours/day, 7 days/week  
WIRE (Women’s Information and 
Referral Exchange) 
1300 134 130 9.30am-5.30pm, Mon-Fri 247 Flinders Lane, Melbourne,  
Telephone support. Interpreter service available 
Men’s Line Australia 1300 78 99 78 24 hours/day, 7 days/week  
Griefline 9596 7799 7am-3am, 7 days/week  
Gamblers Helpline 1800 156 789 24 hours/day, 7 days/week  
HEALTH SERVICES 
Medicines Line 1300 888 763 9am-12 noon, 3-6pm Mon-Fri Medication information line staffed by pharmacists 
Mental Health Foundation of 
Victoria 
9427 0406 9am-5pm, Mon-Fri 270 Church Street Richmond 
Information, referral & support service, including mood disorders 
support groups 
SANE Australia 1800 688 382 9am-5pm, Mon-Fri Mental illness information and referral 
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Mental Illness Fellowship 9482 4189 10am-4.30 pm, Mon-Fri  
PANDA (Post & Ante Natal 
Depression Association) 
9482 9400 9.30am-4.30pm, Mon-Thurs Telephone support service 
 
Maternal & Child Health Line 13 22 29 24 hours Interpreter service available 
TRANX (Tranquiliser Recovery and 
New Existence) 
9886 0955 9am-5pm, Mon-Fri 222 Burke Rd, Glen Iris 
Assistance in withdrawal from benzodiazepines 
PADA (Panic and Anxiety Disorder 
Association) 
9886 9400 9am-5pm, Mon-Fri 222 Burke Rd Glen Iris 
Assistance for people with panic and anxiety 
Hepatitis C Helpline 9349 1111 
1800 800 241 
9am-10pm, Mon-Fri 
9-11am, 6-8pm Sat & Sun 
Hepatitis C information and support 
(24 hour/day recorded Hep C info in Vietnamese call 1800 456 007) 
VIVAIDS 
Victorian Drug User Group 
9419 3633 10am-6pm, Mon-Fri 275B Smith Street Fitzroy 
Information & advocacy 
Alcoholics Anonymous 9429 1833 9am-9.30pm, Mon-Fri 407 Bridge Road Richmond 
Narcotics Anonymous 9525 2833 10am-6pm, 7 days/week  
AIDS Line 9347 6099 
1800 133 392 
9am-10pm, Mon-Fri 
9-11am, 6-8pm Sat & Sun 
For information about AIDS and other sexually transmitted diseases 
Melbourne Sexual Health Centre 9347 0244 
1800 032 017 
9am-12.30pm & 1.30-5.30pm Mon-
Thurs, 1.30-5.30pm Fri 
1st Floor, 580 Swanston Street, Carlton 
 
DOMESTIC VIOLENCE, CHILD ABUSE & SEXUAL ASSAULT 
Women’s Domestic Violence Crisis 
Service 
9329 8433 
1800 015 188 
24 hours/day, 7 days/week Crisis intervention, support, information, advocacy and referral. For 
women and children only. 
Advocate for Survivors of Child 
Abuse 
1300 657 380 Hours variable Self help organisation staffed by volunteers 
Centre Against Sexual Assault 
(CASA House) 
9344 2210 9am-5pm Mon-Fri. After hours call 
9349 1766 Country callers 1800 806 
292 
24 hour confidential telephone counselling, information and referral 
for victims of sexual assault and non-offending family members 
ACCOMODATION 
Argyle Housing Service 9417 2500 9am-5pm, Mon-Fri 2/107 Cambridge St, Collingwood 
Housing assistance for people within the City of Yarra 
Homeless Crisis Service 1800 882 500 9am-10pm, 7 days/week For people who are homeless or escaping violence 
 
 
Version 2 - Feb 2004 
Appendix G Interview Schedule 
Card number |___|___|___|___|  Date |___|___| / |___|___| / |___|___|___|___| 
 
Interviewer |___|___|  Duration interview |___|___|___| minutes 
 
DEMOGRAPHIC INFORMATION 
 
1 0 Female    2 Aged _____ years 
1 Male  
 
3a Current suburb ______________________ 
 
3b Who do you currently live with? 
1 Housemates/Friends  5 Alone 
 2 Parents    6 With children (not partner) 
3 Spouse/partner   7 Other relative(s) 
 4 Spouse/partner and children 8 Other (please specify) _____________ 
 
3c What is your current accommodation? 
 1 Owner occupied   4 Institution 
 2 Rental property   5 No fixed abode 
 3 Rooming/boarding house  6 Other (please specify) _____________ 
 
4a What was your highest year of school completed?  Year/Form ______ 
 
4b Have you completed any further education since school? 
 0 No 
 1 Yes, short courses only (e.g. Centrelink, hospitality courses, etc) 
2 Yes, trade/technical 
 3 Yes, university/college 
 
5 What is your current employment status? 
 1 Unemployed   5 Part time/Casually employed 
 2 Pensioner   6 Full time employed 
 3 Home duties   7 Other (please specify) _____________ 
 4 Student 
 
6a What is the main language you speak at home? 
0 English 
1 Other (please specify) ______________ 
 
 
6b What cultural or ethnic background you identify with? (e.g. Aboriginal or Torres Strait 
Islander, Vietnamese-Australian, Italian-Australian) 
0 Australian 
1 Other (please specify) ______________ 
 
7 How would you describe your sexual orientation? 
 0 Straight/Heterosexual   2 Bisexual 
1 Gay/Lesbian    3 Other (please specify) ______ 
 
8 Do you have children? (include step-children whom you regard as your own) 
 0 No 
 1 Yes ⇐  how many? ________ 
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 TREATMENT HISTORY & GENERAL HEALTH 
Very briefly, are you currently experiencing any significant medical problems. I will go through the body systems one by one; please let me know if you have a medical 
problem in that area, how long you have had the problem, how severe it is (mild, moderate, severe) and whether it is currently being treated. 
 
  
1 = Yes 
0 = No 
 
If yes, briefly describe the problem 
Duration of 
problem 
(days, mths, yrs)
1 = Mild 
2 = Moderate 
3 = Severe 
Current treatment 
(e.g. none, medicated, 
inpatient, outpatient) 
CARDIOVASCULAR 
Heart & blood vessels 
e.g. high blood pressure, arrhythmia 
     
RESPIRATORY 
Breathing/lungs 
e.g. emphysema, bronchitis 
     
GASTROINTESTINAL 
Stomach & intestines 
e.g. digestion, liver, bowel 
     
GENITO-URINARY 
Genitals & urinary system 
e.g. kidneys, incontinence, STDs 
     
MUSCULO-SKELETAL 
Muscles & skeleton 
e.g. arthritis, osteoporosis 
     
NEUROLOGICAL 
Nervous system 
e.g. Parkinsons, MS, epilepsy 
     
ENDOCRINOLOGICAL 
Glands & hormones 
e.g. thyroid problems, diabetes 
     
ALLERGIES 
e.g. food, pollen, animal fur 
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1 = Yes 
0 = No 
 
If yes, briefly describe the problem 
Duration of 
problem 
(days, mths, yrs)
1 = Mild 
2 = Moderate 
3 = Severe 
Current treatment 
(e.g. none, medicated, 
inpatient, outpatient) 
DERMATOLOGICAL 
Skin 
e.g. eczema, psoriasis 
     
EYES, EARS, NOSE, THROAT 
 
     
PSYCHIATRIC (note next page)   
 
   
OTHER 
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 Now I am going to ask you about some questions about your mental and emotional wellbeing. 
Would you say you have depression? When did it begin? Have you been diagnosed? When? What was the first treatment you received? (medication/counselling/etc) What 
other treatment/help have you had since? What medications are you on now? Do you have a psychiatrist at the moment? So far as you are aware, has anybody else in your 
family been diagnosed with depression? Record same details for each condition 
 
Prompts for medications 
What do you think x is meant to be used for? 
Is that mainly why you use x? (Other reasons?) 
What kind of instructions did you have for using x? 
Do you take x as prescribed? 
What do you know about any side effects of x? 
How often does your doctor review your use of this medication? 
Do you see more than one doctor? How many? (Reasons for more >1 doctor?) 
Is your doctor aware of other medications being taken or alcohol use…? 
Prompts for help seeking 
Who have you sought help from (e.g. GP, friend, family, counsellor, hospital, phone 
line). When? 
Which problem did that relate to? 
What was the response? 
Did you find this helpful/unhelpful? 
What response were you hoping for? 
Who listens to you? 
 
  
1 = Yes 
0 =  No 
 
If yes, approximate date first diagnosed and 
briefly describe the problem 
Treatment 
(e.g. none, medicated, inpatient, 
outpatient, counselling) 
Currently 
medicated 
1 = Yes 
0 =  No 
How many 
relatives 
diagnosed? 
0 =  None 
Relationship 
 
Mood disorder 
(depression, dysthymia, 
bipolar) 
 
 
 
 
 
 
 
 
 ___/___/___  / Never diagnosed 
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1 = Yes 
0 =  No 
 
If yes, approximate date first diagnosed and 
briefly describe the problem 
Treatment 
(e.g. none, medicated, inpatient, 
outpatient, counselling) 
Currently 
medicated 
1 = Yes 
0 =  No 
How many 
relatives 
diagnosed? 
0 =  None 
Relationship 
 
Anxiety (GAD, 
agoraphobia, specific 
phobia, social phobia, 
OCD, PTSD) 
 
 
 
 
 
 
 ___/___/___  / Never diagnosed 
 
 
 
    
 
Substance use disorder 
(dependence) 
 
Prev. problem substances 
Current problem 
substances 
How much x used 
Why do you think you use 
x 
DSM - dependence 
Treatment? 
 
 
 
 ___/___/___  / Never diagnosed 
 
 
 
 
 
 
 
 
Dependent: Y/N 
(substance_________________) 
 
IDU: no/current/past (approx last inj 
_________) 
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1 = Yes 
0 =  No 
 
If yes, approximate date first diagnosed and 
briefly describe the problem 
Treatment 
(e.g. none, medicated, inpatient, 
outpatient, counselling) 
Currently 
medicated 
1 = Yes 
0 =  No 
How many 
relatives 
diagnosed? 
0 =  None 
Relationship 
 
Eating disorder 
(Anorexia, Bulimia) 
 
 
 
 
 ___/___/___  / Never diagnosed 
 
    
 
Schizophrenia or other 
psychotic disorder 
 
 
 
 ___/___/___  / Never diagnosed 
 
    
 
Attention deficit disorder 
 
 
 
 ___/___/___  / Never diagnosed 
 
    
 
Other (please specify) e.g. 
substance related 
psychosis, Axis II 
disorders 
 
 
 
 ___/___/___  / Never diagnosed 
 
    
  
MEDICATION RELATED EMERGENCY CARE 
 
1 As we talk about what you experienced on (day), I am going to use the word “overdose”. Is 
that term OK with you? Is there another word/term you would prefer to use? 
 
 
 
2 Date and time of OD ____/____/____ at ___:___ am/pm 
 
 
 
3 Now I just want to know a little bit about the medications and any other drugs or alcohol you 
took that day 
 
ª Use 24 hour chart here to record substances used – prompt for details/source of any 
medication not already covered in health section 
 
 
 
4 Next I’d like to ask you about the type of care you received from the ambulance and in 
hospital 
 
4a How did you get to hospital? Were you taken to hospital by ambulance? Who called them? 
What do you remember about that? 
 
 
 
 
 
4b What do you remember about being in the emergency department? Who spoke to you? (e.g. 
Psych Triage) Were you given any referrals or follow-up? 
 
 
 
 
 
4c What happened when you were discharged from hospital? 
 
 
 
 
 
 
4d Does your GP/psychiatrist know about your overdose? Who told them? 
 
 
 
 
 
4e Was there anything you wanted to happen in hospital that didn’t? 
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 4f How did you feel about the experience afterwards? 
 
 
 
 
 
 
 
5a Considering the overdose on (day), on a scale of 1-5, how accidental or deliberate would 
you say your overdose was? (if 1 equals completely accidental with no intention to od and 5 equals 
completely deliberate with intention to od) 
 
          
1 2 3 4 5 
completely 
accidental/no 
intention to od 
   completely 
deliberate/intende
d to od 
  
Why would you say 1/2/3/4/5? 
 
 
 
 
 
 
 
5b Considering the overdose on (day), on a scale of 1-5, how strong would you say your wish to 
die was? (if 1 equals no wish to die and 5 equals strong wish to die) 
 
          
1 2 3 4 5 
no wish to die    strong wish to die 
 
Why would you say 1/2/3/4/5? 
 
 
 
 
 
 
 
ª Administer BSS and BDI (Fast Screen) here. Please note, reference period is “Thinking 
back to how you were feeling on (day) when you took the medication(s)”. Mark card number on 
forms 
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6a How many other times have you ever received emergency medical care as a result of taking 
too much medication? (i.e. ambulance or hospital) – establish when was first, temporal 
pattern, etc 
 
 
 
 
 
 
 
 
 
6b Earlier you described what happened when you went to hospital this time. Have there been 
any other times you can remember when something different happened? 
 
 
 
 
 
 
 
 
 
7 Have there been other times where you have taken too much medication, but where you 
haven’t had emergency medical care? How many times? – establish when was first, temporal 
pattern, etc 
 
 
 
 
 
 
 
 
 
8 Have there been any situations in which you have overdosed on other drugs? (e.g. illicit 
drugs). How many times? – establish when was first, temporal pattern, etc 
 
 
 
 
 
 
 
 
 
9 (If have previously overdosed) For what reasons have you overdosed on previous occasions? 
(on any substance) 
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PERSONAL & FAMILY HISTORY 
 
1 Have you ever deliberately hurt yourself without meaning to commit suicide? (e.g. burns, cuts) 
 
0 No    2 Don’t know/can’t remember 
1 Yes    3 Refuse 
 
 Most recent occasion ____/____/____ best approximation 
 Further comments 
 
 
2 So far as you know, has anyone in your family attempted or committed suicide? 
 
0 No    2 Don’t know/can’t remember  
1 Yes (attempt , commit ) 3 Refuse 
      4  Not sure whether death acc. or suicide 
 
Most recent occasion ____/____/____ best approximation 
 Relationship 
 
 
 
3 Have any of your friends or close acquaintances attempted or committed suicide? 
 
 0 No    2 Don’t know/can’t remember
  
1 Yes (attempt , commit ) 3 Refuse 
      4  Not sure whether death acc. or suicide 
 
Most recent occasion ____/____/____ best approximation 
 Relationship 
 
 
 
4a Earlier (BSS), you said you have attempted suicide ___  times altogether. Is that right? 
 
 
4b When was your first attempt? ____/____/____ best approximation 
 
 
4c When was your last attempt? (if > 1 attempt) ____/____/____ best approximation 
 
 
4d What methods have you ever used? OPEN ENDED (multiple answers ok) 
 Drug overdose/poisoning   Jumping 
 Cutting/slashing    Drowning 
 Hanging     Exhaust/fumes 
 Gunshot     Other (please specify) 
 
Further comments 
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SIGNIFICANT LIFE EVENTS 
 
In the last 6 months, have you experienced unhappiness or distress as a result of any of the following 
issues? 
 
 1 = 
yes 
0 = no 
 1 = 
yes 
0 = no 
Problems with parents  Sexual abuse  
Problems with friends  Unplanned pregnancy  
Anxiety about school/uni 
performance 
 Suicide of a friend  
Relationship break-up  Own violent or criminal 
behaviour 
 
Financial hardship  Sexual identity conflict  
Family member’s death  Physical abuse  
Problems at work  Death of a parent  
Failure at school/uni  Abortion  
Unemployment  Physical illness  
Parental divorce  Sexually transmitted diseases  
Friend’s death  Physical disability  
Own alcohol consumption  Homelessness  
Own drug use  Suicide of a family member  
Violence in the home  Mental illness  
Being bullied  Other (please specify) 
 
 
  Total number of events  
 
What has been the biggest contributing factor to you feeling stressed lately? How has it affected you? 
 
 
 
 
 
 
 
SOCIAL SUPPORT 
 
1 Do you feel as though you receive much support from friends? Explain/expand 
 
 
 
 
 
2 Do you feel as though you receive much support from family? Explain/expand 
 
 
 
 
 
3 Do you feel as though you receive much support from your partner? (if you have one) 
Explain/expand 
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OTHER CONSIDERATIONS 
 
Is there anything else that you feel is important to mention that I haven’t already asked you about? Is 
there anything else you want to say? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTERVIEWER COMMENTS 
 
Person offered referral sheet 
No 
Yes 
 
 
 
 We are having this interview today because you received emergency medical attention on (date) after consuming some medications. I would like to know what substances you consumed that day. I will ask you about all 
the medicines and drugs you may have taken in the 24 hours beforehand. This includes prescription and over the counter medications, illicit drugs and alcohol.  
For each drug type mark approximate time at which used (or range if using over a  period of time e.g. drinking). Mark both quantity used and specific drug type, e.g. Zoloft: 10 x 50mg tablets @3pm, Cannabis: 3 
bongs between 11.30 am and 2.00 pm. 
Put a line through those substances NOT consumed.         Time of OD (or ambulance attendance/hospitalisation?)              È 
 24 hours prior to overdose (Mark time in squares below, with square on far right being the hour prior to overdose, the next square being 2 hours prior to overdose, etc) 
Time (am/pm)                         
Prescription & OTC                         
Antidepressan  ts                         
Benzodiazepines                         
Anti psychoti  cs                         
Analgesi  cs                         
Methadone/Bupr                         
Oth  er                         
Alcohol                         
Spir  its                         
Be  er                         
Wi  ne                         
Other (e.g. po  rt)                         
Other drugs                         
Canna  bis                         
Hero  in                         
Amphetamin  es                         
Cocai  ne                         
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Hallucinogens                         
Inhalan  ts                         
Ecsta  sy                         
Additional substances                         
                         
                         
                         
                         
                         
 
 
  
Appendix H  DSM-IV-TR Criteria for Substance Dependence 
 
The criteria for Substance Dependence are as follows (American Psychiatric 
Association, 2000): 
 
1 Tolerance, as defined by either of the following:  
 (a) A need for markedly increased amounts of the substance to achieve 
intoxication or desired effect  
 (b) Markedly diminished effect with continued use of the same amount of the 
substance 
2 Withdrawal, as manifested by either of the following:  
 (a) The characteristic withdrawal syndrome for the substance 
 (b) The same (or closely related) substance is taken to relieve or avoid 
withdrawal symptoms 
3 The substance is often taken in larger amounts or over a longer period than was 
intended 
4 There is persistent desire or unsuccessful efforts to cut down or control substance 
use 
5 A great deal of time is spent in activities necessary to obtain or use the substance, 
or to recover from its effects 
6 Important social, occupational, or recreational activities are given up or reduced 
because of substance use 
7 Substance use is continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or 
exacerbated by the substance 
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 Appendix I Day of Week of Presentations for MOD, DOD & SH 
Day of the week % 
 MOD DOD SH ED Total 
 (n=453) (n=409) (n=545) (n=32,139) 
Monday 15.0 9.8 15.6 14.8 
Tuesday 11.9 11.7 14.5 14.2 
Wednesday 15.5 11.7 13.6 13.8 
Thursday 13.0 11.5 14.5 13.6 
Friday 12.6 14.9 13.6 14.3 
Saturday 17.0 20.5 14.9 14.4 
Sunday 15.0 19.8 13.4 14.9 
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Appendix J Length of Time between Being Seen by Treating Staff and Discharge 
from the ED for MOD, DOD & SH 
MOD (n=436) DOD (n=383) SH (n=525) Time in 
department 
% Cumulative % Cumulative % Cumulative
No time 1.4 1.4 1.6 1.6 6.1 6.1 
1-10 minutes 1.6 3.0 2.3 3.9 5.3 11.4 
11 to 30 minutes 2.5 5.5 8.9 12.8 6.5 17.9 
31 to 60 minutes 4.8 10.3 12.5 25.3 13.5 31.4 
1 to 2 hours 10.8 21.1 15.7 41.0 20.0 51.4 
2 to 4 hours 21.1 42.2 21.4 62.4 24.6 76.0 
4 to 8 hours 32.1 74.3 23.2 85.6 14.9 90.9 
8 to 12 hours 14.0 88.3 9.1 94.8 5.5 96.4 
12 to 18 hours 6.9 95.2 3.7 98.4 2.5 98.9 
18 to 24 hours 2.5 97.7 .3 98.7 .8 99.6 
24 to 36 hours 1.6 99.3 1.0 99.7 .4 100.0 
36 to 48 hours .5 99.8 - 99.7 - - 
> 48 hours .2 100.0 .3 100.0 - - 
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Appendix K Ten Principles of Treatment and Care, Victorian Mental Health Act 
1986 Act No. 59/1986, Amended by No. 98/1995 
6A. Principles of treatment and care 
It is the intention of Parliament that the following principles be given effect to with 
respect to the provision of treatment and care to people with a mental health disorder  
1 people with a mental disorder should be provided with timely and high quality 
treatment and care in accordance with professionally accepted standards; 
2 wherever possible, people with a mental disorder should be treated in the 
community; 
3 the provision of treatment and care should be designed to assist people with a 
mental disorder to, wherever possible, live, work and participate in the 
community; 
4 the provision of treatment and care for people with a mental disorder should 
promote and assist self reliance; 
5 be provided with appropriate and comprehensive information about their mental 
disorder, proposed and alternative treatments, including medication, and 
services available to meet their needs; 
6 people with a mental disorder should be treated near their homes or the homes 
of relatives or friends where possible; 
7 when receiving treatment and care the age-related, gender-related, religious, 
cultural, language and other special needs of people with a mental disorder 
should be taken into consideration; 
8 the prescription of medication should meet the best health needs of the person 
with a mental disorder and should be given only for therapeutic or diagnostic 
purposes and never as punishment or for the convenience of others; 
9 treatment and care should be provided by appropriately qualified people and 
within a multi-disciplinary framework; 
10 every effort that is reasonably practicable should be made to involve a person 
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with a mental disorder in the development of an ongoing treatment plan. 
Treatment and care of a person with a mental disorder should be based on this 
plan. The plan should be reviewed regularly and revised as necessary. 
 
 
 
 
 
 
 
 
 
 
 
